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1Childhood overweight and obesity are of major public health concern. The global prevalence 
of obesity in boys increased from 0.7% to 5.6% between 1975 and 2016, whereas in girls 
the prevalence increased from 0.9% to 7.8% in the same period (1). Childhood overweight 
and obesity have serious consequences for health. Children with obesity are at increased risk 
of obesity in adulthood (2). In addition, obesity is a strong risk factor for a range of other 
health problems, including cardio-metabolic disease (type 2 diabetes, dyslipidemia, hyperten-
sion, coronary heart disease, stroke), asthma, osteoarthritis, mental health problems and 
premature death (3). Overweight and obesity are defined by the World Health Organization 
(WHO) as “abnormal or excessive fat accumulation that may impair health” (4). Overweight 
and obesity are defined using the body mass index, which is a measure of body weight 
relative to height. In adults, overweight and obesity are defined as a body mass index of 
25.0-29.9 kg/m2 and ≥ 30 kg/m2, respectively (5). In children, the cut offs for overweight 
and obesity depend on the sex and age of the child and are defined according to reference 
charts for body mass index, such as those by Cole et al (6) and those by the WHO (7, 8). 
Body mass index is a simple and inexpensive measure of general adiposity. However, it is a 
suboptimal measure of fat mass, as it does not distinguish between fat mass and lean mass. 
Also, it does not provide any information on fat distribution. It has been suggested that an 
abdominal fat distribution, especially accumulation of visceral fat and liver fat, is strongly 
linked to metabolic disturbances and the risk of cardio-metabolic disease, independent of 
the total amount of body fat (9, 10).
The etiology of obesity and related cardio-metabolic diseases is complex and multifactorial. 
Risk factors include, but are not limited to, genetic predisposition, excess energy intake, 
sedentary behavior, lack of or excess of sleep, stress, and certain diseases. In addition, a 
large body of research suggests that obesity and other cardio-metabolic diseases might 
already originate in early life. The ‘Developmental Origins of Health and Disease (DOHaD) 
Hypothesis’ suggests that adverse exposures during fetal and early postnatal life may lead 
to developmental adaptations in organ structure or function, which may predispose these 
children to cardio-metabolic disease in later life (11). Early life adverse exposures suggested 
to influence offspring growth and development include for instance maternal pre-pregnancy 
obesity, unfavorable nutritional status, maternal smoking, gestational diabetes and gesta-
tional hypertensive disorders (11, 12). Studies assessing the early origins of adult disease 
often use birth weight, or its gestational age adjusted equivalent, as an indicator of subop-
timal intra-uterine environment and fetal growth. These studies consistently showed that 
children born with a low birth weight are at increased risk of developing cardio-metabolic 
disease in later life (11, 13, 14). On the other side of the spectrum, children born with a 
high birth weight are also at risk of these diseases (11, 13, 14). However, birth weight is the 
result of different fetal growth patterns and is the starting point of infant growth. It has been 
observed that both children born with a low or a high birthweight that grow rapidly in early 
childhood are at the highest risk of later obesity and cardio-metabolic disease (15-18).
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Thus, childhood obesity and more specifically an adverse body fat distribution are major 
health problems and important risk factors for other cardio-metabolic diseases. Susceptibility 
to these diseases might be partly established in early life, as reflected by different growth pat-
terns from fetal life onwards. Identifying the factors related to adverse growth patterns and 
body fat development as well as the underlying mechanisms will broaden the understanding 
of the early origins of disease and is vital to effectively target interventions aiming to reduce 
the burden of these diseases. Therefore, the studies in this thesis were designed to assess 
the associations of common maternal dietary factors and maternal adiposity with growth, 
body fat development and cardio-metabolic risk factors in children, as well as the metabolic 
mechanisms that might underlie these associations (Figure 1).
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maternal common dietary factors
Adequate nutrition during pregnancy is important for the health status of both the preg-
nant woman and her child (19). The Dutch Famine Study, a birth cohort study of men and 
women born around the Dutch famine of 1944-1945 provided important first evidence 
that prenatal undernutrition increases the risk of a variety of diseases in adulthood, such 
as obesity, diabetes and cardiovascular disease (12). Up until now, numerous studies have 
shown associations of maternal dietary factors during pregnancy, such as diet quality, dietary 
patterns, total energy intake and macro- and micronutrient intake with both short- and 
long-term offspring health outcomes (19, 20). Less studied but common components of the 
human diet, such as caffeine-containing beverages and cow’s milk, might also be important 
for offspring growth and development. Both caffeine-containing beverages and cow’s milk 
are frequently consumed among pregnant women and are associated with fetal growth and 
the risk of adverse birth outcomes (21-30). The long-term offspring health effects of these 
common dietary factors remain unclear.
Caffeine is a component of several food products, including coffee and tea. It has the 
ability to cross the placental barrier and freely enters the fetal circulation (31). The activity 
of the principal enzyme in caffeine metabolism, cytochrome CYP1A2, decreases progres-
sively during pregnancy and is absent in the placenta and fetus (32-34). Consequently, fetal 
exposure to caffeine is prolonged and might adversely affect fetal development. Previous 
research has suggested that caffeine intake by pregnant women is related to an increased 
risk of fetal death, impaired fetal growth and low birth weight (21-23). Based on the risks 
of adverse pregnancy and birth outcomes, the current recommendations for maximum caf-
feine intake range between 200-300 mg per day, equivalent to approximately 2-3 cups of 
coffee per day (35-37). In addition to these short-term outcomes, recent studies suggest 
that maternal caffeine intake might also affect offspring growth and body fat development, 
possibly by altering the development of the offspring hypothalamic-pituitary-adrenal (HPA) 
axis (38, 39). Also, studies in adult populations suggest that caffeine intake might affect body 
fat accumulation and the risks of several diseases (40-45).
Cow’s milk has a high bioavailability of nutrients important for growth and development, 
including protein, vitamins, calcium and other minerals. It has been suggested that maternal 
cow’s milk intake during pregnancy stimulates fetal growth (24-30). The current recommen-
dation of the Dutch Nutrition Centre for pregnant and non-pregnant women is 375 mg of 
milk and milk products a day, equivalent to approximately 2-3 glasses (46). Translational 
research has suggested that milk intake during pregnancy may activate the nutrient-sensitive 
kinase mechanistic target of rapamycin complex 1 (mTORC1) in the placenta, leading to an 
increased placental nutrient transfer and activated mTORC1 in the fetus (47, 48). mTORC1 
is involved in the regulation of cell growth and adipogenesis, and overactivation of mTORC1 
is related to a variety of diseases, including obesity, insulin resistance and cardiovascular 
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disease (47, 49, 50). This may suggest that maternal milk intake during pregnancy might also 
influence offspring cardio-metabolic development.
Thus, maternal caffeine intake during pregnancy and maternal milk intake during preg-
nancy might influence long-term body fat development and cardio-metabolic risk factors. 
Exploring these associations might provide insight in whether intake of these two commonly 
consumed beverages should be considered risks factors for offspring cardio-metabolic dis-
ease.
maternal adiPosity
Overweight and obesity in women of reproductive age are highly prevalent (51). Maternal 
pre-pregnancy obesity is an important and well-known risk factor for both short- and long-
term adverse outcomes for both the mother and the child, including gestational hypertensive 
and diabetic disorders, fetal death, pre-term birth, large-size for gestational age at birth 
(LGA) and childhood obesity (13, 51-55). Studies have shown that children of mothers with 
obesity have an 54% increased risk to be born prematurely, a 2-fold increased risk to be born 
LGA and a 3-fold increased risk of childhood obesity, as compared to children of mothers 
with a normal pre-pregnancy weight (13, 53). Next to maternal weight before pregnancy, 
maternal weight gain during pregnancy is also a risk factor of these short- and long-term 
maternal and offspring outcomes (56-59). Gestational weight gain is usually categorized 
into inadequate, adequate and excessive according to pre-pregnancy body mass index using 
the criteria of the US Institute of Medicine (IOM, currently known as the National Academy 
of Medicine (NAM)) (60). For instance, studies have shown that excessive gestational weight 
gain according to these criteria was associated with an 85% increased risk of LGA, a 30% 
increased risk of caesarian delivery and an 40% increased risk of childhood obesity (57, 58).
Maternal pre-pregnancy obesity and gestational weight gain reflect different components. 
Maternal pre-pregnancy obesity reflects maternal genetic predisposition, nutritional status, 
fat accumulation and low-grade inflammation. Gestational weight gain additionally reflects 
maternal and amniotic fluid expansion, and growth of the fetus, placenta and uterus (61, 
62). Intra-uterine programming mechanisms may, at least partly, underlie the associations of 
maternal pre-pregnancy obesity and gestational weight gain with offspring outcomes. In-
creased fetal exposure to nutrients in children from mothers with obesity has been suggested 
to lead to alterations in the structure and function of adipose tissue, appetite regulation, and 
energy metabolism (63, 64).
Thus, maternal pre-pregnancy BMI and gestational weight gain seem to be important 
modifiable risk factors of adverse maternal and offspring health outcomes. Despite the 
well-studied associations of maternal weight before and during pregnancy with offspring 
outcomes, refined and more in-depth understanding of the separate and combined relation-
15
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1ships of maternal pre-pregnancy body mass index and gestational weight gain with these 
outcomes is needed in order to effectively target future preventive strategies.
maternal and childhood metabolism
The mechanisms linking adverse exposures in early life to later obesity and cardio-metabolic 
disease are incompletely understood, but might involve alterations in maternal or offspring 
metabolic pathways. Maternal metabolite profiles in pregnancy may influence fetal growth 
and development by direct influences on fetal nutrient availability, or indirectly by influences 
on fetal metabolic processes resulting from adaptions in endocrine function or placental 
metabolism (65, 66). Thus far, studies mainly focused on conventional metabolites to char-
acterize maternal and offspring metabolic status. For instance, increased maternal glucose 
and lipid concentrations during pregnancy have been related to increased fetal and postnatal 
growth, and obesity, type 2 diabetes and the metabolic syndrome in the offspring (67-77). 
Detailed characterization of maternal and offspring metabolite profiles by metabolomics 
techniques may provide more in-depth insights in the metabolic mechanisms underlying the 
early origins of obesity and cardio-metabolic disease (78-80). Metabolomics is the study of 
a large number of small molecular weight metabolites in biological tissues and fluids. The 
metabolome is the most downstream component of the ‘omics technologies and is there-
fore closely linked to the phenotype. It carries information about gene-expression, but also 
about lifestyle- and environmental factors (79, 80). Metabolomics studies have already been 
successfully performed in adults for characterization of disease status, development and pro-
gression as well as the underlying mechanisms (81-83). In studies addressing the early origins 
of health and disease metabolomics has been used less extensively, and existing studies are 
often small and assessed cross-sectional relationships only. Exploring the interrelationships 
of detailed maternal and offspring metabolite profiles as well as their determinants and 
outcomes over time, will help to disentangle the mechanisms underlying the early origins of 
cardio-metabolic disease.
General objective
The general objective of this thesis was to assess the associations of common maternal 
dietary factors and maternal adiposity with offspring growth, body fat development and 




The studies presented in this thesis were embedded in the Generation R Study and in the 
Lifecycle - Maternal Obesity and Childhood Outcomes (MOCO) collaboration.
The Generation R Study
The Generation R Study is a population-based prospective cohort study from fetal life on-
wards in the city of Rotterdam, the Netherlands (84). The Generation R Study is designed 
to identify early environmental and genetic determinants of normal and abnormal growth, 
development and health from fetal life and young adulthood. All pregnant women living 
in the study area with a delivery date between April 2002 and January 2006 were eligible 
for enrollment in the study. Enrolment was aimed at early pregnancy, but was possible until 
the birth of the child. In total, 9778 mothers were enrolled in the study, of whom 8879 
(91%) were included during pregnancy. Assessments were planned in early pregnancy (<18 
weeks of gestation), mid-pregnancy (18 - 25 weeks of gestation) and late pregnancy (≥ 25 
weeks of gestation), and included parental physical examinations, maternal blood and urine 
collection, fetal ultrasound examinations and self-administered questionnaires. Assessments 
of the newborn at birth included a physical examination and cord blood collection. In the 
preschool period, from birth to 4 years of age, data collection was performed in all children 
by questionnaires and visits to the routine child health care centers. At the ages of 6 and 10 
years, all children were invited to a dedicated research center in the Erasmus MC – Sophia 
Children’s Hospital to participate in detailed body composition and cardiovascular follow-up 
measurements. Measurements during these visits included anthropometrics, body composi-
tion, cardiovascular development and collection of blood and urine. Currently, the 13-years 
old follow-up examination has been finished and the 17-years follow-up examination is 
ongoing.
The Lifecycle - Maternal Obesity and Childhood Outcomes 
collaboration
The Lifecycle - Maternal Obesity and Childhood Outcomes (MOCO) collaboration is an 
international collaboration of pregnancy and birth cohort studies, aiming to assess the as-
sociations of maternal pre-pregnancy body mass index and gestational weight gain with 
maternal and offspring outcomes. The collaboration consists of a total of 39 pregnancy and 
birth cohort studies from Europe, North-America and Australia, including a total of 277042 
participants. Cohorts were selected based on existing collaborations on childhood health (the 
EarlyNutrition project, the CHICOS project and Birthcohorts.net assessed until July 2014). 
Inclusion criteria were the inclusion of mothers with singleton live-born children born from 
1989 onwards, available information on maternal pre- or early pregnancy body mass index 
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1and at least one offspring measurement (birth weight or childhood body mass index) and 
approval by the local ethical committee.
outline of this thesis
The general objective of this thesis is addressed in several studies presented in this the-
sis. Chapter 2 describes studies on the influence of common maternal dietary factors on 
childhood growth, adiposity and cardio-metabolic risk factors. In Chapter 2.1, we assessed 
the associations of maternal caffeine intake during pregnancy with childhood growth and 
general adiposity, whereas in Chapter 2.2 we assessed the association of maternal caffeine 
intake during pregnancy with detailed measures of abdominal and liver fat. In Chapter 2.3, 
we focused on the association of maternal milk intake during pregnancy with childhood 
general and organ fat mass and cardio-metabolic risk factors.
Chapter 3 describes studies on the influences of maternal adiposity before and during 
pregnancy on offspring adiposity at birth and in childhood. In Chapter 3.1, we examined 
the separate and combined associations of maternal body mass index and gestational weight 
gain with the risks of overweight and obesity across childhood. In Chapter 3.2, we estimated 
ranges of optimal gestational weight gain associated with adverse maternal and infant 
outcomes.
Chapter 4 describes studies on the potential metabolic mechanisms linking adverse ex-
posures in early life to later obesity and cardio-metabolic disease. Chapter 4.1 describes the 
associations of maternal glucose and insulin levels with childhood general and abdominal 
body fat and cardio-metabolic risk factors. In Chapter 4.2, we identified critical periods 
and longitudinal growth patterns from fetal life onwards associated with childhood insulin 
and c-peptide levels. In Chapter 4.3, we describe metabolite profiles in pregnant women, 
newborns and children as well as their interrelationships. In Chapter 4.4 we describe the 
associations of metabolite profiles in pregnant women and newborns with detailed measures 
of fetal growth and the risks of adverse birth outcomes.
Finally, Chapter 5 provides a general discussion in which the main findings and impli-
cations of studies described in this thesis are discussed. English and Dutch summaries are 
provided in Chapter 6.
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2 Maternal common dietary factors

2.1 Maternal caffeine intake during pregnancy, early growth, and childhood 
adiposity
Voerman E, Jaddoe VWV, Gisthi O, Hofman A, Franco OH, 
Gaillard R. Maternal caffeine intake during pregnancy, early 
growth, and body fat distribution at school age.




Objective: The associations of maternal caffeine intake during pregnancy with offspring 
growth patterns and body fat and insulin levels at school age were examined.
Methods: In a population-based birth cohort among 7,857 mothers and their children, 
maternal caffeine intake during pregnancy was assessed by questionnaires. Growth char-
acteristics were measured from birth onward. At 6 years, body fat and insulin levels were 
measured.
Results: Compared to children whose mothers consumed <2 units of caffeine per day during 
pregnancy (1 unit of caffeine is equivalent to 1 cup of coffee (90 mg caffeine)), those whose 
mothers consumed ≥6 units of caffeine per day tended to have a lower weight at birth, 
higher weight gain from birth to 6 years, and higher body mass index from 6 months to 6 
years. Both children whose mothers consumed 4-5.9 and ≥6 units of caffeine per day during 
pregnancy tended to have a higher childhood body mass index and total body fat mass. Only 
children whose mothers consumed ≥6 units of caffeine per day had a higher android/gynoid 
fat mass ratio.
Conclusions: These results suggest that high levels of maternal caffeine intake during 
pregnancy are associated with adverse offspring growth patterns and childhood body fat 
distribution.
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introduction
Caffeine is frequently consumed during pregnancy (1). Caffeine crosses the placenta and 
enters the fetal circulation freely (2). Fetal exposure to caffeine is prolonged as a result of a 
slow clearance of caffeine in pregnant women and slow fetal metabolism (3). Ours and other 
previous studies have reported associations of high levels of maternal caffeine intake during 
pregnancy with higher risks of low birth weight (4-7). High maternal caffeine intake during 
pregnancy also has been associated with impaired fetal length growth from the second 
trimester onward (7).
Although previous studies have consistently suggested that children born with a low 
birth weight are at higher risk of an adverse body fat distribution and insulin resistance in 
later life (8-12), not much is known about the direct long-term offspring consequences of 
maternal caffeine intake during pregnancy. A recent prospective cohort study in the United 
States among 615 mothers and children reported a higher overall risk of obesity before the 
age of 15 years in children exposed to any caffeine during pregnancy (13). Another recent 
study among 1,986 mothers and children in the United States did not observe consistent 
associations between maternal serum paraxanthine concentrations, the primary metabolite 
of caffeine, during pregnancy and childhood body mass index at the ages of 4 and 7 years 
(14). In addition, animal studies have shown a decreased expression of insulin-like growth 
factor-1 (IGF-1), IGF-1 receptors, and insulin receptors in the offspring of rats exposed to caf-
feine during pregnancy, suggesting that fetal exposure to caffeine may disturb early growth 
and glucose metabolism (15, 16). To the best of our knowledge, no previous studies have 
assessed the associations of maternal caffeine intake during pregnancy with early growth, 
detailed body fat outcomes, or insulin levels in childhood.
Therefore, in a population-based prospective cohort study from early pregnancy onward 
among 7,857 mothers and their children, we examined the associations of maternal caffeine 
intake from coffee and tea during pregnancy with repeatedly measured growth character-
istics from birth until the age of 6 years and detailed body fat measures and insulin and 
c-peptide levels at the age of 6 years.
methods
Study design
This study was embedded in the Generation R Study, a population-based prospective cohort 
study from fetal life until young adulthood performed in Rotterdam, the Netherlands (17, 
18). Pregnant women were enrolled between 2001 and 2005. Of all eligible children, 61% 
participated in the study at birth. The study was approved by the local Medical Ethical Com-
mittee (MEC 198.782/2001/31). Written informed consent was obtained from all mothers.
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In total, 8,879 mothers were enrolled during pregnancy, of whom 8,099 had informa-
tion available on maternal caffeine intake during pregnancy. Of their children, 7,902 were 
singleton and live-born, 7,857 had data available on infant or childhood growth, and 5,562 
participated in the follow-up measurements at 6 years and had data available on body mass 
index, body fat, insulin, or c-peptide levels (flow-chart is given in Figure 1).



















Mothers enrolled during pregnancy with information on 
caffeine intake during pregnancy  
N= 7,857 
 
Population for longitudinal analyses: 
Singleton live births with information on maternal 




N= 5,562  
Population for analyses at 6 years: 
Singleton live births with information on maternal 
caffeine intake during pregnancy, infant or childhood 
growth and participation in the follow-up measurements 
at 6 years 
Body mass index    N= 5,562 
Total body fat mass    N= 5,407 
Android/gynoid fat mass ratio   N= 5,405 
Abdominal preperitoneal fat area  N= 4,508 
Insulin levels     N= 3,654 




Fetal deaths (N= 71) 
Loss to follow-up (N= 33) 
Twin pregnancies (N= 93) 
N = 2,295 
Excluded: 
No participation in follow-up 
measurements at 6 years (N= 2,295) 
N= 7,902 
 
Singleton live births with information on maternal 
caffeine intake during pregnancy  
 
 
N = 45 
Excluded: 
No infant or childhood growth 
measurements (N= 45) 
N= 8,879 
Mothers enrolled during pregnancy N=780 
Excluded: 
No information on maternal caffeine 
intake during pregnancy (N= 780) 
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Maternal caffeine intake during pregnancy
Information on maternal caffeine intake during pregnancy was obtained by postal question-
naires in the first, second, and third trimester of pregnancy (7). Response rates for these 
questionnaires were 91%, 80%, and 77%, respectively (7). Mothers who reported to drink 
any coffee or tea were asked how many cups of coffee or tea on average they consumed per 
day and what type of coffee or tea they consumed (caffeinated, decaffeinated, or a combina-
tion of both). According to standard values for caffeine content, a regular coffee serving 
(125 mL) in the Netherlands contains ~90 mg caffeine, decaffeinated coffee contains ~3 mg, 
and tea contains ~45 mg (19). To calculate the total caffeine intake in each trimester, the 
type of coffee or tea was weighted according to its caffeine content (caffeinated coffee = 1, 
caffeinated and decaffeinated coffee = 0.5, decaffeinated coffee = 0, caffeinated tea = 0.5, 
caffeinated and decaffeinated tea = 0.25, decaffeinated tea = 0; herbal tea = 0, and green 
tea = 0.5) (7). Thus, in our analyses, each unit of caffeine intake reflects caffeine exposure 
based on 1 cup of caffeinated coffee (90 mg caffeine). Total maternal caffeine intake was 
subsequently categorized (<2, 2-3.9, 4-5.9, ≥6 units per day, equivalent to <180, 180-359, 
360-539, and ≥540 mg per day, respectively). The average maternal caffeine intake of the 
trimesters of pregnancy was used for further analyses. When we used maternal caffeine 
intake in each trimester separately, results were similar (results not shown).
Infant and childhood growth
Information about length and weight at birth was obtained from medical records. Infant and 
childhood height and weight were measured using standardized methods at the ages of 6, 
12, 24, 36, 48, and 72 months. We calculated body mass index (kg/m2) from the age of 6 
months onward. We created age- and sex-adjusted standard deviation scores (SDS) within 
our study population using North-European reference growth charts for birth measurements 
(20) and Dutch reference growth charts for infant and childhood measurements (Growth 
Analyzer 3.5, Dutch Growth Research Foundation) (21). We defined childhood overweight 
or obesity at the age of 72 months using the International Obesity Task Force cut offs (boys: 
body mass index ≥17.55 and ≥19.78, girls: body mass index ≥17.37 and ≥19.65 for over-
weight and obesity, respectively) (22).
Childhood body fat distribution
At the age of 6 years, we measured total and regional body fat mass using Dual-Energy X-ray 
absorptiometry (DXA) (iDXA, General Electrics-Lunar, 2008, Madison, WI) (23). Total body 
fat mass was calculated as a percentage of total body weight measured by DXA. Android/
gynoid fat mass ratio was calculated (23). Pre-peritoneal fat mass was used as a proxy for 
visceral fat and was measured using abdominal ultrasound examinations with ultrasound 
LOGIQ E9 (GE Medical System, Wauwatosa, WI) and ATL-Philips Model HDI 5000 (Seattle, 
WA), as described in detail previously (24). Briefly, a linear (L12-5 MHz) transducer was placed 
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perpendicular to the skin surface on the median upper abdomen (25). We scanned longitu-
dinally from the xiphoid process to the navel along the midline (linea alba). Pre-peritoneal fat 
mass was measured as areas of 2 cm length along the midline starting from the reference 
point in direction of the navel.
Childhood insulin and c-peptide levels
Childhood insulin (pmol/L) and c-peptide levels (nmol/L) were obtained enzymatically from 
30 min fasting venous blood samples at the age of 6 years using a Cobas 8000 analyzer 
(Roche, Almere, the Netherlands). Quality control samples demonstrated intra- and inter-
assay coefficients of variation of 1.39% and 2.40%, respectively.
Covariates
We assessed maternal age, pre-pregnancy body mass index, parity, ethnicity, educational 
level, and folic acid supplementation use by questionnaire at enrolment in the study. Smok-
ing and alcohol consumption during pregnancy were repeatedly assessed by questionnaire. 
We obtained information on gestational hypertensive disorders (gestational hypertension 
and pre-eclampsia) and gestational diabetes, date of birth, and the child’s sex from midwife 
and hospital registries. We obtained information on breastfeeding and the timing of intro-
duction to solid foods by questionnaire during infancy. Average television-watching time was 
assessed by questionnaire at the age of 6 years.
Statistical analysis
First, we used unbalanced repeated measurement regression models to examine the asso-
ciations of maternal caffeine intake during pregnancy with longitudinally measured growth 
characteristics. These models take the correlation between repeated measurements of the 
same subject into account and allow for incomplete outcome data. The models are described 
in more detail in Supplemental Methods 1.These models were adjusted for child’s sex, and 
maternal and childhood socio-demographic and lifestyle-related characteristics.
Second, we used multiple linear regression models to examine the associations of mater-
nal caffeine intake during pregnancy with childhood body fat distribution and insulin and 
c-peptide levels. These models were first adjusted for child’s sex, age at follow-up measure-
ment, and height at follow-up measurement (for fat mass outcomes only) and subsequently 
additionally adjusted for maternal and childhood socio-demographic and lifestyle-related 
characteristics. We included covariates in the models based on their associations with the 
outcomes of interest in previous studies, a significant association with the determinants and 
outcomes, or a change in effect estimates of >10%. To examine whether a dose–response 
relationship is present, we performed tests for trends by entering the categorized variable as 
a continuous term to the models. Finally, we used logistic regression models to examine the 
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associations of maternal caffeine intake during pregnancy with childhood overweight at the 
age of 6 years using similar adjustments.
In order to obtain normal distributions, we log transformed fat mass outcomes and square 
root transformed insulin and c-peptide levels. We constructed standard deviation scores (SDS) 
for all outcomes. Since no significant interaction between maternal caffeine intake during 
pregnancy and child’s sex was present (all P-values >0.05), we performed no sex-stratified 
analyses. We used Multiple Imputation for missing values of covariates, by generating five 
independent datasets using the Markov Chain Monte Carlo (MCMC) method (26). We 
included all covariates in the imputation model. In addition, childhood body mass index and 
insulin levels at the age of 6 years, maternal pre-pregnancy weight, maternal height, income, 
maternal caffeine intake, and paternal body mass index were used as predictors only, and 
were not imputed themselves. Percentages missing values in the population for analysis were 
all lower than 22%, except for timing of introduction of solid foods (37.6%). Pooled effect 
estimates were presented. The repeated measurement analysis was performed using the 
Statistical Analysis System version 9.3 (SAS, Institute Inc., Cary, NC). All other analyses were 




Table 1 shows that, as compared to mothers who consumed <2 units of caffeine per day 
during their pregnancy, those who consumed ≥6 units per day were more likely to be higher 
educated, nulliparous, and from European descent. Their children had a lower birth weight 
and a higher body mass index at the age of 6 years (P-values< 0.05). Supplemental Table 
1 shows infant and childhood growth characteristics. Supplemental Table 2 shows limited 
to moderate correlations between the outcome measures at 6 years. Non-response analyses 
at baseline (Supplemental Table 3) and at follow-up measurement (Supplemental Table 
4) showed that both mothers excluded because of missing data on caffeine intake during 
pregnancy and mothers lost to follow-up were lower educated and less often of European 
descent, compared to those included in the analysis. Their children had a lower birth weight. 
However, no large differences were observed between the caffeine intake during pregnancy 
of mothers of children not included in the analyses at 6 years and mothers of children in-











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Infant and childhood growth patterns
Figure 2 A-C shows the associations of maternal caffeine intake during pregnancy with re-
peatedly measured growth characteristics from birth to 72 months, obtained from repeated 
measurement regression models. As compared to children whose mothers consumed <2 
units of caffeine per day during pregnancy, children whose mothers consumed ≥6 units 
of caffeine per day were shorter, but these differences decreased over time. At the age of 
6 years, children whose mothers consumed ≥6 units of caffeine per day still tended to be 
shorter. These children also had lower birth weights and had higher weight gain from birth 
to 72 months. Body mass index tended to be higher from 6 months to 72 months in children 
whose mothers consumed ≥6 units of caffeine per day during pregnancy, as compared to 
children whose mothers consumed <2 units of caffeine per day.
Childhood body fat distribution
Compared to children whose mothers consumed <2 units of caffeine per day during their 
pregnancy, both those whose mothers consumed 4-5.9 units and ≥6 units of caffeine per 
day tended to have a higher childhood body mass index (differences: 0.09 Standard devia-
tion score (SDS) (95% confidence interval (CI): -0.01, 0.19) and 0.16 SDS (95% CI: -0.03, 
0.36), respectively) and a higher childhood total body fat mass (differences: 0.10 SDS (95% 
CI: 0.01, 0.20) and 0.18 SDS (95% CI: -0.01, 0.37), respectively) (Table 2). Only children 
whose mothers consumed ≥6 units of caffeine per day during their pregnancy had a higher 
childhood android/gynoid fat mass ratio (difference: 0.27 SDS (95% CI: 0.05, 0.49)). Similar 
tendencies were present when we combined the upper two maternal caffeine intake cat-
egories into one category (results not shown). Supplemental Table 5 shows similar results 
from the basic models. Supplemental Table 6 shows that as compared to children whose 
mothers consumed <2 units of caffeine per day during pregnancy, those whose mothers 
consumed ≥6 units of caffeine per day tended to have higher risks of childhood overweight 
(odds ratio (OR): 1.25 (95% CI: 0.68, 2.30)) in the fully adjusted model.
Childhood insulin and c-peptide levels
Table 3 shows no consistent associations of maternal caffeine intake during pregnancy with 
childhood insulin and c-peptide levels in the fully adjusted models. Similar results were pres-
ent in the basic models (Supplemental Table 7).
discussion
We observed that, as compared to children whose mothers consumed no or less than 2 units 
of caffeine per day during their pregnancy, children whose mothers consumed 6 units of 
caffeine or more per day tended to have a lower weight at birth, higher weight gain from 
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Figure 2. Associations of maternal caffeine intake during pregnancy with longitudinally mea-













































































C Body mass index 
2 - 3.9 units 4 - 5.9 units ≥ 6 units
Results are based on repeated linear regression models and reflect the differences in SDS of (A) height (based on 51,691 
measurements), (B) weight (based on 58,124 measurements) and (C) body mass index (based on 36,953 measure-
ments) growth in children whose mothers consumed 2-3.9, 4-5.9 and ≥6 units of caffeine per day during pregnancy, 
respectively, as compared to those whose mothers consumed <2 units of caffeine per day. 1 unit of caffeine intake 
represents the equivalent of 1 cup of coffee (90 mg caffeine). The reference value is an SDS of 0. The models were 
adjusted for child’s sex, maternal age, pre-pregnancy body mass index, parity, ethnicity, educational level, folic acid 
supplementation use, smoking and alcohol consumption during pregnancy, pregnancy complications, breastfeeding 
and timing of introduction of solid foods. All p-values for interaction <0.05.
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birth to 6 years and a higher body mass index from 6 months to 6 years. Also, at the age of 
6 years, children of mothers with higher levels of caffeine intake during pregnancy tended to 
have a higher childhood total body fat mass and android/gynoid fat mass ratio. We did not 
observe differences for childhood insulin or c-peptide levels.
Strengths and limitations
We used a large population-based cohort followed from early pregnancy onward. In total, 
30% of the eligible participants with information on maternal caffeine intake during preg-
nancy were not participating in follow-up measurements at 6 years. This loss to follow-up 
could have reduced the statistical power of our study and could have led to biased effect 
estimates if associations of interest differ between children included and not included in 
the analysis. This seems unlikely, since only minor differences were observed between the 
caffeine intake during pregnancy of mothers of children not included in the analysis and the 
caffeine intake of mothers of children included in the analysis. Since maternal caffeine intake 
during pregnancy was self-reported, misclassification by underreporting may be present. In 
addition, in accordance with the Netherlands Nutrition Centre (27), we assumed that coffee 
Table 2. Maternal caffeine intake during pregnancy and childhood body fat distribution at 6 
years (fully adjusted models) (N=5,562)
Body mass index 
(SDS)
Total body fat 
mass (SDS)
Android/gynoid 





N=5,562 N=5,407 N=5,405 N=4,508
Maternal caffeine intake categories
< 2 units Reference Reference Reference Reference
N=3,295 N= 3,199 N=3,197 N=2,658
2 – 3.9 units -0.03 (-0.08, 0.03) 0.02 (-0.03, 0.07) 0.04 (-0.02, 0.09) -0.05 (-0.11, 0.01)
N= 1,819 N=1,771 N=1,771 N= 1,475
4 – 5.9 units 0.09 (-0.01, 0.19) 0.10 (0.01, 0.20)* 0.02 (-0.09, 0.13) -0.04 (-0.15, 0.07)
N=368 N=357 N=357 N=306
≥ 6 units 0.16 (-0.03, 0.36) 0.18 (-0.01, 0.37) 0.27 (0.05, 0.49)* -0.15 (-0.37, 0.07)
N=80 N=80 N=80 N=69
P-value for trend 0.220 0.015 0.068 0.075
Values are regression coefficients (95% confidence interval) that reflect the difference in childhood outcomes in children 
whose mothers consumed 2-3.9, 4-5.9 and ≥6 units of caffeine per day during pregnancy, respectively, as compared 
to those whose mothers consumed <2 units of caffeine per day. 1 unit of caffeine intake represents the equivalent of 
1 cup of coffee (90 mg caffeine). The models were adjusted for child’s sex, age at follow-up measurement, height at 
follow-up measurement, maternal age, pre-pregnancy body mass index, parity, ethnicity, educational level, folic acid 
supplementation use, smoking and alcohol consumption during pregnancy, gestational diabetes, gestational hyperten-
sive disorders, birth weight, gestational age at birth, breastfeeding, introduction of solid foods and television-watching 
time. P-values for trend were obtained from models in which the categorized caffeine intake variable was entered as 
continuous variable. * P-value <0.05.
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was consumed in cups of 125 mL. However, this might have differed between participants, 
which may have led to some misclassification of the categories of maternal caffeine intake. 
We also assessed only caffeine intake from coffee and tea and not intake from other sources, 
such as soft drinks, chocolate, and medications. However, at the time of data collection 
(2002-2006), coffee and tea accounted for 70 and 26%, respectively, of all caffeine ingested 
(1). We categorized maternal caffeine intake during pregnancy in units of caffeine instead 
of calculating the exact milligrams of caffeine consumed per day. The highest category of 
maternal caffeine intake in our study (≥6 units) should be considered equivalent to a caffeine 
intake of ≥540 mg per day. However, since caffeine contents per unit of coffee might differ 
between countries, our results should be interpreted carefully with regard to other popula-
tions. We were able to adjust our analyses for many possible confounders. However, as in any 
observational study, residual confounding might still be an issue. For example, in our study 
we were unable to adjust the analyses for detailed maternal and childhood dietary habits.
Interpretation of main findings
Maternal caffeine intake during pregnancy may affect fetal growth and development. Among 
the same population as the present study and in line with other large observational studies 
Table 3. Maternal caffeine intake during pregnancy and childhood insulin and c-peptide levels 
at 6 years (fully adjusted models) (N=3,667)
Insulin (SDS) C-peptide (SDS)
N=3,654 N=3,667
Maternal caffeine intake categories
< 2 units Reference Reference
N= 2,116 N=2,128
2 -3.9 units -0.03 (-0.11, 0.04) -0.05 (-0.12, 0.03)
N= 1,239 N=1,237
4 – 5.9 units 0.14 (0.01, 0.28)* 0.10 (-0.03, 0.24)
N= 241 N=243
≥ 6 units -0.18 (-0.45, 0.08) -0.13 (-0.39, 0.14)
N= 58 N=59
P-value for trend 0.900 0.869
Values are regression coefficients (95% confidence interval) that reflect the difference in childhood outcomes in children 
whose mothers consumed 2-3.9, 4-5.9 and ≥6 units of caffeine per day during pregnancy, respectively, as compared to 
those whose mothers consumed <2 units of caffeine per day. 1 unit of caffeine intake represents the equivalent of 1 
cup of coffee (90 mg caffeine). The models were adjusted for child’s sex, age at follow-up measurement, maternal age, 
pre-pregnancy body mass index, parity, ethnicity, educational level, folic acid supplementation use, smoking and alcohol 
consumption during pregnancy, gestational diabetes, gestational hypertensive disorders, birth weight, gestational age 
at birth, breastfeeding, introduction of solid foods and television-watching time. P-values for trend were obtained from 
models in which the categorized caffeine intake variable was entered as continuous variable. *P-value <0.05.
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(4-6), we previously reported that high levels of maternal caffeine intake during pregnancy 
are associated with impaired fetal growth and higher risks of low birth weight (7).
Not much is known about the long-term offspring consequences of maternal caffeine 
intake during pregnancy. A recent study in the United States among 615 mothers and their 
children suggested that any caffeine intake during pregnancy was associated with an 87% 
higher overall risk of childhood obesity before the age of 15 years. Also, a dose–response 
relation for maternal caffeine intake was observed (13). In contrast, another recent study 
among 1,986 mothers and their children in the United States did not observe consistent 
associations of maternal serum paraxanthine concentrations, caffeine’s primary metabolite, 
during pregnancy with childhood body mass index (14). We observed that children of moth-
ers with the highest caffeine intake during pregnancy were shorter and had lower weights 
at birth, as compared to children of mothers with low caffeine intake, but gained more 
weight from birth to 6 years. Also, they tended to have higher body mass indexes from 6 
months to 6 years. We observed a tendency to a higher risk of overweight at the age of 6 
years in children of mothers with the highest caffeine intake during pregnancy, although 
not statistically significant. This may be due to smaller numbers, since only 80 mothers in 
our study consumed 6 units of caffeine per day or more. Thus, these findings suggest that 
maternal caffeine intake during pregnancy might not only affect fetal development, but may 
have persistent consequences for childhood growth.
Although body mass index is a widely accepted measure of adiposity, previous studies have 
shown that more specific body fat measures, such as total fat mass, waist circumference, 
and waist to hip ratio, are predictors of cardiovascular risk factors and disease in children and 
adults, independent of body mass index (28-30). Thus, detailed body composition measures 
provide useful additional information in assessing adiposity and its consequences. To the best 
of our knowledge, no previous studies have been performed focused on the associations of 
maternal caffeine intake during pregnancy with detailed measures of childhood body fat 
distribution. We observed that high maternal caffeine intake during pregnancy tended to be 
associated with a higher childhood total body fat mass and an adverse childhood body fat 
distribution, as reflected by a higher android/gynoid fat mass ratio. We observed no effect of 
maternal caffeine intake during pregnancy on pre-peritoneal fat mass. This discrepancy could 
be attributed to a larger measurement error for preperitoneal fat mass measurements in 
childhood (31, 32). Thus, our results suggest that maternal caffeine intake during pregnancy 
may affect childhood total fat and body fat distribution, next to body mass index.
Studies in adults showed that coffee consumption is consistently associated with lower 
risks of insulin resistance and type 2 diabetes (33-35). However, associations with both caf-
feinated and decaffeinated coffee were observed, suggesting that next to caffeine, other 
coffee components may also play a role in the underlying mechanisms. In contrast to these 
findings in non-pregnant adults, animal studies suggest that maternal caffeine intake during 
pregnancy may increase insulin resistance and disturb glucose metabolism in the offspring 
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(15, 16). We did not observe consistent associations of maternal caffeine intake during 
pregnancy with childhood insulin and c-peptide levels. Our results should be interpreted 
carefully, since the fasting period before blood draw for the childhood insulin and c-peptide 
measurements was limited. This may have led to some non-differential misclassification and 
an underestimation of the observed effect estimates. This may especially affect childhood 
insulin levels, which are less stable and have a shorter half-life as compared to c-peptide 
levels. Further studies are needed to assess the detailed associations of maternal caffeine 
intake during pregnancy with offspring glucose and insulin metabolism.
The mechanisms by which maternal caffeine intake during pregnancy might influence 
childhood body fat distribution are not clear. It has been suggested that caffeine induces an 
increase in circulating maternal and fetal glucocorticoid concentrations (36, 37). Studies in 
rats suggest that fetal overexposure to glucocorticoids leads to an altered development of 
the hypothalamic–pituitary–adrenal axis (HPA-axis), impaired fetal growth, altered structure 
of the endocrine pancreas, insulin target-tissues and adipose depots, and increased HPA-axis 
activity (37-39). Whether this mechanism partly underlies the observed associations needs to 
be further studied.
Although the observed effect estimates are small and without direct individual clinical 
consequence, our results suggest that maternal caffeine intake during pregnancy is associ-
ated with infant and childhood growth and body fat distribution. As caffeine is frequently 
consumed during pregnancy and the prevalence of obesity is still rising (40), our results 
underline the need to study the long-term health consequences of maternal caffeine intake 
during pregnancy.
Conclusion
Our results suggest that high levels of maternal caffeine intake during pregnancy are associ-
ated with adverse offspring growth patterns and childhood body fat distribution, but not 
with childhood insulin and c-peptide levels. Further studies are needed to assess whether 
maternal caffeine intake during pregnancy affects long-term offspring health outcomes, as 
well as the causality and underlying mechanisms.
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Supplemental Methods 1. Unbalanced repeated measurement regression models
We used unbalanced repeated measurement regression models to analyze the infant and 
childhood growth patterns among children whose mothers consumed 2-3.9, 4-5.9 and ≥6 
units of caffeine per day during their pregnancy, as compared to children whose mothers 
consumed <2 units of caffeine per day. These models allow for incomplete outcome data and 
take the correlation between repeated measurements of the same subject into account by 
modelling the correlated errors of these measurements (1, 2). To model the correlated errors, 
a compound symmetry covariance structure was assumed. The models can be written as:
Height (SDS) = ß0 + ß1 × caffeine intake category + ß2 × age + ß3 × caffeine intake category 
× age
Weight (SDS) = ß0 + ß1 × caffeine intake category + ß2 × age + ß3 × caffeine intake category 
× age
Body mass index (SDS) = ß0 + ß1 × caffeine intake category + ß2 × age + ß3 × caffeine intake 
category × age
In these models, ‘ß0 + ß1 × caffeine intake category’ reflects the intercept. The intercept 
reflects the mean growth characteristic value in SDS for each caffeine intake category. The 
term ‘ß2 × age’ reflects the change in growth characteristics per month. The term ‘ß3 × 
caffeine intake category × age’, reflects the difference in change in growth characteristics per 
month between the different caffeine intake categories.
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Supplemental Table 2. Correlation coefficients between childhood body fat measures and in-
sulin and c-peptide levels (N=5,562) 1









































































1Values are correlation coefficients using Spearman’s rho tests for skewed variables.
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N= 8,099 N= 780
Maternal characteristics
Age, median (95% range), years 30.4 (19.3, 39.3) 28.4 (18.7, 39.3) <0.001
Height, mean (SD), cm 167.4 (7.4) 164.3 (7.3) <0.001
Pre-pregnancy weight, median (95% range), kg 64.0 (48.0, 99.0) 63.0 (46.6, 100.0) 0.418
Pre-pregnancy body mass index, median (95% range), 
kg/m2
22.6 (17.9, 35.0) 23.3 (17.6, 35.6) 0.048
Education, No. (%)
Primary 436 (6.0) 47 (14.1) <0.001
Secondary 3160 (43.2) 179 (53.6)
Higher 3712(50.8) 108 (32.3)
Parity, No. nulliparous (%) 4536 (56.4) 386 (54.3) 0.001
Ethnicity, No. European (%) 4618 (58.4) 150 (31.5) <0.001
Folic acid supplementation use, No. Yes (%) 4504 (71.2) 128 (53.8) <0.001
Smoking during pregnancy, No. Yes (%) 1381 (18.6) 59 (18.6) 0.997
Alcohol consumption during pregnancy, No. Yes (%) 2737 (37.3) 49 (16.1) <0.001
Gestational diabetes, No. Yes (%) 82 (1.1) 9 (1.3) 0.600
Pre-eclampsia, No. Yes (%) 169 (2.3) 18 (2.5) 0.633
Gestational hypertension, No. Yes (%) 301 (4.0) 17 (2.4) 0.039
Child characteristics
Males, No. (%) 4024 (50.4) 377 (51.3) 0.627
Birth weight, median (95% range), g 3425 (2200, 4482) 3340 (1948, 4460) <0.001
Gestational age at birth, median (95% range), weeks 40.1 (35.4, 42.3) 40.0 (32.3, 42.4) <0.001
Ever breastfeeding, No. Yes (%) 5336 (91.9) 275 (95.5) 0.028
Introduction of solid foods, No. before 6 months (%) 3899 (89.4) 123 (89.8) 0.900
1Values represent means (SD), median (95% range) or number of subjects (valid %). 2Differences in subject character-
istics between the groups were tested using Independent Samples T-tests for continuous variables and Chi-square tests 
for proportions.
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Supplemental Table 4. Non-response analysis at follow-up measurement (N=7,902)1
Follow-up at 6 
years
Lost to follow-up 
at 6 years
P-value2
N= 5,562 N= 2,340
Maternal characteristics
Age, median (95% range), years 30.9 (19.8, 39.4) 28.8 (18.5, 38.5) <0.001
Height, mean (SD), cm 167.7 (7.4) 166.6 (7.3) <0.001
Pre-pregnancy weight, median (95% range), kg 64.0 (49.0, 98.0) 63.0 (47.0, 100.0) 0.145
Pre-pregnancy body mass index, median (95% range), 
kg/m2
22.6 (18.1, 34.6) 22.6 (17.7, 35.6) 0.300
Caffeine intake during pregnancy, median (95% 
range), units
1.5 (0, 5.0) 1.3 (0, 5.0) <0.001
Caffeine intake during pregnancy, No. (%)
<2 units 3,295 (59.2) 1,545 (66.0) <0.001
2 – 3.9 units 1,819 (32.7) 635 (27.1)
4 – 5.9 units 368 (6.6) 130 (5.6)
≥ 6 units 80 (1.4) 30 (1.3)
Education, No. (%)
Primary 272 (5.4) 152 (7.2) <0.001
Secondary 1,976 (39.3) 1,116 (53.1)
Higher 2,780(55.3) 833 (39.6)
Parity, No. nulliparous (%) 3,195 (57.7) 1,238 (53.5) 0.001
Ethnicity, No. European (%) 3,412 (62.1) 1,091 (49.2) <0.001
Folic acid supplementation use, No. Yes (%) 3,287(75.2) 1,105 (61.6) <0.001
Smoking during pregnancy, No. Yes (%) 871 (17.1) 478 (22.2) <0.001
Alcohol consumption during pregnancy, No. Yes (%) 2,056 (40.9) 630 (29.6) <0.001
Gestational diabetes, No. Yes (%) 55 (1.0) 25 (1.1) 0.679
Pre-eclampsia, No. Yes (%) 99 (1.9) 55 (2.6) 0.082
Gestational hypertension, No. Yes (%) 228 (4.3) 66 (3.1) 0.012
Child characteristics
Males, No. (%) 2,772 (49.8) 1,207 (51.6) 0.147
Birth weight, median (95% range), g 3,450 (2260, 4460) 3,400 (2205, 4528) 0.002
Gestational age at birth, median (95% range), weeks 40.1 (35.9, 42.3) 40.0 (35.0, 42.4) <0.001
Ever breastfeeding, No. Yes (%) 4,114 (92.5) 1,168 (90.1) 0.005
Introduction of solid foods, No. before 6 months (%) 3,105 (89.4) 755 (89.8) 0.754
1Values represent means (SD), median (95% range) or number of subjects (valid %). 2Differences in subject character-




Supplemental Table 5. Maternal caffeine intake during pregnancy and childhood body fat dis-
tribution at 6 years (basic models) (N=5,562)
Body mass index 
(SDS)
Total body fat 
mass (SDS)
Android/gynoid 





N=5,562 N=5,407 N=5,405 N=4,508
Maternal caffeine intake categories
< 2 units Reference Reference Reference Reference
N=3,295 N=3,199 N=3,197 N=2,658
2 -3.9 units -0.10 (-0.15, -0.04)* -0.08 (-0.13, -0.03)* -0.02 (-0.08, 0.04) -0.12 (-0.18, -0.06)*
N=1,819 N= 1,771 N=1,771 N=1,475
4- 5.9 units 0.03 (-0.08, 0.13) -0.01 (-0.11, 0.09) -0.04 (-0.15, 0.07) -0.13 (-0.24, -0.02)*
N= 368 N=357 N=357 N=306
≥ 6 units 0.08 (-0.13, 0.29) 0.09 (-0.11, 0.29) 0.24 (0.02, 0.46)* -0.23 (-0.45, 0)*
N=80 N=80 N=80 N=69
P-value for trend 0.245 0.202 0.852 <0.001
Values are regression coefficients (95% confidence interval) that reflect the difference in childhood outcomes in chil-
dren whose mothers consumed 2-3.9, 4-5.9 and ≥6 units of caffeine per day during pregnancy, respectively, as com-
pared to those whose mothers consumed <2 units of caffeine per day. 1 unit of caffeine intake represents the equiva-
lent of 1 cup of coffee (90 mg caffeine).The models were adjusted for child’s sex, age at follow-up measurement and 
height at follow-up measurement (fat mass outcomes only). P-values for trend were obtained from models in which the 
categorized caffeine intake variable was entered as continuous variable. *P-value <0.05.
Supplemental Table 6. Maternal caffeine intake during pregnancy and childhood overweight 
at 6 years (N=5,562)
Odds Ratio (95% Confidence Interval)
Maternal caffeine intake categories
< 2 units Reference
N=3,295
2 -3.9 units 0.91 (0.77, 1.08)
N=1,819
4 – 5.9 units 1.09 (0.80, 1.49)
N=368
≥ 6 units 1.25 (0.68, 2.30)
N=80
P-value for trend 0.937
Values are Odds Ratio’s (95% confidence interval) that reflect the risk of overweight/obesity in children whose mothers 
consumed 2-3.9, 4-5.9 and ≥6 units of caffeine per day during pregnancy, respectively, as compared to those whose 
mothers consumed <2 units of caffeine per day. 1 unit of caffeine intake represents the equivalent of 1 cup of cof-
fee (90 mg caffeine).The model was adjusted for the child’s sex, age at follow-up measurement, maternal age, pre-
pregnancy body mass index, parity, ethnicity, educational level, folic acid supplementation use, smoking and alcohol 
consumption during pregnancy, gestational diabetes, gestational hypertensive disorders, birth weight, gestational age 
at birth, breastfeeding, timing of introduction of solid foods and television-watching time. P-values for trend were ob-
tained from models in which the categorized caffeine intake variable was entered as continuous variable.
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Supplemental Table 7. Maternal caffeine intake during pregnancy and childhood insulin and 
c-peptide levels at 6 years (basic models) (N=3,667)
Insulin (SDS) C-peptide (SDS)
N=3,654 N=3,667
Maternal caffeine intake categories
< 2 units Reference Reference
N=2,116 N=2,128
2 – 3.9 units -0.02 (-0.09, 0.05) 0.01 (-0.09, 0.06)
N= 1,239 N=1,237
4 – 5.9 units 0.16 (0.02, 0.29)* 0.16 (0.03, 0.29)*
N=241 N=244
≥ 6 units -0.19 (-0.45, 0.07) -0.10 (-0.36, 0.16)
N=58 N=59
P-value for trend 0.738 0.415
Values are regression coefficients (95% confidence interval) that reflect the difference in childhood outcomes in chil-
dren whose mothers consumed  2-3.9, 4-5.9 and ≥6 units of caffeine per day during pregnancy, respectively, as 
compared to those whose mothers consumed <2 units of caffeine per day. 1 unit of caffeine intake represents the 
equivalent of 1 cup of coffee (90 mg caffeine).The models were adjusted for child’s sex and age at follow-up measure-
ment. P-values for trend were obtained from models in which the categorized caffeine intake variable was entered as 
continuous variable. *P-value <0.05.

2.2 Maternal caffeine intake during pregnancy and childhood abdominal and liver fat 
deposition
Voerman E, Jaddoe VWV, Hulst ME, Oei EHG, Gaillard R. 
Associations of maternal caffeine intake during pregnancy 
with abdominal and liver fat deposition in childhood.




Background: Maternal caffeine intake during pregnancy is associated with an increased risk 
of childhood obesity. Studies in adults suggest that caffeine intake might also directly affect 
visceral and liver fat deposition, which are strong risk factors for cardio-metabolic disease.
Objective: To assess the associations of maternal caffeine intake during pregnancy with 
childhood general, abdominal, and liver fat mass at 10 years of age.
Methods: In a population-based cohort from early pregnancy onwards among 4770 moth-
ers and children, we assessed maternal caffeine intake during pregnancy and childhood fat 
mass at age 10 years.
Results: Compared with children whose mothers consumed <2 units of caffeine per day 
during pregnancy, those whose mothers consumed 4-5.9 and ≥6 units of caffeine per day 
had a higher body mass index, total body fat mass index, android/gynoid fat mass ratio, and 
abdominal subcutaneous and visceral fat mass indices. Children whose mothers consumed 
4-5.9 units of caffeine per day had a higher liver fat fraction. The associations with abdominal 
visceral fat and liver fat persisted after taking childhood total body fat mass into account.
Conclusions: High maternal caffeine intake during pregnancy was associated with higher 
childhood body mass index, total body fat, abdominal visceral fat, and liver fat. The as-
sociations with childhood abdominal visceral fat and liver fat fraction were independent of 
childhood total body fat. This suggests differential fat accumulation in these depots, which 
may increase susceptibility to cardio-metabolic disease in later life.
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introduction
Caffeine is a methylxantine that occurs naturally in several food products. Caffeine-containing 
beverages, including coffee and tea, are widely consumed by pregnant women. Caffeine 
crosses the placenta and enters the fetal circulation freely (1). The activity of the principal 
enzyme in caffeine metabolism, cytochrome CYP1A2, decreases progressively during preg-
nancy and is absent in placenta and fetus (2-4). As a consequence, fetal exposure to caffeine 
is prolonged and might adversely influence the development of organ systems. Consumption 
of caffeine-containing beverages during pregnancy has been related to an increased risk of 
fetal death, impaired fetal growth, and low birth weight (5-9). In addition to these short-term 
outcomes, maternal caffeine intake during pregnancy may also influence long-term offspring 
body fat development. We previously observed among 7857 mothers and their children 
from the Netherlands that high maternal caffeine intake during pregnancy was associated 
with a higher childhood body mass index and total body fat mass at the age of 6 years 
(10). Similarly, studies among 615, 50 943, and 558 mothers and children from the United 
States, Norway, and Ireland, respectively, observed that any maternal caffeine intake during 
pregnancy was associated with an increased risk of obesity in childhood (11-13).
In contrast, consumption of caffeine-containing beverages by non-pregnant adults seems 
to have beneficial effects on body fat accumulation and the risks of several diseases (14-19). 
Previous studies suggest that consumption of caffeine-containing beverages is associated with 
lower visceral fat accumulation and lower risks of non-alcoholic fatty liver disease (NAFLD), 
possibly by influencing blood concentrations of adiponectin and pro-inflammatory cytokines 
(15-19). Previous research suggests that blood concentrations of adipokines and cytokines 
in pregnant women are related to childhood body fat development (20-22). However, it is 
not known whether maternal caffeine intake during pregnancy is also related to offspring 
abdominal and liver fat accumulation. Thus far, only animal studies have shown that in utero 
exposure to caffeine increases intra-hepatic fat content and the susceptibility to NAFLD (23, 
24). As visceral and liver fat accumulation are related to the development of hypertension, 
type 2 diabetes, NAFLD, and the metabolic syndrome independent of excess body fat per se 
(25, 26), it is important to obtain further insight into whether maternal caffeine intake during 
pregnancy differentially affects offspring visceral and liver fat deposition.
Therefore, in a population-based cohort among 4770 mothers and children from early 
pregnancy onwards, we assessed the associations of maternal caffeine intake during preg-
nancy with childhood general, abdominal, and liver fat at the age of 10 years, with the main 





This study was embedded in the Generation R Study, a prospective population-based cohort 
study from early pregnancy onwards performed in Rotterdam, the Netherlands (27). The 
study was approved by the Medical Ethical Committee of the Erasmus Medical Center, Uni-
versity Medical Center, Rotterdam (MEC 198.782/2001/31). Written informed consent was 
obtained from all mothers at enrolment in the study. The response rate at birth was 61%. Of 
the 8879 mothers that were prenatally included in the study, 8097 had information available 
on caffeine intake during pregnancy. Of their children, 7900 were singleton and live born. Of 
these children, 4770 participated in body composition follow-up measurements at 10 years 
of age and were included in the analyses (Supplemental Figure 1).
Maternal caffeine intake during pregnancy
As described previously, information on maternal caffeine intake from coffee and tea during 
pregnancy was obtained by postal questionnaires in the first, second, and third trimesters 
of pregnancy (7, 10). Response rates for these questionnaires were 91%, 80%, and 77%, 
respectively (7, 10). Mothers who reported to drink any coffee or tea were asked how many 
cups of coffee or tea they consumed on average per day and what type of coffee or tea they 
consumed (caffeinated, decaffeinated, or a combination of both). According to standard 
values for caffeine content, a regular coffee serving (125 mL) in the Netherlands contains 
~90 mg caffeine, decaffeinated coffee contains ~3 mg, and black tea contains ~45 mg (28).
To calculate the total caffeine intake in each trimester, the type of coffee or tea was weighted 
according to its caffeine content (caffeinated coffee = 1, caffeinated and decaffeinated cof-
fee = 0.5, decaffeinated coffee = 0, caffeinated tea = 0.5, caffeinated and decaffeinated tea 
= 0.25, decaffeinated tea = 0, herbal tea = 0, and green tea = 0.5) (7). Thus, in our analyses, 
each unit of caffeine intake reflects caffeine exposure based on one cup of caffeinated coffee 
(90 mg caffeine) (10). Based on data availability, total caffeine intake was categorized into 
categories of <2, 2-3.9, 4-5.9, and ≥6 units per day (equivalent to <180, 180-359, 360-539, 
and ≥540 mg per day, respectively). For the main analyses using caffeine intake during the 
full pregnancy, caffeine intake of the trimesters was averaged.
Childhood body fat mass
At the age of 10 years, we measured height and weight without shoes and heavy clothing 
and calculated body mass index (kg/m2). We created age- and sex-adjusted standard devia-
tion scores (SDS) of body mass index using a Dutch reference chart (29). In addition, we de-
fined childhood overweight/obesity according to the International Obesity Task Force cut-offs 
(30). We measured total and regional body fat mass using dual-energy X-ray absorptiometry 
(DXA) (iDXA, General Electrics–Lunar, 2008, Madison, Wisconsin) (31). Android/gynoid fat 
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mass ratio was calculated and used as a measure of body fat distribution comparable with 
waist/hip ratio (31). Abdominal and organ fat were measured in a subgroup by magnetic 
resonance imaging (MRI), as described previously (27). Briefly, all children were scanned using 
a 3.0 Tesla MRI (Discovery MR750w, General Electric Healthcare, Milwaukee, Wisconsin). The 
MRI protocol included an axial 3-point Dixon sequence for fat and water separation (IDEAL 
IQ) for liver fat measurements. This technique also enables the generation of liver fat fraction 
images (32). An axial abdominal scan from lower liver to pelvis and a coronal scan centred at 
the head of the femurs were also performed with a 2-point Dixon acquisition (LavaFlex). The 
obtained fat scans were analysed by the Precision Image Analysis company (PIA, Kirkland, 
Washington), using the sliceOmatic (TomoVision, Magog, Canada) software package. All 
extraneous structures and any image artefacts were removed manually (33). Total subcutane-
ous and visceral fat volumes ranged from the dome of the liver to the superior part of the 
femoral head. Fat masses were obtained by multiplying the total volumes by the specific 
gravity of adipose tissue, 0.9 g/mL. Liver fat fraction was determined by defining four regions 
of interest of at least 4 cm2 in the central portion of the hepatic volume. Subsequently, 
the mean signal intensities were averaged to generate an overall mean liver fat fraction 
estimation. To create fat measures independent of child’s height, we estimated the optimal 
adjustment by log-log regression analyses and subsequently divided total and subcutaneous 
fat mass by height4 and visceral fat mass by height3 (Supplemental Methods 1) (34, 35).
Covariates
Information on maternal age, pre-pregnancy body mass index, parity, ethnicity, educational 
level, and folic acid supplementation use was obtained by questionnaire at enrolment in the 
study. Smoking and alcohol intake during pregnancy were repeatedly assessed by question-
naire. Information on gestational diabetes, gestational hypertensive disorders (gestational 
hypertension and pre-eclampsia), date of birth, child’s sex, and birth weight was obtained 
from midwife and hospital registries. Average television watching time was assessed by 
questionnaire at the age of 10 years.
Statistical analysis
First, we performed a non-response analysis comparing participants included the analysis with 
those lost to follow up at the age of 10 years. Second, we assessed the associations of ma-
ternal caffeine intake during pregnancy with childhood general fat measures and the risk of 
overweight/obesity at age 10, using linear and logistic regression models. Third, we assessed 
the associations of maternal caffeine intake during pregnancy with childhood abdominal sub-
cutaneous and visceral fat mass indices and liver fat fraction, using linear regression models. 
Non-normally distributed outcome variables were log-transformed. To enable comparison of 
effect estimates across the different outcomes, we calculated SDS for each of the outcomes. 
The models were first adjusted for child’s age and sex only (basic models). Next, we addition-
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ally adjusted the models for maternal ethnicity, education, smoking during pregnancy, alcohol 
consumption during pregnancy, folic acid supplementation use, and childhood television 
watching time (confounder models). These confounders were selected based on existing liter-
ature, associations with the exposure and outcome in the study sample, and a change in effect 
estimates of >10%. Maternal age, pre-pregnancy body mass index, parity, and gestational 
hypertensive disorders were also considered, but were not associated with either the exposure 
or the outcome or did not change the effect estimates with >10% and were therefore not 
included in the models. To explore whether any observed associations of caffeine intake during 
pregnancy with the outcomes were mediated by gestational age at birth and birth weight, we 
added these variables to the confounder models (mediator models). We performed tests for 
trend by adding the categorized caffeine intake variable to the models as continuous variable. 
Fourth, to further explore whether maternal caffeine intake during pregnancy was specifically 
associated with childhood abdominal fat mass and liver fat fraction, independent from total 
body fat mass, we used conditional regression analyses. We created measures of childhood 
abdominal subcutaneous fat mass, abdominal visceral fat mass, and liver fat fraction that are 
independent of total body fat mass by regressing these detailed childhood fat measures on 
childhood total body fat mass index. The standardized residuals from these models were used 
as an outcome for the regression models focused on the associations of maternal caffeine 
intake during pregnancy with conditional childhood abdominal and liver fat measures (36). 
Fifth, to identify potential critical periods, we assessed the associations of trimester-specific 
maternal caffeine intake with childhood general, abdominal, and liver fat using linear regres-
sion models. As sex differences in childhood body fat development have been reported (37, 
38), we tested for interactions between maternal caffeine intake during pregnancy and child’s 
sex, but these interaction terms were not statistically significant (P values > .05). Missing values 
of covariates (maximum percentage of missing values: 20.8%) were imputed using Multiple 
Imputation, and pooled results from five imputed datasets were reported. All statistical tests 
were two-sided, with a significance threshold of 0.05. The analyses were performed using the 
Statistical Package for the Social Sciences version 24.0 (IBM Corp, Armonk, New York, USA) 
and R version 3.3.4 (R Foundation for Statistical Computing).
results
Participants’ characteristics
Table 1 shows that, of the 4770 women included, 2780 (58.3%), 1583 (33.2%), 329 
(6.9%), and 78 (1.6%) consumed <2 units, 2-3.9 units, 4-5.9 units, and ≥6 units of caf-
feine per day, respectively, during pregnancy. Women who had higher caffeine intakes were 
older and were more likely to be higher educated, multiparous, and from European descent. 
They used less often folic acid supplementation and smoked and consumed alcohol more 
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often during pregnancy. Supplemental Table 1 shows that, as compared with women 
included in the analyses, those lost to follow up had slightly lower caffeine intakes and a 
lower pre-pregnancy BMI, were younger, were more often multiparous, and were less often 
from European descent. These women used folic supplementation less often, smoked more 
often, and consumed alcohol less often during pregnancy.
Maternal caffeine intake during pregnancy and childhood general 
body fat mass
Figure 1 shows that in the confounder model, as compared with children whose mothers 
consumed <2 units of caffeine per day during pregnancy, those whose mothers consumed 
4-5.9 and ≥6 units of caffeine per day during pregnancy had a higher body mass index 
(differences: 0.12 standard deviation [SD] [95% confidence interval (CI), 0.01-0.24] and 0.24 
[95% CI, 0.01-0.47], respectively), total body fat mass index (differences: 0.14 SD [95% CI, 
0.04-0.25] and 0.22 [95% CI, 0.02-0.43], respectively), and android/gynoid fat mass ratio 
(differences: 0.16 SD [95% CI, 0.05-0.27] and 0.22 [95% CI, 0.01-0.44], respectively) at the 
age of 10 years (exact differences are given in Supplemental Table 2). A dose-response 
relationship was present for each of these outcomes (P-values for trend < .05). Children 
whose mothers consumed ≥6 units of caffeine per day also tended to have a higher risk of 
overweight/obesity (odds ratio: 1.59 [95% CI, 0.92-2.75], Figure 2). Results from the basic 
model were similar (Supplemental Table 3). Additional adjustment for gestational age at 
birth and birth weight did not change the results (Supplemental Table 4). Supplemental 
Figure 1. Associations of maternal caffeine intake during pregnancy with childhood general 
body fat mass
P for trend: 0.048
N=2,768 N=1,579 N=329 N=78
P for trend: 0.008
N=2,732 N=1,559 N=327 N=78
P for trend: 0.003
N=2,741 N=1,562 N=327 N=78
Body mass index (N=4,754) Total fat mass index (N=4,696) Android/gynoid fat mass ratio (N=4,708)

























<2 units 2−3.9 units 4−5.9 units >=6 units
General fat measure
Values are regression coefficients (95% confidence intervals) from the confounder models that reflect the difference 
in childhood body mass index, total body fat mass index, android/gynoid fat mass ratio in children of mothers who 
consumed 2-3.9, 4-5.9 and ≥6 units of caffeine per day, as compared to those whose mothers consumed <2 units of 
caffeine per day. 1 unit of caffeine represents the equivalent of 1 cup of coffee (90 mg). The models are adjusted for 
child’s sex, child’s age at follow-up measurement, maternal ethnicity, maternal education, maternal smoking, maternal 
alcohol use, folic acid supplementation and television watching time. P-values for trend were obtained from models 
in which the categorized caffeine intake variable (<2, 2-3.9, 4-5.9 and ≥6 units) was entered as continuous variable.
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Table 5 shows that no trimester-specific associations were present, but rather that associa-
tions were similar across pregnancy.
Maternal caffeine intake during pregnancy and childhood 
abdominal fat mass and liver fat fraction
Figure 3A shows that in the confounder model, as compared with children whose mothers 
consumed <2 units of caffeine per day during pregnancy, those whose mothers consumed 
4-5.9 and ≥6 units of caffeine per day during pregnancy had a higher abdominal subcu-
taneous fat mass index (differences: 0.15 SD [95% CI, −0.01 to 0.30] and 0.35 SD [95% 
CI, 0.04-0.65], respectively) and a higher abdominal visceral fat mass index (differences: 
0.14 SD [95% CI, −0.03 to 0.30] and 0.43 SD [95% CI, 0.11-0.76], respectively). Children 
whose mothers consumed 4-5.9 units of caffeine per day also had a higher liver fat frac-
tion, as compared with those whose mothers consumed <2 units per day during pregnancy 
(difference: 0.20 SD [95% CI, 0.04-0.36]); exact differences are given in Supplemental 
Table 6). A dose-response relationship was present for each of the outcomes (P values for 
trend < .05). Results from the basic model were similar (Supplemental Table 7). Additional 
adjustment for gestational age at birth and birth weight did not influence the observed 
estimates (Supplemental Table 8). Supplemental Table 9 shows that the associations for 
each trimester separately were comparable with those for the full pregnancy.
Figure 3B shows that after conditioning on total body fat mass index to assess the effects 
of maternal caffeine intake during pregnancy on childhood abdominal fat and liver fat frac-
tion independent of childhood total body fat, maternal caffeine intake during pregnancy 
Figure 2. Associations of maternal caffeine intake during pregnancy with the risk of childhood 
overweight/obesity
P for trend: 0.996
N=2,565 N=1,476 N=306 N=74
Overweight/obesity (N=4,421)

























Values are odds ratios (95% confidence intervals) from the confounder models that reflect the risk of overweight/
obesity in children of mothers who consumed 2-3.9, 4-5.9 and ≥6 units of caffeine per day, as compared to those 
whose mothers consumed <2 units of caffeine per day. 1 unit of caffeine represents the equivalent of 1 cup of coffee 
(90 mg). The models are adjusted for child’s sex, child’s age at follow-up measurement, maternal ethnicity, maternal 
education, maternal smoking, maternal alcohol use, folic acid supplementation and television watching time. P-values 
for trend were obtained from models in which the categorized caffeine intake variable (<2, 2-3.9, 4-5.9 and ≥6 units) 
was entered as continuous variable.
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of ≥6 units and 4-5.9 units per day remained associated with abdominal visceral fat mass 
index and liver fat fraction, respectively (differences: 0.32 SD [95% CI, 0.00-0.64] and 0.20 
SD [95% CI, 0.04-0.36]). A significant dose-response relationship remained also present for 
these outcomes (P values for trend < .05). No associations were present with childhood 
abdominal subcutaneous fat mass index conditioned on childhood total body fat mass index.
discussion
In this population-based prospective cohort study, high maternal caffeine intake during 
pregnancy was associated with higher childhood general body fat mass, abdominal fat mass, 
and liver fat fraction at the age of 10 years. The associations of high maternal caffeine intake 
with childhood abdominal visceral fat mass and liver fat fraction seemed to be independent 
from childhood total body fat mass.
Figure 3. Associations of maternal caffeine intake during pregnancy with childhood abdominal 
fat mass and liver fat fraction
P for trend: 0.023
N=1,405 N=797 N=153 N=36
P for trend: 0.003
N=1,406 N=797 N=153 N=36
P for trend: 0.004
N=1,589 N=903 N=171 N=40
Subcutaneous fat mass index (N=2,391) Visceral fat mass index (N=2,392) Liver fat fraction (N=2,703)

























A. Abdominal or liver fat measure
P for trend: 0.774
N=1,397 N=792 N=153 N=36
P for trend: 0.044
N=1,398 N=792 N=153 N=36
P for trend: 0.023
N=1,575 N=895 N=171 N=40
Subcutaneous fat mass index (N=2,378) Visceral fat mass index (N=2,379) Liver fat fraction (N=2,681)

























<2 units 2−3.9 units 4−5.9 units >=6 units
B. Abdominal or liver fat measure conditional on total fat mass index
Values are regression coefficients (95% confidence intervals) from the confounder models that reflect the difference 
in (A) childhood outcomes in SDS and (B) childhood outcomes in standardized residuals in children of mothers who 
consumed 2-3.9, 4-5.9 and ≥6 units of caffeine per day, as compared to those whose mothers consumed <2 units of 
caffeine per day. 1 unit of caffeine represents the equivalent of 1 cup of coffee (90 mg). The models are adjusted for 
child’s sex, child’s age at follow-up measurement, maternal ethnicity, maternal education, maternal smoking, maternal 
alcohol use, folic acid supplementation and television watching time. P-values for trend were obtained from models 
in which the categorized caffeine intake variable (<2, 2-3.9, 4-5.9 and ≥6 units) was entered as continuous variable.
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Interpretation of main findings
Caffeine-containing beverages are frequently consumed during pregnancy. Increasing evi-
dence suggests that maternal caffeine intake during pregnancy might be related to long-term 
offspring body fat development (10-12, 39). We previously showed among 7857 6-year-old 
children from the same cohort as the current study that maternal caffeine intake during 
pregnancy of ≥4 units per day was associated with a higher body mass index and total body 
fat mass. Maternal caffeine intake during pregnancy of ≥6 units per day was also associated 
with a higher android/gynoid fat mass ratio, reflecting a central body fat accumulation (10). 
A study among 272 mother-child pairs from Brazil observed that any caffeine intake by 
women with an uncomplicated pregnancy was associated with a higher offspring sum of 
skinfold thicknesses at age 3 months (39). A study among 50 943 participants from Norway 
showed that any caffeine intake during pregnancy was associated with an increased risk of 
childhood overweight at ages 3 and 5, whereas at 8 years, this association was only present 
for high caffeine intakes (12). In an Irish study among 558 mother-child pairs, higher mater-
nal caffeine intake during pregnancy was associated with higher risks of overall and central 
obesity at the ages of 5 and 9 years (13). In line with these previous studies, we observed in 
the current study that higher maternal caffeine intake during pregnancy was associated with 
higher body mass index, total body fat mass, and android/gynoid fat mass ratio at the age 
of 10 years, as indicated by significant tests for trend. The strongest effects were present for 
maternal caffeine intake during pregnancy 4 or more units per day. For instance, as com-
pared with children whose mothers consumed <2 units of caffeine per day, children whose 
mothers consumed ≥6 units of caffeine per day during their pregnancy had a 0.24 SD higher 
body mass index, corresponding to a difference of approximately 0.7 kg/m2. These effect 
sizes are comparable with those observed for well-known determinants of childhood body 
mass index, such as maternal pre-pregnancy overweight and smoking during pregnancy 
(40-42). These associations were similar across the trimesters of pregnancy. Mothers with 
high caffeine intakes during pregnancy also had higher alcohol intakes and smoked more 
often during their pregnancies. However, associations were present across the full range of 
maternal caffeine intake, and adjusting the models for these lifestyle-related factors did not 
influence the results. We therefore do not consider it likely that the observed associations can 
be fully explained by differences in these factors. Thus, these findings suggest that maternal 
caffeine intake throughout pregnancy has long-term consequences for offspring body fat 
development, as reflected by higher total body fat mass and a central body fat distribution.
Studies in adults suggest that consumption of caffeine-containing beverages might also 
be associated with abdominal and ectopic fat deposition, although the direction of these 
associations might be different from the direction of the associations of maternal caffeine 
intake during pregnancy with offspring body fat development (15-17). A study among 364 
Japanese men showed inverse associations of coffee consumption with visceral fat mass and 
visceral to subcutaneous fat mass ratio (15). A meta-analysis of five studies showed that 
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the risk of NAFLD was 30% lower in participants who consumed coffee as compared with 
those who did not (18). It is not known whether caffeine intake by pregnant women is also 
related to offspring fat deposition in these specific fat depots. Only one study, among 7857 
participants from our cohort from the Netherlands, showed that maternal caffeine intake 
during pregnancy was not associated with pre-peritoneal fat mass measured by abdominal 
ultrasound at age 6, which was used as proxy of visceral fat (10). In the current study, we 
observed that higher maternal caffeine intake during pregnancy was associated with higher 
childhood abdominal subcutaneous fat mass, abdominal visceral fat mass, and liver fat frac-
tion measured by MRI at age 10. This inconsistency might be explained by differences in 
measures of abdominal visceral fat mass. Pre-peritoneal fat mass provides an estimation 
of abdominal visceral fat mass, while MRI provides more precise measures and is the gold 
standard for the measurement of intra-abdominal and organ fat deposition (33). Also, the 
associations of maternal caffeine intake during pregnancy might only become apparent at 
older childhood ages. The results for each of the trimesters separately were comparable with 
those for the full pregnancy. The associations with abdominal visceral fat mass and liver fat 
fraction persisted after taking total body fat mass into account. This suggests that maternal 
caffeine intake throughout pregnancy might differentially affect fat deposition in these de-
pots in the offspring, independent of their total body fat development. As visceral and liver 
fat accumulation are related to the development of cardio-metabolic disease independently 
of total body fat, these children might be at risk of later cardio-metabolic disease (25, 26). 
The associations with abdominal subcutaneous fat mass were not independent from total 
body fat mass. This might be explained by subcutaneous fat being the main compartment 
of fat storage across the full body. Thus, maternal caffeine intake throughout pregnancy 
might affect offspring visceral and liver fat deposition, independent from their total amount 
of body fat.
The mechanisms underlying the observed associations are not well known. Studies in 
adults have suggested that consumption of caffeine-containing beverages might increase 
adiponectin concentrations and decrease concentrations of pro-inflammatory cytokines, 
subsequently influencing visceral and liver fat masses (15, 19). Although high maternal 
adiponectin concentrations during pregnancy have been related to a higher risk of childhood 
obesity (20), the role of adipokines and cytokines in the association of maternal caffeine in-
take during pregnancy with offspring fat deposition is unknown. We speculate that caffeine 
intake by pregnant women may affect adiponectin concentrations and the pro-inflammatory 
state, which may affect fetal nutrient supply and subsequently lead to developmental adap-
tations in adipose tissue. Alternatively, animal studies have suggested that in utero exposure 
to caffeine may overexpose the developing fetus to glucocorticoids, leading to an altered 
development of the HPA-axis (43, 44). High glucocorticoid concentrations have been related 
to increased central obesity. In addition, the concentration of glucocorticoid receptors is 
higher in visceral adipose tissue as compared with other fat depots, possibly resulting in dif-
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ferential fat deposition in these depots (45). Rats exposed to caffeine in utero had increased 
intra-hepatic fat concentrations and increased susceptibility to NAFLD (23, 33), possibly by 
similar mechanisms. Finally, the associations might be explained by confounding by un-
healthy lifestyle factors that are shared within families. However, a negative control analysis 
among 50 943 participants showed stronger associations for maternal caffeine intake during 
pregnancy with the risk of childhood overweight at the age of 3 years, as compared with 
those for paternal caffeine intake at the time of their partners pregnancy (12). Similarly, 
in another recent negative control analysis among 558 participants, maternal caffeine in-
take, but not paternal caffeine intake, was associated with childhood body mass index and 
waist circumference at ages 5 and 10 years (13). These results suggest that an intra-uterine 
programming mechanism might at least partly underlie these associations. Further studies 
are needed to disentangle the mechanisms underlying the associations of maternal caffeine 
intake and childhood abdominal and liver fat deposition.
Our results are consistent with those of previous studies and further highlight the importance 
of limiting maternal caffeine intake during pregnancy with respect to its potential adverse ef-
fects on long-term body fat development in the offspring. The current recommendations for 
maternal caffeine intake during pregnancy range between 200 and 300 mg per day and are 
based on the risks of adverse pregnancy and birth outcomes (46-48). The most pronounced 
effects observed in our study were for caffeine intakes above these guidelines. However, the 
dose-response relationship in our and previous studies (5, 6, 8-13) suggest that the adverse 
effects of maternal caffeine intake with respect to both pregnancy outcomes and long-term 
body fat development are not restricted to high caffeine intakes, but increase across the 
range of maternal caffeine intake. A review of randomized controlled trials had insufficient 
evidence to confirm that avoiding caffeine consumption during pregnancy is beneficial with 
respect to adverse pregnancy outcomes (49). Based on our findings and findings from other 
observational studies, further adequately powered randomized controlled trials are needed to 
assess whether avoiding caffeine consumption during pregnancy improves both pregnancy 
and long-term offspring health outcomes, as compared with current recommendations. Our 
findings and findings from other observational studies need to be incorporated in future 
guidelines regarding maternal caffeine consumption during pregnancy, and these guidelines 
need to further emphasize potential beneficial effects on offspring health outcomes by 
further reducing caffeine intake during pregnancy below the current recommendations.
Strengths and limitations
This study was embedded in a large population-based cohort from early pregnancy onwards, 
enabling us to prospectively study the associations of interest. Of all participants with in-
formation on maternal caffeine intake during pregnancy, 39.6% did not participate in the 
follow-up measurements at age 10. This non-response might have led to biased estimates if 
the associations of interest differ between participants included and lost to follow up. This 
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seems unlikely as only a minor difference in maternal caffeine intake was observed between 
these groups. However, the selection towards a higher educated, healthier population might 
have affected the generalizability of our results. Maternal caffeine intake might have been 
underreported, possibly leading to misclassification of the caffeine intake categories and 
underestimation of the effect estimates. In accordance with the Dutch Nutrition Centre, 
we assumed that coffee and tea were consumed in cups of 125 mL (46). This might have 
differed between participants, which may have led to some misclassification of maternal 
caffeine intake. We only had data available about caffeine intake from coffee and tea and 
not from other sources, such as soft drinks, energy drinks, chocolate, and medications. 
However, at the time of data collection (2002-2006), coffee and tea accounted for 70% and 
26%, respectively, of all caffeine consumed (50). We had data available on many possible 
confounders. However, residual confounding might still be present, for example, by maternal 
and child’s physical activity and dietary habits.
Conclusions
Our results suggest that high maternal caffeine intake during pregnancy is associated with 
higher general body fat, abdominal subcutaneous and visceral fat mass and liver fat fraction 
in childhood. The associations of maternal caffeine intake during pregnancy with childhood 
visceral fat mass and liver fat seem to be largely independent from childhood total body 
fat mass. This suggests differential fat accumulation in these depots, which may increase 
susceptibility to cardio-metabolic disease.
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Mothers enrolled during pregnancy 
N=8,097 
Mothers enrolled during pregnancy with information 
on caffeine intake during pregnancy  
N= 782 
No information on caffeine intake during pregnancy  
N=7,900 
Singleton live births with information on caffeine 
intake during pregnancy  
N= 197 
Fetal deaths (N=71) 
Loss to follow-up (N=33) 
Twin pregnancies (N=93)  
N= 3,130 
No participation in 10-year follow-up 
measurements  
N= 4,770 
Population for analyses: 
 
Singleton live-births with information on maternal 
caffeine intake during pregnancy and at least one 
childhood outcome measurement 
 
Body mass index   N= 4,754 
Total body fat mass  N= 4,696 
Android/gynoid fat mass ratio N= 4,708 
Abdominal subcutaneous fat mass N= 2,391 
Abdominal visceral fat mass N= 2,392 





Supplemental Methods 1. Log-log regression analyses
As adiposity is highly dependent on the current height of the child, we created measures 
of adiposity that are independent of height using log-log regression analyses. We log-
transformed total fat mass, abdominal subcutaneous fat mass, abdominal visceral fat mass, 
and height, using natural logs. We subsequently regressed the log-adiposity measures on 
log-height. The regression slope corresponds to the power by which height should be raised 
in order to calculate an index of the adiposity measure that is uncorrelated with height. Thus, 
we divided total fat mass by height4, abdominal subcutaneous fat mass by height4, and 
abdominal visceral fat mass by height3.
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N= 4,770 N= 3,130
Maternal characteristics
Caffeine intake during pregnancy, median (95% 
range), units
1.6 (0.0, 5.2) 1.3 (0.0, 5.0) <0.001
Caffeine intake during pregnancy, N (%)
<2 units 2,780 (58.3) 2,059 (65.8) <0.001
2-3.9 units 1,583 (33.2) 870 (27.8)
4-5.9 units 329 (6.9) 169 (5.4)
≥6 units 78 (1.6) 32 (1.0)
Age, median (95% range), years 31.2 (20.4, 39.6) 28.6 (18.5, 38.5) <0.001
Pre-pregnancy BMI, median (95% range), kg/m2 22.6 (18.1, 34.5) 22.7 (17.7, 35.6) <0.001
Education, N (%) <0.001
Primary 340 (7.4) 481 (16.7)
Secondary 1,944 (42.2) 1,520 (52.8)
Higher 2,324 (50.4) 876 (30.4)
Parity, nulliparous (%) 2,793 (58.8) 1,640 (52.9) <0.001
Ethnicity, European (%) 3,113 (65.8) 1,389 (46.6) <0.001
Folic acid supplementation use, Yes (%) 2,955 (78.2) 1,437 (60.2) <0.001
Smoking during pregnancy, Yes (%) 1,065 (24.3) 908 (31.8) <0.001
Alcohol consumption during pregnancy, Yes (%) 2,495 (57.5) 1,152 (41.0) <0.001
Gestational hypertensive disorders, Yes (%) 272 (5.9) 176 (5.9) 0.999
Gestational diabetes, Yes (%) 46 (1.0) 34 (1.1) 0.614
Child characteristics
Males, No. (%) 2,361 (49.5) 1,618 (51.7) 0.057
Gestational age at birth, median (95% range), weeks 40.1 (35.9, 42.3) 40.0 (35.3, 42.3) <0.001
Birth weight, median (95% range), g 3,460 (2,261, 4,479) 3,390 (2,200, 4,490) <0.001
Gestational age adjusted birth weight, mean (SD) -0.1 (1.0) -0.1 (1.0) <0.001
Ever breastfeeding, Yes (%) 3,627 (92.6) 1,655 (90.4) 0.004
Introduction of solid foods, before 6 months (%) 2,800 (89.1) 1,059 (90.4) 0.271
Values represent mean (SD), median (95% range) or number of participants (valid %).
1 unit of caffeine represents the equivalent of 1 cup of coffee (90 mg of caffeine).
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Supplemental Table 3. Associations of maternal caffeine intake during pregnancy with child-
hood general body fat mass
Body mass index 
(SDS)






N=4,754 N=4,696 N=4,708 N=4,421
Maternal caffeine intake
<2 units Reference Reference Reference Reference
2-3.9 units -0.11 (-0.17, -0.04) -0.12 (-0.18, -0.06) -0.06 (-0.13, 0.00) 0.66 (0.55, 0.78)
4-5.9 units 0.02 (-0.10, 0.14) 0.00 (-0.11, 0.11) 0.06 (-0.05, 0.18) 0.91 (0.69, 1.19)
≥6 units 0.24 (0.00, 0.47) 0.20 (-0.02, 0.42) 0.24 (0.01, 0.46) 1.49 (1.28, 1.74)
P-value for trend 0.575 0.242 0.563 0.009
Values are regression coefficients (95% confidence intervals) from the basic models that reflect the difference in child-
hood body mass index, total body fat mass index, android/gynoid fat mass ratio or odds ratios (95% confidence 
intervals) reflecting the risk of overweight/obesity in children of mothers who consumed 2-3.9, 4-5.9 and ≥6 units 
of caffeine per day, as compared to those whose mothers consumed <2 units of caffeine per day. 1 unit of caffeine 
represents the equivalent of 1 cup of coffee (90 mg). The models are adjusted for child’s sex and child’s age at follow-
up measurement. P-values for trend were obtained from models in which the categorized caffeine intake variable (<2, 
2-3.9, 4-5.9 and ≥6 units) was entered as continuous variable.
Supplemental Table 2. Associations of maternal caffeine intake during pregnancy with child-
hood general body fat mass
Body mass index 
(SDS)
Total body fat 
mass index (SDS)
Android/gynoid 





N=4,754 N=4,696 N=4,708 N=4,421
Maternal caffeine intake
<2 units Reference Reference Reference Reference
2-3.9 units -0.01 (-0.07, 0.05) 0.01 (-0.05, 0.06) 0.03 (-0.03, 0.09) 0.82 (0.69, 0.99)
4-5.9 units 0.12 (0.01, 0.24) 0.14 (0.04, 0.25) 0.16 (0.05, 0.27) 1.06 (0.76, 1.47)
≥6 units 0.24 (0.01, 0.47) 0.22 (0.02, 0.43) 0.22 (0.01, 0.44) 1.59 (0.92, 2.75)
P-value for trend 0.048 0.008 0.003 0.996
Values are regression coefficients (95% confidence intervals) from the confounder models that reflect the difference in 
childhood body mass index, total body fat mass index, android/gynoid fat mass ratio or odds ratios (95% confidence 
intervals) reflecting the risk of overweight/obesity in children of mothers who consumed 2-3.9, 4-5.9 and ≥6 units 
of caffeine per day, as compared to those whose mothers consumed <2 units of caffeine per day. 1 unit of caffeine 
represents the equivalent of 1 cup of coffee (90 mg). The models are adjusted for child’s sex, child’s age at follow-up 
measurement, maternal ethnicity, maternal education, maternal smoking, maternal alcohol use, folic acid supplemen-
tation and television watching time. P-values for trend were obtained from models in which the categorized caffeine 
intake variable (<2, 2-3.9, 4-5.9 and ≥6 units) was entered as continuous variable
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Supplemental Table 4. Associations of maternal caffeine intake during pregnancy with child-
hood general body fat mass
Body mass index 
(SDS)
Total body fat 
mass index (SDS)
Android/gynoid 




N=4,754 N=4,696 N=4,708 N=4,421
Maternal caffeine intake
<2 units Reference Reference Reference Reference
2-3.9 units -0.01 (-0.08, 0.05) 0.01 (-0.05, 0.07) 0.03 (-0.03, 0.09) 0.82 (0.68, 0.98)
4-5.9 units 0.11 (-0.01, 0.23) 0.14 (0.04, 0.25) 0.16 (0.05, 0.27) 1.03 (0.74, 1.44)
≥6 units 0.27 (0.04, 0.49) 0.23 (0.02, 0.43) 0.23 (0.01, 0.45) 1.63 (0.94, 2.83)
P-value for trend 0.053 0.007 0.002 0.929
Values are regression coefficients (95% confidence intervals) from the mediator models that reflect the difference in 
childhood body mass index, total body fat mass index, android/gynoid fat mass ratio or odds ratios (95% confidence in-
tervals) reflecting the risk of overweight/obesity in children of mothers who consumed 2-3.9, 4-5.9 and ≥6 units of caf-
feine per day, as compared to those whose mothers consumed <2 units of caffeine per day. 1 unit of caffeine represents 
the equivalent of 1 cup of coffee (90 mg). The models are adjusted for child’s sex, child’s age at follow-up measurement, 
maternal ethnicity, maternal education, maternal smoking, maternal alcohol use, folic acid supplementation, television 
watching time, gestational age at birth weight and birth weight. P-values for trend were obtained from models in which 
the categorized caffeine intake variable (<2, 2-3.9, 4-5.9 and ≥6 units) was entered as continuous variable.
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Supplemental Table 5. Associations of trimester-specific maternal caffeine intake with child-
hood general body fat mass





First trimester N=3,629 N=3,587 N=3,595
<2 units Reference Reference Reference
2-3.9 units -0.04 (-0.12, 0.03) -0.02 (-0.08, 0.05) 0.02 (-0.05, 0.09)
4-5.9 units 0.08 (-0.05, 0.20) 0.08 (-0.03, 0.19) 0.07 (-0.04, 0.19)
≥6 units 0.30 (0.10, 0.50) 0.26 (0.08, 0.43) 0.31 (0.12, 0.49)
P-value for trend 0.053 0.023 0.006
Second trimester N=4,035 N=3,985 N=3,995
<2 units Reference Reference Reference
2-3.9 units -0.01 (-0.07, 0.06) 0.01 (-0.05, 0.07) 0.03 (-0.03, 0.10)
4-5.9 units 0.00 (-0.11, 0.11) 0.03 (-0.07, 0.12) 0.04 (-0.06, 0.14)
≥6 units 0.16 (-0.04, 0.36) 0.18 (0.00, 0.36) 0.18 (-0.02, 0.37)
P-value for trend 0.437 0.144 0.082
Third trimester N=3,834 N=3,792 N=3,801
<2 units Reference Reference Reference
2-3.9 units 0.04 (-0.03, 0.11) 0.04 (-0.03, 0.10) 0.03 (-0.04, 0.09)
4-5.9 units 0.07 (-0.05, 0.19) 0.07 (-0.03, 0.18) 0.11 (0.00, 0.22)
≥6 units 0.29 (0.07, 0.50) 0.27 (0.08, 0.46) 0.34 (0.14, 0.54)
P-value for trend 0.014 0.008 0.002
Values are regression coefficients (95% confidence intervals) from the confounder models that reflect the difference in 
childhood outcomes in children of mothers who consumed 2-3.9, 4-5.9 and ≥6 units of caffeine per day, as compared 
to those whose mothers consumed <2 units of caffeine per day. 1 unit of caffeine represents the equivalent of 1 cup 
of coffee (90 mg). The models are adjusted for child’s sex, child’s age at follow-up measurement, maternal ethnicity, 
maternal education, maternal smoking, maternal alcohol use, folic acid supplementation and television watching time. 
P-values for trend were obtained from models in which the categorized caffeine intake variable (<2, 2-3.9, 4-5.9 and 
≥6 units) was entered as continuous variable.
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Supplemental Table 6. Associations of maternal caffeine intake during pregnancy with child-
hood abdominal fat mass and liver fat fraction
Abdominal 
subcutaneous fat mass 
index (SDS)
Abdominal visceral fat 
mass index (SDS)
Liver fat fraction (SDS)
Maternal caffeine intake
A. Abdominal and organ-specific fat measure
N=2,391 N=2,392 N=2,703
<2 units Reference Reference Reference
2-3.9 units 0.01 (-0.07, 0.09) 0.08 (-0.01, 0.16) 0.08 (0.00, 0.16)
4-5.9 units 0.15 (-0.01, 0.30) 0.14 (-0.03, 0.30) 0.24 (0.08, 0.40)
≥6 units 0.35 (0.04, 0.65) 0.43 (0.11, 0.76) 0.09 (-0.23, 0.40)
P-value for trend 0.023 0.003 0.004
B. Abdominal or liver fat measure, conditional on total fat mass index
N=2,378 N=2,379 N=2,681
<2 units Reference Reference Reference
2-3.9 units -0.07 (-0.16, 0.02) 0.08 (-0.01, 0.16) 0.08 (0.00, 0.16)
4-5.9 units -0.01 (-0.18, 0.15) 0.04 (-0.13, 0.20) 0.20 (0.04, 0.36)
≥6 units 0.21 (-0.12, 0.54) 0.32 (0.00, 0.64) -0.04 (-0.36, 0.27)
P-value for trend 0.774 0.044 0.023
Values are regression coefficients (95% confidence intervals) from the confounder models that reflect the difference 
in (A) childhood outcomes in SDS and (B) childhood outcomes in standardized residuals in children of mothers who 
consumed 2-3.9, 4-5.9 and ≥6 units of caffeine per day, as compared to those whose mothers consumed <2 units of 
caffeine per day. 1 unit of caffeine represents the equivalent of 1 cup of coffee (90 mg). The models are adjusted for 
child’s sex, child’s age at follow-up measurement, maternal ethnicity, maternal education, maternal smoking, maternal 
alcohol use, folic acid supplementation and television watching time. P-values for trend were obtained from models 
in which the categorized caffeine intake variable (<2, 2-3.9, 4-5.9 and ≥6 units) was entered as continuous variable.
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Supplemental Table 7. Associations of maternal caffeine intake during pregnancy with child-
hood abdominal fat mass and liver fat fraction
Abdominal 
subcutaneous fat mass 
index (SDS)
Abdominal visceral fat 
mass index (SDS)
Liver fat fraction (SDS)
Maternal caffeine intake
A. Abdominal and organ-specific fat measure
N=2,391 N=2,392 N=2,703
<2 units Reference Reference Reference
2-3.9 units -0.09 (-0.18, -0.01) 0.04 (-0.05, 0.13) 0.02 (-0.06, 0.10)
4-5.9 units 0.03 (-0.13, 0.19) 0.11 (-0.05, 0.28) 0.18 (0.02, 0.33)
≥6 units 0.36 (0.04, 0.67) 0.48 (0.15, 0.81) 0.09 (-0.22, 0.41)
P-value for trend 0.910 0.011 0.070
B. Abdominal or liver fat measure, conditional on total fat mass index
N=2,378 N=2,379 N=2,681
<2 units Reference Reference Reference
2-3.9 units -0.05 (-0.13, 0.04) 0.14 (0.06, 0.23) 0.07 (-0.01, 0.16)
4-5.9 units 0.03 (-0.14, 0.20) 0.14 (-0.03, 0.30) 0.20 (0.04, 0.36)
≥6 units 0.26 (-0.07, 0.59) 0.39 (0.06, 0.72) -0.02 (-0.34, 0.29)
P-value for trend 0.707 <0.001 0.021
Values are regression coefficients (95% confidence intervals) from the basic models that reflect the difference in (A) 
childhood outcomes in SDS and (B) childhood outcomes in standardized residuals in children of mothers who consumed 
2-3.9, 4-5.9 and ≥6 units of caffeine per day, as compared to those whose mothers consumed <2 units of caffeine per 
day. 1 unit of caffeine represents the equivalent of 1 cup of coffee (90 mg). The models are adjusted for child’s sex and 
child’s age at follow-up measurement. P-values for trend were obtained from models in which the categorized caffeine 
intake variable (<2, 2-3.9, 4-5.9 and ≥6 units) was entered as continuous variable.
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Supplemental Table 8. Associations of maternal caffeine intake during pregnancy with child-
hood abdominal fat mass and liver fat fraction
Abdominal 
subcutaneous fat mass 
index (SDS)
Abdominal visceral fat 
mass index (SDS)
Liver fat fraction (SDS)
Maternal caffeine intake
A. Abdominal and organ-specific fat measure
N=2,391 N=2,392 N=2,703
<2 units Reference Reference Reference
2-3.9 units 0.02 (-0.07, 0.10) 0.08 (-0.01, 0.17) 0.08 (0.00, 0.16)
4-5.9 units 0.15 (0.00, 0.30) 0.14 (-0.03, 0.3) 0.25 (0.09, 0.40)
≥6 units 0.35 (0.05, 0.66) 0.44 (0.11, 0.76) 0.08 (-0.23, 0.39)
P-value for trend 0.020 0.002 0.003
B. Abdominal or liver fat measure, conditional on total fat mass index
N=2,378 N=2,379 N=2,681
<2 units Reference Reference Reference
2-3.9 units -0.07 (-0.16, 0.02) 0.08 (-0.01, 0.17) 0.08 (0.00, 0.17)
4-5.9 units -0.01 (-0.18, 0.16) 0.04 (-0.12, 0.20) 0.21 (0.05, 0.37)
≥6 units 0.21 (-0.12, 0.55) 0.32 (0.00, 0.64) -0.05 (-0.36, 0.27)
P-value for trend 0.806 0.041 0.020
Values are regression coefficients (95% confidence intervals) from the mediator models that reflect the difference in (A) 
childhood outcomes in SDS and (B) childhood outcomes in standardized residuals in children of mothers who consumed 
2-3.9, 4-5.9 and ≥6 units of caffeine per day, as compared to those whose mothers consumed <2 units of caffeine per 
day. 1 unit of caffeine represents the equivalent of 1 cup of coffee (90 mg). The models are adjusted for child’s sex, 
child’s age at follow-up measurement, maternal ethnicity, maternal education, maternal smoking, maternal alcohol 
use, folic acid supplementation, television watching time, gestational age at birth weight and birth weight. P-values 
for trend were obtained from models in which the categorized caffeine intake variable (<2, 2-3.9, 4-5.9 and ≥6 units) 
was entered as continuous variable.
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Supplemental Table 9. Associations of trimester-specific maternal caffeine intake with child-
hood abdominal fat mass and liver fat fraction
Abdominal 
subcutaneous fat mass 
index (SDS)
Abdominal visceral fat 
mass index (SDS)
Liver fat fraction (SDS)
Maternal caffeine intake
First trimester N=1,790 N=1,790 N=2,016
<2 units Reference Reference Reference
2-3.9 units -0.03 (-0.12, 0.06) 0.03 (-0.07, 0.13) 0.01 (-0.08, 0.11)
4-5.9 units 0.03 (-0.12, 0.19) 0.00 (-0.17, 0.17) 0.12 (-0.04, 0.28)
≥6 units 0.24 (-0.04, 0.51) 0.46 (0.17, 0.76) 0.13 (-0.15, 0.40)
P-value for trend 0.383 0.066 0.159
Second trimester N=2,064 N=2,065 N=2,325
<2 units Reference Reference Reference
2-3.9 units 0.03 (-0.06, 0.12) 0.10 (0.01, 0.19) 0.08 (-0.01, 0.17)
4-5.9 units 0.06 (-0.07, 0.20) 0.04 (-0.11, 0.19) 0.15 (0.01, 0.29)
≥6 units 0.18 (-0.08, 0.44) 0.29 (0.02, 0.57) 0.16 (-0.11, 0.43)
P-value for trend 0.133 0.034 0.011
Third trimester N=1,938 N=1,939 N=2,184
<2 units Reference Reference Reference
2-3.9 units 0.02 (-0.07, 0.11) 0.10 (0.00, 0.19) 0.04 (-0.04, 0.13)
4-5.9 units 0.03 (-0.12, 0.19) 0.05 (-0.11, 0.22) 0.06 (-0.10, 0.21)
≥6 units 0.40 (0.14, 0.67) 0.41 (0.13, 0.69) 0.21 (-0.07, 0.48)
P-value for trend 0.050 0.008 0.114
Values are regression coefficients (95% confidence intervals) from the confounder models that reflect the difference in 
childhood outcomes in children of mothers who consumed 2-3.9, 4-5.9 and ≥6 units of caffeine per day, as compared 
to those whose mothers consumed <2 units of caffeine per day. 1 unit of caffeine represents the equivalent of 1 cup 
of coffee (90 mg). The models are adjusted for child’s sex, child’s age at follow-up measurement, maternal ethnicity, 
maternal education, maternal smoking, maternal alcohol use, folic acid supplementation and television watching time. 
P-values for trend were obtained from models in which the categorized caffeine intake variable (<2, 2-3.9, 4-5.9 and 
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Background: Maternal obesity and excessive gestational weight gain may have persistent 
effects on offspring fat development. However, it remains unclear whether these effects 
differ by severity of obesity, and whether these effects are restricted to the extremes of ma-
ternal body mass index (BMI) and gestational weight gain. We aimed to assess the separate 
and combined associations of maternal BMI and gestational weight gain with the risk of 
overweight/obesity throughout childhood, and their population impact.
Methods and findings: We conducted an individual participant data meta-analysis of data 
from 162,129 mothers and their children from 37 pregnancy and birth cohort studies from 
Europe, North America, and Australia. We assessed the individual and combined associations 
of maternal pre-pregnancy BMI and gestational weight gain, both in clinical categories and 
across their full ranges, with the risks of overweight/obesity in early (2.0–5.0 years), mid 
(5.0–10.0 years) and late childhood (10.0–18.0 years), using multilevel binary logistic regres-
sion models with a random intercept at cohort level adjusted for maternal sociodemographic 
and lifestyle related characteristics. We observed that higher maternal pre-pregnancy BMI 
and gestational weight gain both in clinical categories and across their full ranges were 
associated with higher risks of childhood overweight/obesity, with the strongest effects in 
late childhood (odds ratios [ORs] for overweight/obesity in early, mid, and late childhood, 
respectively: OR 1.66 [95% CI: 1.56, 1.78], OR 1.91 [95% CI: 1.85, 1.98], and OR 2.28 [95% 
CI: 2.08, 2.50] for maternal overweight; OR 2.43 [95% CI: 2.24, 2.64], OR 3.12 [95% CI: 
2.98, 3.27], and OR 4.47 [95% CI: 3.99, 5.23] for maternal obesity; and OR 1.39 [95% CI: 
1.30, 1.49], OR 1.55 [95% CI: 1.49, 1.60], and OR 1.72 [95% CI: 1.56, 1.91] for excessive 
gestational weight gain). The proportions of childhood overweight/obesity prevalence at-
tributable to maternal overweight, maternal obesity, and excessive gestational weight gain 
ranged from 10.2% to 21.6%. Relative to the effect of maternal BMI, excessive gestational 
weight gain only slightly increased the risk of childhood overweight/obesity within each clini-
cal BMI category (p-values for interactions of maternal BMI with gestational weight gain: p = 
0.038, p < 0.001, and p = 0.637 in early, mid, and late childhood, respectively). Limitations 
of this study include the self-report of maternal BMI and gestational weight gain for some 
of the cohorts, and the potential of residual confounding. Also, as this study only included 
participants from Europe, North America, and Australia, results need to be interpreted with 
caution with respect to other populations.
Conclusions: In this study, higher maternal pre-pregnancy BMI and gestational weight gain 
were associated with an increased risk of childhood overweight/obesity, with the strongest 
effects at later ages. The additional effect of gestational weight gain in women who are over-
weight or obese before pregnancy is small. Given the large population impact, future interven-
tion trials aiming to reduce the prevalence of childhood overweight and obesity should focus 
on maternal weight status before pregnancy, in addition to weight gain during pregnancy.
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introduction
Maternal pre-pregnancy obesity and excessive gestational weight gain are major public 
health problems. Maternal obesity is an important risk factor of gestational hypertensive 
and diabetic disorders, fetal death, pre-term birth, and macrosomia (1, 2). An accumulating 
body of evidence suggests that maternal obesity also has persistent effects on long-term 
health in offspring (3). A meta-analysis of published studies showed a 3-fold increased risk 
of overweight in children of mothers with pre-pregnancy obesity, as compared to those of 
mothers with a normal pre-pregnancy weight (4). It remains unclear whether these risks 
differ by severity of obesity, and whether these effects are restricted to the extremes of 
maternal BMI or are present across the full range. In addition to maternal pre-pregnancy 
obesity, excessive gestational weight gain also seems to be associated with increased risks of 
childhood overweight and obesity (2). Previous meta-analyses of published studies showed a 
30%–40% increased risk of childhood overweight in children of mothers with excessive ges-
tational weight gain (5-7). From a prevention perspective, insight into the combined effects 
of maternal BMI and gestational weight gain on offspring obesity risk and their population 
impact in different geographical regions is needed.
We conducted an individual participant data (IPD) meta-analysis among 162,129 mothers 
and their children from 37 pregnancy and birth cohorts from Europe, North America, and 
Australia, to assess the separate and combined associations of maternal pre-pregnancy body 
mass index (BMI) and gestational weight gain with the risk of overweight/obesity throughout 
childhood, and their population impact.
methods
Inclusion criteria and participating cohorts
This study was embedded in the international Maternal Obesity and Childhood Outcomes 
(MOCO) collaboration (8, 9). Pregnancy and birth cohort studies were eligible to participate if 
they included mothers with singleton live-born children born from January 1, 1989, onwards, 
had information available on maternal pre- or early pregnancy BMI and at least 1 offspring 
measurement (birth weight or childhood BMI), and were approved by their local institutional 
review boards. We invited 50 Western cohorts from Europe, North America, and Austra-
lia, selected from existing collaborations on childhood health (the EarlyNutrition project, 
the CHICOS project, and Birthcohorts.net assessed until July 2014), of which 39 agreed 
to participate. In total, 37 cohorts had data available on childhood BMI, corresponding to 
162,129 mothers and their children eligible for analyses (Figure 1). All cohorts included were 
approved by their local institutional review boards, and all participants gave written informed 
consent. The plan for analyses given to the cohorts when inviting them to participate in the 
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MOCO collaboration is provided in Supplemental Text 1. Based on data availability and 
additional research questions, it was decided among the collaborators to refine the existing 
questions and to extend the project with additional questions to be addressed. Statistical 
analyses were adapted to these questions. Anonymized datasets were stored on a single 
central secured data server with access for the main analysts (EV, SS).
Figure 1. Flow chart of the cohorts and participants
 
n = 50 cohorts 
Invited 
n = 39 cohorts  
n = 39 signed agreements 
n = 39 datasets received 
 
n = 277,042 participants suitable for analysis 
 
n = 8 cohorts 
No response (n = 4) 
Not able to share data (n = 4) 
  
 n = 42 cohorts 
Agreed to participate 
n = 37 cohorts 
n = 162,129 participants 
Population for analysis: Information on maternal 
pre- or early pregnancy BMI and childhood BMI in 
at least one age interval available 
 
Early childhood (2.0-5.0 years)  n=85,813 
Mid childhood (5.0-10.0 years)  n=121,803 
Late childhood (10.0-18.0 years) n=18,477 
 
n = 3 cohorts 
No signed agreement returned (n = 2) 
No dataset received (n = 1) 
  
 
n = 2 cohorts 
n = 105,409 participants 
No childhood BMI data available 
  
 
n = 39 cohorts 
n = 267,538 participants 
Information on maternal pre- or early pregnancy 
BMI available 
 
n = 9,504 participants 
No information on maternal pre- or early 
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Maternal pre-pregnancy BMI and gestational weight gain
Maternal BMI (kg/m2) was measured, derived from clinical records, or self-reported (cohort-
specific information in Supplemental Table 1). If available, we used information on maternal 
pre-pregnancy BMI for analyses. For participants without information on pre-pregnancy BMI 
(4.8% of the study population), we used BMI measured before 20 weeks of gestation. Maternal 
pre-pregnancy BMI was categorized into clinical categories according to World Health Organiza-
tion (WHO) cutoffs (underweight [<18.5 kg/m2], normal weight [18.5–24.9 kg/m2], overweight 
[25.0–29.9 kg/m2], and obesity [≥ 30.0 kg/m2]). The obesity category was further stratified into 
obesity grade 1 (30.0–34.9 kg/m2), grade 2 (35.0–39.9 kg/m2), and grade 3 (≥ 40.0 kg/m2) (10). 
Maternal pre-pregnancy BMI was also categorized into 11 groups with a range of 2.5 kg/m2 
each. Data on gestational weight gain (kg), defined as the difference between the latest weight 
before delivery and pre-pregnancy weight, was provided by the cohorts, and was categorized 
as inadequate, adequate, or excessive weight gain in relation to maternal pre-pregnancy BMI 
according to the guidelines of the US Institute of Medicine (IOM) (11). We calculated z-scores 
of gestational weight gain based on maternal pre-pregnancy BMI-category-specific reference 
charts for gestational weight gain by gestational age created using the data of the cohorts 
participating in this collaboration (8), and categorized them into 6 categories (<−2.0 SD, −2.0 
to −1.0 SD, −1.0 to −0.0 SD, 0.0 to 1.0 SD, 1.0 to 2.0 SD, and ≥2.0 SD).
Childhood overweight/obesity
Childhood BMI (kg/m2) was measured, derived from clinical records, or reported by parents/ 
caregivers or the child itself (cohort-specific information in Supplemental Table 1). BMI mea-
surements were available in 3 age intervals: early childhood (≥ 2 to <5 years), mid childhood (≥ 5 
to <10 years), and late childhood (≥ 10 to <18 years), hereafter referred to as 2.0–5.0, 5.0–10.0, 
and 10.0–18.0 years, respectively. If there were multiple measurements of a child available 
within the same age interval, we used the measurement at the highest age for our analyses. We 
calculated the sex- and age-adjusted standard deviation score (SDS) of childhood BMI based on 
WHO reference growth charts (Growth Analyser 4.0, Dutch Growth Research Foundation) (12, 
13). We categorized childhood BMI into underweight, normal weight, overweight, and obesity, 
using WHO cutoffs (12, 13). For models focused on the risk of overweight/obesity, children with 
underweight were excluded, and overweight and obesity were combined. For models focused 
on the risk of underweight, children with overweight and obesity were excluded.
Covariates
Information on covariates was mostly assessed by questionnaires. We included as con-
founders the following: maternal age (<25.0 years, 25.0–30.0 years, 30–35.0 years, ≥35.0 
years), maternal educational level (low, medium, high), maternal ethnicity (European/white, 





We conducted 1-stage meta-analyses, analyzing IPD from all cohorts simultaneously in 
multilevel linear or binary logistic regression models, accounting for clustering of participants 
within cohorts (14). In these models, we included a random intercept at the cohort level, 
allowing intercepts to differ between cohorts. First, we examined the separate associations 
of maternal pre-pregnancy BMI and gestational weight gain, across their full ranges and in 
clinical categories, with BMI SDS, the risk of childhood underweight, and the risk of child-
hood overweight/ obesity in early, mid, and late childhood. Second, we calculated, both for 
the total study population and per country, the population attributable risk fraction (PAR), 
indicating the proportion of childhood underweight and childhood overweight/obesity at-
tributable to each maternal BMI or gestational weight gain category. For these analyses, we 
used the adjusted odds ratio (OR) and the prevalence of the exposure in the study population 
(15). Country-specific analyses were performed for mid childhood only, based on available 
data. Third, we assessed the associations of the combinations of maternal pre-pregnancy 
BMI and gestational weight gain clinical categories with the outcomes. To assess whether 
the combined effects of maternal BMI and gestational weight gain on the outcomes were 
different from the separate effects, we tested for interaction between these 2 exposures.
Models were adjusted for maternal age, educational level, ethnicity, parity, and smoking 
during pregnancy. Models concerning gestational weight gain z-scores were additionally 
adjusted for maternal pre-pregnancy BMI. To examine whether any associations of mater-
nal pre-pregnancy BMI with the risk of childhood overweight/obesity were explained by 
gestational diabetes, gestational hypertensive disorders, or gestational-age-adjusted birth 
weight, we added this information to the models. Covariates in the analyses were selected 
based on existing literature and data availability in participating cohorts. Findings from the 
unadjusted models were similar to the findings from the adjusted models and therefore are 
not presented separately. We did not observe consistent significant interactions of maternal 
pre-pregnancy BMI and gestational weight gain with child’s sex. As sensitivity analyses, we 
conducted 2-stage random effects meta-analyses to study the associations of maternal pre-
pregnancy BMI and gestational weight gain with the risk of childhood overweight/obesity 
in each cohort and to test for heterogeneity between estimates (14). All covariates were 
categorized. To deal with missing values of covariates, we used the missing values as an ad-
ditional category, to prevent exclusion of non-complete cases. Exposures and outcomes were 
not imputed. If information on a covariate was available for less than 50% of the cohort 
sample used for each analysis, available information was not used and the corresponding 
data for that full cohort sample was assigned to the missing category. We also conducted a 
sensitivity analysis with complete cases only.
The statistical analyses were performed using the IBM SPSS Statistics version 21.0 for Win-
dows (IBM, Armonk, NY, US), RevMan version 5.3 (Nordic Cochrane Centre, Copenhagen, 
Denmark), and R statistical software version 3.3.3.
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Table 1 shows that the median maternal pre-pregnancy BMI was 22.7 kg/m2 (95% range: 
18.1, 34.3) and the median gestational weight gain was 14.0 kg (95% range: 4.0, 26.0). 
Of all children, 6.5%, 20.1%, and 22.2% were overweight/obese in early, mid, and late 
childhood, respectively. The country-specific prevalences of maternal overweight and 
obesity, excessive gestational weight gain, and mid childhood overweight/obesity ranged 
12.9%–53.1%, 22.2%–57.0%, and 10.6%–43.1%, respectively (Supplemental Figure 1). 
Supplemental Table 2 shows cohort-specific information on covariates.
Maternal pre-pregnancy BMI and gestational weight gain clinical 
categories
Table 2 shows that, as compared to maternal normal weight, maternal underweight was 
associated with lower risks of overweight/obesity throughout childhood (p-values < 0.05). 
As compared to maternal normal weight, maternal overweight and obesity were associated 
with higher risks of overweight/obesity throughout childhood, with stronger associations at 
later ages (ORs for overweight/obesity in late childhood: 2.28 [95% CI: 2.08, 2.50] and 4.47 
[95% CI: 3.99, 5.23] for maternal overweight and obesity, respectively). Among women 
with obesity, the risk of offspring overweight/obesity increased further for higher classes 
of maternal obesity (ORs for overweight/obesity in late childhood: 4.16 [95% CI: 3.56, 
4.87], 5.98 [95% CI: 4.50, 7.94], and 5.55 [95% CI: 3.25, 9.45] for obesity grade 1, grade 
2, and grade 3, respectively, as compared to normal weight; Table 2). These associations 
were not explained by gestational diabetes or gestational hypertensive disorders (Supple-
mental Tables 3 and 4). Additional adjustment for gestational-age-adjusted birth weight 
attenuated the associations only slightly (Supplemental Table 5). As compared to adequate 
gestational weight gain, inadequate gestational weight gain was associated with a lower risk 
of overweight/obesity in early and mid childhood (p-values < 0.05), but not in late childhood. 
As compared to adequate gestational weight gain, excessive gestational weight gain was 
associated with a higher risk of childhood overweight/obesity in early, mid, and late child-
hood (ORs 1.39 [95% CI: 1.30, 1.49], 1.55 [95% CI: 1.49, 1.60], and 1.72 [95% CI: 1.56, 
1.91], respectively). Supplemental Table 6 shows that, as compared to maternal normal 
weight, maternal underweight was associated with a higher risk of childhood underweight, 
whereas maternal overweight and obesity were associated with a lower risk of childhood 
underweight in early, mid, and late childhood. Similarly, as compared to adequate gestational 
weight gain, inadequate gestational weight gain was associated with higher risks of child-
hood underweight, and excessive gestational weight gain with lower risks. The associations 
of maternal BMI and gestational weight gain clinical categories with childhood BMI SDS are 
presented in Table 3.
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Raine Study, n=2,092, 1989-1992 (Australia)
21.3
(17.1, 34.0)
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Values are expressed as medians (95% range) or numbers of participants (valid %). NA: Not available. SDS: Standard 
Deviation Score. aOnly information available on BMI assessed in early pregnancy (<20 weeks of gestation).bSubset of 
participants with 4-years follow-up completed.
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Raine Study, n=2,092, 1989-1992 (Australia)
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(17.1, 34.0)
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Values are expressed as medians (95% range) or numbers of participants (valid %). NA: Not available. SDS: Standard 
Deviation Score. aOnly information available on BMI assessed in early pregnancy (<20 weeks of gestation).bSubset of 
participants with 4-years follow-up completed.
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The estimated proportions of childhood overweight/obesity attributable to maternal pre-
pregnancy overweight and obesity were respectively 11.5% and 10.2% in early childhood, 
15.1% and 14.4% in mid childhood, and 20.1% and 21.6% in late childhood (Table 2). The 
estimated proportions of childhood overweight/obesity attributable to excessive gestational 
weight gain were 11.4%, 15.4%, and 19.2%, in early, mid, and late childhood, respectively 
(Table 2). The country-specific proportions of mid childhood overweight/obesity are given in 
Supplemental Figure 2.
Table 3. Associations of maternal pre-pregnancy BMI and gestational weight gain clinical cat-
egories with childhood BMI SDS
Childhood BMI (SDS)
Early childhood Mid childhood Late childhood
2.0-5.0 years 5.0-10.0 years 10.0-18.0 years
Maternal pre-pregnancy BMI
Underweight (<18.5 kg/m2) -0.29 (-0.33, -0.26) -0.41 (-0.45, -0.38) -0.48 (-0.54, -0.41)
n =3,240 n =4,673 n=917
Normal weight (18.5-24.9 kg/m2) Reference Reference Reference
n =58,177 n =84,119 n=13,737
Overweight (25.0-29.9 kg/m2) 0.19 (0.17, 0.21) 0.33 (0.32, 0.35) 0.45 (0.41, 0.49)
n=17,258 n =23,671 n=2,819
Obesity (≥30.0 kg/m2) 0.34 (0.32, 0.37) 0.62 (0.60, 0.64) 0.92 (0.86, 0.99)
n =7,138 n =9,340 n=1,004
Obesity grade 1 (30.0-34.9 kg/m2) 0.32 (0.29, 0.35) 0.57 (0.54, 0.59) 0.85 (0.76, 0.93)
n =5,197 n =6,944 n =730
Obesity grade 2 (35.0-39.9 kg/m2) 0.39 (0.33, 0.44) 0.72 (0.67, 0.77) 1.09 (0.96, 1.23)
n =1,509 n =1,854 n =215
Obesity grade 3 (≥40.0 kg/m2) 0.45 (0.35, 0.55) 0.94 (0.85, 1.03) 1.18 (0.92, 1.44)
n =343 n =542 n =59
Gestational weight gain
Inadequate weight gain -0.10 (-0.12, -0.08) -0.09 (-0.11, -0.07) -0.09 (-0.13, -0.05)
n =15,782 n =21,094 n=3,998
Adequate weight gain Reference Reference Reference
n =25,829 n =37,142 n=5,247
Excessive weight gain 0.14 (0.12, 0.16) 0.22 (0.21, 0.24) 0.28 (0.24, 0.32)
n=27,965 n =40,879 n=3,742
Values are regression coefficients (95% confidence intervals) from multilevel linear regression models that reflect differ-
ences in early childhood (2.0-5.0 years), mid childhood (5.0-10.0 years) and late childhood (10.0-18.0 years) in children 
of mothers in the different pre-pregnancy BMI groups or gestational weight gain groups, as compared with the refer-
ence group (normal weight for pre-pregnancy BMI and adequate weight gain for gestational weight gain). The models 
are adjusted for maternal age, education level, ethnicity, parity, and smoking during pregnancy.
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Maternal pre-pregnancy BMI and gestational weight gain across 
their full ranges
Figures 2A and 2B show that higher maternal pre-pregnancy BMI was across the full range 
associated with higher risk of offspring overweight/obesity and higher offspring BMI SDS 
throughout childhood. The ORs for childhood overweight/obesity per kg/m2 increase in 
maternal pre-pregnancy BMI were 1.08 (95% CI: 1.07, 1.09), 1.12 (95% CI: 1.11, 1.12), 
and 1.16 (95% CI: 1.15, 1.17), in early, mid, and late childhood, respectively. Similarly, higher 
maternal gestational weight gain across its full range was associated with a higher risk of 
overweight/obesity and higher childhood BMI in early, mid, and late childhood (Figures 2C 
and 2D). The ORs for childhood overweight/obesity per SD increase in gestational weight 
gain were 1.14 (95% CI: 1.11, 1.17), 1.16 (95% CI: 1.14, 1.18), and 1.14 (95% CI: 1.09, 
1.20), in early, mid, and late childhood, respectively. Similar results were observed when 
performing 2-stage random effects meta-analyses, with low to moderate heterogeneity 
(Supplemental Figures 3 and 4).
Combined effects of maternal pre-pregnancy BMI and gestational 
weight gain clinical categories
Table 4 shows the combined effect of clinical categories of maternal pre-pregnancy BMI 
and gestational weight gain on childhood overweight/obesity. Regardless of their mothers’ 
gestational weight gain, children of mothers with underweight tended to have a lower risk 
of overweight/ obesity, whereas children of mothers with overweight or obesity had a higher 
risk of overweight/obesity, as compared to children whose mothers had normal weight and 
adequate gestational weight gain. Within each maternal BMI category, excessive gestational 
weight gain tended to increase the risk of overweight/obesity in early and mid childhood only 
slightly. The combined associations of clinical categories of maternal pre-pregnancy BMI and 
gestational weight gain with childhood BMI SDS are given in Table 5.
discussion
In this IPD meta-analysis, we observed that higher maternal pre-pregnancy BMI and ges-
tational weight gain were across their full ranges associated with higher risks of offspring 
overweight/ obesity throughout childhood. The effects tended to be stronger at older ages. 
However, the effect of gestational weight gain in addition to that of pre-pregnancy BMI was 
small. At the population level, 21.7% to 41.7% of childhood overweight/obesity prevalence 
was estimated to be attributable to maternal overweight and obesity together, whereas 
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Table 4. Combined associations of maternal pre-pregnancy BMI and gestational weight gain 
clinical categories with the risk of childhood overweight/obesity
 Childhood overweight/obesity (OR (95% CI))
Maternal pre-pregnancy BMI Early childhood Mid childhood Late childhood
2.0-5.0 years 5.0-10.0 years 10.0-18.0 years
Underweight (<18.5 kg/m2)
Inadequate weight gain 0.58 (0.42, 0.81) 0.39 (0.31, 0.48) 0.36 (0.22, 0.58)
ncases/total =40/970 ncases/total =97/1,284 ncases/total =19/266
Adequate weight gain 0.58 (0.42, 0.80) 0.46 (0.38, 0.56) 0.37 (0.22, 0.62)
ncases/total =44/1,087 ncases/total =126/1,538 ncases/total =16/226
Excessive weight gain 0.75 (0.49, 1.15) 0.75 (0.60, 0.95) 1.28 (0.67, 2.42)
ncases/total=25/455 ncases/total=85/635 ncases/total=13/56
Normal weight (18.5-24.9 kg/m2)
Inadequate weight gain 0.87 (0.78, 0.96) 0.91 (0.86, 0.96) 0.95 (0.84, 1.08)
ncases/total =583/12,027 ncases/total =2,462/16,163 ncases/total =536/3,255
Adequate weight gain Reference Reference Reference
ncases/total =1,032/19,502 ncases/total =4,326/28,316 ncases/total =677/4,173
Excessive weight gain 1.28 (1.17, 1.41) 1.36 (1.30, 1.43) 1.30 (1.14, 1.49)
ncases/total =1,010/14,927 ncases/total =4,381/22,400 ncases/total =446/2,162
Overweight (25-29.9 kg/m2)
Inadequate weight gain 1.49 (1.21, 1.82) 1.61 (1.44, 1.81) 2.04 (1.52, 2.74)
ncases/total =118/1,417 ncases/total =447/1,767 ncases/total =74/239
Adequate weight gain 1.62 (1.41, 1.86) 1.87 (1.73, 2.01) 1.94 (1.58, 2.38)
ncases/total=295/3,451 ncases/total=1,224/4,656 ncases/total=163/574
Excessive weight gain 1.85 (1.68, 2.04) 2.25 (2.13, 2.37) 2.65 (2.28, 3.08)
ncases/total=828/9,010 ncases/total=3,660/12,786 ncases/total=395/1,119
Obesity (≥30 kg/m2)
Inadequate weight gain 2.04 (1.66, 2.52) 2.95 (2.62, 3.31) 5.62 (3.94, 8.02)
ncases/total =112/1,070 ncases/total =509/1,382 ncases/total =76/137
Adequate weight gain 2.49 (2.09, 2.97) 3.45 (3.12, 3.82) 4.64 (3.39, 6.34)
ncases/total =171/1,378 ncases/total =728/1,881 ncases/total =88/179
Excessive weight gain 2.63 (2.32, 2.98) 3.70 (3.44, 3.97) 6.02 (4.79, 7.56)
 ncases/total =402/3,198 ncases/total =1,758/4,380 ncases/total =207/366
Values are odds ratios (95% confidence intervals) from multilevel binary logistic regression models that reflect the risk 
of childhood overweight/obesity in early childhood (2.0-5.0 years), mid childhood (5.0-10.0 years) and late childhood 
(10.0-18.0 years) in children of mothers in the different BMI and gestational weight gain categories, as compared to the 
reference group (normal weight mothers with adequate gestational weight gain). The models are adjusted for maternal 
age, education level, ethnicity, parity, and smoking during pregnancy. P-values for interaction between maternal BMI 
and gestational weight gain for the risk of childhood overweight/obesity: p=0.038, p<0.001 and p=0.637, in early-, 
mid- and late childhood, respectively.
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Table 5. Combined associations of maternal pre-pregnancy BMI and gestational weight gain 
clinical categories with childhood BMI SDS
 Childhood BMI (SDS (95%CI))
Maternal pre-pregnancy BMI Early childhood Mid childhood Late childhood
 2.0-5.0 years 5.0-10.0 years 10.0-18.0 years
Underweight (<18.5 kg/m2)
Inadequate weight gain -0.32 (-0.39, -0.25) -0.52 (-0.58, -0.47) -0.53 (-0.65, -0.41)
n =991 n =1,351 n= 280
Adequate weight gain -0.27 (-0.34, -0.21) -0.37 (-0.42, -0.31) -0.43 (-0.57, -0.30)
n =1,118 n =1598 n= 236
Excessive weight gain -0.14 (-0.24, -0.05) -0.19 (-0.26, -0.11) -0.21 (-0.47, 0.04)
n =469 n =666 n =60
Normal weight (18.5-24.9 kg/m2)
Inadequate weight gain -0.10 (-0.12, -0.07) -0.07 (-0.09, -0.05) -0.06 (-0.11, -0.01)
n =12,264 n =16,549 n= 3,340
Adequate weight gain Reference Reference Reference
n =19,815 n =28,928 n =4,249
Excessive weight gain 0.10 (0.08, 0.13) 0.14 (0.13, 0.16) 0.12 (0.06, 0.17)
n =15,121 n =22,825 n =2,187
Overweight (25-29.9 kg/m2)
Inadequate weight gain 0.06 (0.00, 0.12) 0.22 (0.17, 0.27) 0.32 (0.19, 0.45)
n = 1,445 n =1,803 n =241
Adequate weight gain 0.13 (0.09, 0.17) 0.29 (0.26, 0.32) 0.34 (0.25, 0.43)
n =3,501 n=4,715 n=581
Excessive weight gain 0.23 (0.20, 0.25) 0.41 (0.39, 0.43) 0.55 (0.49, 0.62)
n =9,137 n =12,962 n =1,127
Obesity (≥30 kg/m2)
Inadequate weight gain 0.26 (0.20, 0.26) 0.58 (0.52, 0.63) 0.94 (0.77, 1.11)
n =1,082 n =1,391 n =137
Adequate weight gain 0.36 (0.30, 0.41) 0.64 (0.59, 0.69) 0.88 (0.73, 1.03)
n=1,395 n =1,901 n =181
Excessive weight gain 0.36 (0.33, 0.40) 0.69 (0.66, 0.72) 1.01 (0.90, 1.11)
n =3,238 n =4,426 n=368
Values are regression coefficients (95% confidence intervals) from multilevel linear regression models that reflect dif-
ferences in early childhood (2.0 – 5.0 years), mid childhood (5.0 – 10.0 years) and late childhood (10.0 – 18.0 years) 
BMI SDS between children of mothers in the different BMI and total gestational weight gain groups compared with 
the reference group (normal weight and adequate gestational weight gain). The models are adjusted for maternal age, 
education level, ethnicity, parity, and smoking during pregnancy. P-values for interaction between maternal BMI and 
gestational weight gain for childhood BMI SDS: p=0.016, p=0.002 and p=0.406, in early-, mid- and late childhood, 
respectively.
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Interpretation of main findings
Maternal obesity does not only affect pregnancy outcomes, but may also have persistent 
effects on offspring fat development. Previous studies showed consistently that maternal 
overweight and obesity were positively associated with offspring BMI (2-4). In this IPD meta-
analysis, we observed not only that maternal overweight and obesity were associated with 
higher risks of childhood overweight/obesity, but that these risks were progressively higher 
among children of mothers with grade 1, grade 2, and grade 3 obesity, respectively. In 
addition, we observed that this association was not limited to the extremes of maternal BMI, 
but was present across the full range. We observed a stronger association of maternal BMI 
with the risk of childhood overweight/obesity at later ages. Although we used a different 
reference chart in early childhood and did not correct for correlations between BMI measure-
ments due to the large sample size, the observed association is unlikely to be explained by 
methodological issues as the observed risk also increased between mid and late childhood, 
where we used the same reference charts. Also, 2 recent studies among 1,494 Australian 
and 3,805 Dutch participants observed stronger associations of maternal BMI with child-
hood growth and obesity risk with increasing age, while accounting for correlated repeated 
measures (16, 17). This increasing strength of the association with age might reflect an 
intra-uterine programming mechanism becoming more apparent when children get older, 
or might be explained by a stronger influence of lifestyle characteristics of the child at later 
ages. We estimated that about 10% to 20% of overweight/obesity cases throughout child-
hood are attributable to maternal pre-pregnancy overweight and obesity, with the highest 
proportions explained by maternal overweight. Thus, our results suggest that high maternal 
BMI has a considerable population impact, and can be used as a target for preventive strate-
gies. Importantly, the risk of childhood overweight and obesity is not confined to maternal 
obesity, but increases gradually over the full range of maternal pre-pregnancy BMI.
In addition to pre-pregnancy BMI, the amount of weight gain during pregnancy also seems 
to be associated with offspring obesity (18, 19). Previous meta-analyses of published studies 
showed a 33% to 40% increased risk of overweight or obesity in children of mothers with 
excessive gestational weight gain (6, 7). In line with these studies, we observed that excessive 
gestational weight gain was related to a 39%–72% higher risk of overweight throughout 
childhood. On a population level, 11% to 19% of childhood overweight/obesity could be at-
tributed to excessive gestational weight gain. Also, gestational weight gain z-scores (specific 
for maternal BMI and gestational age) across the full range tended to be associated with an 
increased risk of offspring overweight/obesity. Thus, higher gestational weight gain across 
the full range, rather than only lower or higher gestational weight gain than recommended 
by the IOM, seems to be related to offspring weight status.
For the prevention of childhood overweight and obesity, insight into the combined ef-
fects of maternal BMI and gestational weight gain is important. Only 2 previous studies 
assessed the combined associations of maternal pre-pregnancy BMI and gestational weight 
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gain with childhood adiposity (20, 21). A study among 100,612 participants from China 
reported that, compared to normal maternal weight and adequate weight gain, normal 
weight or overweight/ obesity and excessive gestational weight gain was associated with 
an increased risk of overweight at 3–6 years of age in children (20). In a study in the US 
among 4,436 participants describing trajectories of maternal weight from pre-pregnancy 
until the postpartum period, the trajectory with the highest risk of offspring obesity at ages 
6–11 and 12–19 years consisted almost entirely of women who were overweight or obese 
at the start of pregnancy, but only half of this group had excessive gestational weight gain 
(21). We observed that, compared to children of women with normal weight and adequate 
gestational weight gain, children of overweight and obese mothers had a higher risk of 
overweight/obesity, regardless of gestational weight gain. Within the BMI categories, there 
was only a small effect of gestational weight gain on offspring overweight/obesity. These 
findings suggest that the effects of gestational weight gain add only to a limited extent to 
the effects of maternal pre-pregnancy BMI.
Our results strongly suggest that maternal pre-pregnancy BMI and gestational weight 
gain are associated with increased risk of overweight and obesity throughout childhood. It 
remains unclear whether these associations are causal and which mechanisms are underlying 
these associations. Maternal pre-pregnancy obesity and excessive gestational weight gain are 
complex traits, which reflect multiple components. Maternal pre-pregnancy obesity reflects 
maternal genetic predisposition, nutritional status, fat accumulation, and low-grade inflam-
mation, whereas maternal weight gain during pregnancy also reflects fluid expansion and 
growth of the fetus, placenta, and uterus (22, 23). Both may, at least partly, be explained 
by intra-uterine programming mechanisms. The fetal over-nutrition hypothesis suggests that 
increased fetal exposure to nutrients may lead to persistent adaptations in the structure 
and function of adipose tissue, appetite regulation, and energy metabolism, leading to an 
increased susceptibility to later obesity (24, 25). Epigenetic processes may play an impor-
tant role in these adaptations (26). The associations may also reflect genetic predisposition 
to obesity (27, 28) or sociodemographic or lifestyle factors shared by mother and child. 
Common pregnancy disorders, including gestational diabetes and gestational hypertensive 
disorders, have also been related to offspring obesity risk (29-31). However, using data from 
the same studies as our current analyses, we previously reported that these associations were 
not independent of maternal BMI (9). In the current analysis, the associations of maternal 
BMI with the risk of childhood overweight/ obesity were independent of gestational diabetes 
and gestational hypertensive disorders. Unfortunately, no information on maternal glucose 
concentrations was available to assess the role of maternal glycemic status in further detail. 
Previous research has shown that there are sex differences in weight and body fat develop-
ment in childhood (32, 33). We hypothesized that maternal BMI and gestational weight gain 
would influence the risk of childhood overweight/obesity differently or with a different timing 
in boys and girls. However, we did not observe sex differences in the observed associations, 
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possibly due to the fact that BMI does not distinguish between fat and lean mass. Further 
research is needed into the causality and underlying mechanisms of these associations (22).
Maternal pre-pregnancy BMI and, to a smaller extent, gestational weight gain are im-
portant modifiable risk factors of childhood weight status with a considerable population 
impact. Thus far, intervention trials have been focused on maternal weight during mid or late 
pregnancy, mostly showing reductions in gestational weight gain, but not showing any effect 
on birth outcomes or infant body composition (34-36). Only 1 small Swedish study including 
a lifestyle intervention reported results on childhood adiposity and showed no difference in 
BMI at age 5 years (37). We observed that the effect of excessive gestational weight gain 
was small in women with pre-pregnancy overweight and obesity. We also observed that the 
highest proportion of childhood overweight/obesity on a population level could be attributed 
to maternal pre-pregnancy overweight. Future intervention studies should shift their focus 
to preconceptional weight management, targeting women of reproductive age to achieve a 
normal weight.
Strengths and limitations
We meta-analyzed original data of different pregnancy and birth cohorts, limiting the poten-
tial of publication bias and enabling a consistent definition of exposures and outcomes and 
adjustment for potential confounders. Due to the large sample size, we were able to study 
effects in people with relatively rare conditions, such as severely obese women. We had data 
available at different childhood ages, enabling us to study the effects throughout childhood. 
We did not assess the associations of maternal BMI and gestational weight gain with the risk 
of childhood overweight/obesity over time in longitudinal analyses, as the data needed for 
such analyses were only available in a small subgroup of children and cohorts. Further stud-
ies are needed specifically exploring the development of childhood overweight and obesity 
over time in response to maternal BMI and gestational weight gain. Cohorts were initiated 
between 1989 and 2011. Given the rise in obesity prevalence in the past decades (38), it 
is likely that the current obesity prevalence and consequently the proportions of childhood 
overweight/obesity attributable to maternal overweight and obesity are underestimated. In 
our study, fewer cohorts reached the age for the late childhood analyses than for the early or 
mid childhood analyses. Our results for the late childhood analyses may be biased by cohort 
effects. We consider that the bias would most likely lead to an underestimation of the age 
differences because of the higher prevalences of childhood obesity in more recently started 
cohorts with younger children. As this study only included cohorts from Europe, North 
America, and Australia, and demographic characteristics in other continents may be differ-
ent, results can only be generalized to participants from these continents. Further studies are 
needed to address similar research questions in other populations. We performed sensitivity 
analyses based on 2-stage random effects meta-analyses, which gave similar results with 
low to moderate heterogeneity between the cohorts. We used a missing value category to 
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deal with missing data for covariates. Due to data availability and the size of the dataset, 
we were not able to apply more advanced imputation strategies. We observed similar results 
when we conducted a complete case analysis (Supplemental Tables 7 and 8). Because 
maternal BMI was self-reported in some cohorts, some misclassification and underestimation 
of the effect estimates might be present. For the cohorts with no information on maternal 
pre-pregnancy BMI available, we used BMI measured in early pregnancy, which might have 
led to an overestimation of BMI as a result of gestational weight gain. For the country-
specific analyses, it is important to note that countries are represented by 1 to 5 cohorts of 
different sample sizes per country and that not all cohorts are population-based, affecting 
the representativeness of the results for the full country. Although we adjusted the models 
for potential confounders, residual confounding by, for example, physical activity and dietary 
intake might still be an issue.
Conclusions
Higher maternal pre-pregnancy BMI and gestational weight gain are across their full ranges 
associated with an increased risk of offspring overweight/obesity throughout childhood and 
have a considerable population impact. The effect of gestational weight gain in addition 
to the effect of maternal pre-pregnancy BMI was small. Future intervention trials aiming to 
reduce childhood overweight and obesity should focus on maternal weight status before 
pregnancy, in addition to weight gain during pregnancy.
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Self-reported Self-reported NA Measured
ALSPAC (United 
Kingdom)
Self-reported Self-reported Clinical records Measured
AOB/F (Canada) Self-reported Self-reported NA Reported









Measured Measured Clinical records Measured
CHOP (Multiple) Measured Self-reported NA Measured
Co.N.ER (Italy) Self-reported Self-reported Self-reported Reported
DNBC (Denmark) Self-reported Self-reported Self-reported Reported or 
measured
EDEN (France) Measured Self-reported Clinical records Measured or clinical 
records
FCOU (Ukraine) Clinical records Clinical records Clinical records Clinical records
GASPII (Italy) Self-reported Self-reported Self-reported Measured
GECKO Drenthe 
(The Netherlands)
Self-reported Self-reported Self-reported Measured
GENERATION R
(The Netherlands)
Measured Self-reported Self-reported Measured
GENERATION XXI 
(Portugal)
Measured or ID card Self-reported Self-reported Measured
GENESIS (Greece) Self-reported Self-reported Self-reported Measured
GINIplus (Germany) Self-reported Self-reported Self-reported Clinical records at 
4y, measured and 
reported at 10 and 
15y
HUMIS (Norway) Self-reported Self-reported Self-reported Reported
INMA (Spain) Measured or self-
reported
Self-reported Clinical records Measured
KOALA (The 
Netherlands)
Self-reported Self-reported Self-reported Reported
Krakow Cohort 
(Poland)
Self-reported Self-reported Self-reported Measured
LISAplus (Germany) Self-reported Self-reported Self-reported Clinical records at 
4y, measured and 
reported at 10 and 
15y
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LUKAS (Finland) Self-reported Self-reported Self-reported or 
clinical records
Reported
MoBa (Norway) Self-reported Self-reported Self-reported Reported
NINFEA (Italy) Self-reported Self-reported Self-reported Reported
PÉLAGIE (France) Self-reported Self-reported NA Reported
PIAMA (The 
Netherlands)
Self-reported Self-reported Self-reported Reported and 
measured (4 and 
8y)
Piccolipiù (Italy) Self-reported Self-reported Self-reported Measured
Project Viva (United 
States)
Self-reported Self-reported Clinical records Measured
Raine Study 
(Australia)
Measured Self-reported NA Measured
REPRO_PL (Poland) Measured Self-reported Measured Measured
RHEA (Greece) Measured Self-reported Measured Clinical records or 
measured
ROLO (Ireland) Measured Measured Measured Measured
SCOPE BASELINE 
(Ireland)
Measured Measured Measured Measured
SEATON (United 
Kingdom)
Measured Measured NA Measured
Slovak PCB study 
(Slovakia)
Self-reported Self-reported Self-reported Measured
STEPS (Finland) Self-reported Self-reported Self-reported Measured
SWS (United 
Kingdom)
Measured Measured Measured Measured
NA: Not available or not applicable
CHAPTER 3.1
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Supplemental Figure 1. Country-specific description of exposures and outcomes
Values are valid percentages. The CHOP cohort was excluded from the country-specific analyses, as participants come 
from multiple countries.
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Supplemental Table 3. Associations of maternal pre-pregnancy BMI clinical categories with the 












0.57 (0.47, 0.69) 0.44 (0.40, 0.49) 0.44 (0.35, 0.55)




ncases/total =3,092/57,293 ncases/total =13,870/82,438 ncases/total =2,505/13,497
Overweight
(25.0-29.9 kg/m2)
1.66 (1.55, 1.77) 1.91 (1.84, 1.98) 2.28 (2.08, 2.50)
ncases/total =1,476/17,013 ncases/total =6,556/23,359 ncases/total =968/2,799
Obesity
(≥30.0 kg/m2)
2.40 (2.21, 2.61) 3.11 (2.97, 3.26) 4.57 (3.99, 5.24)
ncases/total =864/7,058 ncases/total =3,612/9,248 ncases/total =528/1,000
 Obesity grade 1
 (30.0-34.9 kg/m2)
2.33 (2.12, 2.56) 2.88 (2.73, 3.04) 4.17 (3.56, 4.87)
ncases/total =613/5,142 ncases/total =2,552/6,874 ncases/total =363/726
 Obesity grade 2
 (35.0-39.9  kg/m2)
2.53 (2.16, 2.97) 3.55 (3.23, 3.91) 5.98 (4.50, 7.95)
ncases/total =190/1,489 ncases/total =782/1,836 ncases/total =129/215
 Obesity grade 3
 (≥40.0 kg/m2)
2.85 (2.16, 3.77) 5.14 (4.32, 6.12) 5.54 (3.25, 9.45)
ncases/total =61/427 ncases/total =278/538 ncases/total =36/59
Values are odds ratios (95% confidence intervals) from multilevel binary logistic regression models that reflect the risk of 
childhood overweight in early childhood (2.0-5.0 years), mid childhood (5.0-10.0 years) and late childhood (10.0-18.0 
years) in children of mothers in the different pre-pregnancy BMI groups, as compared with the reference group (normal 




Supplemental Table 4. Associations of maternal pre-pregnancy BMI clinical categories with 














0.57 (0.47, 0.69) 0.44 (0.40, 0.49) 0.44 (0.35, 0.55)




ncases/total =3,092/57,293 ncases/total =13,870/82,438 ncases/total =2,505/13,497
Overweight
(25.0-29.9 kg/m2)
1.66 (1.56, 1.78) 1.91 (1.84, 1.98) 2.26 (2.06, 2.48)
ncases/total =1,476/17,013 ncases/total =6,556/23,359 ncases/total =968/2,799
Obesity
(≥30.0 kg/m2)
2.45 (2.25, 2.66) 3.12 (2.98, 3.26) 4.46 (3.89, 5.11)
ncases/total =864/7,058 ncases/total =3,612/9,248 ncases/total =528/1,000
 Obesity grade 1
 (30.0-34.9 kg/m2)
2.37 (2.15, 2.60) 2.89 (2.74, 3.05) 4.08 (3.49, 4.77)
ncases/total =613/5,142 ncases/total =2,552/6,874 ncases/total =363/726
 Obesity grade 2
 (35.0-39.9 kg/m2)
2.59 (2.21, 3.04) 3.56 (3.24, 3.93) 5.82 (4.37, 7.73)
ncases/total =190/1,489 ncases/total =782/1,836 ncases/total =129/215
 Obesity grade 3
 (≥40.0 kg/m2)
2.96 (2.24, 3.91) 5.16 (4.34, 6.14) 5.27 (3.09, 9.00)
ncases/total =61/427 ncases/total =278/538 ncases/total =36/59
Values are odds ratios (95% confidence intervals) from multilevel binary logistic regression models that reflect the risk of 
childhood overweight in early childhood (2.0-5.0 years), mid childhood (5.0-10.0 years) and late childhood (10.0-18.0 
years) in children of mothers in the different pre-pregnancy BMI groups, as compared with the reference group (normal 
weight). The models are adjusted for maternal age, education level, ethnicity, parity, smoking during pregnancy, and 
gestational hypertensive disorders (gestational hypertension and pre-eclampsia).
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Supplemental Table 5. Associations of maternal pre-pregnancy BMI clinical categories with 














0.60 (0.49, 0.72) 0.46 (0.42, 0.51) 0.45 (0.36, 0.56)




ncases/total =3,092/57,293 ncases/total =13,870/82,438 ncases/total =2,505/13,497
Overweight
(25.0-29.9 kg/m2)
1.61 (1.50, 1.72) 1.86 (1.80, 1.93) 2.25 (2.05, 2.46)
ncases/total =1,476/17,013 ncases/total =6,556/23,359 ncases/total =968/2,799
Obesity
(≥30.0 kg/m2)
2.29 (2.11, 2.49) 2.98 (2.84, 3.12) 4.42 (3.86, 5.07)
ncases/total =864/7,058 ncases/total =3,612/9,248 ncases/total =528/1,000
 Obesity grade 1
 (30.0-34.9 kg/m2)
2.23 (2.03, 2.45) 2.77 (2.62, 2.92) 4.02 (3.44, 4.71)
ncases/total =613/5,142 ncases/total =2,552/6,874 ncases/total =363/726
 Obesity grade 2
 (35.0-39.9 kg/m2)
2.40 (2.05, 2.82) 3.37 (3.06, 3.72) 5.82 (4.38, 7.74)
ncases/total =190/1,489 ncases/total =782/1,836 ncases/total =129/215
 Obesity grade 3
 (≥40.0 kg/m2)
2.69 (2.04, 3.55) 4.85 (4.07, 5.77) 5.35 (3.13, 9.13)
ncases/total =61/427 ncases/total =278/538 ncases/total =36/59
Values are odds ratios (95% confidence intervals) from multilevel binary logistic regression models that reflect the risk of 
childhood overweight in early childhood (2.0-5.0 years), mid childhood (5.0-10.0 years) and late childhood (10.0-18.0 
years) in children of mothers in the different pre-pregnancy BMI groups, as compared with the reference group (normal 




Supplemental Table 6. Associations of maternal pre-pregnancy BMI and gestational weight 




















1.46 (1.15, 1.86) 1.8 1.94 (1.66, 2.27) 3.5 2.40 (1.69, 3.39) 5.2




ncases/total =884/55,085 ncases/total =1,681/70,249 ncases/total =240/11,232
Overweight
(25.0-29.9 kg/m2)
0.93 (0.81, 1.08) NA 0.71 (0.63, 0.81) NA 0.49 (0.31, 0.78) NA
ncases/total =245/15,782 ncases/total =6,556/23,359 ncases/total =20/1,851
Obesity
(≥30.0 kg/m2)
0.74 (0.58. 0.93) NA 0.60 (0.49, 0.75) NA 0.38 (0.14, 1.03) NA
ncases/total =80/6,274 ncases/total =312/17,115 ncases/total =4/367
 Obesity grade 1
 (30.0-34.9 kg/m2)
0.69 (0.53, 0.91) NA 0.60 (0.47, 0.76) NA 0.49 (0.18, 1.34) NA
ncases/total =55/4,584 ncases/total =70/4,392 ncases/total =4/476
 Obesity grade 2
 (35.0-39.9 kg/m2)
0.88 (0.56, 1.38) NA 0.64 (0.40, 1.03) NA NA NA
ncases/total =20/1,319 ncases/total =18/1,072 ncases/total =0/86
 Obesity grade 3
 (≥40.0 kg/m2)
0.77 (0.32, 1.88) NA 0.55 (0.20, 1.47) NA NA NA




1.24 (1.06, 1.44) 4.1 1.25 (1.11, 1.40) 4.2 1.15 (0.92, 1.43) 2.6




ncases/total =411/24,287 ncases/total=751/30,738 ncases/total=95/4,303
Excessive weight 
gain
0.84 (0.73, 0.97) NA 0.83 (0.74, 0.92) NA 0.88 (0.69, 1.14) NA
ncases/total=375/25,700 ncases/total=678/30,995 ncases/total=39/2,681
Values are odds ratios (95% confidence intervals) from multilevel binary logistic regression models that reflect the risk of 
childhood underweight in early childhood (2.0-5.0 years), mid childhood (5.0-10.0 years) and late childhood (10.0-18.0 
years) in children of mothers in the different pre-pregnancy BMI groups or gestational weight gain groups, as compared 
with the reference group (normal weight for pre-pregnancy BMI and adequate weight gain for gestational weight gain) 
or population attributable risk fractions (PAR), indicating the proportion of childhood underweight cases attributable 
to each maternal BMI or gestational weight gain category. The models are adjusted for maternal age, education level, 
ethnicity, parity, and smoking during pregnancy. NA: not applicable.
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Supplemental Figure 2. Overall and country-specific population attributable risk fractions of 
maternal overweight, obesity and excessive gestational weight gain for mid childhood over-
weight/obesity
Values are population attributable risk fractions (PAR) indicating the proportion of mid childhood overweight/obesity 
cases attributable to (A) maternal overweight, (B) maternal obesity and (C) excessive gestational weight gain. The CHOP 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplemental Table 7. Associations of maternal pre-pregnancy BMI and gestational weight 












0.65 (0.49, 0.85) 0.42 (0.35, 0.51) 0.48 (0.37, 0.61)




ncases/total =1,055/19,057 ncases/total =4,625/22,872 ncases/total =1,791/9,176
Overweight
(25.0-29.9 kg/m2)
1.73 (1.54, 1.95) 2.07 (1.94, 2.21) 2.36 (2.12, 2.64)
ncases/total =469/5,289 ncases/total =1,997/5,832 ncases/total = 691/1,908
Obesity
(≥30.0 kg/m2)
2.82 (2.43, 3.26) 3.72 (3.40, 4.08) 4.84 (4.09, 5.72)
ncases/total =295/2,197 ncases/total =1,115/2,325 ncases/total =359/649
 Obesity grade 1
 (30.0-34.9 kg/m2)
2.66 (2.27, 3.18) 3.53 (3.18, 3.92) 4.47 (3.69, 5.42)
ncases/total =204/1,568 ncases/total =785/1,689 ncases/total =252/476
 Obesity grade 2
 (35.0-39.9 kg/m2)
3.29 (2.52, 4.30) 3.92 (3.26, 4.72) 5.50 (3.85, 7.87)
ncases/total =71/477 ncases/total =243/491 ncases/total =79/134
 Obesity grade 3
 (≥40.0 kg/m2)
2.77 (1.71, 4.48) 5.88 (4.18, 8.28) 8.56 (4.22, 17.36)
ncases/total =20/152 ncases/total =87/145 ncases/total =28/39
Gestational weight gain
Inadequate weight gain 0.84 (0.72, 0.98) 0.84 (0.78, 0.91) 0.92 (0.80, 1.05)
ncases/total = 303/4,974 ncases/total= 1,315/6,355 ncases/total= 511/2,614
Adequate weight gain Reference Reference Reference
ncases/total = 475/6,676 ncases/total= 1,938/8,425 ncases/total= 646/3,207
Excessive weight gain 1.49 (1.30, 1.70) 1.53 (1.42, 1.64) 1.75 (1.55, 1.99)
ncases/total= 567/5,939 ncases/total= 2,341/7,471 ncases/total= 731/2,321
Values are odds ratios (95% confidence intervals) from multilevel binary logistic regression models with complete cases 
that reflect the risk of childhood overweight/obesity in early childhood (2.0-5.0 years), mid childhood (5.0-10.0 years) 
and late childhood (10.0-18.0 years) in children of mothers in the different pre-pregnancy BMI groups or gestational 
weight gain groups, as compared with the reference group (normal weight for pre-pregnancy BMI and adequate 
weight gain for gestational weight gain). The models are adjusted for maternal age, education level, ethnicity, parity, 
and smoking during pregnancy.
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Supplemental Table 8. Associations of maternal pre-pregnancy BMI and gestational weight 




Early childhood Mid childhood Late childhood




-0.29 (-0.34, -0.23) -0.43 (-0.34, -0.23) -0.45 (-0.53, -0.37)




n =19,127 n =23,007 n=9,280
Overweight
(25.0-29.9 kg/m2)
0.22 (0.19, 0.25) 0.39 (0.36, 0.42) 0.47 (0.42, 0.52)
n=5,303 n =5,852 n=1,918
Obesity
(≥30.0 kg/m2)
0.34 (0.36, 0.45) 0.76 (0.72, 0.80) 0.94 (0.86, 1.02)
n =2,200 n =2,330 n=653
 Obesity grade 1
 (30.0-34.9 kg/m2)
0.38 (0.33, 0.43) 0.71 (0.66, 0.76) 0.88 (0.78, 0.97)
n =1,570 n =1,693 n=480
 Obesity grade 2
 (35.0-39.9 kg/m2)
0.45 (0.36, 0.54) 0.81 (0.72, 0.90) 1.05 (0.88, 1.23)
n =478 n =492 n =134
 Obesity grade 3
 (≥40.0 kg/m2)
0.453 (0.38, 0.69) 1.15 (0.98, 1.31) 1.38 (1.06, 1.70)
n =152 n =145 n =39
Gestational weight gain
Inadequate weight gain -0.10 (-0.14, -0.06) -0.12 (-0.16, -0.09) -0.10 (-0.15, -0.04)
n =5,064 n =6,447 n=2,676
Adequate weight gain Reference Reference Reference
n =6,768 n =8,515 n=3,264
Excessive weight gain 0.18 (0.14, 0.21) 0.24 (0.21, 0.27) 0.30 (0.25, 0.36)
n=5,981 n =7,526 n=2,345
Values are regression coefficients (95% confidence intervals) from multilevel linear regression models with complete 
cases that reflect differences in early childhood (2.0-5.0 years), mid childhood (5.0-10.0 years) and late childhood 
(10.0-18.0 years) in children of mothers in the different pre-pregnancy BMI groups or gestational weight gain groups, 
as compared with the reference group (normal weight for pre-pregnancy BMI and adequate weight gain for gesta-
tional weight gain). The models are adjusted for maternal age, education level, ethnicity, parity, and smoking during 
pregnancy.

3.2 Gestational weight gain and maternal and infant adverse outcomes
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Importance: Both low and high gestational weight gain have been associated with adverse 
maternal and infant outcomes, but optimal gestational weight gain remains uncertain and 
not well defined for all prepregnancy weight ranges.
Objectives: To examine the association of ranges of gestational weight gain with risk of 
adverse maternal and infant outcomes and estimate optimal gestational weight gain ranges 
across prepregnancy body mass index categories.
Design, setting and participants: Individual participant-level meta-analysis using data from 
196 670 participants within 25 cohort studies from Europe and North America (main study 
sample). Optimal gestational weight gain ranges were estimated for each prepregnancy 
body mass index (BMI) category by selecting the range of gestational weight gain that was 
associated with lower risk for any adverse outcome. Individual participant-level data from 
3505 participants within 4 separate hospital-based cohorts were used as a validation sample. 
Data were collected between 1989 and 2015. The final date of follow-up was December 
2015.
Exposures: Gestational weight gain.
Main outcomes and measures: The main outcome termed any adverse outcome was 
defined as the presence of 1 or more of the following outcomes: preeclampsia, gestational 
hypertension, gestational diabetes, cesarean delivery, preterm birth, and small or large size 
for gestational age at birth.
Results: Of the 196 670 women (median age, 30.0 years [quartile 1 and 3, 27.0 and 33.0 
years] and 40 937 were white) included in the main sample, 7809 (4.0%) were categorized 
at baseline as underweight (BMI <18.5); 133 788 (68.0%), normal weight (BMI, 18.5-24.9); 
38 828 (19.7%), overweight (BMI, 25.0-29.9); 11 992 (6.1%), obesity grade 1 (BMI, 30.0-
34.9); 3284 (1.7%), obesity grade 2 (BMI, 35.0-39.9); and 969 (0.5%), obesity grade 3 (BMI, 
≥40.0). Overall, any adverse outcome occurred in 37.2% (n = 73 161) of women, ranging 
from 34.7%(2706 of 7809) among women categorized as underweight to 61.1%(592 of 
969) among women categorized as obesity grade 3. Optimal gestational weight gain ranges 
were 14.0 kg to less than 16.0 kg for women categorized as underweight; 10.0 kg to less 
than 18.0 kg for normal weight; 2.0 kg to less than 16.0 kg for overweight; 2.0 kg to less 
than 6.0 kg for obesity grade 1; weight loss or gain of 0 kg to less than 4.0 kg for obesity 
grade 2; and weight gain of 0 kg to less than 6.0 kg for obesity grade 3. These gestational 
weight gain ranges were associated with low to moderate discrimination between those 
with and those without adverse outcomes (range for area under the receiver operating char-
acteristic curve, 0.55-0.76). Results for discriminative performance in the validation sample 
were similar to the corresponding results in the main study sample (range for area under the 
receiver operating characteristic curve, 0.51-0.79).
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Conclusions and relevance: In this meta-analysis of pooled individual participant data from 
25 cohort studies, the risk for adverse maternal and infant outcomes varied by gestational 
weight gain and across the range of prepregnancy weights. The estimates of optimal gesta-
tional weight gain may inform prenatal counseling; however, the optimal gestational weight 




Gestational weight gain has been found to be related to the risk of pregnancy complications, 
maternal postpartum weight retention, and obesity in offspring (1-3). Gestational weight 
gain reflects multiple characteristics, including maternal fat accumulation, fluid expansion, 
and the growth of the fetus, placenta, and uterus (4). Gestational weight gain is necessary 
to ensure a healthy fetus, but excessive gestational weight gain has been associated with 
adverse outcomes.
Higher prepregnancy body mass index (BMI; calculated as weight in kilograms divided 
by height in meters squared) also has been associated with lower gestational weight gain 
and increased risk for adverse maternal and infant outcomes. Therefore, optimal gestational 
weight gain ranges should account for prepregnancy BMI (5, 6). Existing guidelines for ges-
tational weight gain from the US National Academy of Medicine (NAM; formerly the Institute 
of Medicine) have limitations such as the reliance on a limited number of observational 
studies relating gestational weight gain to 5 maternal and offspring outcomes and insuf-
ficient information about important pregnancy outcomes (eg, gestational hypertension and 
gestational diabetes) (7). In addition, the NAM guidelines do not include recommendations 
for obesity grade 1, 2, and 3 separately even though the prevalence of extreme obesity is 
increasing in Western populations. Information regarding optimal gestational weight gain 
across a range of maternal BMI categories is important for the identification of groups at 
increased risk.
This study pooled individual participant data from 25 pregnancy and birth cohorts from 
Europe and North America to assess associations of the amount of gestational weight gain 
with maternal and infant outcomes according to baseline weight status of underweight, 
normal weight, overweight, obesity grade 1, obesity grade 2, and obesity grade 3.
methods
Inclusion criteria and participating cohorts
This study was part of an international LifeCycle Project collaboration on maternal obesity 
and childhood outcomes (8, 9). A pregnancy or birth cohort study was eligible for inclusion 
if it included mothers with singleton live-born children who were born between 1989 and 
2015, had information on maternal prepregnancy or early-pregnancy BMI, and had at least 1 
offspring measurement (birth weight or childhood BMI). The final date of follow-up was De-
cember 2015. No exclusions were made based on previous pregnancy or birth complications.
The cohorts included had received institutional review board approval and written informed 
consent had been obtained. We invited 50 Western cohorts from Europe, North America, 
and Oceania that had been selected from existing collaborations on childhood health (the 
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EarlyNutrition Project, the CHICOS Project, and Birthcohorts.net, which was accessed until 
July 2014), of which 39 cohorts agreed to participate. Only participants with information 
on maternal prepregnancy BMI, gestational weight gain, and at least 1 maternal or infant 
outcome of interest were included.
Of the 29 cohorts with the required data, 25 were population based cohorts and were 
included in the main study sample. The remaining 4 hospital-based cohorts were included 
as the external validation sample (Supplemental Figure 1). The included cohorts and the 
data collection methods appear in Supplemental Table 1. Women could be included more 
than once in the analyses if they had multiple singleton pregnancies during the study period. 
Anonymized data sets were stored on a single central secure data server that was only acces-
sible by the main investigator analysts (E.V. and R.G.).
Maternal prepregnancy BMI and gestational weight gain
Maternal prepregnancy BMI was grouped into categories by 2 BMI units and clinical BMI 
groups according to World Health Organization definitions (10). Data on total gestational 
weight gain in kilograms, which was defined as the difference between the latest weight be-
fore delivery and the prepregnancy weight, were provided by the cohorts. Gestational weight 
gain was grouped into categories of 2 kg each, ranging from weight loss to weight gain of 
28 kg or greater. Smaller increments of gestational weight gain were not used because of 
insufficient statistical power among underweight and severely obese women. Categories at 
the extremes of gestational weight gain were combined for maternal underweight, obesity 
grade 2, and obesity grade 3. To be included, women were required to have data for maternal 
prepregnancy BMI, total gestational weight gain, and any adverse outcome (defined below).
Adverse maternal and infant outcomes
The main outcome of the analyses was the composite any adverse outcome, which was 
defined as the presence of at least 1 of the following outcomes: preeclampsia, gestational 
hypertension, gestational diabetes, cesarean delivery, preterm birth, and small or large size 
for gestational age at birth. Preterm birth was defined as gestational age at birth of less than 
37 weeks. Sex- and gestational age–adjusted SD scores for birth weight were calculated 
using a Northern European reference chart (11). Small and large sizes for gestational age 
at birth were defined as sex- and gestational age–adjusted birth weight less than the10th 
percentile and greater than the 90th percentile, respectively, within each cohort.
For the sensitivity analyses, sex- and age-adjusted SD scores were calculated for childhood 
BMI based on reference growth charts from the World Health Organization (12, 13). The SD 
scores were obtained using data from the highest age available for each child (median age, 
84.9 months [quartile 1 and 3, 61.9 and 95.9 months]) and categorized as underweight, 
normal weight, and overweight or obesity (referred to as overweight) using World Health 




Exploratory multilevel linear regression models were used to assess associations of maternal 
baseline characteristics with total gestational weight gain. The absolute risk for any adverse 
outcome was estimated across the full range of maternal prepregnancy BMI and gestational 
weight gain. Absolute risks were calculated as the percentage of women with any adverse 
outcome within each combination of BMI and gestational weight gain categories. Similarly, 
the absolute risks were estimated for any adverse outcome and for each individual outcome 
across the range of gestational weight gain categories within each clinical BMI group.
The optimal gestational weight gain ranges per clinical BMI group were constructed. The 
odds ratios (ORs) for any adverse outcome were calculated for each gestational weight gain 
category within the particular clinical BMI group vs all other women within that BMI group. 
The individual-level data from all cohorts were analyzed simultaneously using multilevel 
models. The models followed a 2-level hierarchical structure with participants (level 1) nested 
within cohorts (level 2).We used a generalized linear mixed model with a binominal distribu-
tion and logit link. A random intercept at the cohort level was included to allow variation 
in the baseline risk for each cohort. Allowing a random slope for gestational weight gain 
did not improve the models. Model assumptions regarding linearity, independent errors, 
and influential values were met. Optimal gestational weight gain was defined as all weight 
gain categories with a statistically significant protective association (OR <1) for any adverse 
outcome (14). If a gestational weight gain category with a nonsignificant association was 
between 2 significant estimates with an OR of less than 1, that category was included in 
the optimal gestational weight gain range. To construct easily interpretable optimal gesta-
tional weight gain ranges directly applicable for clinical practice, the main analyses were not 
adjusted for maternal age or parity. We also assessed continuous associations of maternal 
prepregnancy BMI and total gestational weight gain in SDs with any adverse outcome and 
compared the strength of these associations by using Z tests for the difference in ORs.
The following sensitivity analyses were performed: (1) we redefined the gestational weight 
gain ranges based on protective associations only (OR <1) regardless of statistical signifi-
cance; (2) we adjusted the models for gestational age at birth and excluded preterm births 
because gestational weight gain depends on length of gestation; (3) we excluded participants 
with missing data on separate adverse maternal and infant outcomes; (4) we adjusted for 
maternal age and parity to explore whether optimal gestational weight gain ranges would 
change when maternal age and parity were taken into account; (5) we excluded cesarean 
delivery as an adverse outcome and included childhood underweight and overweight as 
adverse outcomes to explore whether optimal gestational weight gain ranges would change 
depending on the definition of the composite outcome; and (6) we excluded preeclampsia 
and gestational diabetes as outcomes to address possible reverse causation. We also con-
structed optimal gestational weight gain ranges during the first half of pregnancy, which 
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were defined as the difference between weight at median gestational age of 15.4 weeks 
(quartile 1 and 3, 13.2 and 17.1 weeks) and prepregnancy weight using a similar approach.
The clinical performance of the gestational weight gain ranges in this study were assessed 
as secondary analyses and compared with the NAM guidelines by assessing the number 
of participants classified as having inadequate or excessive weight gain, the associations 
with adverse outcomes using binary logistic multilevel models, and the discriminative per-
formance for both classification systems. The discriminative performance of the classification 
(the ability of the classification to discriminate between those with and those without the 
outcome) from this study and the NAM guidelines was assessed based on the area under the 
receiver operating characteristic curve (AUROC) (15). Predicted probabilities were obtained 
from binary logistic multilevel models assessing the associations of inadequate and excessive 
gestational weight gain with the outcomes. The predicted probabilities were used to calculate 
the AUROC. To assess the associations of the optimal gestational weight gain ranges with 
clinically relevant outcomes not used for the construction of the ranges, we also assessed low 
and high birth weight (≤2500 g or ≥4000 g). In addition, the clinical performance of both 
classification systems was assessed in the external validation sample (n = 3505).
All statistical tests were 2-sided with a significance threshold of .05. However, the sec-
ondary analyses were not adjusted for multiple testing; therefore, these findings should be 
considered exploratory. All statistical analyses were performed using SPSS Statistics version 
24.0 (IBM) and R version 3.3.3 (R Foundation for Statistical Computing).
results
Participant characteristics in main sample
Of the 29 cohorts with the required data (n = 200 175 participants), 25 were population-
based cohorts (n = 196 670 women) and were included as the main study sample (median 
age, 30.0 years [quartile 1 and 3, 27.0 and 33.0 years] and 40 937 were white). At baseline, 
7809 women (4.0%) were categorized as underweight (BMI <18.5); 133 788 (68.0%), nor-
mal weight (BMI, 18.5-24.9); 38 828 (19.7%), overweight (BMI, 25.0- 29.9); 11 992 (6.1%), 
obesity grade 1 (BMI, 30.0-34.9); 3284 (1.7%), obesity grade 2 (BMI, 35.0-39.9); and 969 
(0.5%), obesity grade 3 (BMI, ≥40.0) (Table 1). Overall, any adverse outcome occurred in 
37.2% (n = 73 161) of women, ranging from 34.7% (2706 of 7809) among women catego-
rized as underweight to 61.1% (592 of 969) among women categorized as obesity grade 3.
Women who gained more gestational weight had a lower maternal prepregnancy BMI and 
were slightly younger and more often nulliparous than multiparous (Supplemental Table 2). 
There were no missing data for any individual adverse outcome for 169 437 women (86.2%). 
Of the remainder, 17093 women (8.7%) were missing data for gestational hypertensive 
disorders (including preeclampsia and gestational hypertension), 6898 (3.5%) for gestational 
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diabetes, 9786 (5.0%) for cesarean delivery, 8541 (4.3%) for preterm birth, and 6453 (3.3%) 
for size (small or large) for gestational age at birth (Supplemental Table 3). Based on the 
profiles of all included cohorts, the percentage of women included with multiple singleton 
pregnancies is about 1%.
Participant characteristics in validation sample
There were 3505 women included in the validation sample. They had a median age of 
31.0 years (quartile 1 and 3, 27.7 and 34.7 years) and 1696 were white. There were 277 
women (7.9%) categorized as underweight; 2400 (68.5%), normal weight; 577 (16.5%), 
overweight; 188 (5.4%), obesity grade 1; 53 (1.5%), obesity grade 2; and 10 (0.3%), obesity 
grade 3. Any adverse outcome occurred in 1423 women (40.6%; Supplemental Table 4).
There were no missing data for any individual adverse outcome for 3059 women (87.3%). 
Of the remainder, 423 women (12.1%) were missing data for gestational hypertensive 
disorders (including preeclampsia and gestational hypertension), 421 (12.0%) for gestational 
diabetes, 15 (0.4%) for cesarean delivery, 426 (12.2%) for preterm birth, and 7 (0.2%) for 
size (small or large) for gestational age at birth (Supplemental Table 3). Supplemental 
Tables 5 and 6 provide cohort specific information for both the main sample and the valida-
tion sample.
Maternal prepregnancy BMI, gestational weight gain, and absolute 
risk for any adverse outcome
The absolute risk for any adverse outcome increased across the full range of maternal pre-
pregnancy BMI and was largely independent of gestational weight gain (Figure 1). The 
lowest absolute risks were observed among women with low to normal BMI and a moderate 
to high total gestational weight gain. The lowest risk was 26.7% (16 of 60) for women 
with a BMI of less than 18.0 and gestational weight gain of 26.0 kg to 27.9 kg. The highest 
absolute risks were observed among women with a high BMI and a high gestational weight 
gain. The highest risk was 94.4% (17 of 18) for women with a BMI of 40.0 or greater and 
gestational weight gain of 20.0 kg to 21.9 kg.
Among women categorized as underweight, the absolute risk for any adverse outcome 
ranged from 29.2%(387 of 1326) for gestational weight gain of 14.0 kg to 15.9 kg to 
50.2% (203 of 404) for gestational weight gain of less than 8.0 kg (Figure 2). Of all out-
comes separately, the absolute risk was highest for small size for gestational age (highest risk: 
32.1% [125 of 390] for gestational weight gain <8 kg).
Among women categorized as normal weight, the absolute risk for any adverse outcome 
ranged from 31.7% (7314 of 23 073) for gestational weight gain of 14.0 kg to 15.9 kg to 
46.9% (1256 of 2679) for gestational weight gain of 28.0 kg or greater and was highest at 
both extremes of gestational weight gain.
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Among women categorized as overweight, the absolute risk for any adverse outcome 
increased from 37.3% (249 of 667) for gestational weight gain of 2.0 kg to 3.9 kg to 56.4% 
(624 of 1107) for gestational weight gain of 28.0 kg or greater. Of all outcomes separately, 
the absolute risk was highest for cesarean delivery (highest risk: 25.1% [272 of 1084] for 
gestational weight gain of ≥28.0 kg).
Among women categorized as obesity grade 1, 2, or 3, the absolute risk for any adverse 
outcome increased across the range of gestational weight gain. The highest absolute risks 
were 63.7% (160 of 251) for gestational weight gain of 28.0 kg or greater in women cat-
egorized as obesity grade 1,67.7% (384 of 567) for gestational weight gain of 16.0 kg or 
greater in women categorized as obesity grade 2, and 78.8% (93 of 118) for gestational 
weight gain of 16.0 kg or greater in women categorized as obesity grade 3. The association 
of maternal prepregnancy BMI with the risk for any adverse outcomes was stronger than 
the association of gestational weight gain. The ORs for the risk of any adverse outcome 
were 1.28 (95%CI, 1.27-1.29) and 1.04 (95%CI, 1.03-1.05) per 1-SD increase in maternal 
prepregnancy BMI and gestational weight gain, respectively (P<.001 for comparison).The 
absolute data for each gestational weight gain category appear in Supplemental Table 7.
Figure 1. Heatmap of absolute risk of any adverse maternal or infant outcome
Any adverse outcome (%)
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Values represent the absolute risks of any adverse maternal and infant outcome (left panel) and the percentages of 
participants (right panel) for each combination of body mass index and gestational weight gain. Absolute risk was cal-
culated as No. of participants (any adverse outcome)/No. of participants (body mass index and gestational weight gain 
category) × 100. The percentages of participants were calculated as the number of participants with each combination 
of body mass index and gestational weight gain as a percentage of the total study sample. The total study sample size 
was 196 670. Participants in the extreme categories of prepregnancy body mass index (calculated as weight in kilo-
grams divided by height in meters squared) and gestational weight gain had values beyond the most extreme labeled 
tick marks. Any adverse outcome includes preeclampsia (gestational hypertension plus proteinuria), gestational hyper-
tension (systolic blood pressure ≥140mmHg, diastolic blood pressure ≥90mmHg, or both after 20weeks of gestation in 
previously normotensive women), gestational diabetes (a random glucose level >11.0 mmol/L, a fasting glucose level 
≥7.0 mmol/L, or a fasting glucose level between 6.1 and 6.9 mmol/L with a subsequent abnormal glucose tolerance test 
[glucose level >7.8 mmol/L after glucose intake]), cesarean delivery, preterm birth (gestational age at birth <37weeks), 
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Absolute risk was calculated as (No. of women with adverse outcome/No. of women in gestational weight gain cat-
egory within body mass index group) × 100. The symbols represent the absolute risk for women in each gestational 
weight gain category. The gestational weight gain categories were 2 kg each. Participants in the extreme categories 
of gestational weight gain had values beyond the most extreme labeled tick marks. The maternal body mass index 
(calculated as weight in kilograms divided by height in meters squared) categories were underweight (<18.5), normal 
weight (18.5-24.9), overweight (25.0-29.9), obesity grade 1(30.0-34.9), obesity grade 2 (35.0-39.9), and obesity grade 
3 (≥40.0). Any adverse outcome includes preeclampsia (gestational hypertension plus proteinuria), gestational hyper-
tension (systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or both after 20 weeks of gestation 
in previously normotensive women), gestational diabetes (a random glucose level >11.0 mmol/L, a fasting glucose level 
≥7.0 mmol/L, or a fasting glucose level between 6.1 and 6.9 mmol/L with a subsequent abnormal glucose tolerance test 
[glucose level >7.8 mmol/L after glucose intake]), cesarean delivery, preterm birth (gestational age at birth <37weeks), 
and small or large size for gestational age at birth (sex- and gestational age–adjusted birthweight <10th percentile and 
>90th percentile, respectively). The odds ratios for the risk of any adverse outcome were 1.28 (95%CI, 1.27-1.29) and 
1.04 (95%CI, 1.03-1.05) per 1-SD increase in maternal prepregnancy body mass index and gestational weight gain, 
respectively (P < .001 for comparison). The number of cases for each outcome and the total number of participants in 
each gestational weight gain category appears in Supplemental Table 7.
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Optimal gestational weight gain per clinical BMI group
The optimal gestational weight gain ranges associated with the lowest risks for any adverse 
outcome appear in Figure 3. Among women categorized as underweight, the optimal 
gestational weight gain range was 14.0 kg to less than 16.0 kg, with corresponding OR 
and absolute risk reduction (ARR; the percentage reduction in absolute risk of any adverse 
outcome) of 0.74 (95% CI, 0.65-0.84) and 0.07% (95% CI, 0.04%-0.09%), respectively. 
Among women categorized as normal weight, the optimal gestational weight gain range 
was 10.0 kg to less than 18.0 kg (ORs at the outer ends of this range, 0.96 [95%CI, 0.93- 
0.99] and 0.91 [95%CI, 0.88-0.95]; ARRs, 0.01% [95%CI, 0%- 0.01%] and 0.02% [95%CI, 
0.01%-0.03%]).Among women categorized as overweight, the optimal gestational weight 
gain range was 2.0 kg to less than 16.0 kg (ORs at the outer ends of this range, 0.81 
[95% CI, 0.69-0.95] and 0.90 [95% CI, 0.85- 0.96]; ARRs, 0.05% [95%CI, 0.01%-0.08%] 
and 0.02% [95% CI, 0.01%-0.04%]). Among women categorized as obesity grade 1, the 
optimal gestational weight gain range was 2.0 kg to less than 6.0 kg (ORs at the outer ends 
of this range, 0.76 [95%CI, 0.64-0.91] and 0.73 [95%CI, 0.64-0.84]; ARRs, 0.07% [95% 
CI, 0.02%-0.11%] and 0.08% [95% CI, 0.04%-0.11%]). Among women categorized as 
obesity grade 2, the optimal gestational weight gain range was weight loss or gain of 0 kg 
to less than 4.0 kg (median weight loss: 3.0 kg; ORs at the outer ends of this range, 0.55 
[95%CI, 0.39-0.78] and 0.67 [95%CI, 0.51-0.88]; ARRs, 0.14% [95% CI, 0.06%-0.22%] 
and 0.10% [95% CI, 0.03%-0.17%]). Among women categorized as obesity grade 3, the 
optimal gestational weight gain range was 0 kg to less than 6.0 kg (ORs for the outer ends 
of this range, 0.59 [95%CI, 0.41-0.85] and 0.62 [95%CI, 0.41-0.94]; ARRs, 0.12% [95%CI, 
0.03%-0.21%] and 0.10% [95%CI, 0%-0.20%]). The ORs and ARRs for each gestational 
weight gain category used to determine the optimal ranges appear in Supplemental Tables 
8 and 9, respectively. The gestational weight gain ranges defined in this study and the NAM 
ranges appear in Supplemental Table 10.
The gestational weight gain ranges in this study were roughly comparable with the NAM 
ranges for underweight, normal weight, and overweight, and were lower for all obesity 
grades. This study classified 11.3% of women (n = 22 236) in the main sample as having 
inadequate gestational weight gain and 33.8% of women (n = 66 463) as having excessive 
gestational weight gain. The NAM categories classified 21.5%of women (n = 42 323) as 
having inadequate gestational weight gain and 42.0% of women (n = 82 544) as having 
excessive gestational weight gain. Gestational weight gain outside the ranges from the 
current study and the NAM ranges was associated with adverse outcomes (Supplemental 
Figures 2 and 3). Each classification system had a low to moderate ability to distinguish 




Figure 3. Associations of gestational weight gain categories with any adverse outcome per 
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NAMThis study
Any adverse outcome
OR indicates odds ratio and it reflects the risk for any adverse outcome per gestational weight gain category for women 
with underweight, normal weight, overweight, obesity grade 1, obesity grade 2, and obesity grade 3, parts A-F, respec-
tively, compared with all other gestational weight gain categories in that specific group for clinical maternal body mass 
index (BMI; calculated as weight in kilograms divided by height in meters squared). The solid circles represent the OR 
for all participants in each gestational weight gain category. The error bars indicate 95%CIs. The red area represents 
the optimal gestational weight gain range according to the current analysis, the gray area represents the gestational 
weight gain ranges recommended by the US National Academy of Medicine (NAM; formerly the Institute of Medicine). 
The gestational weight gain categories were 2 kg each. Participants in the extreme categories of gestational weight 
gain had values beyond the most extreme labeled tick marks. The maternal BMI categories were underweight (<18.5), 
normal weight (18.5-24.9), overweight (25.0-29.9), obesity grade 1 (30.0-34.9), obesity grade 2 (35.0-39.9), and 
obesity grade 3 (≥40.0). Any adverse outcome includes preeclampsia (gestational hypertension plus proteinuria), ges-
tational hypertension (systolic blood pressure ≥140mmHg, diastolic blood pressure ≥90mmHg, or both after 20 weeks 
of gestation in previously normotensive women), gestational diabetes (a random glucose level >11.0 mmol/L, a fasting 
glucose level 7.0 mmol/L, or a fasting glucose level between 6.1 and 6.9 mmol/L with a subsequent abnormal glucose 
tolerance test [glucose level >7.8 mmol/L after glucose intake]), cesarean delivery, preterm birth (gestational age at birth 
<37weeks), and small or large size for gestational age at birth (sex- and gestational age–adjusted birthweight <10th 
percentile and >90th percentile, respectively). For the gestational weight gain ranges defined in this study, a statistically 
significant OR lower than 1 for a gestational weight gain category was considered the optimal weight gain. If a non-
significant association (either with an OR >1, <1, or of 1) for a gestational weight gain category was surrounded by 2 
significant estimates with an OR below 1, that gestational weight gain category was included in the optimal gestational 
weight gain range. The number of cases for each outcome and the total number of participants in each gestational 
weight gain category appear in Supplemental Table 7.The optimal gestational weight gain ranges based only on 
protective associations appear in Supplemental Figure 5.
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Sensitivity analyses
The sensitivity analyses, in which optimal gestational weight gain was determined based 
on protective associations regardless of statistical significance, resulted in broader ranges 
of optimal gestational weight gain (Supplemental Figure 5). Optimal gestational weight 
gain ranges similar to those from the main analyses were observed when length of gestation 
was considered and when participants with missing individual outcome data were excluded 
(Supplemental Table 11). In addition, the sensitivity analyses showed that optimal weight 
gain definitions were not altered by including or excluding preterm birth, cesarean delivery, 
childhood underweight or overweight, gestational diabetes, and preeclampsia as adverse 
outcomes or by adjusting for maternal age and parity (Supplemental Table 11).
Of all the women classified as having excessive gestational weight gain during the full 
pregnancy, 84.6% also would be classified as having excessive weight gain during the first 
half of the pregnancy (Supplemental Figure 6 and Supplemental Tables 12 and 13).
Results for the validation sample showed that the discriminative performance of the optimal 
gestational weight gain ranges developed in this study and the weight gain ranges from the 
NAM guidelines were consistent with findings in the main study sample (range for AUROC, 
0.50-0.79; Supplemental Table 14 and Supplemental Figures 7 and 8).
discussion
Maternal prepregnancy BMI, and to a lesser extent gestational weight gain, are associated 
with risks of adverse maternal and infant adverse outcomes. Gestational weight gain ranges 
that were associated with lower risks for adverse outcomes were 14.0 kg to less than 16.0 
kg for women categorized as being underweight; 10.0 kg to less than 18.0 kg for normal 
weight; 2.0 kg to less than 16.0 kg for overweight; 2.0 kg to less than 6.0 kg for obesity 
grade1; weight loss or gain of 0 kg to less than 4.0 kg for obesity grade 2; and weight gain 
of 0 kg to less than 6.0 kg for obesity grade 3.
Gestational weight gain outside these ranges was associated with adverse outcomes. 
However, discriminative performance of gestational weight gain with adverse maternal and 
infant outcomes was low to moderate. Prepregnancy BMI was more strongly associated with 
adverse maternal and infant outcomes than the amount of gestational weight gain.
Prepregnancy BMI is significantly associated with pregnancy complications and offspring 
obesity and also is associated with gestational weight gain (5, 6). Results from this study sug-
gest that maternal prepregnancy BMI was more strongly associated with adverse maternal 
and infant outcomes than gestational weight gain. Therefore, prepregnancy BMI may be an 
important focus for preconception counseling.
Previous studies that attempted to define optimal gestational weight gain associated 
with fewer adverse outcomes differed considerably among study populations, statistical ap-
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proaches, outcomes, and conclusions regarding optimal gestational weight gain ranges (14, 
16-22). Only 1 study of 120 251 obese US women defined optimal gestational weight gain 
ranges according to maternal obesity grade 1 (4.5 kg-11.3 kg), obesity grade 2 (0 kg-4.1 
kg),and obesity grade 3 (weight loss <4 kg), and that study used data from term births only 
(21).
Compared with prior work, the present study focused on common and important adverse 
maternal and infant outcomes, included women from multiple Western countries, and 
compared the associations of gestational weight gain and prepregnancy BMI with adverse 
outcomes. Consistent with the NAM guidelines, this study used total gestational weight gain 
to identify optimal gestational weight gain ranges instead of gestational weight gain per 
week because gestational weight gain does not have a linear pattern (7, 8). Total gestational 
weight gain is dependent in part on pregnancy duration. The observed results were similar 
after adjustment for gestational age at birth and after excluding preterm births. Consistent 
with the NAM guidelines, this study showed that among women with higher prepregnancy 
BMI, lower gestational weight gain was associated with fewer adverse outcomes. Gesta-
tional weight gain ranges for women categorized as obesity grade 1, 2, or 3 were lower 
than the NAM guidelines and even involved weight loss for severely obese women, although 
neither classification was predictive for adverse outcomes. However, the results for severely 
obese women should be interpreted with caution because the optimal gestational weight 
gain ranges for obesity grades 1 through 3 associated with better outcomes fluctuate and 
do not follow a clear linear trend. These results may represent the relatively small sample 
size of obese women and lack of statistical power rather than biological plausibility. Future 
studies should evaluate the effect and safety of weight loss during pregnancy in severely 
obese women.
Gestational weight gain guidelines are used in several Western countries for preconcep-
tion counseling. The gestational weight gain ranges developed in this study classified fewer 
women as having suboptimal weight gain compared with the NAM guidelines. However, the 
discriminative performance, as indicated by the AUROC, was weak for both classification 
systems. This suggests that the use of gestational weight gain guidelines may need to be 
reconsidered for individual prediction of the risk for adverse outcomes.
Future research should assess whether optimal gestational weight gain ranges combined 
with other maternal and fetal pregnancy characteristics are useful for prediction of adverse 
outcomes. The findings from this study suggest that prepregnancy weight might be a more 
important target for interventions than gestational weight gain. Previous studies of dietary 
and physical activity interventions for pregnant women have not shown an effect on preg-
nancy outcomes (23-26). Based on current evidence, future clinical trials designed to reduce 
weight-related maternal and infant adverse outcomes should focus on maternal weight 
before or at the start of pregnancy.
183
Gestational weight gain and adverse outcomes
3.2
Limitations
This study has several limitations. First, not all invited cohorts were able to participate in the 
current analyses. Second, the analyses did not measure changes in the association of gesta-
tional weight gain with adverse outcomes over time. The results may be biased if the associa-
tion of gestational weight gain with adverse outcomes changed over time. Third, data on 
prepregnancy weight was mainly self-reported, and the latest weight during pregnancy was 
either self-reported or measured. This may have led to misclassification of gestational weight 
gain. Fourth, the composite outcome of any adverse outcome might have been misclassified 
as a result of some missing data for individual outcomes. Fifth, all outcomes were considered 
equally important and the analyses did not account for the differences in outcome severity. 
Sixth, cesarean delivery may be due to many factors and may not be an appropriate outcome 
for studying associations of weight change with adverse maternal outcomes (7). Seventh, in-
formation on stillbirth was not available. Eighth, optimal gestational weight gain was defined 
as a protective association with the risk for any adverse outcome, reflecting the best outcome 
possible and limiting the number of participants incorrectly classified as having adequate 
gestational weight gain. The ranges would be slightly broader if optimal gestational weight 
gain was defined as no increased risk for adverse outcomes, which includes both a protective 
association and a null association. Ninth, the analyses were not adjusted for multiple testing. 
Tenth, as a result of the limited sample sizes for underweight and severely obese women, 
heterogeneity was not assessed. Eleventh, based on the profiles of all the included cohorts, 
about 1% of women were included more than once for multiple pregnancies. Twelfth, for 
some outcomes, discriminative performance in the validation sample was lower than in the 
main sample, potentially resulting from overfitting of the models in the main sample.
Conclusions
In this meta-analysis of pooled individual participant data from 25 cohort studies, the risk 
for adverse maternal and infant outcomes varied by gestational weight gain and across 
the range of prepregnancy weights. The estimates of optimal gestational weight gain may 
inform prenatal counseling; however, the optimal gestational weight gain ranges had limited 
predictive value for the outcomes assessed.
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n = 50 cohorts 
Invited 
n = 39 cohorts  
n = 39 signed agreements 
n = 39 datasets received 
 
n = 277042 participants suitable for analysis 
 
 
n = 8 cohorts 
No response (n = 4) 
Not able to share data (n = 4) 
  
 n = 42 cohorts 
Agreed to participate 
Population for analyses: 
 
n = 25 cohorts 
n = 196670 participants 
Participants from population-based cohorts with 
information on maternal pre-pregnancy BMI, total 
gestational weight gain and at least one maternal 
or infant outcome available  
 
n = 3 cohorts 
No signed agreement returned (n = 2) 
No dataset received (n = 1) 
  
 
n = 52 participants 




n = 29 cohorts 
n = 200227 participants 
Information on maternal pre- pregnancy BMI and 
total gestational weight gain available 
 
n= 10 cohorts 
n = 76815 participants 
No information on maternal pre- 
pregnancy BMI and total gestational 
weight gain available 
  
 
n = 29 cohorts 
n = 200175 participants 
Information on maternal pre-pregnancy BMI, total 
gestational weight gain and at least one maternal 




n = 4 cohorts 
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Supplemental Table 2. Associations of general characteristics with total gestational weight 
gaina
Total gestational weight gain, kg (95% CI)
Pre-pregnancy BMI (kg/m2)b -0.25 (-0.26, -0.24)
Underweight (<18.5 kg/m2) -0.16 (-0.29, -0.04)
Normal weight (18.5-24.9 kg/m2) Reference
Overweight (25.0-29.9 kg/m2) -0.79 (-0.85, -0.73)
Obesity grade 1 (30.0-34.9 kg/m2) -3.48 (-3.58, -3.37)
Obesity grade 2 (35.0-39.9 kg/m2) -5.73 (-5.92, -5.54)
Obesity grade 3 (≥40.0 kg/m2) -7.61 (-7.96, -5.54)
Maternal age (years) -0.11 (-0.12, -0.11)
Parity
Nulliparous Reference
Multiparous -1.07 (-1.12, -1.02)
a Values are regression coefficients from exploratory multilevel linear regression models that represent differences in 
total gestational weight gain for each of the characteristics listed. Models are not adjusted for covariates.
b Body mass index is calculated as weight in kilograms divided by height in meters squared.
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Supplemental Table 3. Description of missing data
Information available Information missing
Outcome n % n %
Main sample (n=196670)
Used in models to construct ranges (main analysis)
Pre-pregnancy BMI 196670 100.0 NA NA
Total gestational weight gain 196670 100.0 NA NA
Any adverse outcome a 196670 100.0 NA NA
Separate outcomes (included in ‘any adverse outcome’)
Gestational hypertensive disorders b 179577 91.3 17093 8.7
Gestational diabetes 189772 96.5 6898 3.5
Caesarean section 186884 95.0 9786 5.0
Preterm birth 188129 95.7 8541 4.3
Size-for-gestational-age at birth 190217 96.7 6453 3.3
All of the separate outcomes used to 
construct ranges (complete cases)c
169437d 86.2 27233e 13.8
Validation sample (Hospital-based) (n=3505)
Any adverse outcome 3505 100.0 NA NA
Gestational hypertensive disorders b 3082 87.9 423 12.1
Gestational diabetes 3084 88.0 421 12.0
Caesarean section 3490 99.6 15 0.4
Preterm birth 3089 88.1 416 11.9
Size-for-gestational-age at birth 3498 99.8 7 0.2
All of the separate outcomes (complete cases) 3059d 87.3 446e 12.7
a Any adverse outcome is defined as the presence of at least one of the following outcomes: pre-eclampsia, gestational 
hypertension, gestational diabetes, caesarean section, preterm birth and small or large size-for-gestational age.
b Includes both pre-eclampsia and gestational hypertension.
c Sensitivity analysis with complete cases is shown in Supplemental Table 10.
d Reflects the number of participants with information on all outcomes included in ‘any adverse outcome’.
e Reflects the number of participants with missing information on one or more of the outcomes included in ‘any adverse 
outcome’.
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Supplemental Table 4. Characteristics of the hospital-based population, used as a validation sample.a
Total group
n=3505
Pre-pregnancy body mass index, median (Q1, Q3)b 22.0 (20.1, 24.8)
Pre-pregnancy body mass indexb
Underweight (<18.5 kg/m2) 277 (7.9)
Normal weight (18.5-24.9 kg/m2) 2400 (68.4)
Overweight (25.0-29.9 kg/m2) 577 (16.5)
Obesity grade 1 (30.0-34.9 kg/m2) 188 (5.4)
Obesity grade 2 (35.0-39.9 kg/m2) 53 (1.5)
Obesity grade 3 (≥40.0 kg/m2) 10 (0.3)
Total gestational weight gain (kg)
Median (Q1, Q3) 13.0 (10.7, 16.0)
P2.5, P97.5 4.0, 24.0
Maternal age (years), median (Q1, Q3) 31.0 (27.7, 34.7)
Educationc
Low, n (%) 721 (20.6)
Medium, n (%) 1254 (35.9)
High, n (%) 1521 (43.5)
Country
France, n (%) 1794 (51.2)
Italy, n (%) 1296 (37.0)
Finland, n (%) 415 (11.8)
Gestational hypertension, n (%)d 102 (3.4)
Pre-eclampsia, n (%)e 61 (2.0)
Gestational diabetes, n (%)f 162 (5.3)
Caesarean section, n (%) 653 (18.7)
Preterm birth, n (%)g 140 (4.5)
Small size-for-gestational-age, n (%)h 349 (10.0)
Large size-for-gestational-age, n (%)i 348 (10.0)
Childhood underweight, n (%)j 21 (0.8)
Childhood overweight, n (%)k 563 (20.5)
Any adverse outcome, n (%)l 1423 (40.6)
a Values are median (Q1, Q3), median (P2.5, P97.5) or n (valid %). b Body mass index is calculated as weight in kilograms 
divided by height in meters squared. c Education level was based on cohort-specific criteria. Each cohort used their own 
country-specific criteria to define low, medium and high educational level. These 3 categories were subsequently used 
in the meta-analysis. d Gestational hypertension is defined as systolic blood pressure ≥140 mmHg and/or diastolic blood 
pressure ≥90 mmHg after 20 weeks of gestation in previously normotensive women. e Pre-eclampsia is defined as ges-
tational hypertension plus proteinuria. f Gestational diabetes is defined as either a random glucose level >11.0 mmol/L, 
a fasting glucose level ≥7.0 mmol/L or a fasting glucose level between 6.1 and 6.9 mmol/L with a subsequent abnormal 
glucose tolerance test (glucose level >7.8 mmol/L after glucose intake). g Preterm birth is defined as gestational age at 
birth <37 weeks. h Small size-for-gestational-age at birth is defined as sex- and gestational age adjusted birth weight 
<10th percentile. i Large size-for-gestational-age at birth is defined as sex- and gestational age adjusted birth >90th per-
centile. j Childhood underweight at the highest age available for each child (median (Q1, Q3): 84.9 (61.9, 95.9) months) 
is defined as sex- and age adjusted standard deviation scores (SDS) <-2 SDS for children of 2-5 years of age, and <-2 SDS 
for children of >5 years. k Childhood overweight at the highest age available for each child (median (Q1, Q3): 84.9 (61.9, 
95.9) months) is defined as sex- and age adjusted standard deviation scores (SDS) >2.0 SDS for children of 2-5 years 
of age, and >1 SDS for children of >5 years. l Any adverse outcome includes pre-eclampsia, gestational hypertension, 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total %
Underweight (n=7809)
<8 10 346 2.9 12 348 3.4 5 389 1.3 55 348 15.8 54 381 14.2 125 390 32.1 3 268 1.1 203 404 50.2
8 to 9.9 6 526 1.1 12 532 2.3 9 597 1.5 68 562 12.1 55 568 9.7 147 585 25.1 12 450 2.7 252 619 40.7
10 to 11.9 12 1011 1.2 17 1016 1.7 12 1117 1.1 144 1095 13.2 78 1070 7.3 236 1087 21.7 26 877 3 434 1175 36.9
12 to 13.9 12 1235 1.0 22 1245 1.8 8 1365 0.6 174 1357 12.8 71 1299 5.5 275 1342 20.5 25 1092 2.3 506 1437 35.2
14 to 15.9 18 1181 1.5 19 1182 1.6 8 1269 0.6 134 1269 10.6 39 1217 3.2 195 1237 15.8 33 1075 3.1 387 1326 29.2
16 to 17.9 17 864 2.0 27 874 3.1 5 955 0.5 109 956 11.4 29 930 3.1 161 909 17.7 42 790 5.3 334 993 33.6
18 to 19.9 9 536 1.7 9 536 1.7 2 591 0.3 77 597 12.9 20 577 3.5 69 552 12.5 40 523 7.6 198 623 31.8
20 to 21.9 7 438 1.6 9 440 2.0 3 475 0.6 62 478 13.0 16 481 3.3 72 467 15.4 20 415 4.8 157 499 31.5
>=22 21 628 3.3 24 631 3.8 5 706 0.7 104 699 14.9 21 708 3.0 56 654 8.6 55 653 8.4 235 733 32.1
Normal weight (n=133788)
Weight loss 2 100 2.0 2 100 2.0 3 107 2.8 18 106 17.0 11 98 11.2 16 99 16.2 5 88 5.7 47 109 43.1
0 to 1.9 6 309 1.9 6 309 1.9 9 341 2.6 52 325 16.0 37 343 10.8 74 328 22.6 19 273 7.0 158 356 44.4
2 to 3.9 6 499 1.2 17 510 3.3 22 560 3.9 67 524 12.8 63 537 11.7 113 534 21.2 25 446 5.6 245 577 42.5
4 to 5.9 21 1505 1.4 42 1526 2.8 43 1664 2.6 219 1542 14.2 180 1604 11.2 305 1597 19.1 66 1358 4.9 691 1721 40.2
6 to 7.9 84 3882 2.2 123 3921 3.1 112 4327 2.6 621 4049 15.3 393 4142 9.5 811 4124 19.7 143 3456 4.1 1793 4463 40.2
8 to 9.9 151 8369 1.8 217 8435 2.6 170 9289 1.8 1172 8823 13.3 630 9015 7.0 1488 8901 16.7 370 7783 4.8 3412 9658 35.3
10 to 11.9 271 14885 1.8 405 15019 2.7 233 16444 1.4 2079 15933 13.0 888 16017 5.5 2253 15519 14.5 823 14089 5.8 5742 17081 33.6
12 to 13.9 386 20354 1.9 519 20487 2.5 224 22312 1.0 2910 21916 13.3 916 21971 4.2 2549 20940 12.2 1354 19745 6.9 7424 23217 32.0
14 to 15.9 456 20396 2.2 567 20507 2.8 195 22221 0.9 2963 21973 13.5 716 21973 3.3 2123 20493 10.4 1710 20080 8.5 7314 23073 31.7
16 to 17.9 358 15522 2.3 512 15676 3.3 132 16896 0.8 2326 16731 13.9 502 16737 3.0 1445 15387 9.4 1507 15449 9.8 5648 17498 32.3
18 to 19.9 299 10954 2.7 356 11011 3.2 88 11862 0.7 1671 11794 14.2 341 11817 2.9 925 10543 8.8 1362 10980 12.4 4161 12271 33.9
20 to 21.9 319 8903 3.6 326 8910 3.7 76 9644 0.8 1432 9666 14.8 263 9729 2.7 665 8550 7.8 1208 9093 13.3 3511 10011 35.1
22 to 23.9 209 4962 4.2 155 4908 3.2 33 5330 0.6 851 5358 15.9 125 5369 2.3 333 4569 7.3 803 5039 15.9 2046 5526 37.0
24 to 25.9 187 3473 5.4 137 3423 4 31 3745 0.8 631 3760 16.8 112 3819 2.9 197 3188 6.2 625 3616 17.3 1548 3882 39.9
26 to 27.9 92 1476 6.2 59 1443 4.1 18 1624 1.1 289 1607 18.0 46 1619 2.8 104 1365 7.6 253 1514 16.7 691 1666 41.5
>=28.0 220 2339 9.4 140 2259 6.2 18 2590 0.7 524 2597 20.2 91 2631 3.5 126 2106 6.0 516 2496 20.7 1256 2679 46.9
a Values are number of cases of each outcome, total number of participants, and absolute risks of adverse maternal and 
infant outcomes (%, calculated as (n (outcome) / n (gestational weight gain category within BMI group))*100 ) within 
in each gestational weight gain category.
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Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total %
Underweight (n=7809)
<8 10 346 2.9 12 348 3.4 5 389 1.3 55 348 15.8 54 381 14.2 125 390 32.1 3 268 1.1 203 404 50.2
8 to 9.9 6 526 1.1 12 532 2.3 9 597 1.5 68 562 12.1 55 568 9.7 147 585 25.1 12 450 2.7 252 619 40.7
10 to 11.9 12 1011 1.2 17 1016 1.7 12 1117 1.1 144 1095 13.2 78 1070 7.3 236 1087 21.7 26 877 3 434 1175 36.9
12 to 13.9 12 1235 1.0 22 1245 1.8 8 1365 0.6 174 1357 12.8 71 1299 5.5 275 1342 20.5 25 1092 2.3 506 1437 35.2
14 to 15.9 18 1181 1.5 19 1182 1.6 8 1269 0.6 134 1269 10.6 39 1217 3.2 195 1237 15.8 33 1075 3.1 387 1326 29.2
16 to 17.9 17 864 2.0 27 874 3.1 5 955 0.5 109 956 11.4 29 930 3.1 161 909 17.7 42 790 5.3 334 993 33.6
18 to 19.9 9 536 1.7 9 536 1.7 2 591 0.3 77 597 12.9 20 577 3.5 69 552 12.5 40 523 7.6 198 623 31.8
20 to 21.9 7 438 1.6 9 440 2.0 3 475 0.6 62 478 13.0 16 481 3.3 72 467 15.4 20 415 4.8 157 499 31.5
>=22 21 628 3.3 24 631 3.8 5 706 0.7 104 699 14.9 21 708 3.0 56 654 8.6 55 653 8.4 235 733 32.1
Normal weight (n=133788)
Weight loss 2 100 2.0 2 100 2.0 3 107 2.8 18 106 17.0 11 98 11.2 16 99 16.2 5 88 5.7 47 109 43.1
0 to 1.9 6 309 1.9 6 309 1.9 9 341 2.6 52 325 16.0 37 343 10.8 74 328 22.6 19 273 7.0 158 356 44.4
2 to 3.9 6 499 1.2 17 510 3.3 22 560 3.9 67 524 12.8 63 537 11.7 113 534 21.2 25 446 5.6 245 577 42.5
4 to 5.9 21 1505 1.4 42 1526 2.8 43 1664 2.6 219 1542 14.2 180 1604 11.2 305 1597 19.1 66 1358 4.9 691 1721 40.2
6 to 7.9 84 3882 2.2 123 3921 3.1 112 4327 2.6 621 4049 15.3 393 4142 9.5 811 4124 19.7 143 3456 4.1 1793 4463 40.2
8 to 9.9 151 8369 1.8 217 8435 2.6 170 9289 1.8 1172 8823 13.3 630 9015 7.0 1488 8901 16.7 370 7783 4.8 3412 9658 35.3
10 to 11.9 271 14885 1.8 405 15019 2.7 233 16444 1.4 2079 15933 13.0 888 16017 5.5 2253 15519 14.5 823 14089 5.8 5742 17081 33.6
12 to 13.9 386 20354 1.9 519 20487 2.5 224 22312 1.0 2910 21916 13.3 916 21971 4.2 2549 20940 12.2 1354 19745 6.9 7424 23217 32.0
14 to 15.9 456 20396 2.2 567 20507 2.8 195 22221 0.9 2963 21973 13.5 716 21973 3.3 2123 20493 10.4 1710 20080 8.5 7314 23073 31.7
16 to 17.9 358 15522 2.3 512 15676 3.3 132 16896 0.8 2326 16731 13.9 502 16737 3.0 1445 15387 9.4 1507 15449 9.8 5648 17498 32.3
18 to 19.9 299 10954 2.7 356 11011 3.2 88 11862 0.7 1671 11794 14.2 341 11817 2.9 925 10543 8.8 1362 10980 12.4 4161 12271 33.9
20 to 21.9 319 8903 3.6 326 8910 3.7 76 9644 0.8 1432 9666 14.8 263 9729 2.7 665 8550 7.8 1208 9093 13.3 3511 10011 35.1
22 to 23.9 209 4962 4.2 155 4908 3.2 33 5330 0.6 851 5358 15.9 125 5369 2.3 333 4569 7.3 803 5039 15.9 2046 5526 37.0
24 to 25.9 187 3473 5.4 137 3423 4 31 3745 0.8 631 3760 16.8 112 3819 2.9 197 3188 6.2 625 3616 17.3 1548 3882 39.9
26 to 27.9 92 1476 6.2 59 1443 4.1 18 1624 1.1 289 1607 18.0 46 1619 2.8 104 1365 7.6 253 1514 16.7 691 1666 41.5
>=28.0 220 2339 9.4 140 2259 6.2 18 2590 0.7 524 2597 20.2 91 2631 3.5 126 2106 6.0 516 2496 20.7 1256 2679 46.9
a Values are number of cases of each outcome, total number of participants, and absolute risks of adverse maternal and 
infant outcomes (%, calculated as (n (outcome) / n (gestational weight gain category within BMI group))*100 ) within 
in each gestational weight gain category.
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Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total %
Overweight (n=38828)
Weight loss 11 192 5.7 3 184 1.6 9 206 4.4 34 195 17.4 21 199 10.6 28 188 14.9 18 178 10.1 88 213 41.3
0 to 1.9 15 489 3.1 28 502 5.6 31 530 5.8 82 510 16.1 42 534 7.9 73 501 14.6 35 463 7.6 236 546 43.2
2 to 3.9 16 598 2.7 17 599 2.8 24 651 3.7 98 623 15.7 49 638 7.7 80 603 13.3 40 563 7.1 249 667 37.3
4 to 5.9 31 1120 2.8 47 1136 4.1 47 1235 3.8 218 1206 18.1 71 1205 5.9 160 1134 14.1 96 1070 9.0 505 1271 39.7
6 to 7.9 63 1961 3.2 72 1970 3.7 82 2138 3.8 334 2071 16.1 148 2108 7.0 224 1970 11.4 167 1913 8.7 850 2206 38.5
8 to 9.9 97 2983 3.3 166 3052 5.4 87 3308 2.6 592 3235 18.3 191 3267 5.8 336 3004 11.2 313 2981 10.5 1383 3416 40.5
10 to 11.9 135 4252 3.2 179 4296 4.2 132 4688 2.8 826 4608 17.9 243 4638 5.2 418 4199 10.0 490 4271 11.5 1928 4847 39.8
12 to 13.9 186 4861 3.8 229 4904 4.7 118 5342 2.2 893 5313 16.8 217 5345 4.1 429 4768 9.0 627 4966 12.6 2148 5551 38.7
14 to 15.9 202 4768 4.2 249 4815 5.2 86 5252 1.6 928 5177 17.9 205 5249 3.9 384 4587 8.4 688 4891 14.1 2154 5400 39.9
16 to 17.9 188 3662 5.1 232 3706 6.3 71 4037 1.8 735 3983 18.5 133 4032 3.3 247 3413 7.2 629 3795 16.6 1787 4136 43.2
18 to 19.9 147 2713 5.4 149 2715 5.5 42 2951 1.4 605 2943 20.6 99 2973 3.3 189 2538 7.4 442 2791 15.8 1304 3045 42.8
20 to 21.9 172 2596 6.6 137 2561 5.3 34 2830 1.2 574 2835 20.2 110 2881 3.8 171 2320 7.4 545 2694 20.2 1325 2925 45.3
22 to 23.9 83 1406 5.9 91 1414 6.4 22 1545 1.4 323 1555 20.8 38 1563 2.4 83 1245 6.7 312 1474 21.2 760 1583 48.0
24 to 25.9 101 1159 8.7 80 1138 7.0 13 1272 1.0 282 1272 22.2 42 1288 3.3 73 1025 7.1 257 1209 21.3 636 1304 48.8
26 to 27.9 55 545 10.1 33 523 6.3 6 592 1.0 148 600 24.7 16 601 2.7 25 457 5.5 143 575 24.9 315 611 51.6
>=28.0 135 983 13.7 64 912 7.0 14 1064 1.3 272 1084 25.1 39 1093 3.6 43 786 5.5 297 1040 28.6 624 1107 56.4
Obesity grade 1 (n=11992)
Weight loss 6 251 2.4 12 257 4.7 14 273 5.1 60 260 23.1 26 266 9.8 29 242 12.0 26 239 10.9 128 275 46.5
0 to 1.9 29 541 5.4 26 538 4.8 37 576 6.4 113 575 19.7 46 588 7.8 59 523 11.3 64 528 12.1 280 596 47.0
2 to 3.9 28 473 5.9 23 468 4.9 29 515 5.6 100 509 19.6 36 513 7.0 56 471 11.9 46 461 10.0 234 533 43.9
4 to 5.9 31 741 4.2 52 762 6.8 46 854 5.4 167 817 20.4 54 834 6.5 70 750 9.3 96 776 12.4 377 872 43.2
6 to 7.9 62 898 6.9 77 913 8.4 50 1034 4.8 232 1013 22.9 66 1028 6.4 97 882 11.0 160 945 16.9 549 1068 51.4
8 to 9.9 80 1166 6.9 95 1181 8.0 51 1313 3.9 292 1302 22.4 81 1317 6.2 124 1142 10.9 183 1201 15.2 663 1359 48.8
10 to 11.9 81 1264 6.4 100 1283 7.8 53 1426 3.7 317 1419 22.3 64 1450 4.4 128 1241 10.3 213 1326 16.1 720 1487 48.4
12 to 13.9 82 1246 6.6 107 1271 8.4 34 1419 2.4 321 1405 22.8 83 1435 5.8 108 1181 9.1 254 1327 19.1 741 1463 50.6
14 to 15.9 81 1136 7.1 83 1138 7.3 38 1267 3.0 301 1264 23.8 51 1274 4.0 71 1031 6.9 237 1197 19.8 644 1301 49.5
16 to 17.9 68 774 8.8 73 779 9.4 25 876 2.9 215 870 24.7 38 890 4.3 50 699 7.2 191 840 22.7 472 905 52.2
18 to 19.9 47 484 9.7 40 477 8.4 13 536 2.4 128 542 23.6 22 550 4.0 29 416 7.0 134 521 25.7 290 561 51.7
20 to 21.9 59 507 11.6 32 480 6.7 12 550 2.2 147 556 26.4 33 566 5.8 31 424 7.3 142 535 26.5 319 575 55.5
22 to 23.9 49 301 16.3 26 278 9.4 7 334 2.1 84 335 25.1 16 334 4.8 17 252 6.7 77 312 24.7 197 341 57.8
24 to 25.9 30 238 12.6 17 225 7.6 6 255 2.4 74 258 28.7 13 261 5.0 11 198 5.6 61 248 24.6 144 262 55.0
26 to 27.9 14 116 12.1 17 119 14.3 1 138 0.7 53 138 38.4 3 137 2.2 6 90 6.7 48 132 36.4 101 143 70.6
>=28.0 34 207 16.4 27 200 13.5 4 242 1.7 81 244 33.2 11 249 4.4 14 183 7.7 63 232 27.2 160 251 63.7
a Values are number of cases of each outcome, total number of participants, and absolute risks of adverse maternal and 
infant outcomes (%, calculated as (n (outcome) / n (gestational weight gain category within BMI group))*100 ) within 
in each gestational weight gain category.
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Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total %
Overweight (n=38828)
Weight loss 11 192 5.7 3 184 1.6 9 206 4.4 34 195 17.4 21 199 10.6 28 188 14.9 18 178 10.1 88 213 41.3
0 to 1.9 15 489 3.1 28 502 5.6 31 530 5.8 82 510 16.1 42 534 7.9 73 501 14.6 35 463 7.6 236 546 43.2
2 to 3.9 16 598 2.7 17 599 2.8 24 651 3.7 98 623 15.7 49 638 7.7 80 603 13.3 40 563 7.1 249 667 37.3
4 to 5.9 31 1120 2.8 47 1136 4.1 47 1235 3.8 218 1206 18.1 71 1205 5.9 160 1134 14.1 96 1070 9.0 505 1271 39.7
6 to 7.9 63 1961 3.2 72 1970 3.7 82 2138 3.8 334 2071 16.1 148 2108 7.0 224 1970 11.4 167 1913 8.7 850 2206 38.5
8 to 9.9 97 2983 3.3 166 3052 5.4 87 3308 2.6 592 3235 18.3 191 3267 5.8 336 3004 11.2 313 2981 10.5 1383 3416 40.5
10 to 11.9 135 4252 3.2 179 4296 4.2 132 4688 2.8 826 4608 17.9 243 4638 5.2 418 4199 10.0 490 4271 11.5 1928 4847 39.8
12 to 13.9 186 4861 3.8 229 4904 4.7 118 5342 2.2 893 5313 16.8 217 5345 4.1 429 4768 9.0 627 4966 12.6 2148 5551 38.7
14 to 15.9 202 4768 4.2 249 4815 5.2 86 5252 1.6 928 5177 17.9 205 5249 3.9 384 4587 8.4 688 4891 14.1 2154 5400 39.9
16 to 17.9 188 3662 5.1 232 3706 6.3 71 4037 1.8 735 3983 18.5 133 4032 3.3 247 3413 7.2 629 3795 16.6 1787 4136 43.2
18 to 19.9 147 2713 5.4 149 2715 5.5 42 2951 1.4 605 2943 20.6 99 2973 3.3 189 2538 7.4 442 2791 15.8 1304 3045 42.8
20 to 21.9 172 2596 6.6 137 2561 5.3 34 2830 1.2 574 2835 20.2 110 2881 3.8 171 2320 7.4 545 2694 20.2 1325 2925 45.3
22 to 23.9 83 1406 5.9 91 1414 6.4 22 1545 1.4 323 1555 20.8 38 1563 2.4 83 1245 6.7 312 1474 21.2 760 1583 48.0
24 to 25.9 101 1159 8.7 80 1138 7.0 13 1272 1.0 282 1272 22.2 42 1288 3.3 73 1025 7.1 257 1209 21.3 636 1304 48.8
26 to 27.9 55 545 10.1 33 523 6.3 6 592 1.0 148 600 24.7 16 601 2.7 25 457 5.5 143 575 24.9 315 611 51.6
>=28.0 135 983 13.7 64 912 7.0 14 1064 1.3 272 1084 25.1 39 1093 3.6 43 786 5.5 297 1040 28.6 624 1107 56.4
Obesity grade 1 (n=11992)
Weight loss 6 251 2.4 12 257 4.7 14 273 5.1 60 260 23.1 26 266 9.8 29 242 12.0 26 239 10.9 128 275 46.5
0 to 1.9 29 541 5.4 26 538 4.8 37 576 6.4 113 575 19.7 46 588 7.8 59 523 11.3 64 528 12.1 280 596 47.0
2 to 3.9 28 473 5.9 23 468 4.9 29 515 5.6 100 509 19.6 36 513 7.0 56 471 11.9 46 461 10.0 234 533 43.9
4 to 5.9 31 741 4.2 52 762 6.8 46 854 5.4 167 817 20.4 54 834 6.5 70 750 9.3 96 776 12.4 377 872 43.2
6 to 7.9 62 898 6.9 77 913 8.4 50 1034 4.8 232 1013 22.9 66 1028 6.4 97 882 11.0 160 945 16.9 549 1068 51.4
8 to 9.9 80 1166 6.9 95 1181 8.0 51 1313 3.9 292 1302 22.4 81 1317 6.2 124 1142 10.9 183 1201 15.2 663 1359 48.8
10 to 11.9 81 1264 6.4 100 1283 7.8 53 1426 3.7 317 1419 22.3 64 1450 4.4 128 1241 10.3 213 1326 16.1 720 1487 48.4
12 to 13.9 82 1246 6.6 107 1271 8.4 34 1419 2.4 321 1405 22.8 83 1435 5.8 108 1181 9.1 254 1327 19.1 741 1463 50.6
14 to 15.9 81 1136 7.1 83 1138 7.3 38 1267 3.0 301 1264 23.8 51 1274 4.0 71 1031 6.9 237 1197 19.8 644 1301 49.5
16 to 17.9 68 774 8.8 73 779 9.4 25 876 2.9 215 870 24.7 38 890 4.3 50 699 7.2 191 840 22.7 472 905 52.2
18 to 19.9 47 484 9.7 40 477 8.4 13 536 2.4 128 542 23.6 22 550 4.0 29 416 7.0 134 521 25.7 290 561 51.7
20 to 21.9 59 507 11.6 32 480 6.7 12 550 2.2 147 556 26.4 33 566 5.8 31 424 7.3 142 535 26.5 319 575 55.5
22 to 23.9 49 301 16.3 26 278 9.4 7 334 2.1 84 335 25.1 16 334 4.8 17 252 6.7 77 312 24.7 197 341 57.8
24 to 25.9 30 238 12.6 17 225 7.6 6 255 2.4 74 258 28.7 13 261 5.0 11 198 5.6 61 248 24.6 144 262 55.0
26 to 27.9 14 116 12.1 17 119 14.3 1 138 0.7 53 138 38.4 3 137 2.2 6 90 6.7 48 132 36.4 101 143 70.6
>=28.0 34 207 16.4 27 200 13.5 4 242 1.7 81 244 33.2 11 249 4.4 14 183 7.7 63 232 27.2 160 251 63.7
a Values are number of cases of each outcome, total number of participants, and absolute risks of adverse maternal and 
infant outcomes (%, calculated as (n (outcome) / n (gestational weight gain category within BMI group))*100 ) within 
in each gestational weight gain category.
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Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total %
Obesity grade 2 (n=3284)
Weight loss 5 139 3.6 3 137 2.2 6 150 4.0 31 145 21.4 8 149 5.4 14 127 11.0 21 134 15.7 65 151 43.0
0.0 to 1.9 17 274 6.2 29 286 10.1 31 309 10 80 314 25.5 22 317 6.9 26 270 9.6 46 290 15.9 175 322 54.3
2.0 to 3.9 14 194 7.2 12 192 6.3 19 214 8.9 48 214 22.4 9 216 4.2 17 182 9.3 32 197 16.2 105 221 47.5
4.0 to 5.9 25 241 10.4 26 242 10.7 17 280 6.1 73 284 25.7 20 287 7.0 13 237 5.5 51 275 18.5 168 297 56.6
6.0 to 7.9 25 299 8.4 31 305 10.2 22 349 6.3 90 349 25.8 15 353 4.2 22 288 7.6 62 328 18.9 189 363 52.1
8.0 to 9.9 28 314 8.9 34 320 10.6 16 368 4.3 107 362 29.6 26 374 7.0 21 290 7.2 80 349 22.9 220 380 57.9
10.0 to 11.9 28 337 8.3 32 341 9.4 16 387 4.1 100 380 26.3 22 390 5.6 31 320 9.7 71 360 19.7 212 398 53.3
12.0 to 13.9 39 285 13.7 29 275 10.5 17 323 5.3 93 324 28.7 14 328 4.3 23 255 9.0 73 305 23.9 195 334 58.4
14.0 to 15.9 22 216 10.2 24 218 11 10 247 4.0 77 247 31.2 11 247 4.5 20 186 10.8 60 226 26.5 152 251 60.6
>=16.0 84 463 18.1 64 443 14.4 29 549 5.3 183 554 33.0 30 556 5.4 37 400 9.3 153 516 29.7 384 567 67.7
Obesity grade 3 (n=969)
Weight loss 5 73 6.8 4 72 5.6 9 85 10.6 29 84 34.5 10 85 11.8 7 73 9.6 11 77 14.3 52 87 59.8
0.0 to 1.9 14 120 11.7 7 113 6.2 9 134 6.7 34 140 24.3 11 142 7.7 12 121 9.9 19 128 14.8 73 144 50.7
2.0 to 3.9 5 52 9.6 10 57 17.5 4 64 6.3 25 63 39.7 7 66 10.6 10 48 20.8 18 56 32.1 46 67 68.7
4.0 to 5.9 9 92 9.8 6 89 6.7 8 102 7.8 32 101 31.7 3 108 2.8 7 86 8.1 21 100 21.0 56 108 51.9
6.0 to 7.9 14 79 17.7 10 75 13.3 4 92 4.3 35 93 37.6 6 93 6.5 10 72 13.9 21 83 25.3 64 96 66.7
8.0 to 9.9 8 91 8.8 8 91 8.8 6 101 5.9 32 102 31.4 5 106 4.7 6 83 7.2 20 97 20.6 60 107 56.1
10.0 to 11.9 13 86 15.1 9 82 11.0 5 98 5.1 21 97 21.6 6 100 6.0 10 77 13.0 23 90 25.6 56 101 55.4
12.0 to 13.9 13 64 20.3 5 56 8.9 5 76 6.6 23 74 31.1 8 75 10.7 7 55 12.7 20 68 29.4 48 77 62.3
14.0 to 15.9 7 49 14.3 10 52 19.2 4 59 6.8 22 61 36.1 4 62 6.5 5 40 12.5 21 56 37.5 44 64 68.8
>=16.0 24 102 23.5 13 91 14.3 7 116 6.0 51 114 44.7 9 117 7.7 6 73 8.2 43 110 39.1 93 118 78.8
a Values are number of cases of each outcome, total number of participants, and absolute risks of adverse maternal and 
infant outcomes (%, calculated as (n (outcome) / n (gestational weight gain category within BMI group))*100 ) within 
in each gestational weight gain category.
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Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total % Cases Total %
Obesity grade 2 (n=3284)
Weight loss 5 139 3.6 3 137 2.2 6 150 4.0 31 145 21.4 8 149 5.4 14 127 11.0 21 134 15.7 65 151 43.0
0.0 to 1.9 17 274 6.2 29 286 10.1 31 309 10 80 314 25.5 22 317 6.9 26 270 9.6 46 290 15.9 175 322 54.3
2.0 to 3.9 14 194 7.2 12 192 6.3 19 214 8.9 48 214 22.4 9 216 4.2 17 182 9.3 32 197 16.2 105 221 47.5
4.0 to 5.9 25 241 10.4 26 242 10.7 17 280 6.1 73 284 25.7 20 287 7.0 13 237 5.5 51 275 18.5 168 297 56.6
6.0 to 7.9 25 299 8.4 31 305 10.2 22 349 6.3 90 349 25.8 15 353 4.2 22 288 7.6 62 328 18.9 189 363 52.1
8.0 to 9.9 28 314 8.9 34 320 10.6 16 368 4.3 107 362 29.6 26 374 7.0 21 290 7.2 80 349 22.9 220 380 57.9
10.0 to 11.9 28 337 8.3 32 341 9.4 16 387 4.1 100 380 26.3 22 390 5.6 31 320 9.7 71 360 19.7 212 398 53.3
12.0 to 13.9 39 285 13.7 29 275 10.5 17 323 5.3 93 324 28.7 14 328 4.3 23 255 9.0 73 305 23.9 195 334 58.4
14.0 to 15.9 22 216 10.2 24 218 11 10 247 4.0 77 247 31.2 11 247 4.5 20 186 10.8 60 226 26.5 152 251 60.6
>=16.0 84 463 18.1 64 443 14.4 29 549 5.3 183 554 33.0 30 556 5.4 37 400 9.3 153 516 29.7 384 567 67.7
Obesity grade 3 (n=969)
Weight loss 5 73 6.8 4 72 5.6 9 85 10.6 29 84 34.5 10 85 11.8 7 73 9.6 11 77 14.3 52 87 59.8
0.0 to 1.9 14 120 11.7 7 113 6.2 9 134 6.7 34 140 24.3 11 142 7.7 12 121 9.9 19 128 14.8 73 144 50.7
2.0 to 3.9 5 52 9.6 10 57 17.5 4 64 6.3 25 63 39.7 7 66 10.6 10 48 20.8 18 56 32.1 46 67 68.7
4.0 to 5.9 9 92 9.8 6 89 6.7 8 102 7.8 32 101 31.7 3 108 2.8 7 86 8.1 21 100 21.0 56 108 51.9
6.0 to 7.9 14 79 17.7 10 75 13.3 4 92 4.3 35 93 37.6 6 93 6.5 10 72 13.9 21 83 25.3 64 96 66.7
8.0 to 9.9 8 91 8.8 8 91 8.8 6 101 5.9 32 102 31.4 5 106 4.7 6 83 7.2 20 97 20.6 60 107 56.1
10.0 to 11.9 13 86 15.1 9 82 11.0 5 98 5.1 21 97 21.6 6 100 6.0 10 77 13.0 23 90 25.6 56 101 55.4
12.0 to 13.9 13 64 20.3 5 56 8.9 5 76 6.6 23 74 31.1 8 75 10.7 7 55 12.7 20 68 29.4 48 77 62.3
14.0 to 15.9 7 49 14.3 10 52 19.2 4 59 6.8 22 61 36.1 4 62 6.5 5 40 12.5 21 56 37.5 44 64 68.8
>=16.0 24 102 23.5 13 91 14.3 7 116 6.0 51 114 44.7 9 117 7.7 6 73 8.2 43 110 39.1 93 118 78.8
a Values are number of cases of each outcome, total number of participants, and absolute risks of adverse maternal and 
infant outcomes (%, calculated as (n (outcome) / n (gestational weight gain category within BMI group))*100 ) within 
in each gestational weight gain category.
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Supplemental Table 8. Odds Ratios for the associations of gestational weight gain categories 
with any adverse outcome per maternal clinical body mass index group a

























Weight loss 1.5 (1.15,1.96) Weight loss 0.99 (0.75,1.30) Weight loss 0.87 (0.68,1.11) Weight loss 0.55 (0.39,0.78) Weight loss 0.96 (0.60,1.53)
0 to 1.9 1.57 (1.31,1.88) 0 to 1.9 1.06 (0.89,1.26) 0 to 1.9 0.86 (0.73,1.02) 0 to 1.9 0.89 (0.70,1.13) 0 to 1.9 0.59 (0.41,0.85)
2 to 3.9 1.42 (1.21,1.66) 2 to 3.9 0.81 (0.69,0.95) 2 to 3.9 0.76 (0.64,0.91) 2 to 3.9 0.67 (0.51,0.88) 2 to 3.9 1.39 (0.81,2.39)
4 to 5.9 1.28 (1.16,1.40) 4 to 5.9 0.90 (0.80,1.01) 4 to 5.9 0.73 (0.64,0.84) 4 to 5.9 0.98 (0.77,1.25) 4 to 5.9 0.62 (0.41,0.94)
<8 2.01 (1.64,2.46) 6 to 7.9 1.28 (1.20,1.36) 6 to 7.9 0.84 (0.77,0.92) 6 to 7.9 1.06 (0.94,1.21) 6 to 7.9 0.80 (0.65,1.00) 6 to 7.9 1.33 (0.85,2.08)
8 to 9.9 1.33 (1.12,1.57) 8 to 9.9 1.04 (1.00,1.09) 8 to 9.9 0.91 (0.85,0.98) 8 to 9.9 0.92 (0.82,1.03) 8 to 9.9 1.04 (0.84,1.30) 8 to 9.9 0.79 (0.53,1.19)
10 to 11.9 1.12 (0.98,1.28) 10 to 11.9 0.96 (0.93,0.99) 10 to 11.9 0.89 (0.83,0.94) 10 to 11.9 0.91 (0.82,1.02) 10 to 11.9 0.85 (0.68,1.05) 10 to 11.9 0.77 (0.50,1.16)
12 to 13.9 1.04 (0.93,1.18) 12 to 13.9 0.88 (0.86,0.91) 12 to 13.9 0.85 (0.80,0.90) 12 to 13.9 1.02 (0.91,1.13) 12 to 13.9 1.06 (0.84,1.34) 12 to 13.9 1.08 (0.67,1.76)
14 to 15.9 0.74 (0.65,0.84) 14 to 15.9 0.87 (0.85,0.90) 14 to 15.9 0.90 (0.85,0.96) 14 to 15.9 0.96 (0.86,1.08) 14 to 15.9 1.17 (0.90,1.53) 14 to 15.9 1.43 (0.82,2.47)
16 to 17.9 0.95 (0.82,1.09) 16 to 17.9 0.91 (0.88,0.95) 16 to 17.9 1.07 (1.00,1.14) 16 to 17.9 1.09 (0.95,1.25) >=16 1.81 (1.49,2.19) >=16 2.68 (1.68,4.27)
18 to 19.9 0.88 (0.74,1.05) 18 to 19.9 1.00 (0.96,1.04) 18 to 19.9 1.05 (0.98,1.13) 18 to 19.9 1.09 (0.92,1.30)
20 to 21.9 0.84 (0.69,1.02) 20 to 21.9 1.06 (1.01,1.10) 20 to 21.9 1.18 (1.10,1.28) 20 to 21.9 1.25 (1.06,1.49)
>=22 0.88 (0.75,1.04) 22 to 23.9 1.17 (1.10,1.24) 22 to 23.9 1.33 (1.21,1.47) 22 to 23.9 1.41 (1.13,1.75)
24 to 25.9 1.31 (1.23,1.40) 24 to 25.9 1.36 (1.22,1.52) 24 to 25.9 1.24 (0.97,1.58)
26 to 27.9 1.42 (1.29,1.56) 26 to 27.9 1.56 (1.33,1.82) 26 to 27.9 2.51 (1.74,3.61)
>= 28 1.77 (1.64,1.91) 1.87 (1.66,2.11) >= 28 1.84 (1.42,2.38)
aValues represent odds ratios (95% Confidence Intervals) reflecting the risk of any adverse outcome per gestational 
weight gain category for women with underweight, normal weight, overweight, obesity grade 1, obesity grade 2 
and obesity grade 3, as compared to all other gestational weight gain categories in that specific clinical maternal BMI 
group. Any adverse outcome includes pre-eclampsia, gestational hypertension, gestational diabetes, caesarean section, 
preterm birth, small size-for-gestational-age, and large size-for-gestational-age.
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Weight loss 1.5 (1.15,1.96) Weight loss 0.99 (0.75,1.30) Weight loss 0.87 (0.68,1.11) Weight loss 0.55 (0.39,0.78) Weight loss 0.96 (0.60,1.53)
0 to 1.9 1.57 (1.31,1.88) 0 to 1.9 1.06 (0.89,1.26) 0 to 1.9 0.86 (0.73,1.02) 0 to 1.9 0.89 (0.70,1.13) 0 to 1.9 0.59 (0.41,0.85)
2 to 3.9 1.42 (1.21,1.66) 2 to 3.9 0.81 (0.69,0.95) 2 to 3.9 0.76 (0.64,0.91) 2 to 3.9 0.67 (0.51,0.88) 2 to 3.9 1.39 (0.81,2.39)
4 to 5.9 1.28 (1.16,1.40) 4 to 5.9 0.90 (0.80,1.01) 4 to 5.9 0.73 (0.64,0.84) 4 to 5.9 0.98 (0.77,1.25) 4 to 5.9 0.62 (0.41,0.94)
<8 2.01 (1.64,2.46) 6 to 7.9 1.28 (1.20,1.36) 6 to 7.9 0.84 (0.77,0.92) 6 to 7.9 1.06 (0.94,1.21) 6 to 7.9 0.80 (0.65,1.00) 6 to 7.9 1.33 (0.85,2.08)
8 to 9.9 1.33 (1.12,1.57) 8 to 9.9 1.04 (1.00,1.09) 8 to 9.9 0.91 (0.85,0.98) 8 to 9.9 0.92 (0.82,1.03) 8 to 9.9 1.04 (0.84,1.30) 8 to 9.9 0.79 (0.53,1.19)
10 to 11.9 1.12 (0.98,1.28) 10 to 11.9 0.96 (0.93,0.99) 10 to 11.9 0.89 (0.83,0.94) 10 to 11.9 0.91 (0.82,1.02) 10 to 11.9 0.85 (0.68,1.05) 10 to 11.9 0.77 (0.50,1.16)
12 to 13.9 1.04 (0.93,1.18) 12 to 13.9 0.88 (0.86,0.91) 12 to 13.9 0.85 (0.80,0.90) 12 to 13.9 1.02 (0.91,1.13) 12 to 13.9 1.06 (0.84,1.34) 12 to 13.9 1.08 (0.67,1.76)
14 to 15.9 0.74 (0.65,0.84) 14 to 15.9 0.87 (0.85,0.90) 14 to 15.9 0.90 (0.85,0.96) 14 to 15.9 0.96 (0.86,1.08) 14 to 15.9 1.17 (0.90,1.53) 14 to 15.9 1.43 (0.82,2.47)
16 to 17.9 0.95 (0.82,1.09) 16 to 17.9 0.91 (0.88,0.95) 16 to 17.9 1.07 (1.00,1.14) 16 to 17.9 1.09 (0.95,1.25) >=16 1.81 (1.49,2.19) >=16 2.68 (1.68,4.27)
18 to 19.9 0.88 (0.74,1.05) 18 to 19.9 1.00 (0.96,1.04) 18 to 19.9 1.05 (0.98,1.13) 18 to 19.9 1.09 (0.92,1.30)
20 to 21.9 0.84 (0.69,1.02) 20 to 21.9 1.06 (1.01,1.10) 20 to 21.9 1.18 (1.10,1.28) 20 to 21.9 1.25 (1.06,1.49)
>=22 0.88 (0.75,1.04) 22 to 23.9 1.17 (1.10,1.24) 22 to 23.9 1.33 (1.21,1.47) 22 to 23.9 1.41 (1.13,1.75)
24 to 25.9 1.31 (1.23,1.40) 24 to 25.9 1.36 (1.22,1.52) 24 to 25.9 1.24 (0.97,1.58)
26 to 27.9 1.42 (1.29,1.56) 26 to 27.9 1.56 (1.33,1.82) 26 to 27.9 2.51 (1.74,3.61)
>= 28 1.77 (1.64,1.91) 1.87 (1.66,2.11) >= 28 1.84 (1.42,2.38)
aValues represent odds ratios (95% Confidence Intervals) reflecting the risk of any adverse outcome per gestational 
weight gain category for women with underweight, normal weight, overweight, obesity grade 1, obesity grade 2 
and obesity grade 3, as compared to all other gestational weight gain categories in that specific clinical maternal BMI 
group. Any adverse outcome includes pre-eclampsia, gestational hypertension, gestational diabetes, caesarean section, 
preterm birth, small size-for-gestational-age, and large size-for-gestational-age.
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Supplemental Table 9. Absolute Risk Reductions for the associations of gestational weight 
gain categories with any adverse outcome per maternal clinical body mass index group a

























Weight loss -0.09 (-0.18,0) Weight loss 0.01 (-0.06,0.07) Weight loss 0.04 (-0.02,0.10) Weight loss 0.14 (0.06,0.22) Weight loss 0.01 (-0.09,0.12)
0 to 1.9 -0.10 (-0.15,-0.05) 0 to 1.9 -0.01 (-0.05,0.03) 0 to 1.9 0.03 (-0.01,0.07) 0 to 1.9 0.03 (-0.03,0.08) 0 to 1.9 0.12 (0.03,0.21)
2 to 3.9 -0.08 (-0.12,-0.04) 2 to 3.9 0.05 (0.01,0.08) 2 to 3.9 0.07 (0.02,0.11) 2 to 3.9 0.10 (0.03,0.17) 2 to 3.9 -0.08 (-0.20,0.03)
4 to 5.9 -0.06 (-0.08,-0.04) 4 to 5.9 0.02 (0.00,0.05) 4 to 5.9 0.08 (0.04,0.11) 4 to 5.9 0.00 (-0.06,0.06) 4 to 5.9 0.10 (0.00,0.20)
<8 -0.16 (-0.21,-0.11) 6 to 7.9 -0.06 (-0.08,-0.05) 6 to 7.9 0.04 (0.02,0.06) 6 to 7.9 -0.01 (-0.04,0.02) 6 to 7.9 0.05 (0.0,0.11) 6 to 7.9 -0.06 (-0.16,0.04)
8 to 9.9 -0.07 (-0.11,-0.03) 8 to 9.9 -0.01 (-0.02,0.00) 8 to 9.9 0.02 (0.00,0.03) 8 to 9.9 0.02 (-0.01,0.04) 8 to 9.9 -0.01 (-0.07,0.04) 8 to 9.9 0.06 (-0.04,0.16)
10 to 11.9 -0.03 (-0.06,0,00) 10 to 11.9 0.01 (0.00,0.01) 10 to 11.9 0.02 (0.01,0.04) 10 to 11.9 0.02 (-0.01,0.05) 10 to 11.9 0.04 (-0.01,0.09) 10 to 11.9 0.06 (-0.04,0.17)
12 to 13.9 -0.01 (-0.03,0.02) 12 to 13.9 0.03 (0.02,0.03) 12 to 13.9 0.04 (0.02,0.05) 12 to 13.9 -0.01 (-0.03,0.02) 12 to 13.9 -0.02 (-0.07,0.04) 12 to 13.9 -0.01 (-0.13,0.10)
14 to 15.9 0.07 (0.04,0.09) 14 to 15.9 0.03 (0.02,0.04) 14 to 15.9 0.02 (0.01,0.04) 14 to 15.9 0.01 (-0.02,0.04) 14 to 15.9 -0.04 (-0.10,0.02) 14 to 15.9 -0.08 (-0.20,0.04)
16 to 17.9 0.01 (-0.02,0.04) 16 to 17.9 0.02 (0.01,0.03) 16 to 17.9 -0.01 (-0.03,0.00) 16 to 17.9 -0.02 (-0.06,0.01) >=16 -0.13 (-0.17,-0.09) >=16 -0.20 (-0.28,-0.12)
18 to 19.9 0.03 (-0.01,0.07) 18 to 19.9 0.00 (-0.01,0.01) 18 to 19.9 -0.01 (-0.03,0.01) 18 to 19.9 -0.02 (-0.06,0.03)
20 to 21.9 0.03 (-0.01,0.08) 20 to 21.9 -0.01 (-0.02,0.00) 20 to 21.9 -0.04 (-0.05,-0.02) 20 to 21.9 -0.06 (-0.10,-0.01)
>=22 0.03 (-0.01,0.06) 22 to 23.9 -0.03 (-0.04,-0.02) 22 to 23.9 -0.06 (-0.09,-0.04) 22 to 23.9 -0.08 (-0.13,-0.02)
24 to 25.9 -0.06 (-0.07,-0.04) 24 to 25.9 -0.07 (-0.10,-0.04) 24 to 25.9 -0.05 (-0.11,0.01)
26 to 27.9 -0.07 (-0.10,-0.05) 26 to 27.9 -0.10 (-0.14,-0.06) 26 to 27.9 -0.21 (-0.28,-0.13)
>= 28 -0.13 (-0.15,-0.11) >= 28 -0.15 (-0.18,-0.12) >= 28 -0.14 (-0.20,-0.08)
a Values represent absolute risk reductions (95% Confidence Intervals) reflecting the reduction of absolute risk of any 
adverse outcome per gestational weight gain category for women with underweight, normal weight, overweight, 
obesity grade 1, obesity grade 2 and obesity grade 3, as compared to all other gestational weight gain categories 
in that specific clinical maternal BMI group. Any adverse outcome includes pre-eclampsia, gestational hypertension, 
gestational diabetes, caesarean section, preterm birth, small size-for-gestational-age, and large size-for-gestational-age.
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Supplemental Table 9. Absolute Risk Reductions for the associations of gestational weight 
gain categories with any adverse outcome per maternal clinical body mass index group a

























Weight loss -0.09 (-0.18,0) Weight loss 0.01 (-0.06,0.07) Weight loss 0.04 (-0.02,0.10) Weight loss 0.14 (0.06,0.22) Weight loss 0.01 (-0.09,0.12)
0 to 1.9 -0.10 (-0.15,-0.05) 0 to 1.9 -0.01 (-0.05,0.03) 0 to 1.9 0.03 (-0.01,0.07) 0 to 1.9 0.03 (-0.03,0.08) 0 to 1.9 0.12 (0.03,0.21)
2 to 3.9 -0.08 (-0.12,-0.04) 2 to 3.9 0.05 (0.01,0.08) 2 to 3.9 0.07 (0.02,0.11) 2 to 3.9 0.10 (0.03,0.17) 2 to 3.9 -0.08 (-0.20,0.03)
4 to 5.9 -0.06 (-0.08,-0.04) 4 to 5.9 0.02 (0.00,0.05) 4 to 5.9 0.08 (0.04,0.11) 4 to 5.9 0.00 (-0.06,0.06) 4 to 5.9 0.10 (0.00,0.20)
<8 -0.16 (-0.21,-0.11) 6 to 7.9 -0.06 (-0.08,-0.05) 6 to 7.9 0.04 (0.02,0.06) 6 to 7.9 -0.01 (-0.04,0.02) 6 to 7.9 0.05 (0.0,0.11) 6 to 7.9 -0.06 (-0.16,0.04)
8 to 9.9 -0.07 (-0.11,-0.03) 8 to 9.9 -0.01 (-0.02,0.00) 8 to 9.9 0.02 (0.00,0.03) 8 to 9.9 0.02 (-0.01,0.04) 8 to 9.9 -0.01 (-0.07,0.04) 8 to 9.9 0.06 (-0.04,0.16)
10 to 11.9 -0.03 (-0.06,0,00) 10 to 11.9 0.01 (0.00,0.01) 10 to 11.9 0.02 (0.01,0.04) 10 to 11.9 0.02 (-0.01,0.05) 10 to 11.9 0.04 (-0.01,0.09) 10 to 11.9 0.06 (-0.04,0.17)
12 to 13.9 -0.01 (-0.03,0.02) 12 to 13.9 0.03 (0.02,0.03) 12 to 13.9 0.04 (0.02,0.05) 12 to 13.9 -0.01 (-0.03,0.02) 12 to 13.9 -0.02 (-0.07,0.04) 12 to 13.9 -0.01 (-0.13,0.10)
14 to 15.9 0.07 (0.04,0.09) 14 to 15.9 0.03 (0.02,0.04) 14 to 15.9 0.02 (0.01,0.04) 14 to 15.9 0.01 (-0.02,0.04) 14 to 15.9 -0.04 (-0.10,0.02) 14 to 15.9 -0.08 (-0.20,0.04)
16 to 17.9 0.01 (-0.02,0.04) 16 to 17.9 0.02 (0.01,0.03) 16 to 17.9 -0.01 (-0.03,0.00) 16 to 17.9 -0.02 (-0.06,0.01) >=16 -0.13 (-0.17,-0.09) >=16 -0.20 (-0.28,-0.12)
18 to 19.9 0.03 (-0.01,0.07) 18 to 19.9 0.00 (-0.01,0.01) 18 to 19.9 -0.01 (-0.03,0.01) 18 to 19.9 -0.02 (-0.06,0.03)
20 to 21.9 0.03 (-0.01,0.08) 20 to 21.9 -0.01 (-0.02,0.00) 20 to 21.9 -0.04 (-0.05,-0.02) 20 to 21.9 -0.06 (-0.10,-0.01)
>=22 0.03 (-0.01,0.06) 22 to 23.9 -0.03 (-0.04,-0.02) 22 to 23.9 -0.06 (-0.09,-0.04) 22 to 23.9 -0.08 (-0.13,-0.02)
24 to 25.9 -0.06 (-0.07,-0.04) 24 to 25.9 -0.07 (-0.10,-0.04) 24 to 25.9 -0.05 (-0.11,0.01)
26 to 27.9 -0.07 (-0.10,-0.05) 26 to 27.9 -0.10 (-0.14,-0.06) 26 to 27.9 -0.21 (-0.28,-0.13)
>= 28 -0.13 (-0.15,-0.11) >= 28 -0.15 (-0.18,-0.12) >= 28 -0.14 (-0.20,-0.08)
a Values represent absolute risk reductions (95% Confidence Intervals) reflecting the reduction of absolute risk of any 
adverse outcome per gestational weight gain category for women with underweight, normal weight, overweight, 
obesity grade 1, obesity grade 2 and obesity grade 3, as compared to all other gestational weight gain categories 
in that specific clinical maternal BMI group. Any adverse outcome includes pre-eclampsia, gestational hypertension, 
gestational diabetes, caesarean section, preterm birth, small size-for-gestational-age, and large size-for-gestational-age.
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Supplemental Table 10. Classification of gestational weight gain by classifications from this study and IOM
This study IOM
Range (kg) n (%) Range (kg) n (%)
Underweight (n=7809)
 Inadequate <14.0 3635 (46.5) <12.5 2894 (37.1)
 Adequate 14.0 – <16.0 1326 (17.0) 12.5 – 18.0 3416 (43.7)
 Excessive ≥16.0 2848 (36.5) >18.0 1499 (19.2)
Normal weight (n=133788)
 Inadequate <10.0 16884 (12.6) <11.5 32755 (24.5)
 Adequate 10.0 – <18.0 80869 (60.5) 11.5 – 16.0 55188 (41.2)
 Excessive ≥18.0 36035 (26.9) >16.0 45845 (34.3)
Overweight (n=38828)
 Inadequate <2.0 759 (2.0) <7.0 3691 (9.5)
 Adequate 2.0 – <16.0 233580 (60.1) 7.0 – 11.5 9309 (24.0)
 Excessive ≥16.0 14711 (37.9) >11.5 25828 (66.5)
Obesity grade 1 (n=11992)
 Inadequate <2.0 871 (7.3) <5.0 1798 (15.0)
 Adequate 2.0 – <6.0 1405 (11.7) 5.0 – 9.0 2779 (23.2)
 Excessive ≥6.0 9716 (81.0) >9.0 7415 (61.8)
Obesity grade 2 (n=3284)
 Inadequate NA NA <5.0 835 (25.4)
 Adequate
Weight loss – 
<4.0a
694 (21.1) 5.0 – 9.0 865 (26.3)
 Excessive ≥4.0 2590 (78.9) >9.0 1584 (48.2)
Obesity grade 3 (n=969)
 Inadequate Weight lossb 87 (9.0) <5.0 350 (36.1)
 Adequate 0 – <6.0 319 (32.9) 5.0 – 9.0 246 (25.4)
 Excessive ≥6.0 563 (58.1) >9.0 373 (38.5)
Total group (n=196670)
 Inadequate 22236 (11.3) 42323 (21.5)
 Adequate 107971 (54.9) 71803 (36.5)
 Excessive 66463 (33.8) 82544 (42.0)
Abbreviations: NA, not available; IOM, US Institute of Medicine (nowadays called National Academy of Medicine 
(NAM)).
a Median gestational weight gain in the weight loss category: -3.00 kg (range: -25.00 to -0.13) for obesity grade 2.
b Median gestational weight gain in the weight loss category: -3.00 kg (range: -13.58 to -0.40) for obesity grade 3.
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Supplemental Figure 2. Associations of inadequate and excessive gestational weight gain by 
classifications from this study and IOM with adverse maternal and infant outcomes
Abbreviations: IOM: US Institute of Medicine (nowadays called National Academy of Medicine (NAM)). Values represent 
odds ratios (OR) (95% Confidence Intervals (CI)) reflecting the risk of adverse maternal and infant outcomes in women 
with inadequate and excessive weight gain as compared to women with adequate weight gain, according to this study 
(red triangles) and IOM classifications (black dots). Inadequate and excessive gestational weight gain are defined as 
gestational weight gain below or above the ranges defined by this study and IOM, respectively (Supplemental Table 
10). Any adverse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), 
caesarean section, preterm birth, small size-for-gestational-age (SGA), and large size-for-gestational-age (LGA). Low 
and high birth and childhood under- and overweight were not included for the definition of the optimal weight gain 
ranges. * P-value for the difference between ORs for this study and IOM (calculated using Z= (logodds This study – logodds 
IOM) /sqrt(SEThis study 2+SEIOM2)).
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Supplemental Figure 3. Associations of inadequate and excessive gestational weight gain by 
classifications from this study and IOM with adverse maternal and infant outcomes. by clinical 
body mass index group
Values represent odds ratios (95% Confidence Intervals) reflecting the risk of adverse maternal or infant outcome in 
women with inadequate and excessive weight gain as compared to women with adequate weight gain, according to 
this study, red triangles) and IOM (US Institute of Medicine, nowadays called National Academy of Medicine (NAM)) 
classifications (black dots), per clinical BMI category. Inadequate and excessive gestational weight gain are defined as 
gestational weight gain below or above the ranges defined by this study and IOM, respectively (Supplemental Table 
10). Any adverse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), cae-
sarean section, preterm birth, and small size-for-gestational-age (SGA), large size-for-gestational-age (LGA). Low and 
high birth weight and childhood under- and overweight were not included for the definition of the optimal weight gain 
ranges. * P-value for the difference between ORs for this study and IOM (calculated using Z= (logodds This study – logodds 
IOM) /sqrt(SEThis study 2+SEIOM2)).
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Supplemental Figure 3. Associations of inadequate and excessive gestational weight gain by 
classifications from this study and IOM with adverse maternal and infant outcomes. by clinical 
body mass index group (continued)
Values represent odds ratios (95% Confidence Intervals) reflecting the risk of adverse maternal or infant outcome in 
women with inadequate and excessive weight gain as compared to women with adequate weight gain, according to 
this study, red triangles) and IOM (US Institute of Medicine, nowadays called National Academy of Medicine (NAM)) 
classifications (black dots), per clinical BMI category. Inadequate and excessive gestational weight gain are defined as 
gestational weight gain below or above the ranges defined by this study and IOM, respectively (Supplemental Table 
10). Any adverse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), cae-
sarean section, preterm birth, and small size-for-gestational-age (SGA), large size-for-gestational-age (LGA). Low and 
high birth weight and childhood under- and overweight were not included for the definition of the optimal weight gain 
ranges. * P-value for the difference between ORs for this study and IOM (calculated using Z= (logodds This study – logodds 
IOM) /sqrt(SEThis study 2+SEIOM2)).
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Supplemental Figure 4. Receiver operator characteristic curves of inadequate and excessive 
gestational weight gain by classifications from this study and IOM for the detection of adverse 
maternal and infant outcomes
Abbreviations: AUC, area under the Receiver Operator Characteristic curve; IOM, US Institute of Medicine (nowadays 
called National Academy of Medicine (NAM)). Inadequate and excessive gestational weight gain are defined as ges-
tational weight gain below or above the ranges defined by this study and IOM, respectively (Supplemental Table 
10). Any adverse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), 
caesarean section, preterm birth, small size-for-gestational-age (SGA), and large size-for-gestational-age (LGA). Low 
and high birth weight and childhood under- and overweight were not included for the definition of the optimal weight 
gain ranges.
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Supplemental Figure 4. Receiver operator characteristic curves of inadequate and excessive 
gestational weight gain by classifications from this study and IOM for the detection of adverse 
maternal and infant outcomes (continued)
Abbreviations: AUC, area under the Receiver Operator Characteristic curve; IOM, US Institute of Medicine (nowadays 
called National Academy of Medicine (NAM)). Inadequate and excessive gestational weight gain are defined as ges-
tational weight gain below or above the ranges defined by this study and IOM, respectively (Supplemental Table 
10). Any adverse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), 
caesarean section, preterm birth, small size-for-gestational-age (SGA), and large size-for-gestational-age (LGA). Low 




Supplemental Figure 5. Associations of gestational weight gain categories with any adverse 
outcome per maternal clinical body mass index group, ranges from this study based on protec-
tive associations only
The symbols represent odds ratios (95% Confidence Intervals) reflecting the risk of any adverse outcome per gestational 
weight gain category for women with (A) underweight, (B) normal weight, (C) overweight, (D) obesity grade 1, (E) obe-
sity grade 2 and (F) obesity grade 3, as compared to all other gestational weight gain categories in that specific clinical 
maternal body mass index group. The symbols represent the mean for all participants in each gestational weight gain 
category. The percentages below each of the figures represent the number of participants in that gestational weight 
gain category as a percentage of all participants within that BMI category. Participants in the extreme categories of 
gestational weight gain had values beyond the most extreme labeled tick marks. Any adverse outcome includes pre-
eclampsia, gestational hypertension, gestational diabetes, caesarean section, preterm birth, small size-for-gestational-
age, and large size-for-gestational-age. This figure is equal to Figure 3, but shows ranges from this study when optimal 
weight gain would be defined as all associations below 1, regardless of statistical significance. The red area represents 
the optimal weight gain range according to this study, the grey area represents the weight gain ranges as recom-
mended by the US Institute of Medicine (IOM, nowadays called National Academy of Medicine (NAM)).
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Supplemental Figure 6. Associations of categories of gestational weight gain in first half of 
pregnancy with any adverse outcome per maternal clinical body mass index group
The symbols represent odds ratios (95% Confidence Intervals) reflecting the risk of any adverse outcome per category 
of gestational weight gain in first half of pregnancy for women with (A) underweight, (B) normal weight, (C) over-
weight, (D) obesity grade 1, (E) obesity grade 2 and (F) obesity grade 3, as compared to all other gestational weight gain 
categories in that specific clinical maternal body mass index group. The percentages below each of the figures represent 
the number of participants in that gestational weight gain category as a percentage of all participants within that BMI 
category. The symbols represent the mean for all participants in each gestational weight gain category. Participants in 
the extreme categories of gestational weight gain had values beyond the most extreme labeled tick marks. Because 
of the relatively low levels of gestational weight gain in first half of pregnancy, we categorized weight gain within this 
time interval into categories of 1 kg each. Any adverse outcome includes pre-eclampsia, gestational hypertension, 
gestational diabetes, caesarean section, preterm birth, small size-for-gestational-age, and large size-for-gestational-age. 
The red area represents the optimal weight gain range according to the current analysis. No optimal weight gain range 
was observed for obesity grade 3 due to low numbers.
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Supplemental Table 12. Classification of gestational weight gain in first half of pregnancy by 
classification from this study
This study
Range (kg) n (%)
Underweight (n=4906)
 Inadequate <2.0 1315 (26.8)
 Adequate 2.0 – <3.0 941 (19.2)
 Excessive ≥3.0 2650 (54.0)
Normal weight (n=90084)
 Inadequate Weight lossa 7272 (8.1)
 Adequate 0.0 – <2.0 21481(23.8)
 Excessive ≥2.0 61331 (68.1)
Overweight (n=27128)
 Inadequate NA NA
 Adequate <1.0a 7662 (28.2)
 Excessive ≥1.0 19466 (71.8)
Obesity grade 1 (n=8328)
 Inadequate NA NA
 Adequate Weight lossa 2053 (24.7)
 Excessive ≥0.0 6275 (75.3)
Obesity grade 2 (n=2310)
 Inadequate NA NA
 Adequate Weight lossa 784 (33.9)
 Excessive ≥0.0 1526 (66.1)
Obesity grade 3 NA NA
Total group (n=132756)
 Inadequate 8587 (6.5)
 Adequate 32921 (24.8)
 Excessive 91248 (68.7)
Abbreviations: NA, not available.
a Results need to be interpreted with caution, as the effect and safety of weight loss during pregnancy are not known.
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Supplemental Table 13. Classification table for ranges of this study for weight gain in first half 
of pregnancy vs. total gestational weight gain a, b
Total pregnancy
First half Inadequate Adequate Excessive Total
Inadequate 3634 (25.1) 4462 (5.8) 791 (1.7) 8587
Adequate 5309 (36.6) 21296 (29.5) 6316 (13.7) 32921
Excessive 5545 (38.3) 46683 (64.7) 39020 (84.6) 91248
Total 14488 72141 46127 132756
a Values are n (% within groups of total gestational weight gain (columns)).
b As no inadequate weight gain categories were observed in first half of pregnancy for most BMI categories, classifica-
tion for inadequate gestational weight gain needs to be interpreted carefully.
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Supplemental Table 14. Classification of gestational weight gain by classifications from this 
study and IOM, hospital-based population (used as validation sample)
This study IOM
Range (kg) n (%) Range (kg) n (%)
Underweight (n=277)
 Inadequate <14.0 134 (48.4) <12.5 99 (35.7)
 Adequate 14.0 – <16.0 58 (20.9) 12.5 – 18.0 136 (49.1)
 Excessive ≥16.0 85 (30.7) >18.0 42 (15.2)
Normal weight (n=2400)
 Inadequate <10.0 303 (12.6) <11.5 664 (27.7)
 Adequate 10.0 – <18.0 1656 (69.0) 11.5 – 16.0 1142 (47.6)
 Excessive ≥18.0 441 (18.4) >18.0 594 (24.8)
Overweight (n=577)
 Inadequate <2.0 7 (1.2) <7.0 57 (9.9)
 Adequate 2.0 – <16.0 404 (70.0) 7.0 – 11.5 171 (26.6)
 Excessive ≥16.0 166 (28.8) >11.5 349 (60.5)
Obesity grade 1 (n=188)
 Inadequate <2.0 6 (3.2) <5.0 23 (12.2)
 Adequate 2.0 – <6.0 25 (13.3) 5.0 – 9.0 65 (34.6)
 Excessive ≥6.0 157 (83.5) >9.0 100 (53.2)
Obesity grade 2 (n=53)
 Inadequate NA NA <5.0 15 (28.3)
 Adequate
Weight loss – 
<4.0
13 (24.5) 5.0 – 9.0 17 (32.1)
 Excessive ≥4.0 40 (75.5) >9.0 21 (39.6)
Obesity grade 3 (n=10)
 Inadequate Weight loss 1 (10.0) <5.0 6 (60.0)
 Adequate 0 – <6.0 6 (60.0) 5.0 – 9.0 2 (20.0)
 Excessive ≥6.0 3 (30.0) >9.0 2 (20.0)
Total group (n=3505)
 Inadequate 451 (12.9) 864 (24.7)
 Adequate 2162 (61.7) 1533 (43.7)
 Excessive 892 (25.4) 738 (31.6)
Abbreviations: NA, not available; US Institute of Medicine (nowadays called National Academy of Medicine (NAM)).
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Supplemental Figure 7. Associations of inadequate and excessive gestational weight gain by 
classifications from this study and IOM with adverse maternal and infant outcomes, hospital-
based population (used as validation sample)
Abbreviations: IOM, US Institute of Medicine (nowadays called National Academy of Medicine (NAM)). Values represent 
odds ratios (OR) (95% Confidence Intervals (CI)) reflecting the risk of adverse maternal and infant outcomes in women 
with inadequate and excessive weight gain as compared to women with adequate weight gain, according to this study 
(red triangles) and IOM classifications (black dots). Inadequate and excessive gestational weight gain are defined as 
gestational weight gain below or above the ranges from this study and IOM, respectively (Supplemental Table 14). 
Any adverse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), caesar-
ean section, preterm birth, small size-for-gestational-age (SGA), and large size-for-gestational-age (LGA). Low and high 
birth and childhood under- and overweight were not included for the definition of the optimal weight gain ranges. 
* P-value for the difference between ORs for this study and IOM (calculated using Z= (logodds This study – logodds IOM) /
sqrt(SEThis study 2+SEIOM2)).
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Supplemental Figure 8. Receiver operator characteristic curves of inadequate and excessive 
gestational weight gain by classifications from this study and IOM for the detection of adverse 
maternal and infant outcomes, hospital-based population (used as validation sample)
Abbreviations: AUC, area under the Receiver Operator Characteristic curve; IOM, US Institute of Medicine (nowadays 
called National Academy of Medicine (NAM)). Inadequate and excessive gestational weight gain are defined as gesta-
tional weight gain below or above the ranges from this study and IOM, respectively (Supplemental Table 14). Any ad-
verse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), caesarean sec-
tion, preterm birth, small size-for-gestational-age (SGA), and large size-for-gestational-age (LGA). Low and high birth 
weight and childhood under- and overweight were not included for the definition of the optimal weight gain ranges.
CHAPTER 3.2
222
Supplemental Figure 8. Receiver operator characteristic curves of inadequate and excessive 
gestational weight gain by classifications from this study and IOM for the detection of ad-
verse maternal and infant outcomes, hospital-based population (used as validation sample) 
(continued)
Abbreviations: AUC, area under the Receiver Operator Characteristic curve; IOM, US Institute of Medicine (nowadays 
called National Academy of Medicine (NAM)). Inadequate and excessive gestational weight gain are defined as gesta-
tional weight gain below or above the ranges from this study and IOM, respectively (Supplemental Table 14). Any ad-
verse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), caesarean sec-
tion, preterm birth, small size-for-gestational-age (SGA), and large size-for-gestational-age (LGA). Low and high birth 
















4 Maternal and childhood metabolism

4.1 Maternal glucose concentrations and childhood cardio-metabolic outcomes
Wahab RJ, Voerman E, Jansen PW, Oei EHG, Steegers EAP, 
Jaddoe VWV, Gaillard R. Maternal glucose concentrations 
in early pregnancy and cardiometabolic risk factors in 
childhood.




Objective: This study aimed to examine the associations of maternal early-pregnancy glucose 
and insulin concentrations with offspring cardiometabolic risk factors and fat distribution.
Methods: In a population-based prospective cohort study among 3,737 mothers and their 
children, random maternal glucose and insulin concentrations were measured at a median 
gestational age of 13.2 (95% range 10.5-17.1) weeks. Childhood fat, blood pressure, and 
blood concentrations of lipids, glucose, and insulin at the age of 10 years were measured.
Results: Higher maternal early-pregnancy glucose and insulin concentrations were asso-
ciated with a higher risk of childhood overweight, and higher maternal early-pregnancy 
insulin concentrations were associated with an increased childhood risk of clustering of 
cardiometabolic risk factors (all P < 0.05). These associations were explained by maternal 
prepregnancy BMI. Independent of maternal prepregnancy BMI, one SD score (SDS) higher 
maternal early-pregnancy glucose and insulin concentrations were associated with higher 
childhood glucose (0.08 SDS, 95% CI: 0.04-0.11) and insulin concentrations (0.07 SDS, 95% 
CI: 0.03-0.10), but not with childhood blood pressure, lipids, and fat measures.
Conclusions: These results suggest that maternal early-pregnancy random glucose and 
insulin concentrations are associated with childhood glucose and insulin concentrations but 
not with other childhood cardiometabolic risk factors.
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introduction
Gestational diabetes is associated with increased risks of offspring obesity, type 2 diabetes, 
and metabolic syndrome (1-5). Increasing evidence has suggested that these risks might not 
be confined to women diagnosed with gestational diabetes but that they may already exist 
in offspring exposed to maternal glucose concentrations below diagnostic thresholds (6, 7). 
Previous studies have reported associations of maternal glucose concentrations in mid- and 
late pregnancy with offspring cardiometabolic risk factors (6, 7). However, as fetal cardio-
vascular and metabolic development already starts in the first trimester, early pregnancy 
may already be a critical period for the adverse influence of a suboptimal maternal glucose 
metabolism on the development of the fetal cardiometabolic system. Increases of maternal 
glucose and insulin concentrations from early pregnancy onward may directly affect placental 
development and increase nutrient transfer to the developing fetus. This may subsequently 
lead to increased fetal growth as well as adaptations in adipogenesis and pancreatic and 
vascular development. These adaptations may increase the susceptibility to cardiometabolic 
disease in later life (4, 8-12). Altered childhood body fat development may especially be 
involved in the associations of maternal glycemia with offspring cardiometabolic risk factors 
(9). A few studies have shown an association of maternal fasting glucose concentrations in 
pregnancy with increased childhood sum of skinfolds and waist circumference (6, 7, 13). 
However, it is not clear whether this includes overall fat or more specifically visceral fat 
accumulation, which is known to be more strongly related with cardiometabolic disease 
(14, 15). We hypothesized that higher maternal early-pregnancy glucose concentrations are 
associated with an unfavorable offspring cardiometabolic risk profile and suboptimal body 
fat distribution.
Therefore, in a population-based prospective cohort from early pregnancy onward among 
3,737 mothers and their children, we assessed the associations of maternal early-pregnancy 
glucose and insulin concentrations across the full range with cardiometabolic risk factors and 
detailed measurements of general and abdominal fat in childhood. We additionally explored 
whether these associations are independent of maternal lifestyle factors and birth, infant, or 
childhood characteristics.
methods
Study design and participants
This study was embedded in the Generation R Study, a population-based prospective cohort 
study from early pregnancy onward in Rotterdam, The Netherlands (16). Approval for the 
study was obtained from the Medical Ethical Committee of Erasmus University Medical Cen-
ter, Rotterdam. Written consent was obtained from the parents of all participants. In total, 
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8,879 pregnant women were enrolled between 2001 and 2005. Of these, 6,117 mothers 
had early-pregnancy information on glucose and insulin concentrations available and had 
singleton live-born children. Cardiometabolic follow-up measurements at the age of 10 years 
were available for 3,737 of their children (Figure 1). Main reasons for missing data were 
participants lost to follow-up and no consent or failure of venous punctures (16).
Maternal early-pregnancy glucose and insulin concentrations
Nonfasting blood samples were collected at enrollment in the study before 18 weeks of 
gestation (median: 13.2 weeks; 95% range: 10.5-17.1). Glucose concentration (millimoles 
per liter) is an enzymatic quantity and was measured with c702 module on the Cobas 8000 
analyzer (Roche, Almere, the Netherlands). Insulin concentration (picomoles per liter) was 
measured with electrochemiluminescence immunoassay on the Cobas e411 analyzer (Roche).
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Population for analyses: 
Mother-singleton child couples with information available on 
maternal early-pregnancy glucose or insulin levels and 
childhood cardio-metabolic risk factors 
 
Childhood cardio-metabolic risk factors 
BMI     n=3726 
 Blood pressure    n=3603 
 Cholesterol    n=2589 
 High-density lipoprotein-cholesterol n=2589 
Triglycerides     n=2584 
 Glucose    n=2589 
 Insulin     n=2583 
Childhood general and abdominal fat  
Total body fat mass   n=3691 
Android/gynoid fat mass ratio  n=3691 
Subcutaneous fat mass   n=1923 
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Childhood cardiometabolic risk factors and general and abdominal 
fat measurements
At the age of 10 years, we measured height and weight without shoes and heavy clothing 
and calculated BMI (kilograms per meter squared). Childhood BMI standard deviation scores 
(SDS) adjusted for sex and age were constructed based on Dutch reference growth charts 
(Growth Analyzer 4.0; Dutch Growth Research Foundation, Rotterdam, Netherlands) (17). 
We defined childhood overweight and underweight by categorizing childhood weight status 
according to the International Obesity Task Force cutoffs (18). Overweight and obesity were 
combined into one category, and children with underweight were excluded only in this vari-
able (n = 266). We observed similar results when children with underweight were included 
in the analyses (results not shown). Systolic and diastolic blood pressures (millimeters of mer-
cury) were measured at the right brachial artery, four times with 1-minute intervals, using the 
validated automatic sphygmanometer Datascope Accutorr Plus (Paramus, New Jersey) (19). 
Mean systolic and diastolic blood pressure values were calculated using the last three blood 
pressure measurements. We obtained nonfasting venous blood samples and measured total 
cholesterol (millimoles per liter), high-density lipoprotein (HDL) cholesterol (millimoles per 
liter), triglycerides (millimoles per liter), glucose (millimoles per liter), and insulin (picomoles 
per liter) concentrations.
We measured total, android, and gynoid body fat mass by dual-energy x-ray absorptiom-
etry (Lunar iDXA; GE Healthcare, Madison, Wisconsin) and calculated android/gynoid fat 
mass ratio (20). Abdominal subcutaneous and visceral fat measures were obtained from 
magnetic resonance imaging (MRI) scans using a 3.0-T MRI (Discovery MR750w; GE Health-
care, Milwaukee, Wisconsin) as described previously (16, 21). Childhood body fat mass is 
strongly influenced by height of the child (22). To enable assessment of the associations of 
maternal glucose metabolism with childhood adiposity measures independent of childhood 
size, we constructed childhood fat mass measures independent of height of the child. Using 
log-log regressions, we estimated the optimal adjustment for childhood height needed to 
construct height-independent fat mass measures (details in Supplemental Methods 1) (22-
24). We calculated total fat mass and subcutaneous fat mass indices (total and subcutaneous 
fat mass/height4) and visceral fat mass index (visceral fat mass/height3).
Clustering of cardiometabolic risk factors was defined as having three or more of the 
following components: visceral fat mass index ≥ 75th percentile, systolic or diastolic blood 
pressure ≥ 75th percentile, triglycerides ≥ 75th percentile, or HDL cholesterol ≤ 25th percen-
tile; and insulin ≥ 75th percentile (25). Because waist circumference was not available, we 
used visceral fat mass index as a proxy for waist circumference.
Covariates
Information on maternal educational level, ethnicity, parity, weight just before pregnancy, 
maximum weight during pregnancy, smoking, and total daily energy intake (in kilojoules) dur-
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ing pregnancy was obtained through questionnaires (16). Maternal height was measured at 
intake without shoes and BMI was calculated (16). We obtained information about diagnosis 
of gestational diabetes and child’s sex, gestational age at birth, and birth weight from medical 
records (16). Preterm birth was defined as a gestational age at birth < 37 weeks. We cre-
ated gestational age- and sex-adjusted SDS of birth weight using North-European reference 
growth charts (26). We defined small for gestational age and large for gestational age at 
birth as the lowest and the highest 10 percentiles of gestational-age–adjusted birth weight, 
respectively. We obtained information on breastfeeding in infancy by questionnaire (16).
Statistical analysis
First, we performed a nonresponse analysis to compare children with and without follow-up 
measurements at the age of 10 years. Second, we assessed the associations of maternal 
early-pregnancy glucose and insulin concentrations across the full range with the risks of 
childhood overweight and clustering of cardiometabolic risk factors using multiple logistic 
regression models. Third, we used multiple linear regression models to assess the associations 
of maternal early-pregnancy glucose and insulin concentrations with childhood BMI, blood 
pressure, lipids, and glucose and insulin concentrations across the full range separately and 
with detailed childhood general and abdominal fat measurements. We used three different 
models for the analyses. The first was the basic model, which was adjusted for gestational 
age at enrollment and child’s age and sex at follow-up measurements. The second was 
the confounder model, which was the basic model additionally adjusted for confounding 
covariates and was considered as the main model. Based on literature, maternal ethnicity, 
educational level, parity, smoking, and daily total caloric intake were considered as potential 
confounders. Only maternal ethnicity and educational level were selected in the model 
based on their association with exposures and outcomes and change in effect estimates 
of > 10% in our study sample. The third model was the maternal BMI model, which was the 
confounder model additionally adjusted for maternal prepregnancy BMI. Because previous 
studies have suggested that associations between gestational diabetes and childhood BMI 
are largely explained by maternal prepregnancy BMI, we constructed this separate maternal 
prepregnancy BMI model (12). Correlation coefficients for correlation between maternal 
glucose and insulin concentrations and prepregnancy BMI were 0.16 and 0.20 for maternal 
glucose and insulin concentrations, respectively. For associations that persisted after adjust-
ment for maternal prepregnancy BMI, we further explored whether these associations were 
mediated by gestational weight gain, birth weight, infant breastfeeding, or childhood BMI by 
adding these variables separately to the maternal BMI model. We tested for interactions of 
maternal glucose and insulin with maternal BMI, maternal ethnicity, and child’s sex, but none 
was significant and no further stratified analyses were performed (27-29). We performed 
the following sensitivity analyses: (1) we excluded women with a diagnosis of gestational 
diabetes (n = 34) because we were interested in the associations of maternal glucose and 
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insulin concentrations within a nondiabetic population; (2) we repeated the analyses exclud-
ing children born preterm, small for gestational age at birth, or large for gestational age at 
birth to explore whether these adverse birth outcomes explained potential associations.
Not normally distributed exposure and outcome measures were log transformed. To enable 
comparison of effect estimates, we constructed SDS of exposures and outcomes. To reduce 
selection bias because of missing data, multiple imputations of covariates (pooled results 
of five imputed data sets) were performed (30). We applied Bonferroni correction to take 
multiple testing into account. As outcomes were strongly correlated, we divided the α of 0.05 
by four categories (fat measures, blood pressure, lipid concentrations, and glucose/insulin 
concentrations), resulting in P < 0.013. All analyses were performed using SPSS Statistics 
version 24.0 for Windows (IBM Corp., Armonk, New York).
results
Characteristics of study participants
Table 1 shows the population characteristics. In early pregnancy, the mean maternal glucose 
concentration was 4.4 mmol/L (SD 0.9) and the median insulin concentration was 114.0 
pmol/L (95% range: 24.1-491.8). Nonresponse analyses showed that mothers of children 
included in the analyses compared with mothers lost to follow-up were, on average, older, 
more frequently European, and more highly educated and that they had a higher prepreg-
nancy weight and had children with a higher birth weight. No differences in early-pregnancy 
glucose and insulin concentrations were present (Supplemental Table 1).




Age at enrolment, mean (SD), years 30.7 (4.7)
Height, mean (SD), cm 168.2 (7.4)
Prepregnancy weight, median (95%), kg 65.0 (50.3; 90.0)




Cape Verdean 153 (4.1)






Table 1. Characteristics for the study population (continued)
Total group
(n = 3,737)
Education, n high (%) 1855 (49.6)
Parity, No. nulliparous (%) 2230 (59.7)
Smoking during pregnancy, n yes (%) 853 (22.8)
Gestational weight gain, mean (SD), kg 15.1 (5.7)
Daily energy intake, mean (SD), kJ 8581 (2294)
Gestational age at intake, median (95%), weeks 13.2 (10.5; 17.1)
Glucose concentration, mean (SD), mmol/l 4.4 (0.9)
Insulin concentration, median (95%), pmol/l 114.0 (24.1; 491.8)
Gestational diabetes, n (%) 34 (0.9)
Infant characteristics
Sex, n female (%) 1894 (50.7)
Gestational age at birth, median (95%), weeks 40.3 (37.14; 42.14)
Birth weight, mean (SD), grams 3437 (550)
Small for gestational age, n (%) 373 (10)
Large for gestational age, n (%) 373 (10)
Preterm birth, n (%) 155 (4)
Ever breastfeeding, n yes (%) 2878 (77)
Childhood characteristics
Age, mean (SD), years 9.8 (0.4)
Height, mean (SD), cm 141.6 (6.7)
Weight, median (95%), kg 33.8 (26.4; 49.7)
BMI, median (95%), kg/m2 16.9 (14.4; 23.3)
Fat
Total fat mass, median (95%) 8417 (4905; 19116)
Android/gynoid fat mass ratio, median (95%) 0.24 (0.16; 0.44)
Subcutaneous fat mass, median (95%), g 1294 (642; 4271)
Visceral fat mass, median (95%), g 369 (187; 853)
Blood pressure
Systolic, mean (SD), mmHg 103.1 (7.9)
Diastolic, mean (SD), mmHg 58.5 (6.4)
Lipid concentrations
Total cholesterol, mean (SD), mmol/l 4.31 (0.66)
High-density lipoprotein-cholesterol, mean (SD), mmol/l 1.48 (0.34)
Triglycerides, median (95%), mmol/l 0.98 (0.47; 2.28)
Glucose, mean (SD), mmol/l 5.20 (0.94)
Insulin, median (95%), pmol/l 174.60 (45.87; 512.40)
Overweight/obese, n (%) 643 (17.2)
Clustering of cardio-metabolic risk factors, n (%) 261 (7)
235
Maternal glucose concentrations and childhood cardio-metabolic risk factors 
4.1
Childhood cardiometabolic risk factors
Figure 2 shows that, in the confounder model, 1-SDS higher maternal early-pregnancy 
glucose and insulin concentrations were associated with an increased risk of childhood 
overweight (odds ratio [OR] 1.14, 95% CI: 1.04-1.24 and OR 1.20, 95% CI: 1.10-1.32 per 
SDS increase in maternal glucose and insulin concentrations, respectively). A 1-SDS higher 
maternal early-pregnancy insulin concentration, but not glucose concentration, was associ-
ated with clustering of cardiometabolic risk factors in childhood (OR 1.20, 95% CI: 1.04-1.38 
per SDS increase in maternal insulin concentration). All of these associations attenuated to 
nonsignificance after adjustment for maternal prepregnancy BMI.
Figure 2. Associations of maternal early-pregnancy glucose and insulin concentrations and 

























































concentrations (SD)    
Black triangle: Basic modela
Black circle: Confounding modelb
Black square: Maternal BMI modelc
Maternal insulin
concentrations (SD)    
Maternal glucose 
concentrations (SD)    
Maternal insulin
concentrations (SD)    
Risk of childhood 
overweight
Risk of childhood clustering of 
cardio-metabolic risk factors
Values represent odds ratios (95% confidence interval) from logistic regression models that reflect the risks of childhood 
overweight for SDS change in maternal glucose and insulin concentrations.
aBasic model includes gestational age at enrolment, child’s age and sex at follow up measurements
bConfounding model includes the basic model additionally adjusted for ethnicity, maternal educational level
cMaternal BMI model includes the confounder model additionally adjusted for maternal prepregnancy BMI
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Table 2 shows the associations of maternal glucose and insulin concentrations with each 
of the childhood cardiometabolic risk factors separately. In the confounder model, a 1-SDS 
higher maternal glucose concentration was associated with lower HDL cholesterol (−0.04 
SDS, 95% CI: −0.08 to −0.01 per SDS increase in glucose concentration). A 1-SDS higher 
maternal insulin concentration was associated with higher childhood BMI (0.05 SDS, 95% 
CI: 0.02 to 0.08 per SDS increase in insulin concentration) and systolic blood pressure (0.04 
SDS, 95% CI: 0.01 to 0.07 per SDS increase in insulin concentration). These associations 
attenuated to nonsignificance after adjustment for maternal prepregnancy BMI. A 1-SDS 
higher maternal early-pregnancy glucose concentration was associated with higher glucose 
concentration in childhood (0.08 SDS, 95% CI: 0.04-0.11 per SDS increase in maternal glu-
cose concentration), whereas a 1-SDS higher maternal early-pregnancy insulin concentration 
was associated with higher childhood insulin concentration (0.07 SDS, 95% CI: 0.03-0.10 
per SDS increase in maternal insulin concentration). The association of maternal glucose 
concentration with childhood glucose concentration was not affected by additional adjust-
ment for maternal prepregnancy BMI, whereas the association of maternal early-pregnancy 
insulin concentration with childhood insulin concentration only slightly attenuated after 
adjustment for maternal prepregnancy BMI. Further adjustment for gestational weight gain, 
birth weight, infant breastfeeding, and childhood BMI did not materially affect the associa-
tions (Supplemental Table 2).
Childhood general and abdominal fat
Table 3 shows that in the confounder model, a 1-SDS higher maternal early-pregnancy 
insulin concentration, but not glucose concentration, was associated with higher childhood 
total fat mass index (0.06 SDS, 95% CI: 0.03-0.09 per SDS increase in insulin concentration), 
android/gynoid fat mass ratio (0.05 SDS, 95% CI: 0.02-0.08 per SDS increase in insulin con-
centration), and subcutaneous fat mass index (0.07 SDS, 95% CI: 0.03-0.11 per SDS increase 
in insulin concentration). All of these associations of maternal insulin concentration with 
childhood total fat mass index, android/gynoid fat mass ratio, and abdominal subcutaneous 
fat mass index attenuated to nonsignificance after adjustment for maternal prepregnancy 
BMI. No associations of maternal glucose or insulin concentrations with childhood visceral 
fat mass index were present.
Sensitivity analyses
No differences in findings were present when mothers with gestational diabetes were ex-
cluded from the analyses (data not shown). We observed largely similar results when children 
with adverse birth outcomes were excluded from the analyses (Supplemental Tables 3-6).
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In this prospective cohort study, we observed that higher maternal early-pregnancy glucose 
and insulin concentrations were associated with higher childhood glucose and insulin con-
centrations at the age of 10 years. The associations of maternal early-pregnancy glucose 
and insulin concentrations with other childhood cardiometabolic risk factors and detailed 
measurements of general and abdominal fat were explained by maternal prepregnancy BMI.
Interpretation of main findings
A high number of pregnancies are complicated by gestational diabetes. Next to an increased 
risk of maternal complications, intrauterine exposure to gestational diabetes is associated 
with adverse cardiometabolic outcomes in the offspring (4). Previous studies have already 
reported associations between higher late-pregnancy maternal glucose concentrations 
already below the clinical threshold of gestational diabetes with offspring cardiometabolic 
risk factors (6, 31, 32). A study among 970 Chinese mother-child pairs reported that third-
trimester maternal fasting glucose concentrations were associated with a higher risk for 
obesity, higher systolic blood pressure, and abnormal glucose tolerance at the age of 7 years, 
independent of maternal prepregnancy BMI (6). A cohort study in the United Kingdom 
including 2,563 women and their offspring showed that, independent of maternal prepreg-
Table 3. Associations of maternal early-pregnancy glucose and insulin concentrations with 
childhood general and abdominal fat
















Maternal glucose concentrations (SDS)
Basic modela 0.05 (0.02; 0.08)* 0.04 (0.00; 0.07) 0.04 (-0.01; 0.08) -0.01 (-0.05; 0.04)
Confounding modelb 0.03 (0.00; 0.06) 0.02 (-0.01; 0.05) 0.03 (-0.02; 0.07) -0.01 (-0.06; 0.03)
Maternal BMI modelc N.A. N.A. N.A. N.A.
Maternal insulin concentrations (SDS)
Basic modela 0.11 (0.08; 0.14)* 0.09 (0.06; 0.12)* 0.11 (0.06; 0.15)* 0.03 (-0.01; 0.08)
Confounding modelb 0.06 (0.03; 0.09)* 0.05 (0.02; 0.08)* 0.07 (0.02; 0.11)* 0.02 (-0.02; 0.07)
Maternal BMI modelc 0.01 (-0.02; 0.04) 0.01 (-0.02; 0.04) 0.02 (-0.02; 0.06) N.A.
Values represent regression coefficients (95% confidence interval) from linear regression models that reflect differences 
in childhood outcomes in SDS per SDS change in maternal glucose and insulin concentrations. Estimates are based on 
multiple imputed data.
SDS: standard deviation score, N.A.: not applicable
aBasic model includes gestational age at enrolment, child’s age and sex at follow up measurements
bConfounding model includes the basic model additionally adjusted for ethnicity, maternal educational level
cMaternal BMI model includes the confounder model additionally adjusted for maternal prepregnancy BMI
dMagnetic resonance imaging follow up measurements were performed in a subgroup of children
*p-value<0.013 (Bonferroni corrected p-value for multiple testing)
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nancy BMI, glycosuria in midpregnancy was associated with higher offspring BMI and fasting 
insulin concentrations but not with blood pressure and lipid concentrations (31). It is likely 
that women who develop gestational diabetes or hyperglycemia later in pregnancy already 
have a suboptimal glucose metabolism in early pregnancy, a critical period for placental 
and fetal cardiometabolic development (9, 33). Suboptimal maternal glucose and insulin 
concentrations in early pregnancy may adversely affect placental development, predisposing 
to alterations in fetal nutrient supply, growth, and development (34). In addition, suboptimal 
maternal early-pregnancy glucose concentrations may have direct adverse influences on fetal 
cardiometabolic development (9).
In the current study, we observed that higher maternal glucose and insulin concentrations 
in early pregnancy were associated with higher childhood risks of overweight and clustering 
of cardiometabolic risk factors. However, these associations attenuated after adjustment 
for maternal prepregnancy BMI. These findings suggest that maternal prepregnancy BMI, 
a known risk factor for insulin resistance in pregnancy and cardiometabolic risk factors in 
childhood, explains the associations of maternal early-pregnancy glucose and insulin con-
centrations with childhood overweight and cardiometabolic risk factors (9). When we further 
explored the associations of maternal early-pregnancy glucose and insulin concentrations 
with individual cardiometabolic risk factors, we observed that higher maternal glucose and 
insulin concentrations were associated with higher offspring glucose and insulin concentra-
tions, respectively. These associations were independent of maternal prepregnancy BMI, 
gestational weight gain, birth weight, infant breastfeeding, and childhood BMI. Findings 
were also similar when we excluded children with adverse birth outcomes from the analyses. 
Thus, these factors do not seem to explain the associations of maternal glucose and insulin 
concentrations with childhood glucose metabolism. This suggests that at least part of the as-
sociation may be due to an intrauterine effect of maternal glucose and insulin concentrations 
on offspring glucose metabolism. Similar to previous studies performed later in pregnancy 
using fasting glucose samples, we did not find an association of maternal early-pregnancy 
glucose and insulin concentrations with childhood BMI, blood pressure, and lipid concentra-
tions, independent of maternal prepregnancy BMI (31). Thus, our results suggest that ma-
ternal glucose and insulin concentrations, as soon as early pregnancy, are related to higher 
childhood glucose and insulin concentrations, irrespective of maternal, birth, and childhood 
characteristics, but not to other cardiometabolic outcomes. Whether maternal factors other 
than impaired glucose metabolism as a consequence of higher maternal BMI, such as altered 
maternal hormone status, play a role in the association of maternal prepregnancy BMI with 
childhood BMI, blood pressure, and lipids should be further studied.
Animal and mechanistic studies proposed that offspring fat accumulation and adverse fat 
distribution might be involved in the associations of maternal hyperglycemia with offspring 
cardiometabolic risk factors. Observational studies have confirmed this hypothesis and re-
ported associations of maternal fasting glucose concentrations in pregnancy with adverse 
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offspring body fat composition, measured by sum of skinfolds and waist circumference (6, 7, 
31, 35, 36). However, these measures are suboptimal, as waist circumference does not dis-
tinguish subcutaneous from visceral fat, whereas visceral abdominal fat is much more closely 
related to risk of cardiometabolic disease in later life (14). In the present study, we observed 
that higher maternal early-pregnancy insulin concentrations but not glucose concentrations 
were associated with childhood total body fat mass, android/gynoid fat mass ratio, and sub-
cutaneous abdominal fat mass. In line with the associations of maternal glucose and insulin 
concentrations with childhood BMI, blood pressure, and lipids, all associations of maternal 
glucose and insulin concentrations with detailed measurements of childhood general and 
abdominal fat in the present study were fully explained by maternal prepregnancy BMI. 
Contrary to our hypothesis, no specific associations with childhood visceral fat mass were 
present. It might be that associations with childhood visceral fat are more apparent among 
higher risk populations or at older ages. Further studies are needed to explore the detailed 
role of a suboptimal offspring body fat distribution in response to impaired maternal glucose 
metabolism during pregnancy within different populations and using advanced imaging 
techniques. Based on our results, it seems that maternal early-pregnancy glucose and insulin 
concentrations are associated with childhood subcutaneous fat accumulation, but these as-
sociations are explained by maternal prepregnancy BMI.
Within this study, we only observed independent associations of maternal early-pregnancy 
glucose and insulin concentrations with childhood glucose and insulin concentrations. These 
associations provide insight into potential underlying mechanisms, and they may be explained 
through several pathways. First, shared genetic factors are expected to have a contribution in 
the association between maternal glucose and insulin concentrations with offspring glucose 
and insulin concentrations (37). Second, higher maternal early-pregnancy glucose concentra-
tions lead to fetal hyperinsulinemia, whereas higher maternal early-pregnancy insulin con-
centrations are involved in protein, lipolysis, and early placental development. Together, this 
could cause alternations in fetal nutrient supply, affecting fetal pancreatic beta-cell develop-
ment and increasing fetal insulin secretion. These irreversible alterations may subsequently 
lead to increased glucose and insulin concentrations in childhood (9, 38, 39). Furthermore, 
higher maternal glucose concentrations may also be involved in gene expression through 
DNA methylation, leading to altered insulin secretion in the offspring (40). Further studies 
are needed to disentangle the complex mechanisms underlying the association of maternal 
glucose and insulin concentrations with childhood glucose metabolism.
The observed effect estimates for the associations of maternal early-pregnancy glucose 
and insulin concentrations with childhood glucose and insulin concentrations were relatively 
small but they may be important on a population level. Previous studies have shown that 
childhood glucose and insulin concentrations tend to track into adulthood. A study among 
1,766 children showed that children with higher fasting glucose concentrations at the age 
of 10 years had a higher risk of developing type 2 diabetes in adolescence (6). Similarly, 
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a study among 1,723 children reported that children with higher fasting glucose concen-
trations within the normal range had a higher risk of prediabetes and type 2 diabetes in 
adulthood (7). A study among 4,857 American Indian children without diabetes showed 
that children with higher glucose concentrations after a glucose tolerance test had a higher 
risk of premature death, but this effect was not independent of concurrent childhood BMI 
(41). Together, these findings suggest that even subclinical differences in childhood glucose 
and insulin concentrations may be related to the development of type 2 diabetes in later 
life (42). Maternal prepregnancy BMI seems to explain the associations of maternal glucose 
and insulin concentrations with other childhood cardiometabolic risk factors and childhood 
body fat development. This suggests that preventive strategies, aimed at improving offspring 
cardiometabolic health, might be more effective when focusing on optimizing maternal 
prepregnancy BMI than on optimizing maternal glucose concentrations from early pregnancy 
onward.
Methodological considerations
Strengths of this study are the prospective design, large sample size, and the use of detailed 
fat measures obtained through MRI. Although only 61% of children from mothers with 
information on glucose and insulin concentrations in pregnancy participated in follow-up 
measurements, we do not expect that nonresponse affected our effect estimates, as maternal 
insulin and glucose concentrations did not differ between these groups. The generalizability 
of our results may be affected by a selection toward a relatively healthy, high-educated 
study population. We obtained nonfasting glucose and insulin concentrations, sampled on 
nonfixed times throughout the day. This may have led to nondifferential misclassification, 
causing an underestimation of our associations. Although we simultaneously measured 
insulin concentrations to substantiate our findings, random glucose concentrations cannot 
directly assess insulin resistance. However, random glucose concentrations are useful for 
identifying women at risk for gestational diabetes and they are used in clinical practice as a 
screening method in early pregnancy (43, 44). In addition, we measured maternal glucose 
and insulin concentrations once during early pregnancy. Impaired glucose tolerance in early 
pregnancy has been suggested to persist throughout pregnancy (33). Further studies are 
needed with multiple, more detailed maternal glucose measurements, including fasting glu-
cose concentrations and detailed postprandial glucose measurements throughout pregnancy. 
These studies also need to use more advanced statistical methods to provide further insight 
into critical periods for potential adverse effects of impaired maternal glucose metabolism 
on offspring glucose metabolism. We did not have information available on clinical diagnosis 
of type 2 diabetes in the offspring. However, we expect the percentage of childhood type 2 
diabetes according to clinical diagnosis within our cohort to be low, as the average age of the 
children in our cohort is 9.8 years, whereas the onset of type 2 diabetes mostly occurs at later 
childhood ages (45). Further studies are needed to assess whether maternal early-pregnancy 
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glucose and insulin concentrations are also associated with the risk of type 2 diabetes in the 
offspring during adolescence. Finally, although we had detailed information on maternal 
and childhood sociodemographic and lifestyle factors available, because of the observational 
study design, residual confounding by, for example, childhood dietary factors and physical 
activity may have influenced our results.
Conclusions
Maternal early-pregnancy random glucose and insulin concentrations were associated with 
higher childhood glucose and insulin concentrations, independent of maternal and child-
hood characteristics. When taking maternal prepregnancy BMI into account, no associations 
of maternal glucose and insulin concentrations with other childhood cardiometabolic risk 
factors were present.
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suPPlemental material
Supplemental Methods 1. Log-log regression analyses
For our fat measures, we created index variables, which were made independent of height. 
We did this by dividing our fat measurements by the optimal adjustment for height. The 
optimal adjustment was determined using log-log regression analyses (1). Total fat mass, 
subcutaneous fat mass, visceral fat mass and height were log-transformed using natural logs. 
We performed linear regression analyses with log-fat measures as the dependent variable 
and log- height as the independent variable. The regression slope corresponds with the 
power by which height should be raised. This resulted in the following index values of the fat 
measures: total fat mass divided by height4, subcutaneous fat mass divided by height4 and 
visceral fat mass divided by height3.
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Supplemental Table 1. Non-response analysis for loss to follow-up at the age of 10 years (n=6117)
Follow up at 10 
years (n=3737)




Age at enrolment, mean (SD), years 30.7 (4.7) 28.3(5.2) <0.01
Height, mean (SD), cm 168.2 (7.4) 166.5 (7.3) <0.01
Pre-pregnancy weight, median (95%), kg 65.0 (50.3; 90.0) 63 (50.0; 92.0) <0.01
Pre-pregnancy BMI, median (95%), kg/m2 22.6 (18.8; 31.9) 22.6 (18.6; 32.8) 0.64
Gestational weight gain, mean (SD), kg 15.1 (5.7) 15.1 (6.3) 0.82
Gestational age at intake, median (95%), weeks 13.2 (10.5; 17.1) 13.4 (10.4; 17.4) <0.01
Parity, n nulliparous (%) 2230 (59.7) 1244 (52.3) <0.01
Ethnicity, n (%) <0.01
Dutch/European 2492 (66.7) 1088 (49.7)
Other 1191 (31.9) 1103 (46.3)
Education level, n high (%) 1855 (49.6) 695 (33.0) <0.01
Smoking during pregnancy, n yes (%) 853 (22.8) 673 (29.2) <0.01
Folic acid supplement use, n yes (%) 2363 (63.2) 1126 (47.3) <0.01
Glucose, mean (SD), mmol/l 4.40 (0.86) 4.38 (0.82) 0.39
Insulin, median (95%), pmol/l 114.0 (24.05) 115.35 0.06
Gestational diabetes, n (%) 34 (0.9) 28 (1.2) 0.27
Daily calorie intake, mean (SD), kcal 2050 (548) 2008 (588) 0.02
Birth characteristics
Gender, n female (%) 1894 (50.7) 1123 (47.2) 0.01
Birth weight, mean (SD), grams 3437 (550) 3386 (583) <0.01
Gestational age at birth, median (95%), weeks 40.3 (37.1; 42.1) 40.0 (36.4; 42.0) <0.01
*Differences in subject characteristics between the groups were evaluated using unpaired t-tests for the normally dis-
tributed continuous variables, Mann-Whitney U tests for the not-normally distributed continuous variables and chi-
square tests for proportions.
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Supplemental Table 2. Associations of maternal early-pregnancy glucose and insulin concentrations with 









Maternal glucose concentrations (SDS)
Gestational weight gain modela 0.07 (0.03; 0.12)* 0.03 (-0.02; 0.07)
Birth weight modelb 0.08 (0.04; 0.12)* 0.03 (-0.01; 0.07)
Infant modelc 0.07 (0.03; 0.11)* 0.03 (-0.01; 0.06)
Child BMI modeld 0.07 (0.03; 0.11)* 0.03 (-0.01; 0.07)
Maternal insulin concentrations (SDS)
Gestational weight gain modela 0.02 (-0.02; 0.07) 0.05 (0.01; 0.10)*
Birth weight modelb 0.03 (-0.01; 0.07) 0.06 (0.02; 0.10)*
Infant modelc 0.02 (-0.02; 0.07) 0.06 (0.02; 0.10)*
Child BMI modeld 0.02 (-0.02; 0.07) 0.06 (0.02; 0.09)*
aGestational weight gain model includes the maternal BMI model additionally adjusted for gestational weight gain
bBirth weight model includes the maternal BMI model additionally adjusted for gestational-age-adjusted birth weight
cInfant model includes maternal BMI model additionally adjusted for breastfeeding in infancy
dChild BMI model, the maternal BMI model additionally adjusted for child’s BMI during follow up measurement at 10 
years





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplemental Table 6. Associations of maternal early-pregnancy glucose and insulin concentrations with 
childhood general and abdominal fat after exclusion of children small or large for gestational age at birth
















Maternal glucose concentrations (SDS)
Basic modela 0.04 (0.01; 0.08) 0.04 (0.00; 0.07) 0.04 (-0.01; 0.09) -0.01 (-0.06; 0.04)
Confounding modelb 0.03 (-0.01; 0.06) 0.02 (-0.01; 0.05) 0.03 (-0.02; 0.07) -0.02 (-0.07; 0.03)
Maternal BMI modelc N.A. N.A. N.A. -0.06 (-0.11; -0.01)
Maternal insulin concentrations (SDS)
Basic modela 0.11 (0.08; 0.14)* 0.10 (0.06; 0.13)* 0.11 (0.06; 0.15)* 0.03 (-0.02; 0.08)
Confounding modelb 0.06 (0.03; 0.09)* 0.06 (0.03; 0.10)* 0.07 (0.03; 0.12)* 0.02 (-0.03; 0.06)
Maternal BMI modelc 0.01 (-0.02; 0.04) 0.02 (-0.01; 0.06) 0.02 (-0.03; 0.06) N.A.
Values represent regression coefficients (95% confidence interval) from linear regression models that reflect differences 
in childhood outcomes in SDS per SDS change in maternal glucose and insulin concentrations. Estimates are based on 
multiple imputed data.
N.A.: not applicable, SDS: standard deviation score
aBasic model includes gestational age at enrolment, child’s age and sex at follow up measurements
bConfounding model includes the basic model additionally adjusted for ethnicity, maternal educational level
cMaternal BMI model includes the confounder model additionally adjusted for maternal prepregnancy BMI
dMagnetic resonance imaging follow up measurements were performed in a subgroup of children
*p-value<0.013 (Bonferroni corrected p-value for multiple testing)
Supplemental Table 5. Associations of maternal early-pregnancy glucose and insulin concentrations with 
childhood general and abdominal fat after exclusion of children born premature
















Maternal glucose concentrations (SDS)
Basic modela 0.05 (0.02; 0.08)* 0.04 (0.01; 0.07) 0.03 (-0.01; 0.08) -0.01 (-0.06; 0.03)
Confounding modelb 0.03 (0.00; 0.06) 0.02 (-0.01; 0.06) 0.02 (-0.02; 0.06) -0.02 (-0.06; 0.03)
Maternal BMI modelc N.A. N.A. N.A. N.A.
Maternal insulin concentrations (SDS)
Basic modela 0.11 (0.08; 0.14)* 0.09 (0.06; 0.12)* 0.10 (0.06; 0.15)* 0.03 (-0.02; 0.07)
Confounding modelb 0.07 (0.04; 0.10)* 0.05 (0.02; 0.08)* 0.07 (0.03; 0.11)* 0.02 (-0.03; 0.06)
Maternal BMI modelc 0.02 (-0.01; 0.05) 0.01 (-0.02; 0.05) 0.02 (-0.02; 0.06) N.A.
Values represent regression coefficients (95% confidence interval) from linear regression models that reflect differences 
in childhood outcomes in SDS per SDS change in maternal glucose and insulin concentrations. Estimates are based on 
multiple imputed data.
N.A.: not applicable, SDS: standard deviation score
aBasic model includes gestational age at enrolment, child’s age and sex at follow up measurements
bConfounding model includes the basic model additionally adjusted for ethnicity, maternal educational level
cMaternal BMI model includes the confounder model additionally adjusted for maternal prepregnancy BMI
dMagnetic resonance imaging follow up measurements were performed in a subgroup of children
*p-value<0.013 (Bonferroni corrected p-value for multiple testing)
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childhood insulin levels
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life onwards associated with childhood insulin levels.




Aims/hypothesis: We aimed to identify critical periods and specific longitudinal growth 
patterns from fetal life onwards associated with childhood insulin and C-peptide levels.
Methods: In a prospective population-based cohort study of 4328 children, we repeatedly 
measured (femur) length and (estimated fetal) weight from the second trimester of fetal life 
until 6 years of age. BMI was calculated from 6 months onwards. Insulin and C-peptide levels 
were measured at 6 years of age.
Results: Preterm birth and small or large size for gestational age at birth were not associated 
with childhood insulin levels. Conditional growth modelling showed that, independent of 
growth in other time intervals, weight growth in each time interval from birth onwards, 
length growth from 6 months onwards and BMI growth from 12 months onwards were 
positively associated with childhood insulin levels. The strongest associations were present 
for weight and BMI growth between 48 and 72 months of age. Repeated measurement 
analyses showed that, compared with children in the lowest quartile of childhood insulin, 
those in the highest quartile had a higher length from birth onwards and a higher weight and 
BMI from 24 months onwards. These differences increased with age. No associations were 
observed for fetal growth characteristics. Similar results were observed for C-peptide levels.
Conclusions/interpretation: Our results suggest that rapid length, weight and BMI growth 
from birth onwards, but not during fetal life, is associated with higher insulin levels in child-
hood.
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introduction
A large body of evidence suggests that adverse exposures in early life influence the risk of 
type 2 diabetes in later life (1). Multiple previous studies have shown that adults born with 
either a low or high birthweight are at increased risk of type 2 diabetes (2, 3). Birthweight is 
often used as a proxy for fetal growth. However, since birthweight is the result of different 
fetal growth patterns and is the starting point of infant growth, birthweight is not a causal 
factor per se in the development of type 2 diabetes. Studies assessing the associations of 
directly measured fetal growth characteristics with measures of glucose or insulin metabolism 
in later life are scarce and focused on measures of growth during specific trimesters only (4, 
5). As the development of the endocrine pancreas starts as early as the first trimester (6), 
fetal life might be a critical period for glucose and insulin metabolism, and the development 
of type 2 diabetes in later life.
More research has been performed on childhood growth patterns related to the risk of 
type 2 diabetes in later life (7-11). These studies showed that participants who developed 
type 2 diabetes in adulthood were small at birth and thin in infancy. During childhood, they 
gained weight rapidly, leading to an average or above average BMI at the age of 11 years. 
Furthermore, weight gain during the first 6 months of life was more strongly related to the 
risk of insulin resistance in adulthood compared with weight gain later in infancy (9).
Thus far, there have been no studies to explore the associations of directly measured 
fetal growth characteristics or the combined associations of repeatedly measured fetal and 
childhood growth characteristics with insulin metabolism in later life. It is also not clear 
which time period of growth is most important for later insulin metabolism. Therefore, we 
aimed to identify critical periods and specific growth patterns from fetal life onwards that are 
important for the development of suboptimal insulin metabolism in childhood. Among 4328 
participants of a population-based prospective cohort study from early pregnancy onwards, 
we assessed the associations of directly measured fetal and childhood growth characteristics 
with insulin and C-peptide levels at 6 years of age.
methods
Study design
This study was embedded in the Generation R Study, a population-based prospective cohort 
study from early pregnancy onwards performed in Rotterdam, the Netherlands (12, 13). 
The study was approved by the Medical Ethical Committee of the Erasmus Medical Center, 
University Medical Center, Rotterdam (MEC 198.782/2001/31). Written informed consent 
was obtained from all mothers. The response rate at birth was 61%. In total, 9901 children 
were enrolled in the study. As growth represents a change in size between two time points, 
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we included children who had measurements of fetal or childhood growth characteristics 
available at, at least, two different time points (n=9639). Of these children, 9395 were 
singleton and live-born, 6522 participated in the follow-up measurements at 6 years of age 
and 4328 had information on insulin or C-peptide levels available (Supplemental Figure 1). 
Missing data on insulin and C-peptide levels were mainly due to lack of consent for venous 
punctures or non-successful venous punctures (13).
Fetal and childhood growth characteristics
We performed fetal ultrasound examinations in each trimester of pregnancy. As described 
previously, gestational age was established using data from the first fetal ultrasound exami-
nation (14). Second and third trimester fetal head circumference (HC), abdominal circumfer-
ence (AC) and femur length (FL) were measured to the nearest millimetre using standardised 
ultrasound procedures. We calculated estimated fetal weight (EFW) using the formula of 
Hadlock et al (15): log10 EFW=1.5662−0.0108 (HC)+0.0468 (AC)+0.171 (FL)+0.00034 
(HC)2−0.003685 (AC× FL). Information on child’s sex, gestational age, weight and length 
at birth was obtained from medical records. Preterm birth was defined as a gestational 
age at birth <37 weeks. Low birthweight was defined as a birthweight ≤2500 g and high 
birthweight was defined as a birthweight ≥4000 g. Small and large size for gestational age 
at birth were defined as the lowest and the highest ten percentiles of gestational age and 
sex-adjusted birthweight in the complete cohort.
Well-trained staff in community health centres obtained childhood growth characteristics 
(length and weight) according to standard schedules and procedures at 6, 12, 24, 36 and 48 
months of age. Growth characteristics at 72 months were obtained in a dedicated research 
centre following standardised protocols. We calculated BMI (kg/m2) at each time point 
from 6 months onwards. Standard deviation scores (SDS) were constructed for all growth 
characteristics using reference charts from the complete cohort for fetal measurements (14), 
northern European growth charts for birth measurements (16) and Dutch growth reference 
charts for childhood growth characteristics (Growth Analyzer 3.0; Dutch Growth Research 
Foundation, Rotterdam, the Netherlands) (17).
Childhood insulin and C-peptide levels
At 6 years of age, 30 min fasting venous blood samples were obtained in a well-equipped 
and dedicated research centre in the Erasmus Medical Center Sophia Children’s hospital, Rot-
terdam, the Netherlands (12). All blood samples were stored for a maximum of 4 h at 4°C. 
Blood samples were transported twice daily to the laboratory facility of the regional laboratory 
in Rotterdam, the Netherlands (STAR-MDC), where they were processed and stored within 
4 h of venous puncture (13). Insulin (pmol/l) and C-peptide levels (nmol/l) were obtained 
enzymatically using a Cobas 8000 Analyzer (Roche, Almere, the Netherlands). Quality control 
samples demonstrated intra- and inter-assay coefficients of variation of 1.39% and 2.40%, 
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respectively. As C-peptide is secreted in equal amounts but has a longer half-life compared 
with insulin, we included C-peptide levels as an additional, more stable, outcome measure.
Covariates
We assessed maternal age, pre-pregnancy weight, parity, ethnicity, educational level and 
folic acid use by questionnaire at enrolment in the study. Maternal height was measured and 
pre-pregnancy BMI was calculated. Smoking during pregnancy was repeatedly assessed by 
questionnaire throughout pregnancy. We obtained information on gestational hypertensive 
disorders (gestational hypertension and preeclampsia) and gestational diabetes from medical 
records (18). Information on breastfeeding and the timing of introduction to solid foods 
was assessed by questionnaire during infancy, and the average time watching television was 
assessed by questionnaire at 6 years of age.
Statistical analysis
First, we assessed the associations of gestational age at birth (preterm, term), birthweight 
(low, normal, high) and size for gestational age at birth (small, appropriate, large) with child-
hood insulin and C-peptide levels using multiple linear regression models. Second, to identify 
specific critical periods of growth associated with childhood insulin and C-peptide levels, 
we used conditional growth modelling (19-21). We constructed length, weight and BMI 
growth variables, which are statistically independent from each other, using the standardised 
residuals obtained from the linear regression models of length, weight and BMI regressed 
on all prior corresponding growth measurements (Supplemental Methods 1). This enables 
inclusion of the growth measurements at all time points simultaneously in one model, and 
thus to estimate the independent and mutually adjusted influence of growth during each 
time interval on childhood insulin and C-peptide levels (19-21). Third, in order to examine the 
associations of longitudinal fetal and childhood growth patterns with childhood insulin and 
C-peptide levels, we used unbalanced repeated measurement models. These models allow 
for incomplete outcome data and take the correlation between repeated measurements of 
the same participant into account by modelling the correlated errors of these measurements. 
For these analyses, we constructed quartiles of childhood insulin and C-peptide levels. 
These categories were included in the models as intercept and as interaction terms with 
(gestational) age to study the (gestational) age-independent effects (difference constant over 
time) as well as (gestational) age-dependent effects (difference non-constant over time). The 
actual models are described in more detail in Supplemental Methods 2.
All models were first adjusted for the child’s sex and age at insulin and C-peptide mea-
surement only (basic models), and were subsequently adjusted for maternal and childhood 
sociodemographic and lifestyle related characteristics (adjusted models). The models for birth 
outcomes were also adjusted for childhood BMI at insulin and C-peptide measurement. We 
included covariates in the models based on their associations with the outcomes of inter-
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est in previous studies, a significant association with the determinants and outcomes, or a 
change in effect estimates of >10%. The associations between all growth characteristics and 
childhood insulin and C-peptide levels were linear. We tested for interactions between birth-
weight and BMI at the age of insulin and C-peptide measurement, birthweight and child’s 
sex, and BMI at the age of insulin and C-peptide measurement and child’s sex in the models 
described above, but no significant interactions were present (p values for interaction >0.05). 
In order to obtain normal distributions, we square root transformed insulin and C-peptide 
levels. SDS were constructed for insulin and C-peptide levels, defined as (observed value 
minus mean value of the reference population)/SD, to enable comparison of effect estimates. 
We used multiple imputation for missing values of covariates (<32%) and for the growth 
characteristics (<46%) for conditional growth modelling only by generating five independent 
datasets using the Markov Chain Monte Carlo (MCMC) method. Pooled effect estimates 
were presented. We performed a sensitivity analysis in children with growth characteristics 
available at all time points, which did not materially change the main findings (results not 
shown). The repeated measurement analyses were performed using the Statistical Analysis 
System version 9.3 (SAS Institute, Cary, NC, USA). All other analyses were performed using 
the Statistical Package of Social Sciences version 21.0 for Windows (IBM, Armonk, NY, USA).
results
Study population
Table 1 shows the characteristics of the study population. At 6 years of age, the median 
insulin and C-peptide levels were 112 pmol/l (95% range 17, 395) and 0.95 nmol/l (95% 
range 0.30, 2.14), respectively. Supplemental Table 1 shows the growth characteristics at 
each time point. Nonresponse analysis showed that the mothers of children not included in 
the analyses were more likely to have a lower level of education and to smoke more often 
compared with the mothers of children included in the analyses (Supplemental Table 2). 
Furthermore, children not included in the analysis were less often from European descent. No 
or minor differences in childhood growth characteristics were observed between the groups.
Critical periods of early growth
We did not observe associations of gestational age at birth, birthweight or size for gesta-
tional age at birth with childhood insulin levels in the basic or the adjusted models (Table 2). 
After additional adjustment for childhood current BMI, tendencies to inverse associations of 
birthweight and size for gestational age at birth with childhood insulin levels were present. 
The results were similar for childhood C-peptide levels (Supplemental Table 3).
Figure 1 shows the associations of growth during specific time intervals, conditional on 
prior growth measurements, with childhood insulin levels (adjusted models). No associations 
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were observed for growth during specific periods in fetal life. Independent of growth in 
other time intervals, weight growth in each time interval from birth onwards, length growth 
in each time interval from 6 months onwards and BMI growth in each time interval from 
12 months onwards were positively associated with childhood insulin levels (p <0.05). The 
strongest associations were present for weight and BMI growth between 48 and 72 months. 
The results obtained from the basic model were consistent (Supplemental Figure 2). Similar 
results were also observed for childhood C-peptide levels (Supplemental Figures 2 and 3).




Age at intake (years), mean (SD) 30.7 (5.1)
Height (cm), mean (SD) 167.7 (7.5)
Pre-pregnancy weight (kg), median (95% range) 64.0 (49.0, 98.0)
Pre-pregnancy BMI (kg/m2), median (95% range) 22.7 (18.1, 34.5)




Parity, nulliparous (%) 2299 (55.1)
Ethnicity, European (%) 2605 (61.9)
Folic acid use, yes (%) 2239 (75.3)
Smoking during pregnancy, yes (%) 601 (16.0)
Gestational diabetes, yes (%) 42 (1.0)
Pre-eclampsia, yes (%) 65 (1.8)
Gestational hypertension, yes (%) 155 (4.2)
Child characteristics
Sex, male (%) 2235 (51.6)
Gestational age at birth (weeks), median (95% range) 40.1 (35.8, 42.3)
Birthweight (g), median (95% range) 3450 (2261, 4474)
Ever breastfed, yes (%) 3150 (92.5)
Introduction of solid foods before 6 months, yes (%) 2328 (89.9)
Ethnicity, European (%) 2730 (64.8)
Television watching >2 h/day, n (%) 672 (19.9)
Age at 6-year follow-up examination (years), median (95% range) 6.0 (5.7, 8.0)
BMI (kg/m2), median (95% range) 15.9 (13.7, 21.2)
Insulin at 6 years (pmol/l), median (95% range) 112 (17, 395)
C-peptide at 6 years (nmol/l), median (95% range) 0.95 (0.30, 2.14)
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Fetal and childhood growth patterns
Figure 2a–c shows the growth patterns from fetal life onwards for children in the higher 
childhood insulin quartiles compared with children in the lowest childhood insulin quartile. 
The overall growth patterns for fetal weight and length did not differ between the insulin 
quartiles (p values for trend >0.05). During childhood, length, weight and BMI gain were 
faster for children in the higher insulin quartiles (p values for trend <0.05). The largest dif-
ferences were observed for children in the highest insulin quartile. Compared with children 
in the lowest insulin quartile, children in the highest insulin quartile were taller from birth 
onwards. Furthermore, they had a higher weight and BMI from 24 months onwards. These 
differences increased with age. Supplemental Figure 4a-c shows the growth patterns as-
sociated with childhood C-peptide levels, which were similar to those for insulin levels. The 
regression coefficients for (gestational) age-independent (intercept) and (gestational) age-
dependent effects (interaction between the insulin or C-peptide quartiles and (gestational) 
age) are given in Supplemental Tables 4 and 5.
Table 2. Associations of birth outcomes with childhood insulin levels (n=4286)
Birth outcome n Insulin (SDS [95% CI])
Basic model Adjusted model BMI-adjusted model
Gestational age at birth
Preterm (<37 weeks) 213 0 (-0.14, 0.14) -0.03 (-0.18, 0.13) -0.07 (-0.22, 0.08)
Term (≥37 weeks) 4051 Reference Reference Reference
p value for trend 4264 0.957 0.743 0.358
Birthweight
Low (≤2500 g) 187 -0.01 (-0.16, 0.14) 0.06 (-0.12, 0.23) 0.12 (-0.06, 0.29)
Normal (2500–3999 g) 3474 Reference Reference Reference
High (≥4000 g) 625 -0.03 (-0.12, 0.05) -0.07 (-0.16, 0.02) -0.13 (-0.22, -0.04)*
p value for trend 4286 0.529 0.098 0.002
Size for gestational age
SGA (≤10th percentile) 363 -0.01 (-0.11, 0.10) 0.01 (-0.10, 0.12) 0.08 (-0.03, 0.19)
AGA (10–90th percentile) 3447 Reference Reference Reference
LGA (≥90th percentile) 444 -0.04 (-0.14, 0.06) -0.06 (-0.16, 0.04) -0.12 (-0.22, -0.02)*
p value for trend 4254 0.635 0.276 0.005
Values are regression coefficients that reflect the differences in insulin SDS between the groups of the different birth 
outcomes
The basic models are adjusted for child’s sex and age at insulin and C-peptide measurement. The adjusted models are 
further adjusted for maternal pre-pregnancy BMI, maternal age, parity, smoking during pregnancy, folic acid use, ma-
ternal education level, gestational diabetes, gestational hypertensive disorders, ethnicity of the child, gestational age at 
birth (for birthweight) and birthweight (for gestational age at birth). The BMI-adjusted models are the adjusted models 
with additional adjustment for childhood BMI at insulin and C-peptide measurement
p values for trend were obtained by entering the categorical variables to the models as continuous variables
*p<0.05
AGA, appropriate for gestational age; LGA, large for gestational age; SGA, small for gestational age
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discussion
In this prospective population-based cohort study, rapid length, weight and BMI growth from 
birth onwards was associated with higher childhood insulin levels. Although the strongest as-
sociations were present for weight and BMI growth between 48 and 72 months, we also ob-
served independent associations of postnatal weight and BMI growth with childhood insulin 
levels at earlier time intervals. No associations were observed for fetal growth characteristics.
Strengths and limitations
In this prospective population-based study, we had repeatedly measured growth character-
istics available from fetal life onwards, enabling us to study the combined associations of 
fetal and childhood growth characteristics with childhood insulin and C-peptide levels. Of all 
eligible children at baseline, 54% were not included in the analyses. We consider it unlikely 
that this led to selection bias, since no or only minor differences were observed between the 
growth characteristics of children included in the analyses and children not included in the 
analyses.
The fasting time before venous puncture was limited. Due to the design of the study and 
the young age of the children, we were not able to collect blood samples after a longer 
fasting period (12). This may have led to some non-differential misclassification and un-
Figure 1. Associations of fetal and childhood growth, conditional on prior measurements, with 
























Values are regression coefficients representing differences in childhood insulin SDS per standardised residual change in 
growth characteristic in each time interval. The standardised residuals were obtained from models in which the growth 
measures of interest were regressed on the prior corresponding growth measures. For models presented for length and 
weight, the initial measure of size (starting point) was at 20 weeks of gestation (FL and EFW), and for BMI at 6 months 
of age. The models are adjusted for child’s sex, age at insulin and C-peptide measurement, maternal pre-pregnancy 
BMI, maternal age, parity, smoking during pregnancy, folic acid use, maternal education level, gestational diabetes, 
gestational hypertensive disorders, ethnicity of the child, gestational age at birth, breastfeeding, timing of introduction 
of solid foods and time watching television. Circles, length; squares, weight; triangles, BMI; wks, weeks; mo, months.
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Gestational age Age (months)
(weeks)
c
Results are based on repeated linear regression models and reflect the differences in SDS of (a) length (based on 
39,022 measurements), (b) weight (based on 42,630 measurements) and (c) BMI (based on 23,277 measurements) 
growth in children with insulin levels in the second, third and fourth quartiles (insulin levels 62.7–112.4, 112.5–186.9 
and 187.0–569.7 pmol/l, respectively), compared with those with insulin levels in the first quartile (2.7–62.6 pmol/l). 
The reference value is an SDS of 0. The models were adjusted for child’s sex, maternal pre-pregnancy BMI, maternal 
age, parity, smoking during pregnancy, folic acid use, maternal education level, gestational diabetes, gestational hy-
pertensive disorders, ethnicity of the child, gestational age at birth, breastfeeding, timing of introduction of solid foods 
and time watching television. Circles/dotted line, second insulin quartile; triangles/dashed line, third insulin quartile; 
squares/solid line, fourth insulin quartile.
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derestimation of the observed effect estimates. This may especially affect childhood insulin 
levels, which are less stable and have a shorter half-life compared with C-peptide levels. In 
addition, information on glucose levels was not available and therefore we were unable to 
estimate insulin sensitivity. However, as blood glucose levels are less variable than insulin 
levels, especially in children, and most of the variability in insulin sensitivity is due to insulin 
levels, we consider insulin levels to be a useful proxy of insulin sensitivity (22, 23). Further 
studies are needed to assess the associations of fetal and childhood growth with detailed and 
fasting measures of offspring glucose and insulin metabolism.
As insulin is known to stimulate growth and fat deposition, it might be possible that the 
associations observed were due to reverse causation (24). However, as information on insulin 
and C-peptide levels was only available at 6 years of age, we were not able to assess this 
possibility in our study.
The prospective design of the study from early pregnancy onwards enabled us to take into 
account numerous potential maternal and childhood confounders. However, some residual 
confounding might be present in the reported effect estimates as, for example, detailed 
dietary information was not available.
Interpretation of main findings
An accumulating body of evidence suggests that adverse exposures in early life influence the 
risk of type 2 diabetes in later life. Multiple studies have reported associations of birthweight 
with measures of glucose and insulin metabolism in children as well as adults, some of them 
depending on adjustment for current body size (2-4, 9, 25). We did not observe associations 
of gestational age at birth, birthweight or size for gestational age at birth with childhood 
insulin or C-peptide levels. After adjustment for childhood current BMI, tendencies to inverse 
associations for birthweight and size for gestational age at birth were present. However, it 
has been argued that adjusting early size for later size reflects the change in size between 
these two time points (26). This suggests that the change between the growth characteristics 
at birth and in childhood is related to childhood insulin and C-peptide levels rather than 
birthweight per se.
Thus far, critical periods from fetal life onwards associated with the development of type 
2 diabetes remain unclear, as previous studies mainly used birthweight as a proxy of fetal 
growth. Among 123 Danish adolescents, fetal growth velocity during the third trimester 
was not associated with any measure of insulin or glucose metabolism (4). In our own study 
cohort, first trimester crown to rump length was not associated with childhood insulin levels 
(5). In childhood, results from the Helsinki birth cohort suggest that growth during the first 
6 months is critical for the development of insulin resistance in adulthood (9). In a study of 
1124 children from England and Wales, both a lower birthweight and a higher childhood 
ponderal index were associated with higher fasting and postload insulin levels at 10–11 
years, with stronger effect estimates for the childhood ponderal index (25). Furthermore, a 
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recent study among 3301 European children with a mean age of 8.5 years showed that rapid 
BMI growth between 9 months and 6 years was related to a higher risk of insulin resistance 
(27). In our current study, growth during fetal life was not associated with childhood insulin 
or C-peptide levels, independent of growth in other time intervals. Weight growth from birth 
onwards, length growth from 6 months onwards and BMI growth from 12 months onwards 
were independently and positively associated with childhood insulin and C-peptide levels. 
The strongest associations were present for weight and BMI growth between 48 and 72 
months. These results suggest that growth during childhood, especially in weight and BMI, is 
important for the development of a suboptimal insulin metabolism in childhood, irrespective 
of growth during fetal life.
Observations from previous studies suggest that a growth pattern characterised by a low 
birthweight, followed by a rapid childhood weight gain, is associated with increased risk of 
insulin resistance or type 2 diabetes in later life (9-11). We observed no associations of fetal 
growth patterns with childhood insulin and C-peptide levels. During childhood, children with 
higher insulin and C-peptide levels had a growth pattern characterised by a high weight and 
BMI, which increased throughout childhood. This suggests that children with relatively high 
childhood insulin or C-peptide levels grow faster during childhood but might not have grown 
differently during fetal life.
Thus, our results suggest that rapid growth throughout childhood is important for the 
development of suboptimal insulin metabolism in childhood, rather than fetal growth. It 
has been proposed that adverse exposures during fetal life lead to reduced muscle mass, 
reduced muscle sensitivity to insulin, and changes in the structure and function of the beta 
cells, which may subsequently lead to insulin resistance and beta cell dysfunction in later life 
(28-30). Since only childhood growth characteristics were related to childhood insulin and 
C-peptide levels in our study, the mechanisms underlying these associations may involve 
differences in the body composition of the child, for example an increased body fat mass 
resulting from rapid postnatal growth or genetic influences, rather than developmental 
adaptations during fetal life (21, 31-33). However, it is possible that associations of fetal 
growth with insulin or glucose metabolism become apparent later in life. Furthermore, the 
widely described associations of low birthweight with increased risk of type 2 diabetes may 
be explained by beta cell dysfunction, which we were unable to assess in this study (34). If 
our findings are confirmed by other studies with directly measured fetal growth data, de-
tailed childhood growth data and more detailed measures of childhood glucose and insulin 
metabolism, including measures of beta cell function, our results underline the importance 
of strategies aimed at preventing rapid weight gain throughout childhood to improve insulin 
metabolism in later life.
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Conclusions
Our results suggest that rapid length, weight and BMI gain from birth onwards, but not 
growth during fetal life, is associated with the development of suboptimal insulin metabo-
lism in childhood. Further research is needed to replicate our findings and to explore the 
underlying mechanisms.
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Supplemental Methods 1. Conditional growth modelling
We used conditional growth modelling in order to identify critical periods of growth as-
sociated with childhood insulin and C-peptide levels (1-3). We first calculated the predicted 
value of the growth measurement at the time point of interest, using a linear regression 
model including all prior corresponding growth measurements. The standardised residuals 
of these models indicate to what degree a growth measure of interest differs from that 
predicted by all previous growth measures, and represent the excess growth during the time 
interval prior to the growth measurement of interest. As these standardised residuals are not 
correlated, we subsequently included the standardised residuals plus the initial measure of 
size (femur length and estimated fetal weight at 20 weeks of gestation for models of length 
and weight, and BMI at the age of 6 months for models of BMI) simultaneously in one linear 
regression model, estimating the effect of growth during each time interval on childhood 
insulin or C-peptide levels. The regression coefficients of these models represent the differ-
ence in childhood insulin or C-peptide levels per standardised residual change in growth in 
each time interval, adjusted for growth during the other time intervals. Conditional growth 
modelling enables us to examine the associations of growth during specific time-periods, 
independent of growth in other time intervals and to compare the strength of the effect 
estimates between time intervals. This method thus allows us to identify periods of growth 
which are most important for later childhood insulin and C-peptide levels (1-3).
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Supplemental Methods 2. Unbalanced repeated measurement models
We analysed the fetal and childhood growth patterns among children in the 2nd, 3rd and 4th 
insulin and C-peptide quartiles, as compared to children in the 1st quartiles using unbalanced 
repeated measurement regression models. These models allow for incomplete outcome 
data and take the correlation between repeated measurements of the same participant 
into account by modelling the correlated errors of these measurements (1, 2). As fetal and 
childhood growth were defined using different measures (femur length vs. body length and 
estimated fetal weight vs. measured weight), we constructed best fitting models for fetal 
and childhood growth separately. First, we constructed linear models for fetal and childhood 
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growth characteristics separately and subsequently tested whether adding higher polynomi-
als of (gestational) age to the models improved the fit of the models by checking the good-
ness of fit (smallest –2 log likelihood). Since higher polynomials of (gestational) age did not 
considerably improve the fit of the models and to prevent overfitting of the models, we kept 
the models as simple as possible and did not include higher polynomials of (gestational) age 
to the models. To model the correlated errors, a compound symmetry covariance structure 
was assumed for the models for fetal growth, indicating that measurements are correlated 
equally. For the childhood models, we assumed an autoregressive covariance structure, given 
that measurements closer in time tend to be correlated more strongly. Using alternative 
covariance structures did not change the results.
The final models can be written as:
Fetal length (SDS) = ß0 + ß1 × insulin or C-peptide quartile + ß2 × gestational age + ß3 × 
insulin or C-peptide quartile × gestational age
Childhood length (SDS) = ß0 + ß1 × insulin or C-peptide quartile + ß2 × age + ß3 × insulin 
or C-peptide quartile × age
Fetal weight (SDS) = ß0 + ß1 × insulin or C-peptide quartile + ß2 × gestational age + ß3 × 
insulin or C-peptide quartile × gestational age
Childhood weight (SDS) = ß0 + ß1 × insulin or C-peptide quartile + ß2 × age + ß3 × insulin 
or C-peptide quartile × age
BMI (SDS)= ß0 + ß1 × insulin or C-peptide quartile + ß2 × age + ß3 × insulin or C-peptide 
quartile × age
In these models, ‘ß0 + ß1 × insulin or C-peptide quartile’ reflects the intercept. The intercept 
reflects the mean growth characteristic value in SDS for each insulin or C-peptide quartile. 
The term ‘ß2 × (gestational) age’ reflects the change in growth characteristics per week 
(fetal models) or month (childhood models). The term ‘ß3 × insulin or C-peptide quartile × 
(gestational) age’, reflects the difference in change in growth characteristics per week (fetal 
models) or month (childhood models) between the different insulin or C-peptide quartiles. 
For presentation purposes, we obtained point estimates from these models at time points of 
interest. The regression coefficients for (gestational) age-independent (intercept: ß0 + ß1 × 
insulin or C-peptide quartile) and (gestational) age-dependent differences (slope: ß3 × insulin 
or C-peptide quartile × (gestational) age) are given in Supplemental Tables 4 and 5 below.
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Gestational age (weeks), median (95% range) 20.5 (18.6, 23.3)
Femur length (mm), mean (SD) 34 (4)
Estimated fetal weight (g), median (95% range) 364 (246, 624)
Third trimester
Gestational age (weeks), median (95% range) 30.4 (28.4, 33.1)
Femur length (mm), mean (SD) 58 (3)
Estimated fetal weight (g), median (95% range) 1608 (1175, 2232)
Birth
Gestational age at birth (weeks), median (95% range) 40.1 (35.8, 42.3)
Birth length (cm), mean (SD) 50.2 (2.3)
Birthweight (g), median (95% range) 3450 (2261, 4474)
6 months
Age at follow-up (months), median (95% range) 6.2 (5.2, 8.3)
Length (cm), mean (SD) 67.7 (2.6)
Weight (kg), mean (SD) 7.9 (0.9)
BMI (kg/m2), mean (SD) 17.2 (1.4)
12 months
Age at follow-up (months), median (95% range) 11.1 (10.1, 125)
Length (cm), mean (SD) 74.4 (2.6)
Weight (kg), mean (SD) 9.7 (1.1)
BMI (kg/m2), mean (SD) 17.4 (1.4)
24 months
Age at follow-up (months), median (95% range) 11.1 (10.1, 12.5)
Height (cm), mean (SD) 88.8 (3.7)
Weight (kg), mean (SD) 13.0 (1.6)
BMI (kg/m2), median (95% range) 16.5 (14.1, 19.6)
36 months
Age at follow-up (months), median (95% range) 37.7 (35.3, 40.7)
Height (cm), mean (SD) 97.5 (3.8)
Weight (kg), mean (SD) 15.3 (1.9)
BMI (kg/m2), mean (SD) 16.0 (1.3)
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Age at follow-up (months), median (95% range) 45.7 (44.4, 48.4)
Height (cm), mean (SD) 103.3 (4.1)
Weight (kg), mean (SD) 17.0 (2.2)
BMI (kg/m2), mean (SD) 15.8 (1.4)
72 months
Age at follow-up (months), median (95% range) 72.6 (68.2, 96.3)
Height (cm), mean (SD), cm 119.7 (6.1)
Weight (kg), median (95% range) 22.6 (17.6, 34.4)
BMI (kg/m2), median (95% range) 15.9 (13.7, 21.2)
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Supplemental Table 2. Non-response analysis of children included and not included in the 
analyses (n=9395)
Included in the 
analyses





Age at intake (years), mean (SD) 30.7 (5.1) 29.2 (5.5) <0.001
Height (SD), mean (SD) 167.7 (7.5) 166.6 (7.3) <0.001
Pre-pregnancy weight (kg), median (95% range) 64.0 (49.0, 98.0) 63.0 (47.0, 100.0) 0.039
Pre-pregnancy BMI (kg/m2), median (95% range) 22.7 (18.1, 34.5) 22.6 (17.8, 35.5) 0.684
Highest education completed, n (%)
 Primary 343 (8.7) 565 (13.0) <0.001
 Secondary 1692 (43.1) 2117 (48.7)
 Higher 1887 (48.1) 1662 (38.3)
Parity, Nulliparous (%) 2299 (55.1) 2709 (55.4) 0.747
Ethnicity, European (%) 2605 (61.9) 2502 (54.5) <0.001
Folic acid use, yes (%) 2239 (75.3) 2252 (66.5) <0.001
Smoking during pregnancy, yes (%) 601 (16.0) 837 (19.8) <0.001
Gestational diabetes, yes (%) 42 (1.0) 57 (1.2) 0.444
Pre-eclampsia, yes (%) 65 (1.8) 103 (2.4) 0.060
Gestational hypertension, yes (%) 155 (4.2) 155 (3.6) 0.167
Child characteristics
Sex, male (%) 2235 (51.6) 2522 (49.8) 0.074
Gestational age at birth (weeks), median (95% range) 40.1 (35.8, 42.3) 39.8 (35.3, 42.3) 0.038





Ever breastfed, yes (%) 3150 (92.5) 2919 (91.4) 0.086
Timing of introduction of solid foods, No. before 6 
months (%)
2328 (89.9) 1941 (89.0) 0.300
Ethnicity, European (%) 2730 (64.8) 2686 (58.3) <0.001
Age at follow-up examination at 24 months (months), 
median (95% range)
25.0 (23.4, 31.4) 25.0 (23.4, 31.3) 0.815
BMI at the age of 24 months (kg/m2), mean (SD) 16.6 (1.4) 16.6 (1.5) 0.590
Age at follow-up examination at 48 months (months), 
median (95% range)
45,8 (44.4, 48.4) 45.8 (44.5, 48.7) 0.004
BMI at the age of 48 months, mean (SD), kg/m2 15.8 (1.4) 15.9 (1.5) 0.033
Age at follow-up examination at 6 years (years), 
median (95% range)
6.0 (5.7, 8.0) 6.0 (5.6, 7.6) <0.001
BMI at the age of 6 years (kg/m2), mean (SD) 16.2 (1.8) 16.2 (2.0) 0.651
a Differences in participant characteristics between the groups were tested using Independent Samples T-tests for con-
tinuous variables and Chi-square tests for proportions.
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Supplemental Table 3. Associations of birth outcomes with childhood C-peptide levels (n=4321)
Birth outcome n
C-peptide (SDS (95% CI))
Basic model Adjusted model BMI adjusted model
Gestational age at birth
 Preterm (<37 weeks) 215 0.03 (-0.11, 0.17) 0 (-0.15, 0.16) -0.04 (-0.19, 0.12)
 Term (≥ 37 weeks) 4083 Reference Reference Reference
 p-value for trend 4298 0.683 0.975 0.647
Birthweight
 Low (≤2500 g) 191 0.09 (-0.06, 0.24) 0.15 (-0.03, 0.32) 0.20 (0.03, 0.37)*
 Normal (2500-3999 g) 3503 Reference Reference Reference
 High (≥4000 g) 627 0 (-0.09, 0.08) -0.05 (-0.14, 0.04) -0.10 (-0.19, -0.01)*
 p-value for trend 4321 0.465 0.095 0.005
Size for gestational age
 SGA (≤ 10th percentile) 368 0.03 (-0.08, 0.14) 0.05 (-0.06, 0.16) 0.10 (-0.01, 0.21)
 AGA (10 - 90th percentile) 3475 Reference Reference Reference
 LGA (≥90th percentile) 445 0 (-0.10, 0.10) -0.03 (-0.13, 0.07) -0.08 (-0.18, 0.02)
 p-value for trend 4288 0.730 0.236 0.011
Values are regression coefficients that reflect the differences in C-peptide SDS between the groups of the different 
birth outcomes. The basic models are adjusted for child’s sex and age at insulin and C-peptide measurement. The ad-
justed models are further adjusted for maternal pre-pregnancy BMI, maternal age, parity, smoking during pregnancy, 
folic acid use, maternal education level, gestational diabetes, gestational hypertensive disorders, ethnicity of the child, 
gestational age at birth (for birthweight) and birthweight (for gestational age at birth). The BMI-adjusted models are 
the adjusted models with additional adjustment for childhood BMI at insulin and C-peptide measurement. P-values for 
trend were obtained by entering the categorical variables to the models as continuous variables. *p <0.05. AGA, Ap-
propriate for gestational age. LGA, Large for gestational age; SGA: Small for gestational age
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Supplemental Figure 2. Associations of fetal and childhood growth conditional on prior mea-

















































Values are regression coefficients representing differences in childhood insulin or C-peptide SDS per standardised re-
sidual change in growth characteristic in each time interval. The standardised residuals were obtained from models 
in which the growth measures of interest were regressed on the prior corresponding growth measures. For models 
presented for length and weight, the initial measure of size (starting point) was at 20 weeks of gestation (femur length 
and estimated fetal weight), and for BMI at 6 months of age. The models are adjusted for child’s sex and age at insulin 
and C-peptide measurement. Circles, length; squares, weight; triangles, BMI; wks, weeks; mo, months.
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Supplemental Figure 3. Associations of fetal and childhood growth conditional on prior mea-


























Values are regression coefficients representing differences in childhood C-peptide SDS per standardised residual change 
in growth characteristic in each time interval. The standardised residuals were obtained from models in which the 
growth measures of interest were regressed on the prior corresponding growth measures. For models presented for 
length and weight, the initial measure of size (starting point) was at 20 weeks of gestation (femur length and estimated 
fetal weight), and for BMI at 6 months of age. The models are adjusted for child’s sex, age at insulin and C-peptide 
measurement, maternal pre-pregnancy BMI, maternal age, parity, smoking during pregnancy, folic acid use, maternal 
education level, gestational diabetes, gestational hypertensive disorders, ethnicity of the child, gestational age at birth, 
breastfeeding, timing of introduction of solid foods and time watching television. Circles, length; squares, weight; 
triangles, BMI; wks, weeks; mo, months.
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Gestational age Age (months)
(weeks)
c
Results are based on repeated linear regression models and reflect the differences in SDS of (a) length (based on 39,086 
measurements), (b) weight (based on 42,692 measurements) and (c) BMI (based on 23,310 measurements) growth 
in children with C-peptide levels in the second, third and fourth quartiles (C-peptide levels 0.67-0.95, 0.96-1.28 and 
1.29-3.69 nmol/l, respectively), compared with those with C-peptide levels in the first quartile (0.11-0.66 nmol/l). The 
reference value is an SDS of 0. The models were adjusted for child’s sex, maternal pre-pregnancy BMI, maternal age, 
parity, smoking during pregnancy, folic acid use, maternal education level, gestational diabetes, gestational hyperten-
sive disorders, ethnicity of the child, gestational age at birth, breastfeeding, timing of introduction of solid foods and 
time watching television. Circles/dotted line, second C-peptide quartile; triangles/dashed line, third C-peptide quartile; 
squares/solid line, fourth C-peptide quartile.
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Supplemental Table 4. Longitudinal associations between insulin levels and growth character-
istics (n=4293)
Childhood insulin levels Intercept (SDS) p-value Slope (SDS (95% CI)) p-value
Height
Fetal
 1st insulin quartile -0.287 0.27 Reference
 2nd insulin quartile -0.273 0.90 0.0013 (-0.0059, 0.0086) 0.72
 3rd insulin quartile -0.437 0.18 0.0048 (-0.0024, 0.0119) 0.19
 4th insulin quartile -0.273 0.90 0.0012 (-0.0060, 0.0084) 0.74
Childhood
 1st insulin quartile -4.426 <0.001 Reference
 2nd insulin quartile -4.358 0.07 0.0005 (-0.0004, 0.0017) 0.24
 3rd insulin quartile -4.395 0.41 0.0014 (0.0007, 0.0028) <0.001
 4th insulin quartile -4.337 0.02 0.0022 (0.0016, 0.0037) <0.001
Weight
Fetal
 1st insulin quartile -0.508 0.02 Reference
 2nd insulin quartile -0.345 0.08 -0.0024 (-0.0080, 0.0031) 0.38
 3rd insulin quartile -0.547 0.68 0.0003 (-0.0052, 0.0058) 0.90
 4th insulin quartile -0.440 0.46 -0.0018 (-0.0073, 0.0037) 0.52
Childhood
 1st insulin quartile -3.455 <0.001 Reference
 2nd insulin quartile -3.421 0.34 0.0010 (0.0001, 0.0020) 0.03
 3rd insulin quartile -3.490 0.32 0.0027 (0.0017, 0.0037) <0.001
 4th insulin quartile -3.463 0.78 0.0060 (0.0050, 0.0068) <0.001
BMI
 1st insulin quartile -1.821 <0.001 Reference
 2nd insulin quartile -1.865 0.71 0.0008 (-0.0006, 0.0021) 0.26
 3rd insulin quartile -1.871 0.62 0.0012 (-0.0002, 0.0251) 0.08
 4th insulin quartile -1.865 0.50 0.0035 (0.0021, 0.0048) <0.001
Values are regression coefficients obtained from linear repeated measurement models and reflect the (gestational) age 
independent differences (intercepts) and the (gestational) age dependent differences (slopes: change in growth charac-
teristics SDS per week (fetal models) or per month (childhood models) per insulin quartile, compared with the reference 
group (1st insulin quartile). The models were adjusted for child’s sex, maternal pre-pregnancy BMI, maternal age, par-
ity, smoking during pregnancy, folic acid use, maternal education level, gestational diabetes, gestational hypertensive 
disorders, ethnicity of the child, gestational age at birth, breastfeeding, timing of introduction of solid foods and time 
watching television. P-values reflect the significance levels of the regression coefficients
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Supplemental Table 5. Longitudinal associations between C-peptide levels and growth char-
acteristics (n=4303)
Childhood C-peptide levels Intercept 
(SDS)
p-value Slope (SDS (95% CI)) p-value
Height
Fetal
1st C-peptide quartile -0.279 0.29 Reference
2nd C-peptide quartile -0.220 0.60 -0.0012 (-0.0085, 0.0059) 0.73
3rd C-peptide quartile -0.394 0.30 0.0046 (-0.0026, 0.0118) 0.21
4th C-peptide quartile -0.398 0.29 0.0052 (-0.0021, 0.0125) 0.16
Childhood
1st C-peptide quartile -4.406 <0.001 Reference
2nd C-peptide quartile -4.383 0.54 0.0018 (0.0007, 0.0028) <0.001
3rd C-peptide quartile -4.375 0.42 0.0016 (0.0006, 0.0027) <0.01
4th C-peptide quartile -4.406 0.32 0.0032 (0.0021, 0.0042) <0.001
Weight
Fetal
1st C-peptide quartile -0.562 0.01 Reference
2nd C-peptide quartile -0.375 0.05 -0.0065 (-0.0120, -0.0010) 0.02
3rd C-peptide quartile -0.556 0.95 -0.0006 (-0.0062, 0.0049) 0.83
4th C-peptide quartile -0.554 0.93 -0.0009 (-0.0065, 0.0047) 0.75
Childhood
1st C-peptide quartile -3.440 <0.001 Reference
2nd C-peptide quartile -3.482 0.24 0.0026 (0.0017, 0.0035) <0.001
3rd C-peptide quartile -3.486 0.20 0.0033 (0.0024, 0.0043) <0.001
4th C-peptide quartile -3.482 0.25 0.0057 (0.0048, 0.0067) <0.001
BMI
1st C-peptide quartile -1.872 <0.001 Reference
2nd C-peptide quartile -1.872 0.92 0.0011 (-0.0002, 0.0024) 0.10
3rd C-peptide quartile -1.897 0.56 0.0019 (0.0006, 0.0033) <0.01
4th C-peptide quartile -1.852 0.63 0.0033 (0.0020, 0.0047) <0.001
Values are regression coefficients obtained from linear repeated measurement models and reflect the (gestational) age 
independent effects (intercepts) and the (gestational) age dependent effects (slopes, change in growth characteristics 
SDS per week (fetal models) or per month (childhood models) per C-peptide quartile, compared with the reference 
group (1st C-peptide quartile). The models were adjusted for child’s sex, maternal pre-pregnancy BMI, maternal age, 
parity, smoking during pregnancy, folic acid use, maternal education level, gestational diabetes, gestational hyperten-
sive disorders, ethnicity of the child, gestational age at birth, breastfeeding, timing of introduction of solid foods and 
time watching television. P-values reflect the significance levels of the regression coefficients.
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Introduction: Adverse exposures in early life may predispose children to cardio-metabolic 
disease in later life. Metabolomics may serve as a valuable tool to disentangle the metabolic 
adaptations and mechanisms that potentially underlie these associations.
Objectives: To describe the acquisition, processing and structure of the metabolomics data 
available in a population-based prospective cohort from early pregnancy onwards and to 
examine the relationships between metabolite profiles of pregnant women and their children 
at birth and in childhood.
Methods: In a subset of 994 mothers-child pairs from a prospective population-based 
cohort study among pregnant women and their children from Rotterdam, the Netherlands, 
we used LC–MS/MS to determine concentrations of amino acids, non-esterified fatty acids, 
phospholipids and carnitines in blood serum collected in early pregnancy, at birth (cord 
blood), and at child’s age 10 years.
Results: Concentrations of diacyl-phosphatidylcholines, acyl-alkyl-phosphatidylcholines, 
alkyl-lysophosphatidylcholines and sphingomyelines were the highest in early pregnancy, 
concentrations of amino acids and non-esterified fatty acids were the highest at birth and 
concentrations of alkyl-lysophosphatidylcholines, free carnitine and acyl-carnitines were the 
highest at age 10 years. Correlations of individual metabolites between pregnant women 
and their children at birth and at the age of 10 years were low (range between r = − 0.10 
and r = 0.35).
Conclusion: Our results suggest that unique metabolic profiles are present among pregnant 
women, newborns and school aged children, with limited intergenerational correlations 
between metabolite profiles. These data will form a valuable resource to address the early 
metabolic origins of cardio-metabolic disease.
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introduction
Cardio-metabolic diseases are of major public health concern (1-3). The pathogenesis of these 
cardio-metabolic diseases involves adaptations in metabolic pathways. Thus far, studies mainly 
focused on a small set of conventional biomarkers to assess metabolic status and pathways. 
Recent developments in high-throughput technologies and analytical methods have enabled 
the application of metabolomics for detailed characterization of an individual’s metabolic 
status on a large scale (4-6). Metabolomics measures a large number of low molecular weight 
metabolites in biological tissues and fluids. The metabolome is the most downstream com-
ponent of biological processes and closely linked to the phenotype. It carries information 
about gene expression as well as lifestyle- and environmental factors (5, 6). Metabolomics 
has already been successfully applied in large-scale epidemiological studies, mainly in adult 
populations, to identify new biomarkers of cardio-metabolic disease status, development and 
progression, as well as the underlying pathophysiological mechanisms (7-9).
Accumulating evidence suggests that cardio-metabolic diseases might originate in early 
life. Adverse exposures in early life may lead to developmental adaptations in organ structure 
or function, which may predispose these children to later cardio-metabolic disease (10). Early-
life developmental adaptations in metabolic pathways may underlie these associations. Only 
a limited amount of metabolomics studies on the early origins of cardio-metabolic disease 
have been performed. Most of these studies were small and mainly assessed cross-sectional 
relationships (11, 12). Also, it is unclear whether metabolite profiles correlate between 
mothers and their children. The application of metabolomics in longitudinal birth cohort 
studies may serve as a valuable tool to identify biomarkers of metabolic status, in order 
to disentangle the mechanisms linking adverse exposures in early life to cardio-metabolic 
disease later in life (11).
Therefore, in a population-based cohort from early pregnancy onwards among 994 mother–
child pairs from Rotterdam, the Netherlands, we obtained serum concentrations of a range of 
metabolite groups involved in energy metabolism, including amino acids (AA), non-esterified 
fatty acids (NEFA), phospholipids (PL), and carnitines (Carn) in maternal blood in early-preg-
nancy, and child’s (cord-) blood at birth and at age 10 years. We provide a detailed description 
of the data acquisition, processing and data structure and examined the relationships between 
metabolite profiles of pregnant women and their children at birth and in childhood.
methods
Study population
The Generation R Study is a multi-ethnic population-based prospective cohort study from 
fetal life until adulthood in Rotterdam, the Netherlands, described in detail previously (13). 
CHAPTER 4.3
286
The study was approved by the Medical Ethical Committee of the Erasmus Medical Center, 
University Medical Center, Rotterdam (MEC 198.782/2001/31). Written informed consent 
was obtained from all mothers at enrollment in the study. Measurement of conventional 
biomarkers of metabolic status in pregnancy and childhood has been described previously 
(14-16). For metabolomics, 2,395 blood samples were analyzed from a subsample of 1041 
Dutch mother–child pairs who had their blood drawn at birth (cord blood) and at least 1 
other time point: early pregnancy (mother) or at the age of 10 years (child). A number of 
blood samples (n = 157) was excluded during data acquisition (e.g. low sample volumes, 
hemolytic samples) and processing (e.g. duplicate samples, high proportion of missing 
values, missing or non-Dutch ethnicity), leaving a total of 2,238 blood samples from 994 
mother–child pairs available for analysis. Of these 994 mother–child pairs, a total of 814 
mothers had early pregnancy data available, and 921 and 503 children had data available 
at birth and at the age of 10 years, respectively. Of all mothers included, 10 had a twin 
pregnancy. Metabolomics data was only available for one of the twins. Therefore, mothers 
with twin pregnancies were included only once in the dataset.
Sample collection and processing
Maternal early-pregnancy non-fasting blood samples were obtained at enrollment in the 
study [median gestational age: 12.8 weeks (95% range 9.9, 16.9)] by research nurses at one 
of the dedicated research centers (17). Umbilical venous cord blood samples were collected 
directly after birth [median gestational age at birth: 40.3 weeks (95% range 36.6, 42.4)] by a 
midwife or obstetrician. Child’s non-fasting blood samples were obtained by research nurses 
at the 10-year follow-up visit to the research center [median age: 9.8 years (95% range 9.1, 
10.6)]. All blood samples were transported to the regional laboratory (STAR-MDC), spun and 
stored at − 80°C for further studies within a maximum of 4 h after collection. For metabolite 
measurements, blood serum samples were transported on dry ice to the Division of Meta-
bolic and Nutritional Medicine of the Dr. von Hauner Children’s Hospital in Munich, Germany.
Metabolite measurements
A targeted metabolomics approach was adopted to determine serum concentrations 
(µmol/L) of AA, NEFA, PL and Carn (18). Detailed information is given in Supplemental 
Text 1 and Supplemental Table 1. Briefly, AA were analyzed with 1100 high-performance 
liquid chromatography (HPLC) system (Agilent, Waldbronn, Germany) coupled to a API2000 
tandem mass spectrometer (AB Sciex, Darmstadt, Germany) (19). IUPAC-IUB Nomenclature 
was used for notation of AA (20). NEFA, PL and Carn were measured with a 1200 SL HPLC 
system (Agilent, Waldbronn, Germany) coupled to a 4000QTRAP tandem mass spectrometer 
from AB Sciex (Darmstadt, Germany) (21, 22). The analytical technique used is capable of 
determining the total number of total bonds, but not the position of the double bonds and 
the distribution of the carbon atoms between fatty acid side chains. We used the following 
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notation for NEFA, PL and Carn.a:X:Y, where X denotes the length of the carbon chain, and Y 
the number of double bonds. The ‘a’ denotes an acyl chain bound to the backbone via an es-
ter bond (‘acyl-’) and the ‘e’ represents an ether bond (‘alkyl-’). For analyses, we categorized 
metabolites in to general metabolite groups based on chemical structure (AA, NEFA, PC.aa, 
PC.ae, Lyso.PC.a, Lyso.PC.e, SM, Free Carn and Carn.a) and in detailed metabolite subgroups 
based on chemical structure and physiological and biological relevance (AA: BCAA, aromatic 
amino acids (AAA), essential AA, non-essential AA; NEFA, PC.aa, PC.ae, Lyso.PC.a, Lyso.
PC.e and SM: saturated, mono-unsaturated, poly-unsaturated; Carn.a: short-chain, medium-
chain, long-chain).
Quality control and pre-processing
To assess the precision of the measurements, six quality control (QC) samples per batch were 
consistently measured between study samples. After exclusion of outliers, the coefficients 
of variation (CV; SD/mean) for each batch (intra-batch) and for all batches (inter-batch) of 
the QC samples were calculated for each metabolite. In line with previous studies (23-26), 
for each metabolite we excluded batches with an intra-batch CV higher than 25%. Data on 
complete metabolites were excluded for metabolites with inter-batch CV higher than 35% or 
if less than 50% of the batches passed the QC (i.e. had an intra-batch CV lower than 25%). 
To correct for batch effects, the participant data at each time point were median corrected 
by dividing the metabolite concentration by the ratio of the intra-batch median and the 
inter-batch median of the QC samples (26). In line with previous studies, metabolites and 
participants with more than 50% of missing values were excluded (26, 27). Missing values in 
other participants were imputed using the Random Forest algorithm (R package missForest), 
which has been shown to perform well with MS data (28).
Statistical analysis
First, we calculated the sum of individual metabolite concentrations per general and detailed 
metabolite group and per time point. In order to explore the variability of the metabolites 
between participants and between time points, we obtained the median (95% range) for 
the individual metabolites and the summed metabolite concentrations per general and 
detailed metabolite group per time point. To enable comparison between time points, only 
metabolites that were present at each time point were included in the summed variables. 
Second, we explored the dimensionality of the data, by conducting principal component 
analyses (PCA) at each time point separately. As log transformations did not sufficiently 
normalize the metabolite concentrations, we used square root transformations to normalize 
metabolite concentrations. These normalized metabolite concentrations were subsequently 
standardized by calculating standard deviation scores [SDS; (observed value − mean)/SD]. 
Third, as we considered PCA not informative for describing the information contained in 
our dataset, we further explored the correlation structure of the data by calculating pair-
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wise Pearson’s correlations coefficients between all individual metabolites within each time 
point and between individual metabolites at different points. These correlations within and 
between time points were visualized using two circos plots (R package circlize) (29, 30). 
To facilitate presentation, the first plot only includes correlation coefficients < −0.15 and 
> 0.15. To display correlation coefficients that are at least of weak magnitude, the second 
plot displays correlation coefficients < −0.30 and > 0.30 (31). To obtain further insight in pos-
sible metabolic pathways, we additionally presented correlations between metabolites within 
a time point as correlation networks, as correlations between metabolites were strongest 
within time points (32). To provide a numerical summary of the strength of the correla-
tions, we additionally constructed heatmaps of the median absolute correlation coefficients 
within general and detailed metabolite groups and between general and detailed metabolite 
groups at each of the time points separately. We calculated the correlation coefficients for 
correlations between individual metabolites at different time points. Correlations of 0–0.29, 
0.3–0.49, 0.5–0.69, 0.7–0.89, and 0.9–1.0 were considered to be very low, low, moderate, 
high and very high, respectively (31). As sex differences in metabolite concentrations may 
exist (33), we repeated steps one and three stratified by child’s sex. The statistical analyses 
were performed using R version 3.3.4 (R Foundation for Statistical Computing) (34).
results
Description of the study population
Table 1 provides general characteristics of the study population. Of the 994 mother–child 
pairs with data available, 125 (12.6%), 494 (49.7%) and 375 (37.7%) had data available at 
1, 2, or 3 time points, respectively.
Variability
Data was available on a total of 196 metabolites, of which 195 metabolites in early preg-
nancy, 194 metabolites at birth and 181 metabolites at child’s age 10 years. Descriptive 
information is provided in Supplemental Table 2. Figure 1 shows that the summed 
metabolite concentration for each general metabolite group varied considerably by time 
point. Summed concentrations of PC.aa, PC.ae, Lyso.PC.e and SM were highest in maternal 
blood in early pregnancy, compared to the other time points. Summed concentrations of 
AA and NEFA were highest in children at birth, whereas summed concentrations of Lyso.
PC.a, Free Carn and Carn.a were highest in children of age 10. Supplemental Table 2 gives 
the summed concentrations of the detailed metabolite subgroups, which followed similar 
patterns. Supplemental Figure 1 shows that the summed metabolite concentrations did 
not differ by child’s sex.
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Table 2 shows the number of components (PCs) required to explain percentages of cumula-
tive variance at each time point. At each time point, a relatively high number of PCs was 
needed to explain > 85% of the variance. The obtained PCs did not clearly represent specific 
metabolic pathways (Supplemental Figures 2–4).
Table 2. Number of components required to explain percentages of cumulative proportions of 
variance at each time point
Number of PCs
Time point Number of metabolites 50% 75% 85% 95% 99.5%
Mother early pregnancy 195 3 15 35 88 163
Child at birth 194 4 21 46 101 169
Child age 10 years 181 6 27 50 98 157
Values represent the number of principal components (PCs) derived from principal component analyses required to 
explain 50, 75, 85, 95, and 99.5 percent, respectively, of the variances of the data at each of the time points






















































































Values represent the median (95% range) of the sum of the individual metabolite concentrations in each of the me-
tabolite groups, by time point. Sums only include metabolites with data at all time points, and therefore do not include 
concentrations of lyso.PC.a.C20.2, PC.aa.C32.3, PC.aa.C34.5, PC.aa.C36.0, PC.aa.C38.2, PC.aa.C40.3, PC.ae.C34.4, 
SM.a.C30.1, SM.a.C35.0, SM.a.C37.1, SM.a.C38.3, SM.a.C39.2, SM.a.C40.5, SM.a.C42.4, SM.a.C44.6, SM.e.C36.2, 
and SM.e.C40.5. SM includes SM.a plus one SM.e.
AA: amino acids, PC.aa: diacyl-phosphatidylcholines, PC.ae: acyl-alkyl-phosphatidylcholines, Lyso.PC.a: acyl-lysophos-
phatidylcholines, Lyso.PC.e: alkyl-lysophosphatidylcholines, SM: sphingomyelines, NEFA: non-esterified fatty acids, Free 
Carn: free carnitine, Carn.a: acyl-carnitines.
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Correlation structure
Figure 2 provides an overview of the correlations between individual metabolite concentrations 
within general metabolite groups (outer circle), between metabolites concentrations in different 
general metabolite groups (inner circle) and metabolite concentrations at different time points 
(lines going through the middle of the circle). Figure 2a shows all correlations lower than 
− 0.15 or higher than 0.15, whereas Figure 2b shows all correlations lower than − 0.30 or 
higher than 0.30. At all time points, relatively high correlations were observed of individual 
metabolites within general metabolite groups and between individual metabolites from the 
different PL groups (PC.aa, PC.ae, Lyso.PC.a, Lyso.PC.e, and SM), between AA and Carn.a, and 
between NEFA and Carn.a. These correlations were mainly of positive direction, except some of 
the correlations between AA and Carn.a. In children of age 10 years only, some of the AA were 
negatively correlated with NEFA. Presentation of these correlations within pregnant women, 
children at birth and children at age 10 years as correlation networks showed the strongest cor-
relations for individual metabolites within general metabolite groups (Supplemental Figure 5).
To provide further insight into the strength of these correlations, Figure 3 a–c summarizes 
the correlations as the median absolute correlations of individual metabolites within general 
and detailed metabolite groups (diagonal) per time point. The median absolute correlations 
between general and detailed metabolite groups per time point are shown off-diagonal. 
Median absolute correlations within general and detailed metabolite groups at the same time 
point were low to high, and ranged between r = 0.27 and r = 0.92. The strength of these 
within-group median correlations differed by detailed metabolite subgroup, with BCAA, mono-
unsaturated NEFA, mono-unsaturated PC.aa, mono-unsaturated PC.ae, saturated Lyso.PC.e, 
mono-unsaturated SM and long-chain Carn.a generally having the highest median correla-
tions within their respective general groups. Median absolute correlations between subgroups 
of different metabolite groups were very low, except for correlations between NEFA detailed 
subgroups and medium-chain Carn.a in early pregnancy (r ranging between 0.24–0.34) and 
at age 10 years (r ranging between 0.23–0.44), between BCAA and AAA and short-chain 
Carn.a in early pregnancy (r = 0.26 and r = 0.33, respectively) and at age 10 years (r = 0.30 and 
r = 0.25, respectively), and between BCAA and short-chain Carn.a (r = 0.33) at birth.
Table 3 shows correlations of individual metabolites between each of the time points. For pre-
sentation purposes, this table only gives the 30 strongest correlations at each combination of time 
points, all correlations given in Supplemental Table 3. Correlations between early pregnancy 
and child’s metabolites at birth mainly included Free Carn, and Carn.a, and some long chain- and 
very long chain NEFA and some mainly non-essential AA. Correlations between early pregnancy 
and child age 10 years included a few AA and some PC.aa. In children, metabolites correlated 
between birth and age 10 years mainly included phospholipids. Almost all correlations were very 
weak, except the correlations between early pregnancy and birth Free Carn (r = 0.35) and Carn.a 
C9:0 (r = 0.32). Supplemental Figures 6 and 7 show that the correlations between individual 
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Figure 3. Heatmaps of median absolute correlation of individual metabolites within and be-












































































































































































































































































































































































































































































































































































































































































































































































































































A. Mother early pregnancy
Values represent median absolute correlation coefficients of individual metabolite concentrations within metabolite 
groups (diagonal) and between metabolite groups (off-diagonal) by time point. Mono-unsaturated lyso.PC.e, saturated 
SM and Free Carn include 1 metabolite, resulting in a correlation coefficient of 1 for within-group correlations. For child 
at birth, no data on saturated SM is available.
AA: amino acids, BCAA: branched-chain amino acids, AAA: aromatic amino acids, NEFA: non-esterified fatty acids, 
PC.aa: diacyl-phosphatidylcholines, PC.ae: acyl-alkyl-phosphatidylcholines, Lyso.PC.a: acyl-lysophosphatidylcholines, 
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B. Child at birth
Values represent median absolute correlation coefficients of individual metabolite concentrations within metabolite 
groups (diagonal) and between metabolite groups (off-diagonal) by time point. Mono-unsaturated lyso.PC.e, saturated 
SM and Free Carn include 1 metabolite, resulting in a correlation coefficient of 1 for within-group correlations. For child 
at birth, no data on saturated SM is available.
AA: amino acids, BCAA: branched-chain amino acids, AAA: aromatic amino acids, NEFA: non-esterified fatty acids, 
PC.aa: diacyl-phosphatidylcholines, PC.ae: acyl-alkyl-phosphatidylcholines, Lyso.PC.a: acyl-lysophosphatidylcholines, 
Lyso.PC.e: alkyl-lysophosphatidylcholines, SM: sphingomyelines, Free Carn: free carnitine, Carn.a: acyl-carnitines, Sat.: 
Saturated, Unsat.: Unsaturated.
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Figure 3. Heatmaps of median absolute correlation of individual metabolites within and be-












































































































































































































































































































































































































































































































































































































































































































































































































































C. Child age 10y
Values represent median absolute correlation coefficients of individual metabolite concentrations within metabolite 
groups (diagonal) and between metabolite groups (off-diagonal) by time point. Mono-unsaturated lyso.PC.e, saturated 
SM and Free Carn include 1 metabolite, resulting in a correlation coefficient of 1 for within-group correlations. For child 
at birth, no data on saturated SM is available.
AA: amino acids, BCAA: branched-chain amino acids, AAA: aromatic amino acids, NEFA: non-esterified fatty acids, 
PC.aa: diacyl-phosphatidylcholines, PC.ae: acyl-alkyl-phosphatidylcholines, Lyso.PC.a: acyl-lysophosphatidylcholines, 




Table 3. Correlations of individual metabolite concentrations between time points, subset of 
30 strongest correlations
A. Mother early pregnancy – 
Child at birth
B. Mother early pregnancy – Child 
age 10 years
C. Child at birth – Child age 10 
years
Metabolite n r P-value Metabolite n r P-value Metabolite n r P-value
Free Carn 749 0.35 <0.001 Free Carn 413 0.24 <0.001 Cit 457 0.24 <0.001
Carn.a C9:0 749 0.32 <0.001 PC.aa C36:6 413 0.23 <0.001 SM.a C34:2 457 0.21 <0.001
Carn.a C8:1 749 0.28 <0.001 Carn.a C14:2 413 0.22 <0.001 lyso.PC.a C22:6 457 0.20 <0.001
Carn.a C4:0 749 0.26 <0.001 Cit 413 0.21 <0.001 SM.a C42:6 457 0.20 <0.001
NEFA C26:0 749 0.24 <0.001 Orn 413 0.21 <0.001 His 457 0.19 <0.001
Gly 749 0.22 <0.001 Asn 413 0.17 <0.001 Carn.a C4:0 457 0.19 <0.001
Carn.a C10:1 749 0.22 <0.001 PC.aa C38:4 413 0.17 0.001 PC.aa C38:6 457 0.18 <0.001
Carn.a C15:0 749 0.22 <0.001 PC.aa C38:6 413 0.17 <0.001 PC.ae C32:2 457 0.18 <0.001
Carn.a C3:0 749 0.21 <0.001 NEFA C24:4 413 0.16 0.001 SM.a C32:2 457 0.18 <0.001
Cit 749 0.20 <0.001 PC.aa C38:0 413 0.16 0.001 Free Carn 457 0.18 <0.001
NEFA C20:5 749 0.20 <0.001 PC.aa C36:5 413 0.15 0.002 PC.aa C36:5 457 0.17 <0.001
Carn.a C8:0 749 0.20 <0.001 PC.ae C34:3 413 0.15 0.002 PC.aa C38:0 457 0.17 <0.001
NEFA C22:6 749 0.19 <0.001 NEFA C20:5 413 0.14 0.004 PC.ae C34:1 457 0.17 <0.001
Carn.a C2:0 749 0.19 <0.001 NEFA C24:5 413 0.14 0.004 Orn 457 0.16 <0.001
Carn.a C14:2 749 0.19 <0.001 PC.aa C40:6 413 0.14 0.003 PC.aa C43:6 457 0.16 0.001
His 749 0.18 <0.001 PC.aa C43:6 413 0.14 0.005 PC.ae C32:0 457 0.16 0.001
Carn.a C10:0 749 0.18 <0.001 PC.ae C36:5 413 0.14 0.004 NEFA C26:1 457 0.15 0.001
Carn.a C18:2 749 0.18 <0.001 PC.ae C40:0 413 0.14 0.005 NEFA C26:2 457 0.15 0.001
Carn.a C20:3 749 0.18 <0.001 SM.a C35:1 413 0.14 0.005 PC.ae C38:6 457 0.15 0.001
Carn.a.C20.4 749 0.18 <0.001 Carn.a C4:0 413 0.14 0.004 PC.ae C42:3 457 0.15 0.001
Pro 749 0.17 <0.001 Carn.a C15:0 413 -0.14 0.004 SM.a C33:1 457 0.15 0.001
PC.ae C42:4 749 0.17 <0.001 Carn.a C16:0 413 0.14 0.004 Carn.a C8:1 457 0.15 0.002
lyso.PC.a C22:6 749 0.17 <0.001 Ala 413 0.13 0.007 NEFA C20:5 457 0.14 0.003
Carn.a C12:0 749 0.17 <0.001 Thr 413 0.13 0.007 NEFA C24:1 457 0.14 0.003
NEFA C26:1 749 0.16 <0.001 PC.ae C30:0 413 0.13 0.007 NEFA C24:4 457 0.14 0.003
PC.aa C44:12 749 0.16 <0.001 PC.ae C38:0 413 0.13 0.009 PC.ae C42:5 457 0.14 0.002
Ala 749 0.15 <0.001 PC.ae C40:1 413 0.13 0.009 PC.ae C42:6 457 0.14 0.003
Phe 749 0.15 <0.001 PC.ae C42:5 413 0.13 0.008 SM.a C32:1 457 0.14 0.004
PC.aa C38:6 749 0.15 <0.001 Carn.a C16:0.Oxo 413 0.13 0.008 SM.a C36:2 457 0.14 0.002
lyso.PC.a C20:5 749 0.15 <0.001 Gln 413 0.12 0.018 NEFA C22:3 457 0.13 0.006
Values represent Pearson’s correlation coefficients (r), and corresponding p-values and number of participants for cor-
relations between metabolites at different time points. For presentation purposes, only the 30 strongest correlations 
at each combination of time points were presented. A complete list of correlations is given in Supplemental Table 3.
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discussion
We described the data acquisition, processing and structure of the metabolomics data avail-
able in the Generation R Study and assessed the relationships between metabolite profiles 
of pregnant women and their children at birth and in childhood. Metabolite concentrations 
vary considerably between pregnant women and their children at birth and at the age of 10 
years. The individual metabolites correlate within groups of metabolites with similar chemical 
structures, but to a lesser extent between groups of metabolites with different chemical 
structures. The correlations of individual metabolites between pregnant women and their 
children at birth and age 10 years are relatively low.
Interpretation of main findings
Metabolomics studies targeting cardio-metabolic diseases have already been successfully ap-
plied in adults (7-9), but only a limited number of metabolomics studies have been performed 
on the early origins of these diseases (11, 12). We obtained intergenerational metabolomics 
data at three different time points during pregnancy and postnatal life, that may provide 
more detailed insights in the early origins of cardio-metabolic disease, the underlying mecha-
nisms and identify potential novel biomarkers.
Maternal metabolic profile during pregnancy might influence fetal metabolic profile, either 
directly through placental transfer, or indirectly by influences on hormone levels or placental 
function (11). Maternal blood metabolite concentrations generally tend to decrease across 
pregnancy, likely reflecting increased circulating volume, tissue biosynthesis and placental 
uptake (24). Fetal metabolite concentrations are the result of both placental transfer and 
endogenous synthesis. Concentrations of AA, Carn and NEFA, particularly long-chain poly-
unsaturated fatty acids (LC-PUFA), tend to be higher in fetal blood than in maternal blood 
(35-37). This might be indicative of an active transport mechanism across the placenta 
or increased fetal synthesis. Although the large time differences between the metabolite 
measurements in our study should be noted and preclude direct conclusions about placental 
transfer, our observation that the summed concentrations of AA, NEFA and Carn.a were 
higher in cord blood than in maternal early pregnancy blood is in line with these previous 
studies. The lower PL concentrations observed in cord blood in comparison to maternal 
early pregnancy blood might be explained by the fact that PL do not cross the placenta, but 
are hydrolyzed to NEFA that in turn cross the placental barrier (35, 38, 39). Relatively high 
correlations between individual metabolites within known general and detailed metabolite 
subgroups in pregnant women as well as in cord blood were observed, as expected from the 
shared precursors and biosynthesis pathways. However, correlations of individual metabolites 
between these two time points were relatively weak. These results are in line with those 
from a multi-ethnic study among 1600 participants that showed mostly weak correlations 
of these metabolites between maternal blood at 28 weeks of gestation and cord blood 
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(40). In our study, there is a large time difference between the metabolite measurements 
in mothers and newborns. Therefore, the relatively low correlations between maternal and 
cord blood metabolites might result from changes in metabolism in both pregnant women 
and the fetus that occur throughout pregnancy (24, 38). In addition, placental transfer 
of nutrients throughout pregnancy is tightly regulated by various transport mechanisms 
to ensure stable fetal metabolite concentrations at the expense of variations in maternal 
metabolite concentrations (41, 42). The relatively high correlations for carnitines in our study 
might be explained by the main source of carnitines for the fetus being placental transfer, 
rather than endogenous synthesis (43). Thus, individual metabolite concentrations correlate 
within mothers and newborns, but barely between mothers and newborns. This might result 
from changes in maternal and fetal metabolism throughout pregnancy and from tightly 
regulated active trans-placental transport mechanisms resulting in distinct metabolite profiles 
in pregnant women and their children at birth.
Less is known about the metabolite profiles from birth throughout childhood and the 
influence of maternal metabolite profiles in pregnancy on these profiles. A study among 127 
children from Sweden showed that concentrations of conventional lipids, including total 
cholesterol, LDL cholesterol and HDL cholesterol increased between the age of 6 months and 
4 years, whereas triglyceride concentrations decreased (44). A study among 500 children 
and adolescents aged 0 to 19 years observed that concentrations of AA, NEFA, and Carn.a 
dropped after the neonatal period. However, some of these Carn.a increased again from the 
age of 7 years and returned to neonatal concentrations at age 19 years (45). A large familial 
resemblance in metabolite concentrations has been suggested, which seems to be largely 
genetic (46-48). In cross-sectional studies, correlations of metabolites between parents and 
their offspring vary strongly, ranging from weak to relatively strong (33, 44, 49). Partly in line 
with these previous studies, we observed that AA and NEFA concentrations were lower in 
childhood as compared to cord blood samples, whereas concentrations of PL and Carn were 
higher in childhood. However, the correlations between individual metabolite concentra-
tions of children at birth and at the age of 10 years as well as between mothers in early 
pregnancy and their children at the age of 10 years were very weak. This might be explained 
by the large timespan between the measurements. Also, previous research has indicated 
that metabolite concentrations are highly influenced by nutritional factors, physical activity 
and the gut microbiome (23, 50-53). Differences in these factors between mothers and their 
children and over time might explain the weak correlations between different time points. 
Previous studies observed sex differences in metabolite concentrations in both children and 
adults (33, 45). We did not observe metabolite concentrations to vary between the sexes. 
This could be explained by the relatively young age of the participants, as sex differences in 
metabolite concentrations have been shown to be more pronounced in adolescence and 
adulthood (33, 45). Thus, correlations between individual metabolites between pregnant 
women and their children at school-age and within children over time are very low. This 
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might suggest strong influences of external factors and limited intergenerational correlations 
of metabolite profiles.
We provided the first explorative analyses of a unique large longitudinal dataset consisting 
of metabolomics data of pregnant women and their children at birth and in childhood, and 
studied correlations between a large number of metabolites at these different time points. 
Not much is known yet about the correlations of metabolites between pregnant women 
and their children and the metabolite profiles in children from birth until childhood. We 
observed relatively low correlations of metabolite concentrations between time points. We 
explored whether offspring sex affected these correlations as this is an important baseline 
characteristic which has been suggested to influence metabolite profiles in children and 
adults, but this did not affect our findings. Other maternal and childhood factors are likely 
to influence metabolite profiles in pregnant women, and the development of metabolites 
profiles from birth until childhood. Further studies are needed to obtain detailed insight into 
the influence of maternal and offspring socio-demographic, lifestyle and physical factors 
on the stability of metabolites profiles in pregnancy and from birth throughout childhood. 
Future studies using these data should take into account the correlations of metabolites 
within the same metabolite group. PCA, a data reduction approach commonly used in 
metabolomics, showed that the data were highly dimensional. This indicates that the vari-
ability in the data is difficult to capture in a lower number of components and that each 
metabolite contributes unique information. In addition, the obtained components did not 
describe specific metabolic pathways. Therefore, we do not consider the PCs informative in 
describing the information contained in this dataset. Given the high dimensionality of the 
data and the relatively high correlation of metabolites within metabolite groups, it seems 
that future studies focused on relating these data to exposures and outcomes of interest 
should analyze the data per individual metabolite and per metabolite group with structural, 
physiological and biological relevance. In addition, correlation networks based on correla-
tions between individual metabolites or more advanced pathway analysis may be useful 
for identifying metabolic pathways involved in these associations. Due to the longitudinal 
nature of the data and the large amount of data on relevant exposures and outcomes avail-
able in the cohort, these data will form an important population-based resource for future 
metabolomics analyses on the developmental origins of cardio-metabolic disease.
Methodological considerations
We obtained metabolomics data in a subgroup of the cohort, which consists of Dutch, rela-
tively high educated and healthy participants, as compared to the full cohort (13). This may 
affect the generalizability of our sample to the full cohort and the general population. We 
adopted a targeted metabolomics approach, which enabled us to study absolute metabolite 
concentrations of metabolites known a priori to be relevant for obesity and cardio-metabolic 
disease. However, the targeted design might also be a limitation in future association studies, 
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as relevant biological pathways might be missed. The blood samples used in our study were 
non-fasting and taken during non-fixed times of the day for logistic and ethical reasons 
(relatively young age of the children). Metabolite concentrations are dependent on fasting 
status. Fasting blood samples are usually preferred, as they are more reliable over time (54). 
The use of non-fasting blood samples in our study might influence precision and power to 
detect associations of interest. However, non-fasting blood samples appear to be more in-
formative of metabolic status throughout the day. Also, non-fasting lipids have been shown 
to perform equally or even better than fasting lipids in predicting the risk of cardiovascular 
disease (55). We therefore still consider non-fasting metabolite concentrations to be of 
interest. Due to the longitudinal design of the study, we were able to measure metabolite 
concentrations at 3 different time points during pregnancy and early postnatal life. However, 
due to the large time intervals between the blood samples and differences in the nature of 
the blood samples, small differences in procedures and handling of the blood samples may 
exist. As previous studies showed that different pre-storage temperatures and durations only 
minimally affected measured concentrations of most metabolites, we consider it unlikely that 
this strongly influenced our results.
Conclusions
Metabolite concentrations vary between pregnant women and their children at birth and 
at the age of 10 years. Correlations of individual metabolites between pregnant women 
and their children at birth and in childhood are relatively low. This may suggest that unique 
metabolic profiles are present among pregnant women, newborns and school aged children, 
with limited intergenerational correlations between metabolite profiles. These data are an 
important population-based resource for future metabolomics analyses to address the early 
origins of cardio-metabolic disease.
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Supplemental Text 1. Metabolite measurements
A targeted metabolomics approach was adopted to determine serum concentrations (µmol/L) 
of AA, NEFA, PL and Carn, as described previously (1). Proteins of 50 µL serum were precipi-
tated by adding 450 µL methanol including internal standards: labeled amino acid standards 
set A (NSK-A-1, Cambridge Isotope Laboratories (CIL), USA), 15N2-L-asparagine (NLM-3286-
0.25, CIL, USA), indole-D5-L-tryptophan (DLM-1092-0.5, CIL, USA), U-13C16-palmitic acid 
(CLM-409-MPT-PK, CIL, USA), D3-acetyl-carnitine (DLM-754-PK, CIL, USA), D3-octanoyl-
carnitine (DLM-755-0.01, CIL, USA) and D3-palmitoyl-carnitine (DLM-1263-0.01, CIL, USA), 
tridecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (855476, Avanti Polar Lipids, USA) and 
1,2-dimyristoyl-sn-glycero-3-phosphocholine (850345, Avanti Polar Lipids, USA). If sample 
volume was less than optimal, the concentrations were corrected by the respective factor. 
Sample volumes less than 25 µL were not used and considered missing. After centrifugation 
the supernatant was split into aliquots. AA were analyzed by liquid chromatography tandem 
mass spectrometry (LC-MS/MS) as described previously (2). An aliquot of the supernatant 
was used for the derivatization to AA butylester with hydrochloric acid in 1-butanol. After 
evaporation, the residues were dissolved in water/methanol (80:20; (v/v)) with 0.1% formic 
acid. The samples were analyzed with 1100 high-performance liquid chromatography (HPLC) 
system (Agilent, Waldbronn, Germany) equipped with 150 x 2.1 mm, 3.5 µm particle size 
C18 HPLC column (X-Bridge, Waters, Milford, USA) and 0.1% heptafluorobutyric acid as and 
ion pair reagent in the mobile phases A and B (A: water, B: methanol). Mass spectrometric 
(MS) detection was performed with an API2000 tandem mass spectrometer (AB Sciex, Darm-
stadt, Germany) equipped with an atmospheric pressure chemical ionization (APCI) source 
operating in positive ion ionization mode. IUPAC-IUB Nomenclature was used for notation 
of the AA (3).
NEFA, PL and Carn were measured with a 1200 SL HPLC system (Agilent, Waldbronn, 
Germany) coupled to a 4000QTRAP tandem mass spectrometer from AB Sciex (Darmstadt, 
Germany) (4, 5). NEFA were analyzed by injection of the supernatant to a LC-MS/MS oper-
ating in negative electrospray ionization (ESI) mode where they were separated by gradi-
ent elution on a 100 x 3.0 mm, 1.9 µm particle size Purusuit UPS Diphenyl column from 
Varian (Darmstadt, Germany) using 5 mM ammonium acetate in water as mobile phase A 
and acetonitrile/ isopropanol (80:20; (v/v)) as mobile phase B. NEFA species were quanti-
fied using GLC-85 reference standard mixture (Nu-Chek Prep, USA). PL were analyzed by 
flow-injection analysis (FIA) with LC-MS/MS coupled with ESI (6). The system was run in 
positive ionization mode with 5% water in isopropanol as mobile phase A and 5% water 
in methanol as mobile phase B. The analysis was performed for diacyl-phosphatidylcholines 
(PC.aa), acyl-alkyl-phosphatidylcholines (PC.ae) , acyl-lysophosphatidylcholines (Lyso.PC.a), 
alkyl-lysophosphatidylcholines (Lyso.PC.e) and sphingomyelines (SM)). Carn (Free carnitine 
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(Free Carn) and acyl-carnitines (Carn.a)) were analyzed by flow-injection analysis of the 
supernatant into a LC-MS/MS system using an isocratic elution with 76% isopropanol, 19% 
methanol and 5% water. The mass spectrometer was equipped with electrospray ionization 
and operated in positive ionization mode. PL and acyl-carn were quantified using aliquots of 
a commercial available lyophilized control plasma (ClinChek®, Recipe, Germany), where the 
concentrations have been determined by AbsoluteIDQ p150 Kit from Biocrates®, a previous 
published LC-MS/MS method (7) and by in-house quantification with various standards. The 
calibrators used are given in Supplemental Table 1. The analytical technique used is capable 
of determining the total number of total bonds, but not the position of the double bonds 
and the distribution of the carbon atoms between fatty acid side chains. We used the follow-
ing notation for NEFA, PL and Carn.a: X:Y, where X denotes the length of the carbon chain, 
and Y the number of double bonds. The ‘a’ denotes an acyl chain bound to the backbone via 
an ester bond (‘acyl-’) and the ‘e’ represents an ether bond (‘alkyl-’).
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Supplemental Figure 1. Median metabolite concentrations by metabolite group and time 
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Values represent the median (95% range) of the sum of the individual metabolite concentrations in each of the me-
tabolite groups, by time point and child’s sex. Sums only include metabolites with data at all time points, and therefore 
do not include concentrations of lyso.PC.a.C20.2, PC.aa.C32.3, PC.aa.C34.5, PC.aa.C36.0, PC.aa.C38.2, PC.aa.C40.3, 
PC.ae.C34.4, SM.a.C30.1, SM.a.C35.0, SM.a.C37.1, SM.a.C38.3, SM.a.C39.2, SM.a.C40.5, SM.a.C42.4, SM.a.C44.6, 
SM.e.C36.2, and SM.e.C40.5. SM includes SM.a plus one SM.e. AA: amino acids, PC.aa: diacyl-phosphatidylcholines, 
PC.ae: acyl-alkyphosphatidylcholines, Lyso.PC.a: acyl-lysophosphatidylcholines, Lyso.PC.e: alkyl-lysophosphatidylcho-
lines, SM: sphingomyelines, NEFA: non-esterified fatty acids, Free Carn: free carnitine, Carn.a: acyl-carnitines.
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Childhood overweight and obesity are of major public health concern globally. The prevalence 
of overweight and obesity in children increased extensively in the last couple of decades (1). 
Childhood overweight and obesity are associated with adult overweight and obesity and 
are risk factors of a variety of health problems, including cardio-metabolic diseases, asthma, 
osteoarthritis, mental health problems and premature death (2). Obesity is defined as an 
excess of body fat, and is usually based on the body mass index (3, 4). Body mass index is a 
measure of weight adjusted for height, and is therefore not an exact measure of body fat. 
More direct measures of body fat mass and its distribution seem to be more strongly linked 
to metabolic disturbances and the risks of cardio-metabolic diseases (5, 6).
The etiology of obesity and associated cardio-metabolic diseases is complex and multifac-
torial. Risk factors include, but are not limited to, genetics, excess energy intake, sedentary 
behavior, lack or excess of sleep, stress and certain diseases (7). In addition, an accumulating 
body of research suggest that adverse exposures in fetal and early postnatal life may lead to 
developmental adaptations in organ structure and function, that may increase susceptibility 
to obesity and cardio-metabolic disease in later life (8). This might be reflected by different 
growth patterns from fetal life onwards. It has been observed that both children that grow 
slow and rapid in fetal life and grow rapidly in childhood are at the highest risk to develop 
cardio-metabolic diseases in later life (9-12). Identifying the factors related to adverse growth 
patterns and body fat development and the underlying mechanisms will contribute to the 
understanding of the early origins of these diseases and will help to target interventions 
aiming to reduce the burden of these diseases.
The general objective of this thesis was to assess the associations of common maternal di-
etary factors and maternal adiposity with growth, body fat development and cardio-metabolic 
risk factors in children, as well as the metabolic mechanisms that might underlie these associa-
tions. This chapter provides a general discussion of the main findings of this thesis, discusses 
general methodological considerations and provides suggestions for future research.
interPretation of main findinGs
Maternal common dietary factors
Nutrition during pregnancy is important for both the pregnant woman’s and her child’s 
health (13). Thus far, the associations of maternal dietary factors during pregnancy, such as 
diet quality, dietary patterns, total energy intake and macro- and micronutrient intake with 
offspring health outcomes have been studied extensively (13, 14). In this thesis, we specifi-
cally focused on intake of caffeine and milk, that are less studied, but common components 
of the diet in pregnant women.
CHAPTER 5
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Maternal caffeine intake during pregnancy
Caffeine-containing beverages, including coffee and tea, are frequently consumed. Con-
sumption of these beverages seems to be beneficial for the risks of several diseases in non-
pregnant adults such as type 2 diabetes and non-alcoholic fatty liver disease (15-20), but 
might have unfavorable consequences in pregnant women. Previous studies, including one in 
our own cohort, have observed that maternal caffeine intake was associated with increased 
risks of fetal death, impaired fetal growth and increased risks of low birth weight (21-23). In 
addition to these short-term outcomes, previous studies have observed associations of any 
caffeine intake during pregnancy with higher offspring sum of skinfold thicknesses at age 
3 months (24), and with higher risks of obesity and central obesity up until age 15 years 
(25-27). In contrast, a study among 1986 mothers and their children from the United States 
did not show consistent associations of maternal serum concentrations of paraxanthine, 
the primary metabolite of caffeine, during pregnancy with childhood body mass index at 
ages 4 and 7 years (28). In this thesis, we observed that a high caffeine intake tended to be 
associated with a lower birth weight, a higher weight gain from birth until the age of 6 years 
and a higher body mass index from 6 months to 6 years and at the age of 10 years. Children 
of mothers with a high caffeine intake also had a higher total body fat mass and a higher 
android to gynoid fat mass ratio at the ages of 6 and 10 years, suggesting that maternal 
caffeine intake might be related to total body fat mass and a central body fat distribution in 
childhood. In addition, higher caffeine intake during pregnancy was associated with higher 
abdominal subcutaneous and visceral fat masses and liver fat fraction at the age of 10 years. 
The associations of abdominal visceral fat mass and liver fat fraction were independent of 
child’s concurrent total body fat mass. This suggests that maternal caffeine intake throughout 
pregnancy might differentially affect visceral and liver fat accumulation, rather than the total 
amount of body fat, and may increase susceptibility to cardio-metabolic disease.
The mechanisms by which maternal caffeine intake during pregnancy might affect off-
spring growth and body fat development are unclear. Studies in adults have suggested that 
consumption of caffeine may increase adiponectin concentrations and decrease concentra-
tions of pro-inflammatory cytokines (15, 18). We therefore speculate that these altered 
concentrations in pregnant women may affect fetal nutrient supply, which may subsequently 
affect development of the adipose tissue. Also, animal studies have suggested that in-utero 
exposure to caffeine may overexpose the developing fetus to glucocorticoids, leading to an 
altered development of the HPA-axis (29, 30). High glucocorticoid concentrations have been 
related to increased central obesity. In addition, the concentration of glucocorticoid receptors 
is higher in visceral adipose tissue as compared to other fat depots, possibly resulting in 
differential fat deposition in these depots (31). The associations might also be explained by 
confounding by unhealthy lifestyle factors that are shared within families. However, a nega-
tive control analysis among 50,943 participants showed stronger associations for maternal 




as compared to those for paternal caffeine intake (26). This suggests that an intra-uterine 
programming mechanism might at least partly be involved in these associations.
Maternal milk intake during pregnancy
In contrast to maternal caffeine intake during pregnancy, maternal milk intake during preg-
nancy seems to be associated with increased fetal growth, resulting in higher birth weights 
(32-38). However, the long-term effects of maternal milk intake during pregnancy remain 
unclear. A study from the United Kingdom among 6663 mothers and children, did not 
observe associations of maternal milk intake in late pregnancy with child’s height at the age 
of 7.5 years (39). Another study among 685 mothers and children from Denmark observed 
that milk consumption during pregnancy was associated with increased height and increased 
concentrations of insulin-like growth factor 1 (IGF-1) in the 20-year old offspring (40). In this 
thesis, we observed that high maternal milk intake during pregnancy was associated with 
a higher childhood body mass index, a higher total fat mass, a higher lean mass, a higher 
android to gynoid fat mass ratio, a higher abdominal visceral fat mass and a higher risk of 
overweight/obesity at age 10 years. No consistent associations were observed for pericardial 
fat, liver fat, blood pressure, lipids, insulin or glucose concentrations. Thus, maternal milk 
intake during pregnancy seems to be associated with an adverse body fat distribution in 
childhood, but not with other cardio-metabolic risk factors.
The biological mechanisms linking maternal milk intake during pregnancy with offspring 
general and visceral body fat masses is not known. It has been suggested that milk intake 
increases concentrations of insulin, IGF-1, growth hormone, amino acids and fatty acids in 
the blood. In pregnant women, this might activate the nutrient sensitive kinase mTORC1 
in the placenta. Activation of mTORC1 in the placenta might result in increased placental 
transfer of amino acids and glucose and subsequent fetal overnutrition, causing fetal mTORC 
overactivation and stimulation of anabolic processes, cell growth and adipogenesis in the fe-
tus (41, 42). Overactivation of mTORC1 is associated with several cardio-metabolic diseases, 
including obesity, insulin resistance and type 2 diabetes (41, 43, 44). In addition, microRNAs 
that are present in milk involved in epigenetic upregulation of genes that are involved in 
the development of cardio-metabolic diseases might also play a role (45). Further research 





Both higher maternal caffeine intake during pregnancy and higher maternal milk intake 
during pregnancy are associated with higher childhood general- and abdominal adiposity. 
Further research is needed on whether optimizing intake of caffeine and milk during 
pregnancy is beneficial for reducing childhood adiposity and to define recommendations 
for caffeine and milk intake based on these long-term offspring associations.
Maternal adiposity
Both pre-pregnancy obesity and excessive gestational weight gain are important risk factors 
for adverse short- and long-term offspring health outcomes (46-56). We previously observed 
in the Lifecycle - Maternal Obesity and Childhood Outcomes collaboration that both pre-
pregnancy overweight and obesity and excessive gestational weight gain have a high popula-
tion impact on the risks of adverse pregnancy and birth outcomes, with population attribut-
able risk fractions (PAR) ranging between 1.2% and 31.4%, depending on the outcome. 
Also, the associations of maternal body mass index and gestational weight gain with these 
short-term adverse outcomes were present across the full ranges of body mass index and 
gestational weight gain (57). In this thesis, we showed that both pre-pregnancy obesity and 
excessive gestational weight gain also have a considerable population impact with respect 
to the risk of offspring overweight and obesity throughout childhood, with PARs ranging 
between 10.2 and 21.6%. In addition, we observed that not only maternal overweight and 
obesity were associated with higher risks of overweight and obesity in childhood, but also 
that these risks were progressively higher among children of mothers with grade 1, 2, and 3 
obesity, respectively. The risks of childhood overweight and obesity increased across the full 
ranges of maternal body mass index and gestational weight gain. This suggests that these 
risks are not confined to the extremes of maternal body mass index and gestational weight 
gain, but increase gradually over the ranges of maternal pre-pregnancy BMI and gestational 
weight gain. For prevention, insight into the combined effects of maternal body mass index 
and gestational weight gain is needed. We observed that maternal pre-pregnancy obesity 
was associated with the highest risks of both short-term maternal and infant outcomes and 
obesity throughout childhood. Gestational weight gain only added to a limited extend to 
these risks. This suggests that maternal body mass index might be a more important factor 
than gestational weight gain with respect to the risks of maternal and offspring adverse 
outcomes.
Thus far, it is unclear how much weight pregnant women should gain to minimize their 
risk of adverse pregnancy and offspring outcomes. The optimal gestational weight gain 
reflects a trade-off between outcomes occurring at both low and high levels of gestational 
weight gain. Previous studies aimed to identify the optimal gestational weight gain, but 




outcomes, and the acquired optimal gestational weight gain ranges varied across studies 
(58-65). Despite these methodological issues, five of these previous studies were included 
for the construction of the current guidelines of the US Institute of Medicine (IOM; currently 
known as the National Academy of Medicine). These guidelines are criticized because of 
the non-systematic approach, lack of inclusion of maternal pregnancy complications and 
no consideration of obesity severity (63, 66). Only one previous study among 120251 obese 
US women defined separate optimal weight gain ranges for obesity grade 1 (4.5-11.3 kg), 
obesity grade 2 (0-4.1 kg) and obesity grade 3 (<4 kg weight loss), based on four outcomes, 
including preeclampsia, caesarean delivery, small size for gestational age at birth and large 
for size gestational age at birth, using data from term births only (63). In this thesis we identi-
fied ranges of optimal gestational weight gain associated with the lowest risk of maternal 
and infant outcomes. In line with previous studies, the optimal gestational weight gain in our 
study was lower for women with a higher pre-pregnancy BMI. Optimal gestational weight 
gain further decreased with increasing obesity grades and might even involve weight loss for 
severely obese women. However, this result needs be interpreted with caution as the safety 
and effectiveness of weight loss during pregnancy remain to be assessed. In addition, we 
observed that weight gain outside both the ranges defined in our study and IOM ranges was 
associated with adverse maternal and infant outcomes, with generally stronger associations 
for the ranges defined in our study. However, both the ranges defined in our study and IOM 
ranges had limited ability to distinguish between those with and without adverse outcomes. 
This suggests that the optimal gestational weight gain ranges defined in this study may be 
informative for preconception counselling, but also that gestational weight gain guidelines 
in general might not be useful for individual risk prediction.
The mechanisms underlying the associations of maternal weight before and during preg-
nancy with offspring outcomes are not fully understood. The observed associations might be 
explained by genetics (67, 68), estimations of the heritability of obesity go up to 85% (69). 
The remainder might be explained by developmental programming mechanisms or environ-
mental and lifestyle characteristics shared by mother and child. The fetal over-nutrition hy-
pothesis suggests that increased exposure to several types of nutrients in children of women 
with obesity or excessive gestational weight gain may lead to persistent adaptations in the 
structure and function of adipose tissue, appetite regulation and energy metabolism, lead-
ing to an increased susceptibility to offspring adiposity (70-72). Also, epigenetic processes 
may play an important role in these mechanisms (73-75). Increasing evidence suggests that 
maternal adiposity already exerts effects before conception. Increased concentrations of pro-
inflammatory cytokines, hormones and metabolites may accumulate in the ovarian follicular 
fluid and subsequently affect oocyte maturation and reduce embryo quality by metabolic, 




Maternal pre-pregnancy body mass index and gestational weight gain are important 
risk factors for adverse pregnancy and birth outcomes and childhood overweight and 
obesity. The optimal gestational weight gain associated with the risks pregnancy and 
birth outcomes was lower for higher pre-pregnancy body mass indexes. However, the 
predictive ability of these optimal weight gain ranges was limited. These results suggest 
that maternal weight before pregnancy might be more important than weight gain dur-
ing pregnancy with respect to the risks of adverse pregnancy and birth outcomes and 
childhood overweight and obesity. Also, gestational weight gain guidelines might not 
be useful for individual prediction of the risks of adverse pregnancy and birth outcomes.
Maternal and childhood metabolism
Several possible mechanisms underlying the associations of adverse exposures in early life 
with later obesity and cardio-metabolic disease have been proposed, which include, but are 
not limited to, epigenetics, adaptations in placental function, and hormonal and metabolic 
changes (77, 78). The possible underlying mechanisms specific for maternal adiposity and 
dietary factors have been described above. In this thesis, we focused in more detail on poten-
tial metabolic mechanisms underlying the early origins of cardio-metabolic disease.
Conventional biomarkers of metabolic status
Thus far, studies have mainly focused on conventional biomarkers of metabolic status, such 
as glucose, insulin and lipid concentrations. These studies suggest that higher concentrations 
of these biomarkers, already from early pregnancy onwards, are associated with altered fetal 
and early postnatal growth trajectories and increased risks of obesity and associated cardio-
metabolic diseases (79-82). In this thesis, we observed that maternal glucose concentrations 
already in early pregnancy were associated with lower HDL cholesterol and higher glucose 
concentrations in childhood, whereas maternal insulin concentrations were associated with 
a higher body mass index, systolic blood pressure, total fat mass, android to gynoid fat mass 
ratio, subcutaneous fat mass and insulin levels in childhood. All associations, except those 
for childhood glucose and insulin levels, were explained by maternal pre-pregnancy BMI. In 
addition, adverse exposures in early life might also influence offspring metabolic profiles. For 
instance, differences in fetal and postnatal growth patterns are related to adverse metabolic 
profiles and increased risks of cardio-metabolic disease in later life. Previous studies have 
shown that children born with a low birth weight are at increased risk of developing cardio-
metabolic disease in later life (9-12). On the other side of the spectrum, children born with a 
high birth weight are also at risk of these diseases (9-12). However, in this thesis we observed 
that children with relatively high insulin and c-peptide concentrations in childhood, do not 




compared to children with lower insulin and c-peptide concentrations. This might suggest a 
strong influence of postnatal factors, such as childhood body composition.
Metabolomics
Detailed characterization of metabolic status by metabolomics approaches may provide 
additional insights in the mechanisms that link early life adverse exposures to later cardio-
metabolic disease. Several, mostly small, studies have reported associations of amino acids, 
fatty acids, acyl-carnitines, several lipid species and vitamins in pregnancy (83-89) and at 
birth (90-98) with (gestational age adjusted-) birth weight. Only two studies assessed directly 
measured fetal growth and observed associations of maternal urinary branched-chain amino 
acid concentrations, taurine, histidine and malonate and fetal weight change between 12 
and 34 weeks of gestation and fetal anterior abdominal wall width at 34 weeks of gestation 
(88, 89). In this thesis, we compared concentrations of amino acids, non-esterified fatty 
acids, phospholipids, and carnitines in pregnant women, newborns and children. In line 
with previous studies (99-101), concentrations of amino acids, non-esterified fatty acids and 
acyl-carnitines were higher in cord blood as compared to maternal early-pregnancy blood, 
whereas concentrations of phospholipids were higher in maternal early-pregnancy blood. 
The higher amino acids, non-esterified fatty acids, carnitines in cord blood are indicative 
of an active transport of these metabolites across the placenta, whereas polar lipids get 
hydrolyzed to fatty acids before crossing the placenta (99-101). Concentrations of amino 
acids and non-esterified fatty acids were lower in childhood as compared to cord blood 
samples, whereas concentrations of phospholipids and carnitines were higher in childhood. 
Despite these higher exact concentrations, correlations of individual metabolites between 
pregnant women and their children were relatively low, suggesting that distinct metabolite 
profiles exist.
In addition, we assessed the associations of maternal and newborn metabolite con-
centrations with fetal growth from first trimester onwards and the risks of adverse birth 
outcomes. We observed a few associations of maternal phospholipids, particularly acyl-
alkyl-phosphatidylcholines, with femur length and head circumference in third trimester and 
weight and head circumference at birth. No associations were present for other metabolites 
or with earlier fetal growth measures, suggesting that maternal early-pregnancy metabolite 
concentrations are only to a very limited extend related to fetal growth. Contrary, newborn 
metabolite profiles at birth, mainly concentrations of non-esterified fatty acids and acyl-lyso-
phosphatidylcholines, were strongly associated with weight, length and head circumference 
at birth and the risks of SGA and LGA. Concentrations of several diacyl-phosphatidylcholines, 
acyl-alkyl-phosphatidylcholines, sphingomyelines, amino acids and acyl-carnitines were as-
sociated with the risk of pre-term birth, suggesting that suboptimal size at birth and pre-term 
birth are characterized by distinct cord blood metabolite profiles. Thus, results from this thesis 
suggest that cord blood metabolite profiles are strongly associated with growth measures at 
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birth and the risks of adverse birth outcomes. However, it should be noted that as a result 
of the cross-sectional design of these analyses we are not able to draw conclusions on the 
direction of these associations.
Conclusions
Maternal and newborn metabolism might influence offspring growth and cardio-meta-
bolic outcomes in later life. Whether the maternal and offspring metabolite concentra-
tions serve as intermediates in the pathways linking maternal body mass index and other 
lifestyle related exposures to childhood obesity and cardio-metabolic risk factors remains 
to be studied.
relevance and imPlications for Policy and 
clinical Practice
The results from this thesis might have implications for policy and clinical practice. Given the 
high prevalence of childhood obesity and associated cardio-metabolic disease, it is important 
to effectively target factors related to these diseases. Results from this thesis suggest that 
in addition to adverse birth outcomes, maternal caffeine and milk intake during pregnancy 
might influence long-term offspring body fat distribution. Current recommendations for 
maternal caffeine intake during pregnancy are based on the risks of adverse pregnancy 
and birth outcomes and range between a maximum of 200 and 300 mg per day (102-
104). Currently, no specific recommendations of maternal milk intake during pregnancy 
exist. Women of reproductive age are generally advised to consume 2-3 glasses of milk 
or milk products per day, although differences in included products and portion sizes exist 
between countries (105-107). Results of our and previous studies suggest that associations 
with childhood outcomes might already be present for lower intakes. Future studies should 
confirm whether optimizing caffeine or milk intake during pregnancy is beneficial for reduc-
ing childhood adiposity before these results could be incorporated in guidelines. However, 
given the considerable amount of women with caffeine and milk intakes above the current 
recommendations, awareness to the health effects of these factors and adherence to the 
current recommendations could be increased.
The studies described in this thesis suggest that the preconception period provides an 
important opportunity for prevention of offspring short- and long-term adverse outcomes. 
We therefore strongly suggest that prevention strategies focus on optimizing weight and 
diet before conception. We acknowledge that this is challenging because women planning 
to become pregnant are generally not in clinical care and a large proportion of pregnancies 
is unplanned. Therefore, prevention strategies should both involve individual preconception 




pregnancy wish by general practitioners and other health professionals and population-based 
approaches. Population approaches could involve increasing awareness about the impor-
tance of a healthy weight before and during pregnancy with respect to health consequences 
for both mother and child, or could be part of larger population-based health promotion 
strategies for the general population. Next to the preconception period, prevention strate-
gies should target women during pregnancy with respect to dietary intake and weight. An 
advantage of targeting women during pregnancy is that they are easy to target and might 
be more motivated to make lifestyle changes. Our results suggest that optimal gestational 
weight gain guidelines are of limited importance with respect to individual prediction of 
adverse pregnancy and birth outcomes. However, gestational weight gain outside the 
guidelines was strongly associated with adverse pregnancy and birth outcomes at population 
level. Also, these results are limited to the outcomes that were included in the definition of 
the guidelines. Therefore, we consider it important to target and monitor weight gain in 
pregnant women at population level.
In addition, results from our thesis suggest that maternal and newborn metabolite profiles 
from metabolomics might influence offspring growth and cardio-metabolic outcomes in later 
life. Our results serve as a first step in understanding of the biological mechanisms underlying 
the associations of an adverse intrauterine environment with these outcomes. Therefore, 
these results are currently mainly of interest from etiological perspective, rather than for 
clinical practice. However, results from metabolomics studies might potentially be useful for 
the identification of biological biomarkers or individual risk prediction.
methodoloGical considerations
Selection bias
Selection bias is a bias in effect estimates that may occur if the association between the 
exposure and outcomes of interest is different in those included in the study and those in 
the target population. Selection bias in cohort studies may arise at baseline, resulting from 
selective inclusion, or at follow-up, due to selective loss to follow up (attrition bias). Selection 
can either be differential or non-differential. Non-differential selection refers to the situation 
that non-participation is dependent on the exposure but independent of the outcome, or 
vice versa, and is not considered to bias effect estimates. Differential selection bias refers to 
non-participation that is related to both the exposure and outcome under study, and results 
in selection bias (108).
Most studies presented in this thesis were embedded in the Generation R Study. A total of 
61% of all children that were eligible participated at birth. Compared to the general popula-
tion of Rotterdam, women included in the study were less often from ethnic minority groups 
and of lower socio-economic status. Also, pregnancy and birth complications, including 
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gestational hypertensive disorders, preterm birth and low birth weight were less prevalent 
(109). This suggests selection towards a more healthy population of higher socioeconomic 
status. Given the prospective design of the study, it seems unlikely that this selection at 
baseline is differential and might have led to selection bias. However, it seems likely that this 
selective participation may have led to lower prevalence rates and reduced statistical power, 
and a limited generalizability to other populations. Of all children included in the study, 
about 67.5% and 57.4% participated in the follow-up body composition measurements 
at age 6 and 10 years, respectively. Reasons for loss to follow up were movement outside 
study area, non-consent, and death of the child (110). Participation rates were slightly lower 
for measurements involving venous punctures (44.6% and 39.9%), due to non-consent or 
unsuccessful venous punctures, and abdominal and liver fat measurements using magnetic 
resonance imaging at age 10 years (29.2%), due to non-consent. As compared to those lost 
to follow-up, those included in the analyses described in this thesis were generally higher 
educated, more often of European descent, and smoked less often. It is difficult to speculate 
whether this selection to a more healthy, higher educated study population has led to selec-
tion bias. It seems unlikely, as loss to follow up was not related to exposure status in most 
studies.
Two studies presented in this thesis were embedded in the LifeCycle - Maternal Obesity 
and Childhood Outcomes (MOCO) collaboration, a collaboration of 39 pregnancy and birth 
cohort studies. As the majority of the cohorts included was prospective population-based, 
we expect these studies to have selection patterns similar to those of the Generation R Study, 
and therefore consider the risk of selection bias within these studies small. Selection of stud-
ies to participate in the collaboration was based on participation in existing collaborations 
on childhood health and might not be completely at random. Also, of 50 cohorts invited 
for participation, 11 did not participate because they were not reached or did not share 
data. However, it seems very unlikely that non-participation of studies in the collaboration is 
related to the exposures and outcomes under study and has biased the results described in 
this thesis.
Information bias
Information bias, or misclassification, is a bias in effect estimates that arises from measurement 
errors of exposure and outcome measurements. Analogous to selection, misclassification can 
be either differential or non-differential. Differential misclassification refers to misclassifica-
tion where the exposure status is dependent on outcome status, or vice versa, and can either 
result in an under- or overestimation of effect estimates. Non-differential misclassification 
refers to misclassification were exposure status does not depend on outcome status, or vice 
versa, and generally results in an underestimation of effect estimates (108).
In the studies described in this thesis, exposure data was collected longitudinally before as-




ing data on the outcomes. Also, both participants and data collectors were not aware of the 
specific research questions under study. This makes bias due to differential misclassification 
unlikely. However, non-differential misclassification might be present and might have led to 
underestimated effect estimates. Fetal growth was assessed using ultrasound measurements 
in each trimester of pregnancy. Data on crown-rump length or biparietal diameter from the 
first ultrasound visit were used for pregnancy dating for the majority of women. Although 
this method is more accurate than pregnancy dating by last menstrual period, it neglects 
variation in early fetal growth. In offspring of these women, growth variation in second and 
third trimester might be underestimated. Part of the anthropometrics used for calculation of 
maternal body mass index, gestational weight gain and childhood body mass index came 
from self-report or parental report. Information on body mass index by self-report tends to be 
underestimated (111), which might have led to an underestimation of the effect estimates. 
Information on maternal caffeine and milk intake during pregnancy was obtained using 
(food frequency-) questionnaires. As these questionnaires rely on recall, it might be possible 
that some misclassification has occurred. For caffeine, it is likely that women underestimated 
their intakes, which might have led to an underestimation of the effect estimates. Milk intake 
could be either under- or overestimated, leading to an under- or overestimation of the effect 
estimates. Maternal and childhood blood samples were 30 minutes fasting or non-fasting. 
This may have resulted in non-differential misclassification and an underestimation of the 
effect estimates.
Confounding
Confounding is a bias in effect estimates that occurs when the exposure of interest coincides 
with another factor, that is also related to the outcome but is not an intermediate in the 
association between exposure and outcome under study. Due to the observational nature, 
the results described in this thesis might be subject to confounding. The exposures assessed 
in this thesis, weight, diet and metabolic factors, are likely to cluster with each other, but 
also with other socio-economic and lifestyle related factors, such as ethnicity, education, 
physical activity, smoking and alcohol consumption. We had data on many of these factors 
available, which enabled us to adjust our analyses for many possible confounders. These 
possible confounders were selected based on prior knowledge from previous studies, their 
associations with exposures and outcomes of interest, or a change of in effect estimates of 
more than 10%. Adjustment for confounders only changed the effect estimates slightly in 
most of the studies, suggesting that the influence of confounding factors is small. However, 
residual confounding might be present. This may either result from inaccurate adjustment 
for confounding factors due to measurement errors or from unmeasured or unknown con-
founders. For example, physical activity would be an important factor to take into account 
in many of the associations studied in this thesis, but this information was not available and 




The observational nature of this thesis precludes conclusions about causality of the associa-
tions assessed. However, from a clinical and preventive perspective, insight in whether the 
observed associations are causal is of great interest. Sir Bradford Hill’s criteria can help assess-
ing the causality of an observed association. The criteria for a causal relationship are: strength, 
consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment 
and analogy. The effect estimates of the associations of maternal adiposity with childhood 
growth and body fat development are relatively large. However, the effect estimates of com-
mon maternal dietary factors with these outcomes are smaller. The results of the studies 
presented in this thesis are consistent with those of previous studies in humans and coherent 
with the results of animal studies. Exposure assessment took place before assessment of the 
outcomes and dose-response effects were observed for most of the associations assessed. 
Plausible potential mechanisms have been suggested for the associations assessed, although 
some need to be confirmed in further research. Although not assessed in this thesis, the 
associations might not be specific, as the exposures studied are likely to influence other 
outcomes. The experiment and analogy criteria were not assessed in this thesis. Thus, there 
seems to be some evidence for causality, but further studies are warranted to obtain more 
insight in this.
future research
In this thesis, we described associations of maternal common dietary factors and adiposity 
with offspring growth, body fat development and cardio-metabolic risks factors as well as 
potential underlying metabolic mechanisms. However, there are several factors that could be 
improved and clarified in future studies.
General design
The studies in this thesis are based on results from observational pregnancy and birth cohort 
studies with follow-up until age 10 years (The Generation R Study) and 18 years (MOCO 
collaboration). Future studies in other populations should confirm and extend the findings 
presented in this thesis. These future studies should extend beyond the follow-up durations 
of the studies in this thesis, as associations might become more apparent at later ages. As 
results from this thesis as well as from other studies strongly suggest that the preconception 
period is important for offspring health, future cohort studies should already start before 
pregnancy. Also, follow-up of multiple generations is of interest to assess whether the inter-
generational effects of adverse exposures in early life, for instance the intergenerational cycle 
of obesity. These studies would ideally include repeatedly assessed information on exposure 




time. In addition, efforts should be made to study relatively rare populations, such as severely 
obese women and the safety and effectiveness of weight loss during pregnancy in these 
women.
A number of factors could be improved in data collection in future studies. First, maternal 
pre-pregnancy body mass index, gestational weight gain and childhood body mass index 
were partly self- or parent reported, which may have potentially induced non-differential 
misclassification. Measuring these anthropometrics might reduce this risk. More precise mea-
sures of maternal fat mass before and during pregnancy as well as its location will be of inter-
est to obtain further insight into the effects of maternal body composition. It is recognized 
that measuring fat mass by methods such as dual-energy x-ray absorptiometry and magnetic 
resonance imaging in pregnant women is not feasible in observational studies due to safety 
concerns. However, alternative methods such as abdominal ultrasounds early in pregnancy, 
skinfold thicknesses and bioelectrical impedance might already provide important informa-
tion. Third, in the studies described in this thesis, we only had data available on caffeine 
intake from coffee and tea. Although at the time of data collection 80% of all caffeine intake 
was from coffee and tea (112), future studies should also obtain data on other common 
caffeine sources, such as cola, energy drinks, chocolate and medications. Maternal caffeine 
intake during pregnancy and maternal milk intake were assessed using questionnaires. An 
alternative to assessing caffeine intake by questionnaires is measuring urine concentrations 
of paraxanthine, which is the primary metabolite of caffeine. This approach is more objec-
tive and avoids problems as underreporting and recall bias, but depends on differences in 
metabolism and excretion rates between participants. Questionnaires for assessing caffeine 
(regular questionnaire) and milk intake (FFQ) were based on recall about the last 3 months. 
An alternative to FFQ’s would be 24-hours recalls, that are more precise and less prone to 
recall bias and social desirable answers, but reflect the intake of one specific day rather than 
habitual intakes. Fourth, 30-minutes fasting or non-fasting blood samples were used and no 
information was available on the time of the last meal. Use of fasting blood samples would 
avoid misclassification due to food intakes before blood draw. Also, detailed information on 
duration and intensity of physical activity needs to be obtained.
Causality
In this thesis, we described associations of common maternal dietary factors and maternal 
adiposity with offspring growth and development. Drawing conclusions on causality based 
on observational data is difficult. Despite the fact that we adjusted our analyses for many 
possible confounding factors and the fact that there is some evidence for causality based on 
the Bradford Hill criteria, further research is needed to establish causality of these associa-
tions.
The gold standard for assessing causality are randomized controlled trials. By randomizing 
participants to be part of either an intervention or a control group, differences in outcomes 
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can be attributed to the interventions, rather than confounding factors. In addition, these 
studies would also provide insights in the effectivity of these interventions and the timing of 
these interventions. With respect to maternal adiposity, randomized controlled intervention 
trials have been performed to reduce gestational weight gain in second and third trimester. 
These intervention trials, focused on improving diet and physical activity, have been moder-
ately successful in reducing gestational weight gain (113-116). However, these interventions 
did not show any effect on offspring outcomes, such as gestational age at birth, birth weight, 
or childhood weight (113-116). Results from this thesis suggest that pre-pregnancy weight 
is a more important determinant of offspring adverse outcomes than gestational weight 
gain. Thus far, interventions that aim to reduce pre-pregnancy weight are scarce (117). A 
few intervention studies targeted pre-conception lifestyle, such as alcohol intake, smoking, 
nutrition (mainly micronutrients), and showed small effects on the risks of adverse birth 
outcomes, but whether these effects were through pre-pregnancy weight remains unclear 
(118-120). Thus, randomized controlled interventional trials targeting maternal weight in 
the preconception period are needed. With respect to maternal caffeine and milk intake, 
intervention studies would be focused on optimizing intakes of caffeine and milk. Thus far, 
only one intervention study focused on reducing caffeine intake during pregnancy has been 
performed. A study from Denmark randomized 1207 pregnant women to replace their usual 
coffee with either caffeinated instant coffee or decaffeinated instant coffee, but did not 
show any effect on birth weight or length of gestation (121). Further intervention trials 
focused on restricting caffeine intake during pregnancy are needed to confirm these find-
ings and to assess the long-term offspring health effects. To the best of our knowledge, no 
intervention trials focused on maternal milk intake during pregnancy have been performed.
In addition, observational study designs that deal with confounding in a more natural way 
could help in assessing causality. These study designs include parent-offspring comparison 
studies, sibling comparison studies and Mendelian Randomization studies. Parent-offspring 
comparison studies compare the strength of maternal-offspring associations with the strength 
of paternal offspring associations. Stronger maternal-offspring associations than paternal-
offspring associations might suggest that the observed associations can at least partly be 
explained by intra-uterine programming mechanisms. A limitation of this approach is the 
assumption that both parents contribute equally to the shared lifestyle-related characteristics 
between parents and their offspring. This approach has been performed for pre-pregnancy 
body mass index and caffeine intake (26, 122), but results need to be confirmed. Sibling 
comparison studies compare siblings within families, and therefore control for family based 
characteristics and genetics. Sibling-comparison studies have been performed with respect 
to maternal weight before or during pregnancy, and are suggestive of a causal relationship 
(123-127). However, an important limitation of this study design is that it assumes these 
family based characteristics to be constant over time, whereas these might change along 




ant known to be strongly associated with the exposure and not affected by confounding as 
instrumental variable for the exposure, in order to assess whether the exposure is causally 
related to the outcome (129). Mendelian Randomization Studies have been performed with 
respect to the associations of maternal obesity with offspring birth weight and obesity, but 
results are conflicting (68, 130, 131). Sibling-comparison studies and Mendelian Randomiza-
tion studies regarding the offspring effects of maternal caffeine intake during pregnancy 
remain to be performed.
Underlying mechanisms
Unraveling the mechanisms underlying the associations between adverse exposures in early 
life and health and disease in later life is important to design effective interventions interfer-
ing with these mechanisms. In this thesis, we focused on the potential underlying metabolic 
mechanisms, by looking at maternal, newborn and childhood metabolic profiles. We also 
showed newborn, and to a much smaller extent maternal, metabolite profiles associated 
with fetal growth measures. Futures studies should focus on the associations of these me-
tabolomics data with early life adverse exposures and outcomes both short- and long-term. 
Also, mediation analyses addressing the potential mediating role of metabolites in the as-
sociations of early life exposures with the outcome are of interest. We applied a targeted me-
tabolomics approach, which is an efficient and straightforward hypothesis-driven approach 
that provides exact metabolite concentrations, but might miss important metabolites and 
pathways (132). Untargeted metabolomics approaches might provide more detailed insights 
in the metabolic pathways under study. We measured metabolite concentrations in blood 
serum. Other biological samples, such as plasma, urine, saliva, or breast milk may show dif-
ferent metabolic profiles and might therefore provide additional insights. Next to metabolic 
mechanisms, other mechanisms could be involved. These mechanisms include, but are not 
limited to, hormonal changes (alterations in HPA and satiety axes), genetics and changes in 
gene expression (epigenetic mechanisms), and changes in the microbiome. Further studies 
are needed to address potential underlying mechanisms as well as their interrelationships, by 
for example multi-omics approaches (133).
conclusions
Maternal common dietary factors and maternal adiposity are associated with offspring 
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Chapter 1 describes the background and rationale for the studies presented in this thesis. 
Childhood overweight and obesity are a major public health problem. Children with over-
weight and obesity are at risk of a variety of adult diseases, such as overweight and obesity 
in adulthood, cardio-metabolic disease, asthma, osteoarthritis, mental health problems and 
premature death. The etiology of obesity and cardio-metabolic disease is complex and mul-
tifactorial. It has been suggested that, in addition to well-known risk factors such as genetic 
predisposition, excess energy intake, and sedentary behavior, susceptibility to these diseases 
might already be established in early life. This might be reflected by different growth patterns 
from fetal life onwards. Identifying the factors related to adverse growth patterns and body 
fat development as well as the underlying mechanisms will broaden the understanding of 
the early origins of disease and is vital to effectively target interventions aiming to reduce 
the burden of these diseases. Therefore, the general objective of this thesis was to assess 
the associations of common maternal dietary factors and maternal adiposity with growth, 
body fat development and cardio-metabolic risk factors in children, as well as the metabolic 
mechanisms that potentially underlie these associations. The studies presented in this thesis 
used data from the Generation R Study, a population-based cohort study from fetal life 
onwards in Rotterdam, the Netherlands, and the LifeCycle – Maternal Obesity and Childhood 
Outcomes (MOCO) collaboration, an international collaboration of 39 pregnancy and birth 
cohort studies from Europe, North-America and Australia.
Chapter 2 describes studies on the influence of common maternal dietary factors on child-
hood growth, adiposity and cardio-metabolic risk factors. In Chapter 2.1, we examined the 
associations of maternal caffeine intake during pregnancy with childhood growth patterns 
from birth until the age of 6 years and general adiposity at age 6 years. We showed that a 
high maternal caffeine intake tended to be associated with a lower birth weight, a higher 
weight gain from birth until the age of 6 years and a higher body mass index from 6 months 
to 6 years, and a higher total body fat mass and android to gynoid fat mass ratio at the age 
of 6 years. This suggests that maternal caffeine intake is related to total body fat mass and a 
central body fat distribution in childhood. In Chapter 2.2, we showed that these associations 
were also present at the age of 10 years. In addition, higher maternal caffeine intake during 
pregnancy was associated with higher abdominal subcutaneous and visceral fat masses and 
a higher liver fat fraction at the age of 10 years. The associations of abdominal visceral 
fat mass and liver fat fraction were independent of child’s concurrent total body fat mass, 
suggesting that maternal caffeine intake might differentially affect visceral and liver fat ac-
cumulation. In Chapter 2.3 we assessed the associations of maternal milk intake during 
pregnancy with childhood general- and organ fat measures and other cardio-metabolic risk 
factors. We observed that a high maternal milk intake during pregnancy was associated 
with higher childhood body mass index, total body fat mass, lean mass, android to gynoid 
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fat mass ratio, abdominal visceral fat mass and a higher risk of overweight/obesity at age 10 
years. No consistent associations were observed for pericardial fat, liver fat, blood pressure, 
lipids, insulin or glucose concentrations. Thus, results from this thesis suggest that maternal 
milk intake during pregnancy seems to be associated with an adverse body fat distribution in 
childhood, but not with other cardio-metabolic risk factors.
Chapter 3 describes studies on the influences of maternal adiposity before and during 
pregnancy on offspring adiposity at birth and in childhood. In Chapter 3.1 we assessed 
the separate and combined associations of maternal pre-pregnancy body mass index and 
gestational weight gain with the risks of overweight/obesity throughout childhood and their 
population impact. We observed that not only maternal pre-pregnancy overweight and 
obesity are associated with an increased risk of childhood overweight, but that these risks 
increase gradually across the full range of maternal pre-pregnancy body mass index. Similarly, 
the risk of childhood overweight/obesity increased across the full range of gestational weight 
gain. The additional effect of excessive gestational weight gain on the risk of childhood 
overweight was small among women who are already overweight or obese before preg-
nancy. In Chapter 3.2, we identified ranges of optimal gestational weight gain associated 
with the lowest risk of maternal and infant adverse outcomes. These ranges were lower for 
women with a higher pre-pregnancy body mass index. The optimal gestational weight gain 
decreased with increasing severity of obesity. We also observed that weight gain outside both 
the ranges defined in our study and the existing guidelines from the US Institute of Medicine 
(IOM) was associated with adverse maternal and infant outcomes, with generally stronger 
associations for the ranges defined in our study. However, both the ranges defined in our 
study and from the IOM had limited ability to distinguish between those with and without 
adverse outcomes. This suggests that the optimal gestational weight gain ranges defined in 
this study may be informative for preconception counselling, but also that gestational weight 
gain guidelines in general might not be useful for individual risk prediction.
Chapter 4 describes studies on the potential metabolic mechanisms linking adverse expo-
sures in early life to later obesity and cardio-metabolic disease. In Chapter 4.1 we showed 
that maternal glucose concentrations already in early pregnancy were associated with lower 
HDL cholesterol and higher glucose concentrations in childhood, whereas maternal insulin 
concentrations were associated with a higher body mass index, systolic blood pressure, total 
body fat mass, android to gynoid fat mass ratio, subcutaneous fat mass and insulin levels 
in childhood. All associations, except those for childhood glucose and insulin levels, were 
explained by adjustment for maternal pre-pregnancy BMI. In Chapter 4.2 we aimed to 
identify critical periods and specific growth patterns from fetal life onwards associated with 
childhood insulin levels. We showed that, independent of growth in other time intervals, 
weight growth from 6 months onwards and body mass index growth from 24 months 
onwards were positively associated with childhood insulin levels, with the strongest associa-




insulin, those in the highest quartile had a higher length from birth onwards and a higher 
weight and body mass index from 24 months onwards. These differences increased with 
age. No associations were observed for fetal growth characteristics. Thus, results from this 
thesis suggest that rapid length, weight and body mass index growth in childhood, but not 
during fetal life, is associated with higher insulin levels in childhood. In Chapter 4.3 we used 
metabolomics analyses to describe the metabolite profiles in pregnant women, newborns 
and children as well as their interrelationships. We observed that metabolite concentrations 
vary considerably between pregnancy women and their children at birth and at the age of 
10 years. Correlations of individual metabolites between pregnant women and their children 
at birth and in childhood are relatively low. This may suggest that unique metabolic profiles 
are present among pregnant women, newborns and school-aged children, with limited inter-
generational correlations between metabolite profiles. In Chapter 4.4 we examined whether 
maternal early-pregnancy and newborn metabolite profiles are associated with fetal growth 
from first trimester onwards and the risks of adverse birth outcomes. We observed only a few 
associations of maternal phospholipids, particularly acyl-alkyl-phosphatidylcholines, with fe-
mur length and head circumference in third trimester and weight and head circumference at 
birth. Contrary, newborn metabolite profiles at birth, mainly concentrations of non-esterified 
fatty acids and acyl-lysophosphatidylcholines, were strongly associated with weight, length 
and head circumference at birth and the risks of SGA and LGA. Thus, results from this thesis 
suggest that maternal early-pregnancy metabolite are only to very limited extend related to 
fetal growth, whereas cord blood metabolite profiles are strongly associated with growth 
measures at birth and the risks of adverse birth outcomes.
Finally, in Chapter 5 a general discussion of the main findings of this thesis, general 
methodological considerations and suggestions for future research are provided. In conclu-
sion, maternal common dietary factors and maternal adiposity are associated with offspring 







Hoofdstuk 1 beschrijft de achtergrond en rationale voor de studies beschreven in dit 
proefschrift. Overgewicht en obesitas bij kinderen vormen een groot probleem voor de 
volksgezondheid. Kinderen met overgewicht en obesitas hebben een hoog risico op ziekten 
op latere leeftijd, zoals overgewicht en obesitas, cardio-metabole ziekten, astma, osteoar-
tritis, mentale gezondheidsproblemen en vroegtijdig overlijden. De etiologie van obesitas 
en cardio-metabole ziekten is complex en multifactorieel. Naast bekende risicofactoren als 
genetische aanleg, overmatige energie inname and sedentaire leefstijl, lijkt ook het vroege 
leven een rol te spelen in de ontwikkeling van deze ziekten. Dit zou tot uiting kunnen komen 
door middel van afwijkende groeipatronen al vanaf het foetale leven. Het identificeren van 
factoren gerelateerd aan afwijkende groeipatronen en de ontwikkeling van lichaamsvet, 
alsmede de biologische mechanismen die hieraan ten grondslag liggen, zal bijdragen aan 
een beter begrip van de vroege oorsprong van ziekten en is belangrijk voor de ontwikkeling 
van interventies gericht op het verminderen van het vóórkomen van deze ziekten. Het doel 
van dit proefschrift was dan ook het bestuderen van de associaties van veel voorkomende 
voedingscomponenten en maternale adipositas met groei, de ontwikkeling van lichaamsvet 
en cardio-metabole risicofactoren bij kinderen, alsmede de potentiële onderliggende meta-
bole mechanismen. Voor de studies beschreven in dit proefschrift is gebruik gemaakt van 
data van de Generation R studie, een prospectieve cohort studie onder zwangere vrouwen 
en hun kinderen in Rotterdam, en LifeCycle – Maternal Obesity and Childhood Outcomes 
(MOCO), een internationale samenwerking tussen 39 zwangerschaps- en geboorte cohorten 
uit Europa, Noord-Amerika en Australië.
Hoofdstuk 2 beschrijft studies naar de invloed van door zwangere vrouwen vaak ge-
consumeerde voedingscomponenten, namelijk cafeïne en melk, op groei, adipositas en 
cardio-metabole risicofactoren bij hun kinderen. In Hoofdstuk 2.1 hebben we de associatie 
van maternale cafeïne consumptie tijdens de zwangerschap met groeipatronen vanaf de 
geboorte tot de leeftijd van 6 jaar en algemene adipositas op de leeftijd van 6 jaar onder-
zocht. Resultaten van deze studie lieten zien dat een hogere maternale cafeïne consumptie 
was geassocieerd met een lager geboortegewicht, een hogere gewichtstoename vanaf de 
geboorte tot de leeftijd van 6 jaar, een hogere body mass index vanaf de leeftijd van 6 
maanden tot 6 jaar en een hogere totale lichaamsvetmassa en een hogere ratio van androïde 
en genoïde vetmassa op de leeftijd van 6 jaar. Dit wijst erop dat cafeïne consumptie door 
zwangere vrouwen is gerelateerd aan totale lichaamsvetmassa en een centrale vetverdeling 
bij hun kinderen op de leeftijd van 6 jaar. Hoofstuk 2.2 laat zien dat deze associaties ook 
bestaan op de leeftijd van 10 jaar. Daarnaast was een hogere maternale cafeïne consumptie 
tijdens de zwangerschap ook geassocieerd met hogere abdominale subcutane en viscerale 
vet massa’s en een hogere lever vet fractie bij kinderen van 10 jaar. De associaties van abdo-
minale viscerale vetmassa en lever vet fractie waren onafhankelijk van de totale vetmassa van 
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het kind. Dit zou kunnen betekenen dat cafeïne consumptie door zwangere vrouwen in het 
specifiek de ontwikkeling van visceraal en lever vet bij kinderen beïnvloedt. In Hoofdstuk 
2.3 hebben we de associatie tussen maternale melk consumptie met totaal lichaamsvet en 
orgaanvet bij hun kinderen onderzocht. In dit hoofdstuk hebben we laten zien dat een hoge 
maternale consumptie van melk tijdens de zwangerschap was geassocieerd met een hogere 
body mass index, totale lichaamsvetmassa, vetvrije massa, ratio tussen androïde and genoïde 
vetmassa, abdominale viscerale vetmassa en een hoger risico op overgewicht of obesitas bij 
kinderen van 10 jaar. Er waren geen consistente associaties met pericardiaal vet, lever vet 
fractie, bloeddruk, vetten, insuline of glucose concentraties. Samenvattend kunnen we stel-
len dat melk consumptie door zwangere vrouwen gerelateerd lijkt te zijn aan een nadelige 
vetverdeling bij hun kinderen, maar niet aan andere cardio-metabole risico factoren.
Hoofdstuk 3 beschrijft studies naar de invloed van maternale adipositas voor en tijdens 
de zwangerschap op adipositas bij haar kinderen tijdens de geboorte en in de kindertijd. In 
Hoofdstuk 3.1 hebben we de individuele en gecombineerde associaties van maternale body 
mass index voorafgaand aan de zwangerschap en gewichtstoename tijdens de zwanger-
schap met het risico op overgewicht en obesitas tijdens de kindertijd onderzocht, alsmede de 
impact van deze associaties op populatieniveau. De resultaten van dit hoofdstuk laten zien 
dat niet alleen overgewicht en obesitas voorafgaand aan de zwangerschap zijn geassocieerd 
met een verhoogd risico op overgewicht bij kinderen, maar dat deze risico’s geleidelijk stijgen 
naarmate de body mass index stijgt. Het risico op overgewicht bij kinderen steeg ook gelei-
delijk met stijgende gewichtstoename tijdens de zwangerschap. Het effect van overmatige 
gewichtstoename op het risico op overgewicht bij kinderen was beperkt voor vrouwen 
die al overgewicht of obesitas hadden voorafgaand aan de zwangerschap. In Hoofdstuk 
3.2 hebben we de optimale gewichtstoename tijdens de zwangerschap bepaald als de ge-
wichtstoename met het laagste risico op nadelige zwangerschaps- en geboorte uitkomsten. 
De optimale gewichtstoename was lager voor vrouwen die een hogere body mass index had-
den voorafgaand aan de zwangerschap. De optimale gewichtstoename was ook lager voor 
vrouwen met ernstigere obesitas. Zowel gewichtstoename buiten de in dit proefschrift gede-
finieerde categorieën als buiten de bestaande richtlijnen van het instituut der geneeskunde 
(IOM) in de Verenigde Staten was geassocieerd met nadelige zwangerschaps- en geboorte 
uitkomsten. Deze associaties waren over het algemeen sterker voor de categorieën bepaald 
in dit proefschrift. Zowel de in dit proefschrift gedefinieerde categorieën als die van het 
IOM waren echter maar beperkt in staat om onderscheid te maken tussen vrouwen met en 
zonder nadelige uitkomsten. Dit wijst erop dat de optimale gewichtstoename bepaald in dit 
proefschrift informatief kan zijn voor preconceptionele counseling, maar dat richtlijnen voor 
gewichtstoename tijdens de zwangerschap in het algemeen waarschijnlijk niet informatief 
zijn voor risicopredictie op individueel niveau.
Hoofdstuk 4 beschrijft studies naar de metabole mechanismen die onderliggend zouden 




en obesitas en cardio-metabole ziekten later in het leven. In Hoofdstuk 4.1 hebben we 
laten zien dat maternale glucose concentraties in de vroege zwangerschap geassocieerd 
waren met een lager HDL cholesterol en hogere glucose concentraties bij kinderen. Mater-
nale insuline concentraties waren geassocieerd met een hogere body mass index, systolische 
bloeddruk, totale lichaamsvet massa, ratio van androïde tot genoïde vetmassa, subcutane 
vetmassa en insuline concentraties bij kinderen. Alle associaties, behalve die voor glucose en 
insuline concentraties bij het kind, konden worden verklaard door verschillen in maternale 
body mass index voorafgaand aan de zwangerschap. Het doel van Hoofdstuk 4.2 was om 
perioden en groeipatronen geassocieerd met insuline concentraties bij kinderen te identifice-
ren. Resultaten van dit hoofdstuk laten zien dat, onafhankelijk van groei in andere perioden, 
gewichtstoename vanaf de leeftijd van 6 maanden en body mass index toename vanaf de 
leeftijd van 24 maanden geassocieerd waren met insuline concentraties bij kinderen, met de 
sterkste associaties op de leeftijd van 72 maanden. Vergeleken met kinderen in het laagste 
kwartiel van insuline, waren kinderen in het hoogste kwartiel langer vanaf de geboorte en 
hadden een hoger gewicht en een hogere body mass index vanaf de leeftijd van 24 maanden. 
Deze verschillen werden groter naarmate het kind ouder werd. Er waren geen associaties 
voor foetale groei. Deze resultaten wijzen erop dat een snelle groei in lengte, gewicht en 
body mass index in de kindertijd, maar niet tijdens het foetale leven, geassocieerd is met 
hogere insuline concentraties bij kinderen. In Hoofdstuk 4.3 hebben we gebruik gemaakt 
van metabolomics data om de metaboliet profielen van zwangere vrouwen en hun kinderen 
bij de geboorte en op de leeftijd van 10 jaar te beschrijven, alsmede de relaties tussen deze 
profielen. Resultaten van dit hoofdstuk laten zien dat metaboliet concentraties variëren tus-
sen de verschillende tijdspunten. De correlaties van de individuele metabolieten tussen de 
zwangere vrouwen en hun kinderen waren relatief laag. Dit zou kunnen betekenen dat 
unieke metaboliet profielen bestaan voor zwangere vrouwen en hun kinderen bij de geboorte 
en op de leeftijd van 10 jaar, met beperkte correlaties tussen generaties. In Hoofdstuk 4.4 
hebben we onderzocht of maternale metaboliet profielen tijdens de vroege zwangerschap 
en metaboliet profielen van pasgeborenen gerelateerd zijn aan foetale groei vanaf het eer-
ste trimester en het risico op nadelige geboorte uitkomsten. Resultaten van dit hoofdstuk 
laten zien dat maar enkele fosfolipiden, vooral alkyl-fosfolipiden, geassocieerd waren met 
dijbeenlengte en hoofdomtrek van het kind in het eerste trimester van de zwangerschap en 
gewicht en hoofdomtrek bij de geboorte. Metaboliet profielen van pasgeborenen, vooral 
niet-veresterde vetzuren en acyl-lysophosphatidylcholines, waren sterk geassocieerd met 
gewicht, lengte en hoofdomtrek bij de geboorte en met de risico’s om zowel te klein als te 
groot geboren te worden voor de zwangerschapsduur. Dus, de resultaten van dit proefschrift 
wijzen erop dat de metaboliet profielen van de moeder tijdens de vroege zwangerschap 
maar in beperkte mate gerelateerd zijn aan foetale groei, terwijl metabolietprofielen van 




Als laatste geeft Hoofdstuk 5 een algemene discussie van de belangrijkste bevindingen 
van dit proefschrift, methodologische overwegingen en suggesties voor verder onderzoek. 
Concluderend, door zwangere vrouwen vaak geconsumeerde voedingscomponenten en 
adipositas bij zwangere vrouwen zijn geassocieerd met groei, lichaamsvetonwikkeling en 
cardio-metabole risicofactoren bij hun kinderen. Veranderingen in metaboliet profielen 
























Voerman E, Jaddoe VWV, Gisthi O, Hofman A, Franco OH, Gaillard R. Maternal caffeine 
intake during pregnancy, early growth, and body fat distribution at school age. Obesity (Silver 
Spring). 2016;24(5):1170-7.
Voerman E, Jaddoe VWV, Franco OH, Steegers EAP, Gaillard R. Critical periods and growth 
patterns from fetal life onwards associated with childhood insulin levels. Diabetologia. 
2017;60(1):81-88.
Patro Golab B#, Santos S#, Voerman E, Barros H, Bergström A, Charles MA, Chatzi L, 
Chevrier C, Chrousos GP, Corpeleijn E, Costet N, Crozier S, Devereux G, Eggesbø M, Ekström 
S, Fantini MP, Farchi S, Forastiere F, Georgiu V, Godfrey KM, Gori D, Hanke W, Hertz-Picciotto 
I, Heude B, Hryhorczuk D, Inskip H, Ibarluzea J, Kenny LC, Küpers LK, Lagström H, Lehmann 
I, Lenters V, Llop SL, Magnus P, Majewska R, Mäkelä J, Manios Y, McAuliffe FM, McDonald 
SW, Mehegan J, Mommers M, Morgen CS, Moschonis G, Murray D, Ní Chaoimh C, Nøhr 
EA, Nybo Andersen AM, Oken E, Oostvogels AJ, Pac A, Papadopoulou E, Pizzi C, Polanska K, 
Porta D, Richiardi L, Rifas-Shiman SL, Rusconi F, Santos AC, Smit HA, Sørensen TI, Standl M, 
Stoltenberg C, Sunyer J, Taylor M, Thiering E, Thijs C, Torrent M, Tough SC, Trnovec T, Turner 
S, van Rossem L, von Berg A, Vrijheid M, Vrijkotte T, West J, Wright J, Zvinchuk O, Lawlor 
DA, Jaddoe VWV*, Gaillard R*. Influence of maternal obesity on the association between 
common pregnancy complications and risk of childhood obesity: an individual participant 
data meta-analysis. Lancet Child Adolesc Health. 2018;2(11):812-821.
Santos S, Eekhout I, Voerman E, Gaillard R, Barros H, Charles M, Chatzi L, Chevrier C, 
Chrousos GP, Corpeleijn E, Costet N, Crozier S, Doyon M, Eggesbø M, Fantini MP, Farchi S, 
Forastiere F, Gagliardi L, Georgiu V, Godfrey KM, Gori D, Grote V, Hanke W, Hertz-Picciotto 
I, Heude B, Hivert M, Hryhorczuk D, Huang R, Inskip H, Jusko TA, Karvonen AM, Koletzko 
B, Küpers LK, Lagström H, Lawlor DA, Lehmann I, Lopez-Espinosa M, Magnus P, Majewska 
R, Mäkelä J, Manios Y, McDonald SW, Mommers M, Morgen CS, Moschonis G, Murínová L, 
Newnham J, Nohr EA, Nybo Andersen A, Oken E, Oostvogels AJJM, Pac A, Papadopoulou 
E, Pekkanen J, Pizzi C, Polanska K, Porta D, Richiardi L, Rifas-Shiman SL, Roeleveld N, Santa-
Marina L, Santos AC, Smit HA, Sørensen TIA, Standl M, Stanislawski M, Stoltenberg C, Thier-
ing E, Thijs C, Torrent M, Tough SC, Trnovec T, van Gelder MMHJ, van Rossem L, von Berg 
A, Vrijheid M, Vrijkotte TGM, Zvinchuk O, van Buuren S, Jaddoe VWV. Gestational weight 
gain charts for different body mass index groups for women in Europe, North America, and 
Oceania. BMC Med. 2018;16(1):201.
CHAPTER 7
382
Patro Golab B, Voerman E, van der Lugt A, Santos S, Jaddoe VWV. Subcutaneous fat mass 
in infancy and abdominal, pericardial and liver fat assed by Magnetic Resonance Imaging at 
the age of 10 years. Int J Obes (Lond). 2019; 43(2):392-401.
Voerman E, Santos S, Patro Golab B, Amiano P, Ballester F, Barros H, Bergström A, Charles M, 
Chatzi L, Chevrier C, Chrousos GP, Corpeleijn E, Costet N, Crozier S, Devereux G, Eggesbø M, 
Ekström S, Fantini MP, Farchi S, Forastiere F, Georgiu V, Godfrey KM, Gori D, Grote V, Hanke 
W, Hertz-Picciotto I, Heude B, Hryhorczuk D, Huang R, Inskip H, Iszatt N, Karvonen AM, 
Kenny LC, Koletzko B, Küpers LK, Lagström H, Lehmann I, Magnus P, Majewska R, Mäkelä 
J, Manios Y, McAuliffe FM, McDonald SW, Mehegan J, Mommers M, Morgen CS, Mori TA, 
Moschonis G, Murray D, Chaoimh CN, Nohr EA, Nybo Andersen A, Oken E, Oostvogels AJJM, 
Pac A, Papadopoulou E, Pekkanen J, Pizzi C, Polanska K, Porta D, Richiardi L, Rifas-Shiman 
SL, Ronfani L, Santos AC, Standl M, Stoltenberg C, Thiering E, Thijs C, Torrent M, Tough SC, 
Trnovec T, Turner S, van Rossem L, von Berg A, Vrijheid M, Vrijkotte TGM, West J, Wijga A, 
Wright J, Zvinchuk O, Sørensen TIA, Lawlor DA, Gaillard R*, Jaddoe VWV*. Maternal body 
mass index, gestational weight gain and the risk of overweight and obesity across childhood: 
An individual participant data meta-analysis. PLoS Med. 2019;16(2):e1002744.
Koopman ADM, Beulens JW, Voerman E, Rauh SP, van der Heijden AA, McDonald TJ, 
Langendoen-Gort M, Rutters F. The association between GAD65 antibody levels and incident 
Type 2 Diabetes Mellitus in an adult population: A meta-analysis. Metabolism. 2019;95:1-7.
Santos S, Voerman E, Amiano P, Barros H, Beilin LJ, Bergström A, Charles M, Chatzi L, 
Chevrier C, Chrousos GP, Corpeleijn E, Costa O, Costet N, Crozier S, Devereux G, Doyon M, 
Eggesbø M, Fantini MP, Farchi S, Forastiere F, Georgiu V, Godfrey KM, Gori D, Grote V, Hanke 
W, Hertz-Picciotto I, Heude B, Hivert M, Hryhorczuk D, Huang R, Inskip H, Karvonen AM, 
Kenny LC, Koletzko B, Küpers LK, Lagström H, Lehmann I, Magnus P, Majewska R, Mäkelä 
J, Manios Y, McAuliffe FM, McDonald SW, Mehegan J, Melén E, Mommers M, Morgen CS, 
Moschonis G, Murray D, Ní Chaoimh C, Nohr EA, Nybo Andersen A, Oken E, Oostvogels 
AJJM, Pac A, Papadopoulou E, Pekkanen J, Pizzi C, Polanska K, Porta D, Richiardi L, Rifas-
Shiman SL, Roeleveld N, Ronfani L, Santos AC, Standl M, Stigum H, Stoltenberg C, Thiering 
E, Thijs C, Torrent M, Tough SC, Trnovec T, Turner S, van Gelder MMHJ, van Rossem L, von 
Berg A, Vrijheid M, Vrijkotte TGM, West J, Wijga AH, Wright J, Zvinchuk O, Sørensen TIA, 
Lawlor DA, Gaillard R*, Jaddoe VWV*. Impact of maternal body mass index and gestational 
weight gain on pregnancy complications: an individual participant data meta-analysis of 
European, North American, and Australian cohorts. BJOG. 2019;126(8):984-955.
Voerman E, Santos S, Inskip H, Amiano P, Barros H, Charles M, Chatzi L, Chrousos GP, Cor-




D, Hanke W, Hertz-Picciotto I, Heude B, Hivert M, Hryhorczuk D, Iñiguez C, Karvonen AM, 
Küpers LK, Lagström H, Lawlor DA, Lehmann I, Magnus P, Majewska R, Mäkelä J, Manios Y, 
Mommers M, Morgen CS, Moschonis G, Nohr EA, Nybo Andersen A, Oken E, Pac A, Papa-
dopoulou E, Pekkanen J, Pizzi C, Polanska K, Porta D, Richiardi L, Rifas-Shiman SL, Roeleveld 
N, Ronfani L, Santos AC, Standl M, Stigum H, Stoltenberg C, Thiering E, Thijs C, Torrent M, 
Trnovec T, van Gelder MMHJ, van Rossem L, von Berg A, Vrijheid M, Wijga A, Zvinchuk O, 
Sørensen TIA, Godfrey KM, Jaddoe VWV*, Gaillard R*. Association of gestational weight 
gain with adverse maternal and infant outcomes. JAMA. 2019;321(17):1707-1715.
Geurtsen ML#, van Soest EEL#, Voerman E, Steegers EAP, Jaddoe VWV, Gaillard R. Maternal 
glucose metabolism in early-pregnancy, fetal growth, and the risks of adverse birth outcomes. 
Diabetologia. 2019;62(10):1880-1890.
Voerman E, Jaddoe VWV, Gaillard R; LifeCycle Project-Maternal Obesity and Childhood Out-
comes Study Group. Optimal Gestational Weight Gain-Reply. JAMA. 2019;322(11):1107-
1108.
Brand JS, Gaillard R, West J, McEachan RRC, Wright J, Voerman E, Felix JF, Tilling K, Lawlor 
DA. Associations of maternal quitting, reducing and continuing smoking during pregnancy 
with longitudinal fetal growth: findings from Mendelian randomization and parental nega-
tive control studies. PloS Med. 2019;16(11):e1002972.
Voerman E, Jaddoe VWV, Hulst ME, Oei EHG, Gaillard R. Associations of maternal caffeine 
intake during pregnancy with childhood abdominal and liver fat deposition in childhood. 
Pediatr Obes. 2020;15(5):e12607.
Voerman E, Jaddoe VWV, Uhl O, Shokry E, Horak J, Felix JF, Koletzko B*, Gaillard R*. A 
population-based resource for intergenerational metabolomics analyses in pregnant women 
and their children: the Generation R Study. Metabolomics. 2020;16(4):43.
Erkamp JS, Voerman E, Steegers EAP, Mulders AGMGJ, Reiss IKM, Duijts L, Jaddoe VWV, 
Gaillard R. Second and third trimester fetal ultrasound population screening for risks of 
preterm birth and small-size and large-size for gestational age at birth: A population-based 
prospective cohort study. BMC Med. 2020;18(1):63.
Wahab RJ, Voerman E, Jansen PW, Oei EHG, Steegers EAP, Jaddoe VWV, Gaillard R. Mater-




Voerman E, Gaillard R, Geurtsen ML, Jaddoe VWV. Maternal first trimester cow’s milk intake 
is positively associated with childhood general- and abdominal visceral fat mass and lean 
mass but not with other cardio-metabolic risk factors at the age of 10 years. J Nutr. 2021 
(in press).
Blaauwendraad SM, Voerman E, Trasande L, Kannan K, Santos S, Sol C, Marchioro L, Shokry 
E, Koletzko B, Jaddoe VWV, Gaillard R. Associations of maternal bisphenol urine concentra-
tions during pregnancy with neonatal metabolomic profiles. Submitted.
Pinot de Moira A, Haakma S, Strandberg-Larsen K, van Eckevort E, Kooijman MN, Cadman 
T, Cardol M, Corpeleijn E, Crozier S, Duijts L, Elhakeem A, Eriksson JG, Felix JF, Fernández-
Barrés, Foong RE, Forhan A, Grote V, Guerlich K, Heude B, Huang R, Järvelin M, Jørgensen 
AC, Mikkola TM, Nader JLT, Pedersen M, Popovic M, Rautio N, Richiardi L, Ronkainen J, 
Roumeliotaki T, Salika T, Sebert S, Vinther JL, Voerman E, Vrijheid M, Wright J, Yang TC, 
Zariouh F, Charles M, Inskip H, Jaddoe VWV, Swertz M, Nybo Andersen A. The EU Child 
Cohort Network’s core data: establishing a set of findable, accessible, interoperable and 
re-usable (FAIR) variables. Submitted.
Voerman E, Jaddoe VWV, Shokry E, Ruijter GJG, Felix JF, Koletzko B*, Gaillard R*. Associa-
tions of maternal and newborn metabolite profiles with fetal growth and the risks of adverse 
birth outcomes. Submitted.
# Denotes shared first authors





Ellis Voerman was born on February 2nd 1992, in Alkmaar, the Netherlands. In 2014 she 
completed her Bachelor of Science in Health Sciences at VU University, Amsterdam, the 
Netherlands cum laude. In the same year, she started the Research Master of Science in 
Health Sciences, with specialization in Epidemiology at the Netherlands Institute of Health 
Sciences (NIHES) of the Erasmus University, Rotterdam, the Netherlands. She completed her 
master’s thesis at the Generation R Study Group, Erasmus MC, Rotterdam, the Netherlands. 
After her graduation in 2016, she extended her research at the Generation R Study Group, 
Department of Pediatrics into the PhD project ‘Diet, Adiposity and Metabolism in Pregnancy 
and Childhood’ under supervision of Prof. dr. V.W.V. Jaddoe (Department of Pediatrics) and 
Dr. R. Gaillard (Department of Pediatrics). In the final year of her PhD project, she addition-
ally worked as data manager for the international LifeCycle project. The results of her PhD 






Summary PhD training and teaching activities
Name PhD student: Ellis Voerman
Erasmus MC Department: Pediatrics
Research School:  Netherlands Institute for Health Sciences
PhD period: September 2016 - March 2021
Promotor: Prof.dr. V.W.V. Jaddoe




Master of Science in Health Sciences (Research), specialization 




Biostatistical Methods I: Basic Principles 5.7
Biostatistical Methods II: Classical Regression Models 4.3
Scientific Writing in English for Publication 2.0
Research Seminars 0.8
Development Research Proposal 2.5
Oral Research Presentation 1.4
Required courses
Methodologic Topics in Epidemiologic Research 1.4
Principles of Research in Medicine and Epidemiology 0.7
Methods of Public Health Research 0.7
Introduction to Global Public Health 0.7
Primary and Secondary Prevention Research 0.7
Social Epidemiology 0.7
Fundamentals of Medical Decision Making 0.7
Pharmaco-epidemiology and Drug Safety 1.9
Advanced Topics in Clinical Trials 1.9
Advanced Analysis of Prognosis Studies 0.9
Principles of Epidemiologic Data-analysis 0.7
Elective courses
Clinical Epidemiology 5.7
Epidemiology of Infectious Diseases 1.4





Missing Values in Clinical Research 0.7
Women’s Health 0.9
Health Economics 0.7
Methods of Health Services Research 0.7
Causal Mediation Analysis 0.7
Survival Analysis for Clinicians 1.9
Maternal and Child Health 0.9
Quality of Life Measurement 0.9
Courses for the Quantitative Researcher 1.4
Other courses
Instellingsgebonden regelgeving en stralingshygiëne niveau 5R, Erasmus MC, 
the Netherlands
2016 0.7
Research Integrity, Erasmus MC, the Netherlands 2017 0.3
Basic course on R, Postgraduate School Molecular Medicine, Erasmus MC, the 
Netherlands
2017 1.8
Metabolomics Data Processing and Data Analysis (online course), University of 
Birmingham, United Kingdom
2018 0.6
Seminars, congresses and presentations
Generation R Research meetings, Erasmus MC, the Netherlands 2016 - 2021 1.0
Maternal and Child Health meetings, Erasmus MC, the Netherlands 2016 - 2021 1.0
Developmental Origins of Health and Disease (DOHaD), Cape Town, South-
Africa. Oral presentation
2015 1.4
Power of Programming Conference, Munich, Germany. Poster presentations 2016 0.7
Generation R Research meeting, Erasmus MC, The Netherlands 2017 + 2019 2.0
Developmental Origins of Health and Disease (DOHaD), Rotterdam, the 
Netherlands. Oral presentation
2017 1.4
Conference on Epidemiological Birth Cohorts and Longitudinal Studies, Oulu, 
Finland. Poster presentation
2018 0.7
Annual conference of the Metabolomics Society. Poster presentation 2019 0.7




Vereniging Trustfonds Erasmus Universiteit Rotterdam, several travel grants 2015 - 2020
Reviewed articles for Plos One, Eur J Epidemiol, Pediatr Obes 2016 - 2020
Generation R general tasks, including PhD planning for data collection 2016 - 2017





Rama Wahab, PhD student Generation R Study, Clinical Epidemiology, NIHES, 
the Netherlands. Maternal glucose metabolism in early-pregnancy and cardio-
metabolic risk factors in mid-childhood.
2018 - 2019 2.0
Mirjam Hulst, Student Nutrition and Dietetics, The Hague, The Netherlands. 
Maternal caffeine intake during pregnancy: Associations with offspring 
abdominal and organ-specific body fat development and awareness among 
health care professionals and pregnant women.
2018 - 2019 2.0
Development R exercises Biostatistical Methods I, NIHES, The Netherlands 2018 0.5






Na ruim 6 jaar bij Generation R is het moment dan eindelijk daar: mijn proefschrift is af. Ik 
kijk terug op een leuke, gezellige, leerzame periode waarin ik gegroeid ben zowel als onder-
zoeker als als persoon. Dank aan iedereen die hier deel van heeft uitgemaakt. Natuurlijk is er 
een aantal mensen dat ik specifiek wil noemen.
Allereerst: zonder data geen onderzoek. Daarom wil ik graag alle deelnemers aan de Gene-
ration R Studie bedanken. Dit proefschrift zou er nooit geweest zijn zonder jullie jarenlange 
enthousiaste deelname. Ook onmisbaar zijn de medewerkers van het focuscentrum, het 
secretariaat en data management. Heel veel dank voor jullie enorme inzet, gezelligheid en 
support tijdens mijn promotietraject.
Mijn promotor, Prof. Jaddoe. Beste Vincent, ruim 6 jaar geleden ben ik gestart als masterstu-
dent binnen Generation R. Ontzettend bedankt voor het vertrouwen dat je al die tijd in mij 
hebt gehad en alle kansen die je mij hebt gegeven, zoals het voorzetten van mijn masteron-
derzoek in een promotietraject en de functie als datamanager voor LifeCycle. Bedankt voor 
alle waardevolle support, input en feedback op projecten en manuscripten. Dit alles heeft mij 
doen groeien tot de onderzoeker die ik nu ben.
Mijn co-promotor, Dr. Gaillard. Beste Romy, ik had mij geen betere co-promotor kunnen 
wensen. Ondanks de vele coschappen en werkzaamheden in de kliniek was je altijd daar 
voor vragen, hulp of gewoon een praatje en koffie. Jouw nuchtere en pragmatische aanpak 
en altijd aanwezige steun heeft mij door de jaren heen enorm geholpen bij het schrijven 
van dit proefschrift. Ik kijk met heel veel plezier terug op onze samenwerking. Je bent een 
geweldige onderzoeker en persoon en ik weet zeker dat je een mooie toekomst voor je hebt, 
wat die ook mag brengen. Heel erg bedankt voor alles!
De leden van kleine promotiecommissie, Prof. Franx, Prof. Reiss en Prof. Seidell, hartelijk dank 
voor het lezen en beoordelen van proefschrift en voor jullie bereidheid om zitting te nemen 
in de kleine promotiecommissie. De leden van de grote commissie, Prof. van der Beek, Prof. 
Steegers-Theunissen en Dr. Felix, ook jullie wil ik hartelijk bedanken voor jullie bereidheid om 
zitting te nemen in de grote commissie.
Alle co-auteurs die betrokken waren bij het tot stand komen van dit proefschrift. Prof. 
Franco, Prof. Hofman, Prof. Steegers, Dr. Felix, Dr. Jansen, Dr. Oei, Dr. Ruijter, Bernadeta, 
Madelon, Mirjam, Olta, Rama, Susana, bedankt voor de fijne samenwerking. Colleagues 
from Germany, Prof. Koletzko, Dr. Shokry, Dr. Horak, Dr. Uhl, Dr. Marchioro, thank you for 
all your help with the metabolomics measurements, your help with data preparation and 
CHAPTER 7
392
of course your valuable knowledge about metabolomics. All co-authors from the MOCO 
collaboration, thank you for being part of this collaboration and your valuable input in the 
manuscripts.
My paranymphs, Susana and Sunayna. Both of you were already there at the beginning of 
my journey at Generation R. I am very happy that you will also be there at this very special 
day. Dear Susana, we started at the same time, shared offices for a long time and became 
friends along the way. Thanks for always being there for me, for research- or non-research 
related-, quick- or not so quick-, questions and talks. Thanks for the tremendous amount 
of support and for being such a great friend. It means a lot to me. You are one of the 
most ambitious researchers I have ever met and I am very sure that you will have a great 
career in research. Lieve Sunayna, bedankt dat je mij als nieuweling wegwijs hebt gemaakt 
binnen Generation R, zowel op de 29e verdieping als in het focuscentrum. Inmiddels zijn we 
niet alleen collega’s, maar ook vrienden. Bedankt voor alle leuke dagen samen op focus. 
Bedankt voor alle gezelligheid, hulp en positiviteit. Bedankt voor alle gezellige etentjes (en in 
coronatijd videocalls). Hopelijk kunnen we deze snel voortzetten.
Mijn vrienden en collega’s binnen Generation R. Dear Andrea, our friendship is the best 
that resulted from the “flex working” environment. We shared an office for a long time, 
together with “our” plant (which thanks to Janine survived the corona pandemic). Thanks 
for the nice outings, and talks and walks during these strange corona times. And thanks for 
being such a nice office mate, and more important, friend. Dear Aleksandra, thanks for your 
friendship and support, especially during my first years at Generation R. Alle fijne collega’s, 
Carolina, Florianne, Jan, Annemarijne, Laura, Kozeta, Junwen, Rama, Sanne, Carlijn, Evelien, 
Marjolein, Madelon, Dionne, Chen, Rosalie, Marleen, Suzanne, Simone, Bruna, Agatha, Lea, 
Annemiek, Danique, Meddy, Elise, Neelke, Ronald, Claudia, Rose, Lonneke en alle anderen 
(na 6 jaar zijn het er echt teveel om op te noemen..), bedankt voor alle gezelligheid en de 
fijne werksfeer.
Mijn vrienden en kennissen buiten Generation R. Samer, Anniek, Korinne en Miki, bedankt 
dat jullie mij, heel lang geleden tijdens de NIHES master, wegwijs gemaakt hebben in het 
EMC en mij er hebben laten thuisvoelen. Samer, ik hoop dat we nog vaak gesprekken kun-
nen hebben over allerlei onbenullige zaken.. Mijn (voormalige) huisgenoten, Aniek, Melissa, 
Maartje, Marleen en Esmée. Dank voor het aanhoren van al mijn verhalen (waaronder best 
ook wel eens wat gemopper..) en jullie geduld daarin. Bedankt dat jullie zulke fijne huisge-
noten waren en zijn. Lieve Isabella, al vriendinnen sinds de basisschool. Aangezien ik ver weg 
zit in “dat Rotterdam”, zien we elkaar niet vaak en eigenlijk te weinig, maar ik weet dat ik 




En als laatste natuurlijk mijn familie. Lieve Debby, wat ben ik blij met jou als mijn zusje. 
Bedankt voor je hulp en betrokkenheid de afgelopen periode. En dankjewel dat er altijd 
voor mij bent. Lieve Pap, Lieve Mam, bedankt voor jullie onvoorwaardelijke liefde en steun 
in alles. Bedankt voor jullie oneindige geduld de afgelopen periode in het aanhoren van 
mijn verhalen en overwegingen. Bedankt dat jullie altijd voor Debby en mij klaarstaan en 
dat we altijd op jullie kunnen rekenen. Bedankt voor de veilige thuishaven om op terug te 





































DIET, ADIPOSITY AND METABOLISM 
IN PREGNANCY AND CHILDHOOD
